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ABSTRACT 
Pseudomonas aeruginosa causes chronic lung infections in patients with cystic fibrosis 
(CF) and is associated with a marked decline in clinical status. Early detection of the 
organism and aggressive specific antibiotic treatment is beneficial to the patient and delays 
the onset of chronic infection. 
The detection of serum antibodies to P. aeruginosa has been reported utilising a wide range 
of antigens. The first part of this study used SDS-PAGE and immunoblotting to investigate 
protein and lipopolysaccharide (LPS) antigens from reference and clinical strains and the 
CF serum antibody response to them. The A-band LPS species, which was not serotype-
specific, was studied further and its prevalence determined. It was found to be highly 
specific for P. aeruginosa, common to approximately 90 % of clinical strains tested and 
provoked a strong antibody response. 
Serum and non-invasive samples (oral fluid, sputum and urine) from CF patients, patients 
with primary ciliary dyskinesia and healthy volunteers were analysed for A-band LPS-
specific antibodies using SDS-PAGE and immunoblotting. Both oral fluid and sputum 
showed excellent correlation with serum for antibodies to A-band. 
Since Pseudomonas-specific antibodies were found in healthy volunteer samples, it was 
necessary to develop a quantitative ELISA. Both IgM and IgG-specific assays were 
optimised. The serum antibody response was further assessed by comparison to culture of 
P. aeruginosa from sputum, conversion of P. aeruginosa to the mucoid phenotype and lung 
function data. The IgG-specific assay clearly distinguished clinical infection, although no 
patients were shown to seroconvert prior to growth of the organism from sputum. IgM-
specific antibody levels were significantly associated with positive sputum culture, in 83 % 
of patients. 
Finally, the IgG-specific assay was compared to the current in-house ELISA and two 
commercial products. There was moderate correlation between the developed assay, the in-
house assay and one of the commercial kits. 
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CHAPTER 1 INTRODUCTION 
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1.1 	Cystic fibrosis 
`Cystic fibrosis of the pancreas' was first described in 1938, when the destruction of the 
exocrine pancreas function in affected patients was noted (Anderson, 1938). Later in 1953, 
it was also associated with excessive salt loss in sweat and by the mid-twentieth century, 
cystic fibrosis (CF) disease was diagnosed by clinical criteria in addition to the sweat 
electrolyte test (Di Saint'Agnese et al., 1953). In 1989 the 230 kb cystic fibrosis 
transmembrane conductance regulator (CFTR) gene, located on the long arm of 
chromosome 7, was identified and cloned (Kerem et aL, 1989; Riordan et al., 1989; 
Rommens et al., 1989), thus marking the start of the molecular era in CF research. 
CF is a common autosomal recessive genetic disorder resulting from mutations in the 
CFTR gene. The CFTR gene encodes a 1480 amino acid membrane-spanning glycoprotein 
(Figure 1) found at the apical borders of epithelial cells lining most exocrine glands 
(Sheppard and Welsh, 1999). One important function of the CFTR protein is as an ATP-
and cyclic AMP-dependent chloride channel in the apical membrane of epithelial cells. It is 
also involved in the regulation of other channels, including the inhibition of the epithelial 
sodium channel (Vankeerberghen et al., 2002). The protein consists of five domains: two 
Figure 1. Structure of the CFTR protein 
(Source: www.cfgenet herapy.org.uk/i mages/CFT RI small.gi f accessed 19/03/07 09.40) 
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membrane-spanning domains that form the chloride ion channel, two nucleotide-binding 
domains that bind and hydrolyze ATP and a regulatory domain (Sheppard and Welsh, 
1999). The phosphorylation of the regulatory domain, mediated by cyclic AMP, dictates the 
opening of the channel. 
The channel plays a vital role in epithelial fluid homeostasis, by contributing to the control 
of water, sodium and chloride transport. Water is released by cells in response to the low 
intracellular sodium ion concentration (Vankeerberghen et al., 2002). This coupled with a 
negatively charged cell interior causes sodium ions to diffuse into the epithelial cells which 
in turn leads to an accumulation of intracellular chloride ions. The cells are stimulated to 
open the chloride channel to secrete the chloride ions along the electrochemical gradient, 
causing the sodium ions to follow. The resulting osmotic gradient allows water to leave the 
cell (Field and Semrad, 1993). An abnormal CFTR channel impedes chloride absorption, 
and this has many negative consequences in different parts of the body. 
Many additional functions of CFTR (listed in Table 1) have been proposed, although the 
molecular basis of many of these has not been confirmed (Coakley and Stutts, 2006). 
Table 1. Possible functions of the CFTR protein 
(adapted from Coakley et al., 2006) 
Protein / process regulated 
	
Protein function 	 Pathophysiological role 
Aquaporin 	 H2O channel 
ATP release Conduct nucleotides 
Outward rectifying Cl- channels cAMP regulated Cl- conductance 
CaCC 
	
Ca2+ regulated Cl- conductance 
Hydrogen carbonate secretion 	HCO3 conductance I exchange 
NHE3 
	
Na+ / H+ exchange 
ROMK K+ channel 
TRPV 	 Swelling-induced Ca2+ entry 
Cytokine expression 	Inflammatory mediators 
ENaC 	 Na+ channel 
Disrupted H2O permeability 
Disrupted paracrine signalling 
Reduced CI- conductance 
Alternative Cl- conductance 
Diminished alkalinity of secretions 
Hyper Na+ adsorption 
Renal K+ recycling 
Defective regulatory volume 
decrease 
Lung disease 
Dehydrated ASL 
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1.1.1 Incidence 
CF is the most common lethal inherited disorder in Caucasian people with a carriage rate of 
1 in 25 individuals and clinical disease affecting approximately 1 in 2500 live births (Bye et 
al., 1994). CF does affect other ethnic groups, often with a significantly lower incidence. 
US data reports the CF incidence as approximately 1 in 3200 white live births and 1 in 
15000 black live births (Hamosh et al., 1998). 
In the UK, CF patients' details are anonymously registered on the UK CF Database 
(www.cystic-fibrosis.org.uk). Reports are produced annually to provide up to date information 
for clinicians and a comprehensive UK dataset. Currently, there are approximately 7000 
patients with CF registered in the UK, 78 % of whom are under 25 years of age (Figure 2) 
with a mean age of 16 years. There is a male preponderance (53 %) that significantly 
increases with age in adult life (Cystic Fibrosis Trust, 2006). 
Most UK CF diagnoses were previously made clinically (for example, meconium ileus or 
pancreatic insufficiency), but neonatal screening (immunoreactive trypsin from the heel 
prick test, sometimes with genetic analysis) is now used in the UK to detect the condition 
shortly following birth (Lyczak et al., 2002). The sweat test is the "gold standard" for the 
Figure 2. Age profile for UK CF patients in 2004 
(Adapted from Cystic Fibrosis Trust, 2006) 
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definitive diagnosis. A raised sweat chloride concentration greater than 60 mM/L on two or 
more occasions is consistent with diagnosis of CF (Stern, 1997). False positive results can 
arise in neonates who may have a transient increase in sweat chloride, and older adults 
whose sweat chloride levels normally increase (Lyczak et al., 2002). False negative results 
may be obtained in malnourished and dehydrated patients or in those with some unusual 
CFTR mutations (Lyczak et al., 2002). Therefore CFTR genotyping can sometimes be used 
to confirm results, as well as to aid screening of family members. Abnormal nasal electrical 
potential difference is also suggestive of CF (Gowen et al., 1986); however this test is only 
available in very few centres. 
There were 164 new diagnoses of CF in the UK in 2004, with two-thirds being diagnosed 
in the first year of life (Cystic Fibrosis Trust, 2006). Most people with CF are diagnosed in 
this first year with typical lung disease and/or pancreatic insufficiency. However, in recent 
years an increasing number of patients are being diagnosed in adulthood (7 % of new 
diagnoses were from patients 16 years and older in 2004) with atypical disease (Cystic 
Fibrosis Trust, 2006). 
At present there is no cure for CF, but life expectancy of people with CF has improved 
dramatically over the past 20 years (Kulich et al., 2003), and is currently to 31 years of age 
(McCoy et al., 1997). In 2004, there were 123 reported deaths in the UK, the mean age at 
death was 28 years and the median age 26 years (Cystic Fibrosis Trust, 2006). A study by 
Dodge et al. estimated the observed survival of CF patients in 2003. For those born in 
1978, 55 % of males and 49 % of females were still alive in 2003. However, for those born 
in 1988, 91 % of males and 88 % of females had survived to 2003, and for those born in 
1992, 97 and 96 % had survived, respectively (Dodge et al., 2007). The continuing 
improvement in survival means that the previous prediction of median survival of over 50 
years of age for individuals born in 2000 continues to look realistic (Dodge et al., 2007). 
32 
1.1.2 Genetics 
More than 1300 variants of the CFTR gene have been described to date, often with ethnic 
variation in their prevalence and many of which are very rare (McCormick et al., 2002). In 
the UK, 95 % of registered patients have been genotyped (Cystic Fibrosis Trust, 2006). Of 
these, over 74 % carry the 3 bp deletion AF508, representing a phenylalanine deletion at 
codon 508 (McCormick et aL, 2002). Individuals may be homozygous or heterozygous for 
AF508, or may have two non-affected AF508 alleles. Fifty-seven percent of caucasian CF 
patients in the UK are homozygous for AF508 (McCormick et al., 2002). 
CFTR genes may be divided into different classes. The CFTR protein may not be 
synthesised (Class I), there may be defective protein processing (Class II) and defective 
protein regulation (Class III); these are associated with the 'severe' groups. The others, 
defective conductance (Class IV), partly defective production or processing (Class V) and 
defective regulation of other channels (Class VI), are consistent with 'mild' groups 
(McKone et al., 2003; Vankeerberghen et al., 2002). People with mutations in the 
functional classes of defective protein conductance and reduced amounts of functioning 
CFTR protein have a significantly lower mortality rate and a milder clinical phenotype 
(Koch et al., 2001; McKone et at, 2003). These molecular groupings also have 
implications for the development of specific molecular therapies. 
The ultimate cure for CF would be to restore CFTR function. There have been several gene 
therapy clinical trials in CF patients dating back to 1993 (Griesenbach et al., 2004). 
However, the delivery of a gene to the affected cells has been problematic and many 
generations of viral and more recently non-viral vectors and various strategies for vector 
delivery have been used. To date the most promising vectors are cationic liposome/plasmid 
DNA complexes and compacted DNA nanoparticles (Rosenecker et al., 2006). The levels 
of CFTR expression achieved are variable and are often too low and short lived. 
Nevertheless, researchers remain optimistic about the future of gene therapy for CF. 
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1.1.3 Clinical manifestations 
The CFTR defect results in low (or absent) chloride secretion and in many cases a 
secondary increase in sodium ion absorption (Boucher et al., 1988) in many organs of the 
body, in particular the lungs. However, the disease also affects other organs (Figure 3) 
including the gut, pancreas, liver and reproductive tract, thus CF patients exhibit a wide 
range of clinical manifestations of varying severity, with complications increasing with age 
(Lyczak et al., 2002; Ratjen and Doring, 2003). 
The name "cystic fibrosis" derives from the fibrous scar tissue that develops in the 
pancreas. Most CF patients suffer from pancreatic insufficiency, whereby pancreatic 
function is inadequate for proper absorption of nutrients, although approximately 15 % of 
patients possess sufficient exocrine pancreatic function to permit normal digestion 
Figure 3. The main organs of the body affected by cystic fibrosis disease 
(Source: www.merck.com/media/mmhe2/flgures/fg053_1.gif  accessed 19/04/07 13:47) 
(DeBoeck K. et al., 2005). Other gastrointestinal problems include meconium ileus, gastro-
oesophageal reflux, peptic ulceration and distal ileal obstruction. These abnormalities lead 
to malabsorption and nutritional deficiencies (Bronstein et al., 1992), so it is important to 
monitor patients' height and weight so malnutrition can be detected early and treated 
appropriately. 
Chronic liver disease affects 13 to 25 % of CF patients and usually presents in the first 
decade of life (Akata and Akhan, 2007). The defective CFTR protein causes bile duct 
plugging and secondary bile acid related toxicity, leading to portal cirrhosis. A number of 
other mechanisms are also implicated and a small proportion of patients will present with 
variceal bleeding or persistent neonatal jaundice (Westaby, 2006). 
Almost all male CF patients are infertile, due to congenital bilateral absence of the vas 
deferens, although a small proportion have been shown to be fertile (Baretto et al., 1991; 
Taussig et al., 1972). Female CF patients have a structurally normal reproductive tract, 
although there may be dehydrated cervical mucus. Those with a normal body mass index 
and percentage fat menstruate normally and are fertile. 
Although the CF airway is virtually normal and sterile at birth, lung disease accounts for 
much of the morbidity and more than 90 % of the mortality of CF (Lyczak et al., 2002). In 
the bronchial epithelium, the most likely current hypothesis connecting the molecular 
abnormality with the clinical disease is dysregulation of the height of the airway surface 
liquid (ASL, a normally hypotonic thin layer of liquid that coats the upper and lower 
airways), discussed in more detail below (Ratjen and Doring, 2003). Correct ASL 
regulation is critical for normal ciliary function and thus mucus clearance. In CF patients, 
abnormally viscous bronchial secretions are produced, which interfere with mucociliary 
clearance of bacteria, predisposing patients to recurrent airway infection with a rather 
narrow spectrum of micro-organisms (discussed below). Infection is restricted to the airway 
(bacteraemic spread is rare) and there are repeated cycles of infection associated with 
neutrophil-mediated inflammation and progressive irreversible tissue damage. Frequent 
monitoring of pulmonary function (forced expiratory volume in one second (FEVI ) and 
35 
forced vital capacity (FVC)), is therefore essential for patient management and 
administration of appropriate therapy (Wagener and Headley, 2003). 
1.2 	Pulmonary infection in patients with cystic fibrosis 
There are a limited number of pathogenic bacterial species associated with CF lung 
infection. A chronic infectious state is established in most CF lungs with the development 
of bacterial microcolonies which are particularly difficult to clear (Gilligan, 1991). 
Although there is debate about the pathophysiology of the CF lung (is inflammation 
secondary to infection, or is the CF airway inherently pro-inflammatory?), it is widely held 
that early treatment regimes delay the decline to chronic infection and improve lung 
function and long-term survival of patients (Taccetti et al., 2002). It is therefore important 
to identify infection early so appropriate antimicrobial therapy can be started (detailed 
below). It is this which underpins the work of this thesis. 
1.2.1 Species of clinical importance 
Bacterial infection exhibits an age-related pattern, with Staphylococcus aureus, non-
encapsulated Haemophilus influenzae and Pseudomonas aeruginosa being isolated early in 
life (Figure 4) (Cystic Fibrosis Foundation, 2005). Subsequently, nearly all patients become 
chronically infected with P. aeruginosa and less frequently S. aureus. A variety of other 
micro-organisms may also infect the CF airway, including members of the Burkholderia 
cepacia complex (Bcc), Stenotrophomonas maltophilia, Achromobacter xylosoxidans and 
other opportunist Gram-negative species (including anaerobes), often with two or more 
pathogens being present simultaneously. Non-tuberculous mycobacteria, often in 
association with aspergillosis, appear to be on the increase (Mussaffi et al., 2005). Viral 
infections may predispose to secondary bacterial infection but are uncommon. 
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Figure 4. Age-related bacterial colonisation of the lower-respiratory tract in CF 
(Adapted from Cystic Fibrosis Foundation, 2005) 
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1.2.1.1 Staphylococcus aureus 
S. aureus is a significant pathogen of humans which may be cultured from the nose of 
approximately 30 % of healthy individuals, but is infrequent in the throat or respiratory 
secretions (Lyczak et al., 2002). It is one of the first pathogens to be isolated (Govan and 
Nelson, 1992). Its presence is considered clinically important and should be treated, with 
many centres routinely using prophylactic antistaphylococcal agents (Smyth and Walters, 
2003). However, slow-growing small colony variants (SCV) are commonly isolated in 
advanced CF disease and these may have a markedly increased resistance to antibiotics 
(Besier et al., 2007). It has been suggested that a reduction in S. aureus in the sputum of CF 
patients who are given continuous antistaphylococcal antibiotic therapy leads to an increase 
in the rate of P. aeruginosa infection (Ratjen et al., 2001a), but this is likley only if 
cephalosporin prophylaxis is used. 
Some studies have reported an inverse relationship between the levels of P. aeruginosa and 
S. aureus in CF lungs, suggesting antagonism between the two species. Indeed, an 
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antistaphylococcal agent produced by P. aeruginosa was considered to be responsible for 
suppression of S. aureus in the lung (Machan et al., 1991) and recent work has confirmed 
this (Hoffman et al., 2006). 
Despite its prevalence in non-CF patients in hospitals, methicillin resistant S. aureus 
(MRSA) strains are not often problematic in CF patients. Studies on the significance of 
MRSA in CF have been contradictory, with some proposing an association with clinical 
course (Ren et al., 2007) and others reporting no change (Miall et al., 2001). The UK CF 
Trust guidelines recommend that MRSA infection should be avoided in CF patients (UK 
Cystic Fibrosis Trust Antibiotic Group, 2002). Prevalence rates for MRSA in CF centres in 
the UK range from 3 % to 14 % and they are more often a consequence of spread of strains 
endemic in the wider hospital to the CF community (Campana et al., 2004; Steinkamp et 
al., 2005; Valenza et aL, 2008; Vergison et al., 2007). 
1.2.1.2 Haemophilus influenzae 
When H influenzae is isolated from CF respiratory secretions, it is usually non-
encapsulated (Watson et al., 1988). There is little known about the overall contribution of 
this oral commensal, but it causes inflammation and hence damage to CF lung tissue, 
especially in early life, and can be significant enough to warrant therapy (Lyczak et al., 
2002). 
1.2.1.3 Pseudomonas aeruginosa 
P. aeruginosa is the most common organism recovered from the lungs of CF patients. 
Twenty percent of one-year olds, one-third of three-year olds and 80 to 90 % of adults with 
CF are infected with P. aeruginosa (Wang et al., 2001). P. aeruginosa infection and the 
associated inflammatory response are well recognised as the leading cause of morbidity and 
mortality in CF, with a more rapid decline in lung function and reduced survival (Emerson 
et al., 2002). A full account of this organism is given in section 1.3. 
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1.2.1.4 Burkholderia cepacia complex 
Although B. cepacia are generally not harmful to healthy people, they have been 
recognised as significant pathogens in CF patients over the past 20 years (LiPuma, 2005). 
The Bcc consists of ten genomovars (I to X), but the majority of CF infections are caused 
by B. multivorans (genomovar II), B. cenocepacia (genomovars IIIa, IIIb, IIIc and Hid) and 
B. dolosa (genomovar VI) (Kalish et al., 2006; LiPuma, 2005). B. cenocepacia is the 
genomovar most associated with `cepacia syndrome', a necrotising pneumonia often 
resulting in death. A highly transmissible lineage of this genomovar, termed ET12, was 
imported into the UK in the mid 1980s via returning summer camp residents in North 
America, where the original outbreak occurred (Sun et aL, 1995). This strain expresses 
cable pili which facilitate adhesion to respiratory epithelial cells (Urban et al., 2005). Today 
this lineage persists in a number of CF centres, but is gradually being replaced by more 
diverse and apparently less transmissible strains. 
Genomovar HI is also of special importance since it is associated with particularly high 
rates of morbidity and mortality, so patients who grow this strain (in particular the B. 
cenocepacia ET12 lineage) should be considered at increased risk after lung transplant 
(DeSoyza et al., 2004). The correct identification (Turton et al., 2007) of the Bcc is 
therefore of particular significance for hospital infection control practices and the eligibility 
of a patient for transplant. 
1.2.1.5 Other Gram-negative opportunists 
S. maltophilia and A. xylosoxidans are both widespread in the environment and have been 
associated with airway infections in CF patients (Anderson et al., 2007; DeBaets et al., 
2007). Their significance has not been determined and infection rates are probably 
underestimated, but they are amongst a number of micro-organisms that almost certainly 
play a deleterious role in CF lung disease. Other opportunist Gram-negative species (for 
example, Pandorea and Ralstonia) may on occasion also be isolated from the CF airway. 
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With the exception of Bcc and S. aureus, the bacteria mentioned above are usually seen as 
causing intermittent infections, although they can on occasion repeatedly re-infect 
individuals (Renders et al., 2001). P. aeruginosa can however chronically infect the airway 
and is the organism most associated with clinical decline. 
1.2.2 Pathophysiology 
There are a number of conflicting hypotheses as to why the CF airway is hypersusceptible 
to infection, in particular with P. aeruginosa, (Brennan and Geddes, 2002; Davies, 2002; 
Goldberg and Pier, 2000; Pier, 2002; Ratjen and Doring, 2003; Vankeerberghen et al., 
2002; Verkman et al., 2003). The main hypotheses include: i) alterations in the ASL 
composition and viscosity, ii) enhanced binding of bacteria to epithelial cells and mucins, 
and iii) CFTR acting as a receptor for internalisation of bacteria into epithelial cells (Figure 
5). 
The altered ASL composition hypothesis proposes the ASL of CF individuals has a raised 
salt content, which inactivates salt-sensitive antimicrobial peptides, such as 0-defensin 1 
(Goldman et al., 1997). Normally, ASL would be capable of killing P. aeruginosa, but in 
CF this is not so, thereby promoting bacterial survival (Smith et al., 1996). The increased 
viscosity of ASL also compromises mucociliary transport. The reduced airway nitric oxide 
levels in the CF lung probably contributes to the dehydration and increased viscosity of the 
ASL (Davies, 2002). In addition, the hypoxic gradients created within mucus plugs may be 
sensed by bacteria, whilst the lack of oxygen also impairs neutrophil function (Worlitzsch 
et al., 2002). However, although this might be important in the perpetuation of infection, it 
seems less likely as an early mechanism initiating infection. 
The cell-receptor hypothesis suggests that CF cell organelles have an altered pH compared 
to normal cells (Davies, 2002; Imundo et al., 1995; Poschet et al., 2001). This results in the 
production of glycoproteins and glycolipids with an altered glycosylation pattern, including 
a reduction in sialysation and fucosylation of gangliosides. S. aureus and P. aeruginosa 
attach preferentially to these receptors (for example, asialoganglioside 1 (asialoGM1) 
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Figure 5. Hypotheses for hypersusceptibility of the CF lung to P. aeruginosa 
(Adapted from Davies, 2002) 
and fucosylated oligosaccharides), with the latter being mediated by pili and flagella 
(Feldman et al., 1998; Imundo et aL, 1995). Flagellar cap proteins have also been shown to 
promote P. aeruginosa binding to mucins (Arora et al., 2000). Moreover, bacterial binding 
to asialoGM1 receptors on respiratory epithelial cells that are regenerating is enhanced, 
which may explain why damage from previous infection possibly enhances the 
susceptibility to P. aeruginosa (DeBentzmann et al., 1996). This binding to asialoGM1 also 
stimulates interleukin (IL)-8 production, a potent neutrophil attractant. 
The CFTR protein itself has also been suggested to be a bacterial receptor, enabling 
bacterial internalization by epithelial cells (Pier et aL, 1996). In normal, non-CF cells, once 
the bacteria are internalised, the cells are shed, eliminating the bacteria. However, in CF 
cells this mechanism is less efficient, thus allowing bacteria to persist. Possibly connected 
to this, studies have shown that the type and severity of CF pulmonary infections can be 
influenced by the CFTR mutation (McManus et al., 2005). Patients homozygous or 
heterozygous for AF508 appear to have an increased number of positive sputum cultures, an 
increased likelihood of chronic infection with Bcc or P. aeruginosa and a greater chance of 
isolating multiple simultaneous organisms (Pier et al., 1996). Conversely, patients with 
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some mild mutations (for example, RI 17H) appear less likely to be colonised by Gram-
negative organisms (McKone et al., 2003). 
1.2.3 Laboratory diagnosis of pulmonary infection 
There are different approaches taken to the laboratory diagnosis of pulmonary infection 
depending on the patients' symptoms and the possible aetiologic agents. By applying 
various appropriate microbiological tests on suitable clinical specimens, with the addition 
of informative data from the clinician, a specific bacteriological diagnosis can usually be 
made. Since most routine microbiological tests require the isolation of viable pathogens, 
appropriate clinical specimens must be collected, maintained in suitable media and 
delivered in a timely manner to the laboratory, as the quality of specimens profoundly 
influences the test results. A knowledge of commensal flora of the sample site and areas 
adjacent to this is also important, to avoid misinterpretation of results, as sputum samples 
are frequently contaminated by micro-organisms colonising the nose or oropharynx 
(Cattaneo et al., 1975). 
Typical specimens for the diagnosis of pulmonary infection include sputum, 
nasopharyngeal swabs and aspirates, oropharyngeal and cough swabs, and broncho-alveolar 
(BAL) fluid. Oropharyngeal and cough swabs are used particularly in young children who 
cannot expectorate sputum. Indeed, sputum expectoration is often not possible until 
children reach about the age of seven, by which time the window of opportunity for the 
early diagnosis of infection has often passed. 
The diagnostic accuracy of oropharyngeal culture is therefore important, since it is 
currently the most widely used non-invasive technique for assessing respiratory tract 
infection in young, non-expectorating children. Tramper-Stranders has collated the data 
from four studies (Armstrong et al., 1996; Burns et al., 2001; Ramsey et al., 1991; 
Rosenfeld et al., 1999), comparing the diagnostic and predictive values of oropharyngeal 
cultures with BAL fluid cultures, summarized in Table 2 (Tramper-Stranders et al., 2005). 
The data show that in young asymptomatic children, P. aeruginosa-positive oropharyngeal 
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cultures are not reliable indicators of infection (demonstrated by the low positive predictive 
value). However, negative cultures do indicate that P. aeruginosa is unlikely to be present 
(high negative predictive values). The negative predictive value is increased by additional 
oropharyngeal cultures (Burns et al., 2001). Therefore, oropharyngeal swabs are not 
optimal samples and cough swabs and cough plates also lack sensitivity and specificity 
(Equi et al., 2001; Ramsey et al., 1991). Even though BAL fluid is considered to be the 
sample with the highest sensitivity for isolation of bacteria, the technique is invasive, 
usually requiring general anaesthesia, and fluid is only obtained from one or two lobes, at 
most, of the lung, so significant infections may be missed (Copenhaver et al., 1996; 
Gutierrez et al., 2001). 
Table 2. Diagnostic values of oropharyngeal cultures for P. aeruginosa. 
(Adapted from Tramper-Stranders et al., 2005. Sens = sensitivity; spec = specificity; PPV = positive 
predictive value; NPV = negative predictive value; PA = P. aeruginosa) 
Study author 
No. of 
BAL 
Age BAL Fluid culture 
Sens 
rY.9) 
Spec 
(%) 
PPV 
(Y0) 
NPV 
(Xs) 
Armstrong et 
al. (1996) 
150 1 — 52 m BAL PA > 10.5 cfu/mL 71 93 57 96 
141 BAL PA > 10.5 cfulmL 82 94 64 97 
Rosenfeld et BAL PA any growth 
< 60 m 
al. (1999) 119 < 18 m 44 95 44 95 
82 > 18 m 68 94 76 91 
BAL PA any growth 
Bums etal. 
108 < 36 m 1 oropharyngeal culture 69 85 
(2001) 
2 oropharyngeal cultures 83 97 
Ramsey et 
al. (1991) 
43 4 m — 25 y BAL PA any growth 46 93 83 70 
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All the samples mentioned are appropriate for conventional microbiological culture and 
microscopy, but can also be examined for specific bacterial DNA by appropriate molecular 
techniques or immunofluorescence (Brown and Govan, 2007; da Silva Filho et al., 1999; 
Tang, 1992). The latter techniques offer advantages of speed and specificity, and allow the 
direct identification of the bacterial species in the sample. 
The polymerase chain reaction (PCR) assay has been applied to the detection of both P. 
aeruginosa and Bcc organisms in sputum samples (Brown and Govan, 2007; da Silva Filho 
et al., 1999; Xu et al., 2004). A number of target genes (for example, 16S rRNA and OprL) 
have been identified and amplified with specific oligonucleotide primer sequences and 
appropriate cycling conditions. Varying levels of sensitivity using artificially spiked 
samples have been claimed, with detection levels ranging from 104 to 107 colony forming 
units (CFU) per mL of sputum (Brown and Govan, 2007). Fluorescent in situ hybridisation 
(FISH) assays have also been evaluated for the detection of bacteria direct from specimens, 
offering a sensitivity of about 106 CFU per mL (Brown and Govan, 2007). A commercial 
kit, seaFAST Cystic Fibrosis I kit (IZINTA, Hungary) is available and enables the 
identification of B. cepacia, H influenzae, P. aeruginosa and S. maltophilia through the use 
of tandem oligonucleotide probes. Hybridisation of the probe with the target gene is 
visualised by an immunofluorescent label and generates fluorescence in a UV light field in 
a fluorescent microscope. Problems do arise through non-specific binding of labelled 
probes, leading to high background levels of fluorescence. Neither of these techniques have 
been widely applied, and they remain research tools. 
Additionally, in non-sterile body sites, such as the lung, the detection of nucleic acids from 
environmental organisms does not confirm that infection or even colonisation is present, as 
the bacteria may not be viable. Moreover, detection of a micro-organism that is commonly 
present in the environment in a non-sterile area of the body does not necessarily confirm 
that an infection is present. 
The demonstration of pathogenic-specific antibodies in serum is another approach to the 
diagnosis of pulmonary infectious disease. The underlying principle is that if the micro- 
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organism is the cause of an active infection, the host will generate antibodies to antigen 
epitopes and this response serves to confirm the infectious process. Antibodies can also be 
demonstrated in oral fluids, as for example with Bordetella pertussis in patients with 
whooping cough (Litt et al., 2006). The development and evaluation of antibody tests for 
the diagnosis of P. aeruginosa infection in CF is the prime objective of this investigation 
and this will be addressed in further detail in section 1.5. 
Current microbial monitoring is by culture of sputum (or cough swabs in young children) 
taken at routine clinics or at the time of respiratory exacerbation. BAL may be considered, 
particularly with newly diagnosed patients (Hilliard et aL, 2006). Other techniques 
sometimes used include cough plates and induction of sputum by inhalation of hypertonic 
saline. 
1.2.3.1 Culture of respiratory secretions 
Bacteria have been isolated and cultured in artificial media since the early days of 
bacteriology in the era of Robert Koch. Since then, many sophisticated techniques have 
been developed, but traditional culture methods remain the gold standard for diagnosis of 
many infections. Laboratories may use variations of standard methods for processing 
respiratory samples, but the following details a thorough approach, often typical of a 
modem, large microbiology department. On receipt in the laboratory, sputum samples are 
emulsified mechanically by vortexing with glass beads in an equal volume of Ringers' 
solution (an isotonic aqueous solution). Samples are then further diluted to enable an 
estimation of microbial load in the lung. By diluting the sputum samples, any suppression 
from antibiotics is also removed and micro-organisms previously masked by, for example, 
mucoid strains can be seen. 
The sputum samples and dilutions (or BAL fluid or cough swabs, which are processed 
directly), are plated on several differential agar media. These will typically include blood 
agar (for general isolation), MacConkey agar (for differentiation of lactose-fermenting 
organisms), chocolate (heated blood) agar (for H influenzae) and selective agar for P. 
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aeruginosa and B. cepacia. P. aeruginosa-specific agar, such as that produced by Difco/BD 
Diagnostics Systems (Sparks, MI, USA), contains glycerol which allows the expression of 
all P. aeruginosa morphotypes. Sabaroud's medium (for fungal isolation) should also be 
inoculated. Plates are incubated at 37 °C in an aerobic environment for 48 hours and 
examined for characteristic colonies. The Sabaroud's medium should be incubated for five 
days and the chocolate agar in a CO2-enriched atmosphere. 
Identification of organisms to the species level (which may involve the setting up of 
additional tests), semi-quantitative counts and antimicrobial sensitivity testing can take a 
minimum of four days. Even then, due to the viscosity of sputum, and the presence of 
sputum plugs originating from a small area of the lung, microbiological culture results may 
not represent the true status and extent of the infection in the patients' lungs. Additionally, 
mucoid colonies of P. aeruginosa can mask the presence of other organisms, especially 
small colony variants of S. aureus and other species. 
1.2.3.2 Serology 
An alternative approach is to infer the presence of P. aeruginosa infection by testing for 
serum antibodies against this organism, especially as these may be detected before the 
organism is isolated by culture from respiratory samples, thus providing vital additional 
information for the clinician (West et al., 2002). Although there is a large body of evidence 
indicating that chronic infection with P. aeruginosa is characterised by a pronounced 
antibody response, with high antibody levels indicative of a poor prognosis (Pressler et al., 
1992), not all CF centres employ immunological-based techniques for monitoring the 
infectious state of their patients. This is perhaps due to a lack of research into and 
understanding of the implications of a raised antibody titre. The published data clearly 
shows a correlation between microbiological findings, clinical status and antibody detection 
for cohorts of CF patients, however, the impact of a single test result for serum antibodies 
against P. aeruginosa remains difficult to interpret (Brett et al., 1988b; Brett et al., 1992; 
Bums et al., 2001; Doring and Hoiby, 1983; Hollsing et al., 1987). A historical view of 
serodiagnosis of P. aeruginosa is detailed further in section 1.4.7. 
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1.2.4 Control of pulmonary infections 
Prompt recognition and diagnosis of lung infection is paramount for the effective 
management of CF patients. Since inflammation and infection of the respiratory tract 
contribute to the majority of morbidity and mortality in these patients, most treatments aim 
to control these. Regular culturing of respiratory secretions for bacteria is recommended to 
monitor patients. An advantage of this technique over indirect methods such as serology 
and molecular techniques is that the actual pathogen is grown and can therefore be used for 
additional tests. These include confirmation of the species identity, typing of isolates and 
antimicrobial susceptibility testing. The latter is seen as critical in improving lung function 
by some (Regelmann et al., 1990), however, others feel there is a lack of association with 
clinical response (Smith et al., 2003). 
1.2.4.1 Antimicrobial chemotherapy 
Antibiotics are also always prescribed when an organism is first isolated. Most of the other 
decisions regarding when to treat and the most appropriate agent to use are empirical and 
based on the patient's age, severity of exacerbations and organisms present (Lyczak et al., 
2002). Indications of infective exacerbations, which mandate treatment, include: adverse 
changes in sputum production, haemoptysis, increased cough, increased dyspnoea, fever, 
fall in lung function or adverse changes in chest sounds. The doses given to CF patients are 
usually higher and for longer duration than for non-CF individuals, due to pharmacokinetic 
differences and also the underlying lung disease. Indeed, a European consensus on 
antibiotic therapy against P. aeruginosa recommends an aggressive approach, applying 
repeat doses of high-dose antibiotics (Doring et al., 2000). Several antibiotics can be given 
nebulised, which increases the delivery of the drug to the target area, maximising efficacy 
and reducing toxicity (Ratjen and Doting, 2003). Nebulised formulations are used as 
maintenance therapy for patients with chronic infections with P. aeruginosa and also for 
early eradication strategies (shown with nebulised colistin, in conjunction with oral 
ciprofloxacin, and tobramycin) (Littlewood et al., 1985; Valerius et al., 1991; Wiesemann 
et al., 1998). However, patients should be monitored in case of bronchospasm, prior to 
home treatment (Conway, 2005). 
47 
Many studies have shown that antibiotic intervention shortly after first isolation can delay 
the onset of chronic infection with P. aeruginosa (Gibson et al., 2003; Littlewood et al., 
1985; Munck et al., 2001; Ratjen et al., 2001b; Taccetti et al., 2002; Taccetti et al., 2005; 
Valerius et al., 1991; Wiesemann et aL, 1998). Early infection, defined as the intermittent 
detection of non-mucoid strains of P. aeruginosa in respiratory cultures, precedes the 
chronic infectious state, where strains are characteristically mucoid. These early treatment 
regimes are powerful therapeutic options delaying chronic infection and the subsequent 
associated change in bacterial phenotype, including antibiotic resistance. During this 
window of opportunity P. aemginosa can be eradicated with oral ciprofloxacin in 
combination with nebulised colistin, or by nebulised tobramycin, as monotherapy (Valerius 
et al., 1991; Wiesemann et al., 1998). This eradication has been shown to be effective in 
Denmark without any serious side-effects or the development of resistance (Hoiby et al., 
2005). The chronic infectious state also seems to be absent in Danish infants and children, 
without any other bacteria replacing P. aeruginosa, so is officially recommended by a 
European Consensus report (Doring and Hoiby, 2004). 
There is considerable variation between clinics in their prescribing practices for 
staphylococcal prophylaxis, with some centres treating all children less than five years old, 
unless there is a compelling reason not to, such as antibiotic intolerance, whilst others will 
normally only prescribe antibiotics when the pathogen is isolated or chest exacerbations are 
evident (McCaffery et al., 1999). However, a review of clinical trials for antistaphylococcal 
therapy concluded that prophylaxis commenced early in infancy and continued up to six 
years of age leads to fewer children having isolates of S. aureus (Smyth and Walters, 2003). 
Some workers subscribe to the idea that anti-staphylococcal prophylaxis increases the 
possibility of infection with P. aeruginosa. However, many of the studies reporting this are 
based on clinical impressions and retrospective analyses (Gilligan, 1991). Additionally, one 
of the placebo-controlled trials only had 17 recruited patients and 11 of these were already 
infected with P. aeruginosa (Loening-Baucke et al., 1979). Therefore, there is currently 
insufficient evidence to clarify any connection between prophylaxis and subsequent 
infections. 
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Antibiotic intervention may fail to eradicate mucoid P. aeruginosa for a variety of reasons. 
Important factors include the high bacterial load combined with the low metabolic rate of 
bacteria in biofilms. Additionally, antibiotics penetrate mucus poorly and aminoglycosides 
have shown reduced bioactivity in sputum (Levy, 1986). Hypermutator strains with rapid 
development of increased resistance against antimicrobial agents may also emerge (Oliver 
et al., 2000). 
1.2.4.2 Infection control 
Isolating bacteria from sputum samples not only confirms a diagnosis and guides antibiotic 
therapy, but is also important for subsequent investigation of possible cross-infection 
between patients. This occurs when an organism of the same strain is acquired directly 
from another person and is of particular importance when involving antibiotic resistant 
organisms. In the laboratory a number of strain typing techniques are used, depending on 
the organism in question, but may include phenotypic methods, such as serotyping and 
phage typing, or DNA fingerprints and sequence based techniques, for example, pulsed-
field gel electrophoresis (PFGE) or multi-locus sequence typing (Hoiby and Rosendal, 
1980; Speert, 2002). If cross-infection is suspected, segregation of infected patients from 
non-infected individuals is important for hospital infection control. Many clinics have a 
policy of segregating patients with Bcc or antibiotic resistant P. aeruginosa and have 
specific clinics for these cases, since these organisms may be transmitted between patients 
and are associated with adverse outcomes (Festini et al., 2006). 
It is widely held that strains of P. aeruginosa originate from the environment and, up to a 
few years ago, CF patients were considered to have their own unique strain as cross-
infection was very rare unless they had a sibling or close relationship with an infected CF 
patient (da Silva Filho et al., 2001). However, in the late 1990s a multi-drug resistant strain 
of P. aeruginosa emerged in Liverpool which was transmitted from patient to patient 
(Cheng et al., 1996). This particular strain was named the Liverpool Epidemic Strain (LES) 
and was found to contaminate 80 % of rooms in a CF inpatients ward in Liverpool 
(Panagea et al., 2005). Since the discovery of LES, several other distinct epidemic strains 
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have been discovered, including Manchester (Jones et al., 2001), Midlands 1 (Scott and 
Pitt, 2004), Clone C (in Hanover, Germany) (Dinesh et al., 2003) and Pulsotype I (in 
Australia) (Armstrong et al., 2003). A nationwide survey to establish the distribution of 
highly transmissible strains of P. aentginosa in UK CF clinics found at least 72 % of all 
patients harboured strains with unique genotypes, but many were also colonised with 
epidemic strains, with LES and Midlands strains accounting for approximately one fifth of 
isolates (Scott and Pitt, 2004). These data reinforce the need for stringent infection control. 
1.2.4.3 Host immunity 
The human immune system is very complex with many lines of defence for protection 
against pulmonary infection. Mechanical, non-immunological defences include the cough 
reflex, mucociliary clearance and epithelial barriers. If pathogens break through these 
physical defences a more specific second line of defence is the humoral and cellular 
immune response. Mucus lining the respiratory pathways contains a number of molecules, 
such as lysozyme, complement and lactoferrin, which possess antibacterial properties, 
while cells such as phagocytes, and B and T lymphocytes, are produced to specific 
antigens, providing innate (low specificity) and adaptive (high specificity) immune 
responses, respectively. 
The innate immune response (which includes phagocytic cells, complement and other cells 
and molecules involved in acute and chronic inflammation) acts as a first line, rapid 
defence but has a limited ability to recognise and dispose of bacteria. In contrast, 
lymphocytes act more slowly, but with greater precision. They can respond selectively to 
thousands of different non-self antigens, leading to specific immunological memory 
whereby reactions are more vigorous when exposed a second time, even if months or years 
later. Often these innate and adaptive responses act in a cooperative manner, with 
macrophages engulfing pathogens that have been recognised by specific antibodies. 
Antibodies (or immunoglobulins; Igs) are glycoproteins made by B lymphocytes upon 
stimulation by an antigen, whose function is to identify and bind to the antigen. They are 
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composed of four polypeptide chains (two identical heavy chains and two identical smaller 
light chains) held together by disulfide bonds and arranged into several domains (Figure 6). 
There are five main classes of Ig (IgM, IgG (which has 4 subclasses), IgA, IgE and IgD), 
determined by the type of heavy chain, found in different body locations and with different 
functions. 
There are two identical antigen-binding sites (Fab regions) at one end of the molecule 
where a heavy-chain variable domain (VH) and a light-chain variable domain (VL) come 
close together. The other end (Fc region) is involved with biological functions such as 
attachment of phagocytes and complement activation (Playfair et al., 1998). The main 
antibody classes used for diagnostic purposes are IgG, IgA and IgM, since these account for 
up to 80 %, 10-15 % and 10 % of total Ig in serum, respectively. They also occur in 
salivary components, but at significantly lower concentrations (Table 3). Fluid in the oral 
cavity consists of secretions from the salivary glands and transudate from the capillary bed, 
Figure 6. Structure of an antibody 
(Source: www.accessexcellence.org/RCNUGG/ecb/antibody_molecule.html accessed 16/07/07 15:23) 
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Table 3. Mean immunoglobulin concentrations in plasma and saliva 
(McKie et al., 2002) 
Specimen 
	Concentration mg/L 
IgG IgM IgA 
Plasma 	14730 1280 2860 
Parotid saliva 	0.36 	0.43 39.5 
Crevicular fluid 3500 	250 1110 
Whole saliva 	14.4 	2.1 	19.4 
particularly crevicular fluid that flows from the crevice between the gum and the teeth 
(McKie et aL, 2002). Oral fluid samples target the collection of crevicular fluid, since this 
component contains the highest concentrations of IgA, IgM and IgG, however, varying 
collection methods and levels of oral hygiene can alter the concentrations between 
individuals (McKie et al., 2002). 
In CF patients, there is evidence from BAL of a very early inflammatory response 
(Armstrong et al., 1997), and all major Ig classes and all major antigens have been 
reported. Studies have shown a significant increase in IgG and IgA, especially in severe 
disease, and often with IgM (McCrae and Raeburn, 1974; Schwartz, 1966). However, the 
IgG-class antibodies produced by CF patients against P. aeruginosa are not opsonic, so do 
not promote phagocytosis of bacteria and are therefore not protective (Thomassen et al., 
1979). Peripheral monocytes and neutrophils have a protective function, and antibodies 
have been shown to neutralize bacterial toxins (Cukor et al., 1983; Pollack et al., 1976). 
Nevertheless, the antibody response mounted by CF patients is clearly insufficient to 
eliminate bacteria from the airway. 
Many of the Pseudomonas antigens have a role in the micro-organism evading the host 
response. For example, one of the functions of lipopolysaccharide (LPS) is to mediate 
serum resistance, a major virulence factor of bacteria (Pitt, 1989). The chronic infection 
established in CF patients is attributable to the mucoid phenotype that develops during 
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chronic infection and the formation of biofilms. A major surface antigen of these strains is 
mucoid exopolysaccharide, also known as alginate (Pedersen, 1992). During infection, 
patients produce antibodies to alginate, but in vitro studies show that they fail to mediate 
opsonic killing of the bacteria, thus do not protect (Meluleni et al., 1995). The only opsonic 
antibodies produced by CF patients are to antigens in planktonic bacteria, rather than to 
those in biofilms. Although these antibodies are not formed against alginate, it has been 
suggested that if opsonic anti-alginate antibodies could be produced and administered to CF 
patients, they may have therapeutic benefit (Pier, 1997). 
1.2.4.4 Vaccination 
The search for a protective vaccine against P. aeruginosa began with the need to treat and 
protect patients with burns injury. This has led to a number of studies into suitable 
antigenic targets and delivery methods. Many preclinical studies and several actual human 
trials have taken place, but as yet, no single vaccine has been deemed effective (Priebe and 
Pier, 2003). Exotoxin A (ETA), a lethal toxin produced by most strains, was the focus of 
early studies, however, unlike other bacterial toxins, protective efficacy was not shown 
(Pavlovskis et al., 1981). However, a detoxified ETA has been successfully used as a 
carrier protein for a number of other vaccines (Fattom et al., 1996). Other secreted 
virulence factors that have been investigated as candidate vaccines include alkaline 
protease and elastase, but neither target have had demonstrable efficacy (Matsumoto et al., 
1998). 
Much attention has been paid to LPS as a potential vaccine candidate (Pier, 2003). Several 
moieties, including the inner and outer core regions and the A-band antigen have been 
explored, but high molecular weight 0-antigen has been by far the most successful 
candidate in animal studies (Matthews-Greer and Gilleland, 1987). However, toxicity in 
humans has been a major problem and early CF patient studies showed no benefit with 
vaccination (Pennington et al., 1975). A major problem with LPS as a vaccine antigen has 
been its inherent type specificity as different 0-serotypes are not cross-protective, thus 
requiring a multi-valent cocktail. An octavalent 0-antigen-ETA conjugate vaccine was 
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successfully used to stimulate opsonic antibody responses, but these antibodies did not 
protect when given to 'at risk' patients, possibly due to the lack of serotypes covered (Cryz, 
et aL, 1989). However, this vaccine did show promising results for the prevention of 
colonisation in a trial of CF patients (Cryz, et aL, 1997). A recent study using the 
octavalent conjugate vaccine for repeated immunisations of CF patients over ten years 
showed that yearly immunisation led to sustained elevation of serum IgG to all vaccine 
components. Most (72 %) unvaccinated controls developed chronic Pseudomonas lung 
infection, compared with 32 % of vaccinated subjects. The protection was attributed to high 
affinity for the 0-antigen polysaccharide, rather than the core LPS components (Zuercher et 
al., 2006). 
Other vaccine candidates have included alginate (Pier et aL, 1994), various outer membrane 
proteins (Kim et al., 2000), flagella (Doring and Dorner, 1997), pili (Cachia et al., 1998) 
and components of the type III secretion system (TTSS) (Sawa et al., 1999). A trial of a P. 
aeruginosa flagella vaccine in a large cohort of CF patients reported that approximately 
one-third of vaccinated patients had infection compared with 43 % of patients receiving a 
placebo (Doring et al., 2007). Both these studies in patients show that thus far no effective 
vaccine has been developed to P. aeruginosa. 
1.2.4.5 Transplantation 
Double lung or heart-lung transplantation is currently the only treatment option for patients 
who develop respiratory failure despite the best treatment. Survival of lung-transplant 
patients is poorer than for other organ transplantation, with three-year survival at 
approximately 60 % (Ratjen and Doring, 2003), but rates are much lower for patients 
infected with B. cepacia genomovar III, due to higher post-transplant complications (Aris et 
al., 2001). 
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1.3 	Pseudomonas aeruginosa 
P. aeruginosa is a very successful bacterium that has adapted to fit into many 
environmental and clinical niches. One of the few human pathogenic species of its genus, 
this pseudomonad can live at a wide range of temperatures with very low nutritional 
requirements and expresses a large number of virulence factors. Its morphology can vary 
widely, contributing to misidentification, particularly in the CF environment, due to the 
unusual phenotypes expressed during chronic infection. 
1.3.1 Taxonomy 
Pseudomonads are a ubiquitous group of environmental bacteria. They comprise a number 
of true Pseudomonas species (with P. aeruginosa as the type species) as well as many 
species formerly classified in the genus. This genus once comprised over 100 species, but 
over the last decade many of these have been reclassified into different genera (Pitt and 
Simpson, 2005). Many are plant pathogens, with their name reflecting their primary host 
(for example, P. syringae pv. morsprunorum, which is virulent for cherries). There are five 
main groups of pseudomonads of medical interest. The first is the fluorescent or 'true' 
Pseudomonas, P. aeruginosa (formerly known as P. pyocyanea), P. fluorescens and P. 
putida. The second group contains the genus Burkholderia and within this four species (B. 
cepacia, B. dolosa, B. pseudomallei and B. mallet), which are associated with human and 
animal infection. The other three generic groups of pseudomonads are Delftia, 
Brevundimonas and Stenotrophomonas (Pitt and Simpson, 2005). 
1.3.2 Laboratory identification 
P. aeruginosa is a Gram-negative, non-sporing bacillus of approximately 1.5 to 3.0 tm in 
length and 0.5 gm breadth which is motile in aerobic environments due to a single polar 
flagellum. Anaerobic growth is possible in the presence of an alternative electron acceptor 
such as nitrate or arginine (Robinson, 1932; Stonier et al., 1966). The species is able to 
grow over a wide range of temperatures (11 °C to 44 °C) on simple bacteriological media 
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(Haynes and Rhodes, 1962; Stanier et al., 1966). At 37 °C, most isolates produce flat 
diffuse colonies with an irregular shape (type 1) whilst others (type 2) have a `coliform' 
appearance. Rare types include a dry, 'pepper-corn' (type 3), mucoid (type 4), rugose (type 
5) and dwarf (type 6) appearance (Pitt and Simpson, 2005). Isolates have a characteristic 
fruity odour due to formation of aminoacetophenone (Habs and Mann, 1967). 
Most strains produce the blue redox-active phenazine-derivative pigment, pyocyanin, and 
fluorescein (or pyoverdin; yellow), giving the characteristic blue-green coloration to agar 
cultures. Pyocyanin pigmentation is frequently observed in the sputum of P. aeruginosa-
infected CF patients (Lau et al., 2004). Its production is unique to the species and can be 
enhanced by culture on King's A media (King et al., 1954). P. chloraphis can also grow as 
green colonies on King's A agar, but can be distinguished on King's B medium, in which 
P. aeruginosa optimally produces pyoverdin. 
P. aeruginosa metabolises glucose by an oxidative pathway (Hugh and Leifson, 1953). 
Sugar utilisation is best demonstrated in ammonium salts-based media, since acid is 
produced in peptone-water sugars but then neutralised by alkali released by the breakdown 
of peptone. All strains produce a cytochrome oxidase enzyme that is detected in the oxidase 
test with Kovac's reagent. Most strains reduce nitrate and form ammonia from arginine. 
1.3.3 Epidemiology 
The natural habitat of P. aeruginosa ranges from surface waters to vegetation and soil. It 
can multiply in distilled water but is rarely isolated from sea water except near sewage 
outfalls and polluted river estuaries (Pitt and Simpson, 2005). It is frequently recovered 
from fresh vegetables and plants (Rhame, 1980). P. aeruginosa has been isolated from a 
variety of sources including aviation fuel, cutting oils, cosmetics and disinfectants, 
demonstrating its nutritional variability (Bushnell and Haas, 1941; Edmonds, 1965). In the 
hospital environment, P. aeruginosa is invariably found in sinks, showers and drains 
(Panagea et al., 2005). In domestic households, P. aeruginosa can commonly be isolated 
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from washing machines (Pitt, personal communication), although the rest of the 
environment is rarely contaminated (Whitby and Rampling, 1972). 
Faecal carriage rates vary from 15 to 25 % and are possibly higher in vegetarians (Pitt and 
Simpson, 2005). Colonisation appears to be transient in healthy people, with a rapid 
turnover of strain types. P. aeruginosa dies rapidly on dry, healthy human skin but skin 
colonisation of burns patients may reach 80 % by the ninth day following burn injury 
(Holder, 1977). The salivary carriage rate is similar in hospital patients and normal controls 
(approximately 5 %) (Botzenhart et al., 1985). 
P. aeruginosa is an opportunist, often only causing infection in the already compromised 
host. Thermal injury (i.e. burns), neutropenia or the introduction of relatively large inocula 
direct into tissues are often necessary prerequisites for the establishment of infection. 
Despite the ubiquity of the organism, community-acquired infections are relatively rare. 
They primarily cause skin infections in the healthy, often associated with recreational water 
activities, characterised by a self-limiting skin rash or folliculitis (Tate et al., 2003). In the 
immunocompromised, infections occur almost anywhere and may be severe and with a 
high mortality (Hakki et al., 2007). P. aeruginosa may account for 8 to 10 % of all 
hospital-acquired infections (Morrison, Jr. and Wenzel, 1984). Frequently, the pathogen 
causes pneumonia and urinary tract, surgical wound and blood stream infections in 
intensive care patients. The species is particularly common as a cause of chronic respiratory 
infection in CF patients, with over 75 % of patients dying with P. aeruginosa infection 
(Cystic Fibrosis Foundation Patient Registry). It is relatively resistant to many antibiotics. 
An increase in acquired resistance reduces treatment options and multiple drug efflux 
pumps and intrinsic low permeability of the outer membrane to several antimicrobials 
further increases the difficulty in treating infections. 
1.3.3.1 Epidemiological typing 
For epidemiological studies, isolates of P. aeruginosa can be serotyped by slide 
agglutination. Antisera are raised against boiled cells and these are rich in antibodies to the 
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immunodominant surface LPS antigen. There are 20 0-serotypes in the International 
Antigenic Typing Scheme (IATS), but three types (06, 011 and group II, which includes 
02, 05 and 016) account for almost 50 % of clinical and environmental isolates with about 
10 % being non-typable (Pitt, 1988). Further discrimination of strains within serotypes can 
be achieved by DNA fingerprinting using PFGE and other typing systems including 
ribotyping and random PCR typing (Grundmann et al., 1995). 
There are currently seven strains of P. aeruginosa that have had their complete genomes 
sequenced: the type strain P. aeruginosa PAO1 (Stover et al., 2000) and strains PA14 (He 
et al., 2004), PA2192, PACS2, C3719, PA7 and PKS6 (these last five are unpublished but 
their sequence data is available on the NCBI Taxonomy Browser website, 
www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=287). The release of these data has not 
only dramatically increased the options for identifying and discriminating strains using 
PCR-based techniques, but has also allowed the study of specific genes and their 
expression. 
1.3.4 Pathogenicity 
P. aeruginosa is believed to enter the CF lung via the oral or nasal routes. It is unclear as to 
why there is the affinity for the CF lung, but an absence of normal CFTR results in 
increased binding of P. aeruginosa to respiratory epithelial cells (Davies et al., 1997). The 
altered chloride ion epithelial secretions in the airway may also lead to the blocking of 
antimicrobials whilst the organism itself enhances its own virulence by stimulating the 
shedding of syndecan-1 (a cell-surface heparin-sulfate molecule) (Pier, 2002). Survival of 
the organisms in the lumen promotes mucin secretion from submucosal gland cells and 
elicits inflammation. An excess of phagocytes are unable to fully phagocytose the 
microorganisms, leading to the release of toxic factors during necrosis. This further disrupts 
the epithelial surface on which the microbes start to grow into biofilms encased in mucus 
(Pier, 2002). 
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P. aeruginosa has a number of cell-associated and extracellular virulence factors tightly 
controlled by cell-to-cell signalling mechanisms (Van and Iglewski, 1998). Cell-associated 
factors include the flagella, pili and non-pilus adhesins, which aid adherence to host cells; 
alginate helps the bacterium to evade and resist phagocytosis (Cabral et al., 1987) and may 
also resist bacterial penetration by antibiotics; and LPS (endotoxin) is a potent pyrogen. 
Extracellular virulence factors include proteases (such as alkaline protease and elastase), 
haemolysins, exotoxin A, lipases, DNase, exoenzyme S, and pyocyanin, which can cause 
extensive tissue damage (Doring et al., 1987). 
Intrinsic resistance mechanisms (for example, efflux pumps) to several antibiotics increase 
the pathogenic potential of strains and difficulty in treatment of infections, whilst an 
increase in acquired resistance, for example, to carbapenems due to metallo-f3-lactamases, 
reduces therapeutic options (Hancock and Woodruff, 1988; Poole et al., 1993). 
1.3.5 The cystic fibrosis phenotype 
In contrast to environmental strains and those from other clinical conditions, isolates of P. 
aeruginosa from CF patients have an unusual phenotype (Speert et al., 1990). P. 
aeruginosa can undergo a number of morphological changes. One of the most obvious is 
the conversion to a mucoid phenotype, characterised by the production of extra-cellular 
alginate polysaccharide (indicated by a mucoid appearance upon agar culture) (Evans and 
Linker, 1973). At one time, mucoid P. aeruginosa was diagnostic of CF, although mucoid 
strains have been seen in other circumstances, including isolates from chronic urinary tract 
infections and other chronic pulmonary infections (Kilbourn, 1991). Presumably, increased 
alginate production aids the formation of biofilms, which are virtually impossible to 
eradicate due to their ability to resist antimicrobial interventions. It may be that biofilm 
development also accounts for the non-motile, pilus-free strains often isolated from CF 
(Mahenthiralingam et al., 1994). The increased production of alginate may substitute for 
the loss of 0-serotype specific LPS, which is another associated phenotypic change 
(Hancock et al., 1983). 
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CF strains are often (if not always, in advanced disease) 'rough' in LPS structure, with few, 
short or no 0-polysaccharide side chains (Rivera et al., 1988). Strains with long 0-side 
chains (`smooth'), are serum resistant, reflecting a failure of the assembled terminal 
complement complex C5b-9 to insert stably into the outer membrane (Ernst et al., 1999; 
Schiller, 1988), and are therefore protected against complement-mediated host defences. 
Strains with 'rough' LPS, such as found with many CF isolates, are susceptible to the 
bactericidal effect of human serum, which may explain why patients with CF rarely suffer 
from P. aeruginosa bacteraemia (Hancock et al., 1983). Other variations in LPS structure 
of CF strains include the change in the fatty acid acylation pattern (Ernst et al., 1999), 
which increases bacterial resistance to antimicrobial peptides (such as colistin) and the 
ability to elicit inflammatory mediators. 
CF strains are often atypical in growth requirements and may be auxotrophic for specific 
amino acids (Barth and Pitt, 1996). Their exoenzyme and type III protein secretions are 
altered (Jain et al., 2004) and SCVs can be isolated (Haussler et al., 2003). There is 
currently no agreed explanation of this acknowledged change in phenotype, but the main 
hypotheses are that nutritional limitations may trigger the conversion to the CF phenotype 
(Speert et al., 1990), or that the host response causes a release of oxygen radicals from 
polymorphonuclear leukocytes (Mathee et al., 1999), and is selective for the mucoid 
phenotype. However, some believe that the patients' worsening clinical condition is 
directly responsible and this drives the adaptive changes through environmental stress 
(Fegan et al., 1990). Whatever the reason or sequence of events, conditions in the lung are 
extreme for bacterial growth and at this stage of disease the patients' lung function 
deteriorates. Long-term eradication of the pathogen is seldom achieved at this stage, 
although regular intensive antibiotic treatment can improve quality of life and probably 
extends survival (Doring et al., 2000). 
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1.4 	Antigens of P. aeruginosa 
The virulence of P. aeruginosa can be attributed to a number of secreted factors and a 
number of external cell structures. Many of these have already been alluded to, but to 
understand the host-pathogen interaction in CF, these will be discussed further below. The 
envelope of Gram-negative bacteria is more complex than that of Gram-positive organisms, 
with a less substantial peptidoglycan layer and the presence of an outer membrane. This 
selective outer membrane barrier consists of LPS, protein and phospholipids and acts as a 
generally impermeable barrier to hydrophobic and higher molecular weight hydrophilic 
compounds. Pili and flagella are anchored in the outer membrane, and alginate forms a 
loose extracellular matrix but may appear as a definite capsule in young cultures (Figure 7). 
These surface appendages have intimate contact with the host, and thus can potentially 
stimulate a host antibody response. 
1.4.1 Secreted proteins 
P. aeruginosa secretes a number of proteins, which act as toxic virulence factors and play 
an important role in establishing initial infection by preventing the host from mounting a 
local immune response and interfering with non-specific defence mechanisms (Hoiby et al., 
1990). Distinct pathways are used to secrete the proteins into the extracellular medium. 
These pathways include the type II secretion system and the TTSS. The TTSS is 
responsible for the secretion of the majority of extracellular degradative enzymes, including 
exotoxin A (ETA), proteases, such as elastase and protease IV and phospholipase C 
(Hueck, 1998). 
ETA is closely related to the diphtheria toxin and inhibits protein synthesis, via ADP-
ribosylation of elongation factor II (Wretlind and Pavlovskis, 1981). It is encoded by the 
toxA gene, which is found in 90 to 95 % of P. aeruginosa strains (Matar et al., 2002), but 
its expression is controlled by quorum sensing mechanisms and iron availability (Colmer-
Hamood et al., 2006). ETA levels in the sputum of P. aeruginosa-infected CF patients have 
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Figure 7. The cell surface of F. aeruginosa 
(Adapted from Priebe and Pier (2043)) 
been shown to correlate with periods of exacerbated infection (Jaffar-Bandjee et al., 1995) 
and many studies have used the gene as a PCR target for the detection of the species (Khan 
and Cerniglia, 1994; Song et al., 2000). 
The role of proteases in the virulence of P. aeruginosa is speculative (Lau et al., 2005). 
Phospholipase C is a heat-labile haemolysin that degrades phospholipids containing 
quaternary ammonium groups, such as phosphatidylcholine, the major phospholipid of lung 
surfactant (Titball, 1993). Protease IV degrades surfactant proteins A, B and D, which are 
involved in host defence (Malloy et al., 2005). Elastase and alkaline protease, have been 
more extensively studied in regard to their interaction with the human defence system and 
have been shown to inhibit the function of phagocytes, natural killer cells, T cells and IL-1 
and -2 as well as cleaving antibodies and inactivating complement components (Kharazmi, 
1989). These proteases have been detected in the lungs of CF patients in immune 
complexes (Doring et aL, 1984). In fact, the antibody response against proteases appears to 
be delayed compared to other P. aeruginosa antigens, with antibodies not being detected 9 
to 12 months after onset of chronic infection (Doring and Hoiby, 1983). 
The TTSS is a protein-targeting virulence mechanism used by many Gram-negative 
bacteria to transport toxic proteins directly into host cells via a pilus like structure (Hueck, 
1998). In P. aeruginosa, four effector proteins are involved: ExoS, ExoT, ExoU and ExoY 
(Finck-Barbancon et al., 1997; Frank, 1997; Sayner et al., 2004; Vance et al., 2005), 
although ExoT and ExoY are less important in virulence than ExoU and ExoS (Kipnis et 
al., 2006). ExoS and ExoT are proteins with ADP ribosyltransferase activity (Iglewski et 
al., 1978) and although their function in pathogenesis is unclear, the production of ExoS is 
associated with epithelial cell damage and dissemination of P. aeruginosa within infected 
hosts (Apodaca et al., 1995; Kang et al., 1997; Nicas et al., 1985). ExoU is a phospholipase 
and is also linked with epithelial cell damage, but is over 100-fold more cytotoxic than 
ExoS (Lee et al., 2005). Another protein involved with the translocation process of the 
TTSS is PcrV (Yahr et al., 1997). Production of PcrV, ExoS, ExoT, or ExoU has been 
associated with an increased risk of mortality six-fold higher than strains not expressing 
these proteins, demonstrating the large contribution the TTSS has in the virulence of P. 
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aeruginosa. However, they are not expressed in all strains as 28 % of all analysed strains 
(and 22 of 37 strains associated with CF) did not express any of these proteins (Roy-
Burman et al., 2001). This has been further supported by a study of 500 CF-related isolates, 
where 88 % did not secrete any TTSS proteins (Jain et al., 2004). Using specific PCR 
assays for TTSS genes, Wareham and Curtis (2007) found that CF isolates of P. aeruginosa 
were more likely to exhibit an ExoS+/ExoU- genotype than isolates from blood of other 
patients which were predominantly ExoS-/ExoU+. Antibodies to proteins of the TTSS have 
been reported in early CF infection (Corech et al., 2005) and cytotoxity has been shown to 
be greater among strains isolated in early infection (Lee et al., 2005), suggesting the TTSS 
may be important in the initial colonisation of the CF airway. 
From a serodiagnostic perspective, due to the delay in antibody production for secreted 
protein antigens and the fact that many of the toxins are virulence markers and only 
expressed in a proportion of isolates, secreted proteins may be inappropriate antigens if 
seeking a common, species-specific marker, particularly for the early diagnosis of P. 
aeruginosa infection. 
1.4.2 Outer membrane proteins 
The outer membrane of P. aeruginosa is built of bilayers of lipids, showing little 
permeability for hydrophilic solutes, including most nutrients. Therefore, they contain 
channel-forming proteins, for example porins and protein F, to allow the influx of nutrients 
into the cell and for extrusion of metabolic products. 
According to an electrophoretic classification by molecular size, the following outer 
membrane proteins (OMPs or Oprs) have been identified in P. aeruginosa: iron-repressible 
OMPs, OprC, esterase, OprP, OprDl and D2, OprE, OprF, OprG, OprHl and H2 and OprI 
(Hancock et al., 1990), but others also exist. Some are only expressed under particular 
growth conditions, for example OprP is only present in low phosphate medium (Hancock et 
al., 1982), and extra iron-repressible proteins are produced under conditions of iron 
deprivation, forming complexes with siderophores (de Weger et al., 1986). Not all OMP 
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functions are known, but many are analogous to proteins from other species, for example 
OprI and Braun's lipoprotein of E. coli (Mizuno and Kageyama, 1979b). Protein F (OprF) 
is comparable with OmpF of enteric bacteria, but is heat-modifiable (Mizuno and 
Kageyama, 1979a). Its function is contentious, with some studies describing the protein as 
a porin, with a relatively small proportion of the total number of the proteins forming large 
channels to allow passage of saccharides. This results in a low total area for antibiotic 
diffusion and low outer membrane permeability, causing the high intrinsic resistance of P. 
aeruginosa to antibiotics (Hancock, 1986; Hancock et al., 1990). Other studies suggest 
protein F has no porin functions and has a low exclusion limit, but is important in 
maintaining the integrity of the outer membrane (Gotoh et al., 1989). 
Antibodies have consistently been detected against OprF in sera from CF patients, but also 
against others, including OprE, OprL (formerly OprH2, a peptidoglycan-associated 
lipoprotein) and OprI, in some CF patient samples (Hancock et al., 1984). Interestingly, 
only OprF, H2 and I are antigenically related in all serotype strains (Mutharia et al., 1982). 
The earliest antibody response is to Opr G, HI and I, whilst antibodies to the iron-regulated 
OMPs only appear in advanced disease, thus making these proteins useful markers for 
disease onset and progression (Shand et al., 1991). 
1.4.3 Flagella 
P. aeruginosa can be differentiated from other fluorescent species by its single polar 
flagellum, which is comprised of a flagellin filament, hook and basal body. The flagellum 
confers motility and chemotaxis, facilitates adherence to cells and non-organic surfaces and 
contributes to colonization and invasion during the early phase of infection (Drake and 
Montie, 1988; Macnab, 1992; Montie et al., 1987). In fact, flagellin is responsible for the 
binding of P. aeruginosa to the Mucl mucin receptor, expressed on the epithelial cell 
surface (Lillehoj et al., 2001; Lillehoj et al., 2002). This interaction is thought to contribute 
to the inflammatory response induced by P. aeruginosa. Flagellin increases cytokine and 
IL-8 levels and induces tumour necrosis factor (TNF) -a and IL-1(3 production by human 
peripheral blood mononuclear cells. All of these play a role in the considerable 
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inflammation encountered in the CF lung (Ciacci-Woolwine et al., 1999; Cobb et al., 2004; 
DiMango et al., 1995; Honko and Mizel, 2004). 
Although CF patients produce antibodies against flagellin (Anderson et al., 1989; Montie 
and Anderson, 1988), P. aeruginosa isolates obtained from chronically infected CF patients 
tend to be non-flagellated, in contrast to environmental strains (Mahenthiralingam et al., 
1994). Loss of flagella may promote the establishment of chronic infection in CF patients, 
since these strains are generally resistant to macrophage phagocytosis (Feldman et al., 
1998). 
1.4.4 Pili 
The type IV pili (or fimbriae) of P. aeruginosa are polar, non-flagellar, filamentous 
appendages. They are 5.2 nm in diameter and 2.5 gm average length and appear in small 
clusters (2 to 12 per pole) at the ends of cells (Paranchych et al., 1985). They play a central 
role in bacterial conjugation as well as a major role in the mediation of the bacterium to a 
host cell (Comolli et al., 1999a; Comolli et al., 1999b). Additionally, they mediate 
twitching motility in cells lacking flagella, for motility across a solid surface, but also for 
the development of biofilms (Mattick, 2002; O'Toole and Kolter, 1998). The importance of 
the type N pili in P. aeruginosa adhesion has been demonstrated, with non-pilus adhesins 
accounting for only 10 % of the adherence ability of the bacteria (Hahn, 1997). 
There is wide variation in the sequence polymorphism of pilin genes between strains (Kus 
et al., 2004). There is, however, a predominance of group I pilins in strains isolated from 
CF patients (70 %), with a bias apparent early in infection (Kus et al., 2004). These group I 
pilins were also the most common type found in environmental isolates tested, supporting 
the consensus that CF strains are acquired from the natural environment. At present, there 
appear to be no reported studies investigating the employment of P. aeruginosa pili for the 
serodiagnosis of infection in CF patients. 
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1.4.5 Alginate 
P. aeruginosa strains isolated from the respiratory tract of CF patients are initially non-
mucoid (Doggett et al., 1971), but they switch to a mucoid, alginate-producing form upon 
progression of the disease (Hoiby, 1974). Phenotypic and molecular typing methods have 
shown that the mucoid strains are colonial variants of wild type non-mucoid colonies 
(Bergan and Hoiby, 1975; Ogle et al., 1987) and mucoid strains isolated from the sputum 
of CF patients spontaneously revert to the non-mucoid form upon subculture (Bergan and 
Hoiby, 1975). 
Alginate, the extra-cellular polysaccharide responsible for the mucoid appearance, is a 
linear, acetylated polymer of D-mannuronic and L-guluronic acid residues with f31-4 
linkages (Govan and Deretic, 1996). It is a major adhesin, allowing colonisation of host 
cells by adhering to glycoprotein receptors. It envelops the bacteria, providing protection 
and inhibiting polymorphonuclear leukocyte migration and phagocytosis (Pier, 1989). It 
further damages the lungs by stimulating the production of the pro-inflammatory cytokines 
IL-1 and TNF-a (Pedersen, 1992). Antibodies to alginate are produced in CF patients, 
although they are not protective (Pedersen et al., 1989; Pier, 1989), and alginate has been 
shown to interfere with penetration of some antibiotics, particularly aminoglycosides 
(Nichols et al., 1989). 
Conversion from non-mucoid to mucoid colonies correlates with establishment of chronic 
P. aeruginosa infection, with increased antibiotic resistance, reduced pulmonary function 
and a worse prognosis (Ramsey and Wozniak, 2005). There are reports that the average age 
of infection with non-mucoid P. aeruginosa is one year, with transition to mucoidy 
occurring at age 13 years (Li et al., 2005). In the same study, 92 % of the CF children were 
infected with mucoid P. aeruginosa by the age of sixteen, with one patient developing 
mucoid P. aeruginosa at only 1.43 years of age. 
The conversion to a mucoid phenotype can be caused by activated polymorphonuclear 
leukocytes and their hydrogen peroxide by-products, when cells are grown in a biofilm, 
suggesting that such conversion is a defence mechanism exhibited by the bacteria in 
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response to these toxic by-products (Mathee et al., 1999). The mucoid phenotype can be 
stimulated by microaerobic and anaerobic conditions and it has been proposed that this 
provides protection from oxygen diffusion into the cells and thus host immune response 
evasion (Bragonzi et al., 2005; Sabra et al., 2002). 
1.4.6 Lipopolysaccharide antigens 
The LPS of P. aeruginosa is similar to that of other Gram-negative bacteria and is the 
major carbohydrate component of Gram-negative bacteria, forming an integral part of the 
outer membrane and displaying classic endotoxin function (Kropinski et al., 1985). LPS 
consists of three parts: a lipid A moiety, an oligosaccharide core region and a 
heterogeneous long side-chain of repeating oligosaccharide units. The lipid A anchors the 
molecule in the outer membrane by interaction with hydrophobic membrane fatty acids, whilst 
the sugar chains extend into the bacterial environment (Knirel et at, 2006). 
1.4.6.1 Structure 
The three distinct regions of LPS (lipid A, core and side chain) are shown in Figure 7. Lipid 
A contains the hydrophobic, membrane-anchoring region of LPS, consisting of a 
phosphorylated N-acetylglucosamine (NAG) dimer with acyl- and ester-linked fatty acids 
and glycosidically and ester-linked phosphates attached (Bhat et al., 1990). Different forms 
can be synthesised depending on environmental conditions — for example, magnesium-
limitation and human infection (such as CF, bronchiectasis or septicaemia) (Ernst et al., 
1999). 
The conserved LPS core oligosaccharide region is made of two parts. The inner core joins 
to lipid A and consists of two 2-keto-3-deoxyoctulosonic acid (KDO) molecules and two 
heptose molecules (Knirel et al., 2006). These are substituted by various phosphate groups 
and by a 7-O-carbamoyl group. The inner core is linked to the outer core by a conserved 
galactosamine residue that is N-acetylated by an L-alanyl group (Bystrova et al., 2002; 
Knirel et al., 2001). The outer core is more variable among the different serogroups, 
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although glucose and rhamnose are the usual monosaccharides present. Two distinct 
glycoforms exist — one capable of accepting the covalent attachment of 0-side chain 
substituents and one that is not (Bystrova et al., 2002). Substituted core may have just a 
single 0-polysaccharide repeating unit attached or a variable number of 0-polysaccharide 
repeating units (Bystrova et al., 2004). 
The 0-polysaccharide (also known as the 0-antigen or somatic antigen) provides 
hydrophilic charges to the cell surface and forms a surface layer that protects the bacterium 
from the action of complement and other hazards in its environment (Pitt, 1989). 0-antigen 
consists of repeating oligosaccharide subunits comprising three to five sugar molecules. 
The chains vary in length up to 40 repeating units and form the hydrophilic domain of LPS 
(Seid and Sadoff, 1981). This heterogeneity of the side chain specifies the serotype of the 
strain and these molecules of high molecular mass are referred to by some as `B-band' LPS 
(Knirel et al., 1988; Rivera et al., 1988). The B-band structure of PAO1 (Figure 8) is a 
trisaccharide repeating unit of 2-acetamido-3-acetamidino-2,3-dideoxy-D-mannuronic acid, 
2,3-diacetamido-D-mannuronic acid and 2-acetamido-2,6-dideoxy-D-galactose (Knirel et 
al., 1988). Some LPS molecules lack an 0-side chain and consist of trisaccharide repeating 
units of D-rhamnose. These are referred to as 'A-band' LPS and P. aeruginosa strain 
AK1401 (a B-band deficient mutant of strain OT684, a restrictionless derivative of PAO1) 
is regarded as the reference A-band strain (Arsenault et al., 1991; Kocharova et al., 1988; 
Lam et al., 1989). Coincidentally, analysis of the LPS side-chain of AK1401 has shown it 
to be identical to that of P. syringae pv morsprunorum C28, a plant pathogen (Figure 8) 
(Smith et al., 1985). 
Figure 8. Structure of (a) A-band (Smith et al., 1985) and (b) B-band from strain PAO1 (Knirel 
et aL, 1988; Smith et al., 1985) 
a) —*3)-D-Rhap-(al —*3)-D-Rhap-(al —>2)-D-Rhap-(a1—> 
b) —4)-p-D-Man(2NAc3N)A-(1-4)- 13-D-Man(2Nac3NAc)A-(1—>3)- a-D-FucNac-(1—,  
31  
CH3C=NH 
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The presence of these two polysaccharide fractions (based on their resolution in gel 
filtration chromatography) in P. aeruginosa, one of high molecular weight and the other a 
neutral polysaccharide associated with rhamnose, has been reported since the 1970s 
(Wilkinson and Galbrath, 1975). However, there are differing reports as to the true nature 
of the structures. Some studies indicate the A-band and B-band LPS are on the same 
molecule (Hatano et al., 1993), but others suggest they are separate (McGroarty and Rivera, 
1990) and antigenically and chemically distinct (Rivera et al., 1988). During the 
progression of pulmonary infection in patients with CF, P. aeruginosa undergoes 
phenotypic changes, becoming rough, with gradual loss of B-band LPS (Hancock et al., 
1983). This explains the absence of a specific 0-serotype reaction for the majority of CF 
strains (Penketh et aL, 1983; Pitt and Erdman, 1978). Investigations show that, along with 
alginate, the major LPS antigen of these non-typable strains is A-band LPS, which appears 
as a common antigen among other P. aeruginosa strains (Govan and Deretic, 1996; Hatano 
et al., 1993; Lam et al., 1989). However, the true incidence of this antigen is unclear. One 
study investigated the prevalence of an A-band-specific gene, gca (a GDP-D-mannose 
conversion protein for A-band polysaccharide) amongst the 20 P. aeruginosa serotype 
strains and confirmed it was present in all except serotype 012 (Currie et al., 1995). An 
earlier study using specific monoclonal antibodies to investigate A-band occurrence found 
only 10 of 17 serotype reference strains tested expressed the antigen (Lam et al., 1989). 
1.4.6.2 Function 
LPS participates in a number of outer membrane functions that are essential for bacterial 
growth and survival, especially within the context of a host-parasite interaction (Morrison 
and Ryan, 1979). LPS displays classic endotoxin functions with pathophysiological effects, 
including macrophage and complement activation, and LPS-defective mutants are 
significantly less pathogenic (Kropinski et al., 1985). 
Toxicity is associated with the relatively conserved lipid A and immunogenicity and 
antigenic variation is linked with the polysaccharide components (Goldberg and Pier, 
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1996). LPS is particularly antigenic due to its branched structure with multiple repeating 
carbohydrate subunits, but also because lipid A is a potent non-specific B-cell mitogen. 
It has also been proposed that phenotypic variation in the relative expression of A- and B-
band LPS is an important mechanism enabling this opportunistic pathogen to alter its 
surface characteristics to mediate adhesion and to survive under extreme conditions (Makin 
and Beveridge, 1996). The type strain PA01 shows reduced levels of B-band LPS 
expression when grown under stress conditions (high temperature, low pH, low phosphate, 
or high NaCI, MgC12, glycerol or sucrose), but the A-band is not significantly affected 
(McGroarty and Rivera, 1990). In stress-free conditions, PA01 agglutinates only with 
serotype-specific antibodies, suggesting that the common antigen is masked by the long 0-
side-chain. This proposition of A-band being masked by B-band LPS was also suggested 
by Rivera & McGroaty (1989), since in non-typable strains B-band LPS appears to be lost 
but A-band is exposed. 
1.4.6.3 Genetics of 0-antigen biosynthesis 
The biosynthesis of the 0-antigen of P. aeruginosa starts in the cytoplasm, with the 
synthesis of nucleotide-activated sugar donors. These are synthesised by the reaction 
between sugar-l-phosphates and their respective nucleoside triphosphates and then 
different biosynthetic pathways generate the complex sugar residues. Nucleotide-activated 
sugars act as donor molecules for the sequential addition of sugar residues by 
glycosyltransferases onto the lipid carrier molecule to generate individual 0 units. These 
single 0 units are translocated from the cytoplasm to the periplasm and polymerised into 
the 0-antigen (Lam et al., 2004). 
The A-band 0-polysaccharide gene cluster has been isolated from a P. aeruginosa strain 
PAO1 cosmid library on the basis of its ability to restore A-band synthesis to an A-band 
deficient clone (Lightfoot and Lam, 1991). Sequence analysis revealed eight genes in the 
WbPAband gene cluster of cosmid clone pFV3 (Figure 9) thought to be involved in A-band 
LPS synthesis (Currie et al., 1995; Rocchetta et al., 1998b; Rocchetta et al., 1998a; 
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Rocchetta and Lam, 1997). The wb- prefix denotes genes thought to be present in 0-antigen 
biosynthesis and wz- in 0-antigen assembly (Reeves et al., 1996). The predicted functions 
of the eight genes are listed in Table 4 (Rocchetta et al., 1999). The genes involved with the 
D-rhamose (rmd, gmd and wbpW) are positioned at the beginning of the wbpAband gene 
cluster, followed by those encoding the ATP binding cassette (ABC) transport system (wzm 
and wzt) and finally those involved in the assembly of the D-rhamnan repeating unit (wbpX, 
wbpY and wbpZ). 
Figure 9. Location of wbpAband gene cluster from strain PAOI 
(with genes encoding proteins involved in A-band 0-polysaccharide synthesis shown in grey) 
(Rocchetta et al., 1999) 
 
2 kb 
Table 4. Genes involved in A-band LPS biosynthesis in P. aeruginosa 
(Rocchetta et al., 1999) 
Gene name 
New 	Old Demonstrated or proposed function of gene product 
rmd 	 GDP-4-keto-6-deoxy-D-mannose reductase 
gmd 	gca 	 GDP-D-mannose dehydratase 
wbpW 	 Bifunctional enzyme: phosphomannose isomerase and GDP-mannose pyrophosphorylase 
01488 	 AlgA and VVbpW homologue, bifunctional enzyme like WbpW 
wzm 	 Membrane protein of 2-component ABC transporter 
wzt 	 ATP binding component of ABC transporter 
wbpX 	 Rhamnosyltransferase, transfers a132-linked D-Rha to A-band polymer 
wbpY 	 Rhamnosyltransferase, transfers two a133-linked D-Rha to A-band polymer 
wbpZ 	 Rhamnosyltransferase, transfers a single a133-linked D-Rha to the initial A-band acceptor molecule 
wbpZ 	rfbA 	Initial glycosyltransferase, broad specificities:transfers GIcNAc to lipid carrier (for A-band synthesis); transfers Fuc2NAc to lipid carrier (for B-band synthesis) 
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1.4.6.4 Laboratory analytical techniques 
1.4.6.4.1 Antigen analysis 
Several methods have been used to separate the many subclasses of LPS from individual 
strains, including sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) (Jann et al., 1975), gel filtration (Morrison and Leive, 1975) and, more recently, 
using a toludine blue/Stains-All staining procedure with agarose-gel electrophoresis 
(Maccari and Volpi, 2003). SDS-PAGE remains the most popular method and various LPS 
purification and extraction methods have been reported for Psenclomonas and 
Enterobacteriaceae. The simplest and quickest are whole cell preparations (Chart, 1994a). 
This involves the solubilisation of whole cells in a buffer containing sodium dodecyl 
sulphate (SDS) and using Proteinase-K to break LPS and OMP associations. 
Other more complex extraction methods include outer membrane preparations, from which 
LPS can then be purified using a hot phenol-water method (Westphal and Jahn, 1965), a 
phenol-water extraction (Kropinski et al., 1979), or a petroleum ether-chloroform-phenol 
extraction (Galanos et al., 1969), for smooth B-band, neutral A-band and rough LPS 
strains, respectively. 0-repeating units and other hydrophilic structures are preferentially 
soluble in the aqueous phase of the phenol-water mixture, while hydrophobic molecules 
(core and lipid A) will partition into the phenol layer. The proportion of rough or smooth 
LPS in a strain will determine the relative partitioning of these components in the biphasic 
extract. 
SDS-PAGE is a simple method for profiling extracts. The technique is based upon the 
movement of charged molecules (for example, bacterial components) through a medium by 
the application of an electric field (Chart, 1994a). SDS is an anionic detergent whose 
molecules have a net negative charge. It binds to most soluble molecules in aqueous 
solutions over a wide pH range in proportional amounts to the size of the molecules, 
strongly attracting them toward the anode. The lipid A moiety of LPS has a high negative 
charge so leads the migration towards the anode. 
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The SDS-PAGE gel consists of acrylamide cross-linked with N,N-methylenebisacrylamide 
(bisacrylamide) and functions as a molecular sieve (Chart, 1994c). The acrylamide 
/bisacrylamide ratio can be altered to optimise conditions to separate products of almost 
any molecular mass. A polyacrylamide gel with acrylamide content above a critical density 
restrains larger molecules from migrating as fast as smaller molecules. Discontinuous SDS-
PAGE uses an upper stacking gel and a lower separation gel. The stacking gel differs from 
the separation gel by having a lower acrylamide concentration and a lower pH (for 
example, 6.8 compared to 8.8) (Chart, 1994c). Samples are solubilized in a sample buffer, 
with the same pH as the stacking gel preparation buffer, containing SDS, (3-
mercaptoethanol, glycerol and bromophenol blue. The 0-mercaptoethanol (a reducing 
agent) cleaves the disulfide bonds and is incorporated into the solubilization buffer to assist 
the breaking of the quaternary structure of complex proteins, thus allowing protein 
molecules to bind maximally to SDS. The glycerol makes the sample preparations more 
dense than the cathode buffer so prevents them floating out of the sample wells. The 
bromophenol blue permits observation of migration of the glycine front through the gel 
during electrophoresis. Samples travel through the running buffer, which contains Tris 
(hydroxymethyl) methylamine and glycine. At pH 6.8, the proteins migrate sandwiched 
between chloride ions and glycine ions, stacking them into a tight band with proteins of 
similar size coming together (Chart, 1994c). Once the separation gel is reached, the change 
in pH causes the glycine ions to overtake the proteins as well as the chloride ions, leaving 
the proteins to separate according to their mass and charge. The stacking gel allows faster 
moving proteins to position nearer the separation gel, causing them to migrate unhindered 
by larger, slower moving proteins. The distance migrated by an LPS chain depends on the 
length and structure of the polysaccharide chain (not the molecular mass of the 
polysaccharide molecules); small numbers of sugar units migrate further than LPS chains 
with more repeating units (Chart, 1994a). 
When LPS is associated with OMPs, they can migrate into the phenol phase of some 
extraction processes, giving SDS-PAGE profiles where bands are lacking. In these 
situations, purification with, for example, Proteinase-K is required. Techniques include a 
Proteinase-K-SDS treatment, a concentrated culture supernatant method and a modified 
74 
phenol-water extraction method (Conrad and Galanos, 1989; Hitchcock and Brown, 1983; 
Pier et al., 1981). An additional chromatography step is often incorporated in many studies 
for initial separation of complex bacterial fractions (Stanislaysky et al., 1986). Fragments 
can then be further separated by SDS-PAGE before staining or immunob lotting. 
1.4.6.4.2 Antibody analysis 
Immunoblotting (or Western blotting), when combined with SDS-PAGE, can identify 
antibody-antigen reactions within complex mixtures of bacterial components (Chart, 
1994b). The separated OMP and LPS extracts are transferred to nitrocellulose sheets in an 
electrical field, stained, unfilled sites are blocked and antibody added. A second labelled 
antibody detects antibody-antigen complexes. 
Enzyme-linked immunosorbent assays (ELISAs) are one of the most versatile techniques 
for the quantitative detection of specific antibodies. They are performed in plastic 
microtitre plates (normally 96-well), allowing high through-put testing and small sample 
and reagent volumes. The wells can be coated with purified bacterial components or 
specific antibodies and further antibodies or antigens added for detecting the chosen target 
(Chart, 1994b). There are many variations in the design of ELISAs, but the most widely 
used detection methods are direct, indirect or capture systems (Figure 10). A direct ELISA 
utilises a coating antigen to which a specific antibody chemically labelled for direct 
detection is added; an indirect ELISA employs, in sequence, a coating antigen, an antibody 
specific for the antigen and a secondary, labelled antibody; a capture ELISA uses an 
antibody coated to the plate surface to capture antigen in a sample. The most common 
format used for serodiagnosis of bacterial infections is the indirect ELISA. 
Various purified antigens have been used to coat wells in EL1SA technologies. To detect a 
Pseudomonas-specific antibody response, studies have used washed whole cells (Brett et 
al., 1986a), Tris-EDTA extracts (Makarenko et al., 1993), crude water-soluble extracts 
(Sompolinsky et al., 1980), phenol-water purified LPS (Fomsgaard et al., 1988), purified 
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Figure 10. Illustration of 1) direct, 2) indirect and 3) capture ELISAs 
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alkaline protease and elastase (Doring and Hoiby, 1983), alginate (Rehm et al., 1994) and 
outer membranes (Aronoff and Stern, 1988; Likavcanova and Lagace, 1992). Considerable 
variation in the specificity and sensitivity of the various ELISA systems have been 
reported, owing to the variables of choice of coating antigen, the specificity and quality of 
the secondary antibody and the chosen detecting enzyme. 
1.4.7 Historical view of P. aeruginosa serodiagnosis 
The antibody response of CF patients has been investigated for almost 50 years. Early 
studies looked at Ig levels using paper electrophoresis techniques (Green et al., 1960). 
Although the antibodies were not specific for any particular antigen or even pathogen, an 
increase in y-Ig levels were shown to correlate with an increase in disease severity. This 
antibody response was further described to define the rise as being IgA and IgG-classed 
antibodies (Schwartz, 1966). 
Antibodies to specific Pseudomonas antigens, in particular exotoxin and sonicated cell 
extracts, were investigated in the 1970s. One of the first techniques to be employed was 
crossed immunoelectrophoresis (CIE) (Hoiby et al., 1977). Antibodies would precipitate in 
an agarose gel to form visible immune complexes with cell extract antigens. Even then it 
was known that rising antibody titres (with increased precipitin bands) correlated with 
progressive P. aeruginosa infection. Passive hemagglutination assays and radio-
immunoassays were also developed in the 1970s to exotoxin and various proteases (Klinger 
et aL, 1978; Pollack and Taylor, 1977). Other protein antigens were investigated by a 
number of techniques including single radial diffusion and CIE (Fernandes et al., 1981; 
Hoiby et aL, 1980). 
In the mid 1980s, a study evaluated three serological assays (the indirect hemagglutination 
test (IHAT), the complement fixation test and countercurrent immunoelectrophoresis), with 
IHAT appearing to be the most sensitive (Pitt et al., 1985). However, around this time, 
ELISAs were being developed (Borowski et al., 1984; Brett et al., 1986b; Bryan et al., 
1983; Fernandes et al., 1981; Hoiby et aL, 1980; Kusama, 1983; Pedersen et al., 1987). 
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Over the years a number of single and multiple antigens have been used with the various 
ELISA systems, but today ELISAs are still the diagnostic tool of choice. All the ELISAs in 
the literature are of an indirect, sandwich design, with a variety of capture antigens bound 
to the solid phase (for example, whole cells, water-soluble extracts (Proesmans et al., 
2006), LPS (Fomsgaard et al., 1988), alginate (Proesmans et al., 2006), OMPs 
(Likavcanova and Lagace, 1992), ETA, alkaline phosphatase and elastase (West et al., 
2002), and type III cytotoxic system components (Corech et al., 2005)). There has also 
been a return to the differentiation of the antibody classes (Brett et al., 1987; Brett et al., 
1990), with one of the current commercial products for clinical use being an anti-LPS 
ELISA measuring IgA or IgG-classed antibodies (Genesis Diagnostics Ltd, Littleport, UK). 
Another well regarded commercial product is the standard antigen (St-Ag) from the Statens 
Serum Institute (SSI), Copenhagen, Denmark, which pools "over 80 water-soluble antigens 
from 17 strains of P. aeruginosa". In Europe, the main competitor to St-Ag is a kit that 
measures antibodies to three separate antigens - ETA, alkaline phosphatase and elastase 
(Mediagnost, Reutlingen, Germany). This is not commercially available in the UK. 
Recently, several studies have re-evaluated the value of serodiagnosis of P. aeruginosa in 
CF (Kappler et al., 2006; Tramper-Stranders et al., 2006; West et al., 2002). Two of these 
employed the same commercial Mediagnost ELISA kit, for measuring antibodies against 
ETA, alkaline phosphatase and elastase, but the studies varied with their interpretation of 
results by choosing different cut-off ranges (Kappler et al., 2006; Tramper-Stranders et al., 
2006). Kappler used those recommended by the manufacturers whilst Tramper-Stranders 
applied lower titres, which may account for the contrasting conclusions (Farrell and Govan, 
2006). 
The overall results for Kappler's group were that the sensitivity of the assay was 86 %, the 
specificity 96 % and a positive predictive value was 97 %. These values were further 
improved for sputum samples (42 % of patients, with the remainder via oropharyngeal 
swabs), with sensitivity 95 %, specificity 100 % and positive predictive value 97 %. 
Kappler concluded that regular determination of antibodies is reasonable in patients with 
negative or intermittent infection with P. aeruginosa, but not with confirmed chronic P. 
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aeruginosa infection. Additionally, they state positive antibody results almost prove 
infection and negative results indicate the absence of P. aeruginosa with increasing 
probability as age decreases. They therefore recommend starting eradication treatment 
against P. aeruginosa in the absence of positive microbiological culture. In contrast, 
Tramper-Stranders found a sensitivity of 96 % but a specificity of only 79 %, probably due 
to the newly imposed cut-off values. They found that in only 5 of 13 patients did positive 
serology precede first positive culture and concluded that the failure of tests to detect early 
infection in young patients emphasises the need for continued reliance on cultures. 
A critical review of these two studies has recommended the development of alternative and 
more sensitive tests for the serodiagnosis of P. aeruginosa, with specific reference to 
investigating different antigens (Farrell and Govan, 2006). 
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1.5 	The hypothesis and aims of investigation 
P. aeruginosa is the organism most associated with CF patients' clinical decline. 
Universally, patients are currently monitored for the presence of pulmonary infection by 
microbiological culture of respiratory samples. There are problems with this technique, 
particularly in young children who cannot expectorate and who are therefore monitored 
with oropharyngeal swabs, despite their often poor positive and negative predictive values. 
Early treatment regimes delay the decline to chronic infection and improve lung function 
and long-term survival of patients. Recent studies claim that testing for antibodies specific 
to P. aeruginosa can detect infection prior to culture; however, there are recommendations 
for developing new technologies for detecting P. aeruginosa infection in patients with CF. 
An ideal test to detect early infection with P. aeruginosa in CF patients would use non-
invasive samples (thereby allowing samples to be taken at every clinic visit) and would 
differentiate between an on-going infection, that has not responded to treatment, an 
infection which has been overcome by the host defences, and therefore may require no 
further action, and a newly acquired infection. 
The hypothesis to be tested during this project was 'it is possible to detect serological 
evidence of P. aeruginosa infection in CF patients using novel assays employing serum and 
non-invasive samples, with the longer term aim of using the assay to detect early 
pulmonary infection with this organism in patients with CF'. 
The aims of the project were: 
1. To identify and characterise a common antigen specific to P. aeruginosa. 
2. To confirm the occurrence of this antigen. 
3. To evaluate the immunogenic properties of this antigen with patient and volunteer 
samples. 
4. To design and optimise a diagnostic assay and to evaluate the assay from a clinical 
perspective (comparison to other clinical measures such as pulmonary function and 
microbiological culture). 
5. To compare the assay to other available methods and commercial kits. 
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CHAPTER 2 MATERIALS & METHODS 
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	2.1 	Media, chemicals and apparatus 
2.1.1 Media, solutions and buffers 
Details of media, solutions and buffers and their suppliers are listed in Appendix I. 
2.1.2 Chemicals 
An overview of all chemicals, reagents and materials can be found in Appendix II. 
2.1.3 Apparatus 
Specialist equipment and their suppliers are detailed in the text. 
2.2 	Bacterial strains 
2.2.1 Pseudomonas spp. strains 
2.2.1.1 Reference strains 
Serotype type-strains 01 to 020 (from the IATS) and type strain PAOI of P. aeruginosa, 
were obtained from the Laboratory of Healthcare Associated Infection (LHCAI) at the 
Health Protection Agency (HPA), London, UK. The origins of these strains are listed in 
Table 5. 
Table 5. Origins of Pseudomonas strains 
Species 	 Strain 	 Reference 
P. aeruginosa 
P. aeruginosa 
P. aeruginosa 
P. aeruginosa 
P. aeruginosa 
P. aeruginosa 
P. aeruginosa 
P. aeruginosa 
P. syringae pv. morsprunorum 
01 — 012 
013 
014 
015 — 016 
017 
018 — 020 
PAO1 
AK1401 
C28 
(Habs, 1957) 
(Sandvik, 1960) 
(Verder and Evans, 1961) 
(Lanyi, 1966) 
(Meitert, 1964) 
(Liu and Wang, 1990) 
(Holloway, 1955) 
(Berry and Kropinski, 1986) 
(Smith et aL, 1985) 
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2.2.1.2 Clinical collection 
Fifty-two strains of P. aeruginosa were used to evaluate the occurrence of A-band LPS. 
These strains originated from the sputum of 46 different CF patients attending outpatient 
clinics at the Royal Brompton Hospital (RBH), London, UK. They were assigned strain 
names CI 1 to CI 30 and RBH 1 to RBH 16, with the RBH strains defined as being mucoid 
(PAM) or non-mucoid (PA) (details are listed in Appendix III). Those strains with the 
prefix RBH were collected specifically for this study, whilst those with prefix CI had been 
referred to LHCAI for epidemiological typing. 
Twenty-nine sequential isolates of P. aeruginosa, also referred to LHCAI for 
epidemiological typing, from eight separate patients were selected to evaluate the 
persistence of A-band LPS over time. The strains and their details are listed in Appendix 
IV. Strains from the same patient were shown to be epidemiologically indistinguishable 
(judged by the PFGE profiles) by Dr Jane Turton, HPA. 
Ten colistin-resistant P. aeruginosa strains from CF pateints (Table 6, obtained from 
LHCAI) were employed to determine the expression of A-band LPS in the presence of an 
LPS-related antimicrobial resistance mechanism. 
Table 6. Colistin resistant strains ofP. aeruginosa 
Strain Colistin resistance (pg/mL) 
8-2-3 8 
71-2-3 8 
113-3-3 12 
116-2-1 16 
221-1-3 8 
221-2-2 8 
222-6-1 8 
269-5-2 8 
279-4-1 8 
321-5-2 96 
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2.2.1.2.1 RBH microbiology procedures for culture of sputum from CF patients 
Briefly, the procedure at the RBH was as follows: sputa were emulsified mechanically, by 
adding an equal volume of Ringer's solution (Oxoid Ltd, Basingstoke, UK), making a 1:2 
dilution, and six to seven sterile glass beads (Al Laboratory Supplies Ltd, Enfield, UK); the 
samples were vortexed until emulsified and 200 !IL of homogenate added to 10 mL of 
Ringer's solution, making a 1/100 dilution; a further 200 AL of homogenate was added to 
20 mL of Ringer's solution, making a 1/10 000 dilution. 
From the 1/2 dilution, 20 1.11, of homogenate was plated on Pseudomonas Isolation Agar 
(Difco/BD Diagnostics Systems, Sparks, MI, USA), MacConkey agar (Oxoid Ltd), B. 
cepacia agar (Oxoid Ltd), Sabouraud's agar (Oxoid Ltd) and actidone Sabouraud's agar 
(Oxoid Ltd) for discrete colonies and plates were incubated overnight in air at 37 °C. 
Additionally, 20 i.ti, of homogenate from the 1/2 dilution was plated on mannitol salt agar 
(Oxoid Ltd) and spread over the entire plate surface. This plate was incubated overnight in 
air at 37 °C. Finally, 20 }IL of homogenate from the 1/10 000 dilution was plated onto 
chocolate agar, spread over the entire agar surface, a 5 mg optochin disc (Oxoid Ltd) was 
applied and incubated overnight in an environment enriched with 5 to 10 % CO2 at 37 °C. 
All plates were examined for potential pathogens and characteristic colonies identified, 
before re-incubation for a further 24 h (except the Sabouraud's agar which was incubated 
for up to 5 days and the actidione agar for up to 7 days). All plates were re-examined at 48 
h for any organisms not present at 24 h incubation. Pathogens were quantified according to 
Table 7. Samples requested for this study were subcultured and stored on nutrient agar 
(Oxoid Ltd) slopes before sending to LHCAI. 
On receipt at LHCAI, all strains were subcultured on King's A agar (20 g/L bacto peptone, 
10 g/L glycerol, 10 g/L K2SO4, 3 g/L MgC12.6H20, 15 g/L bacto agar, adjusted to pH 7.2). 
Plates were incubated in air overnight at 37 °C and if characteristic green morphology was 
observed, strains were regarded as being P. aeruginosa. If there was doubt, PCR was 
employed, as detailed in section 2.6.1. 
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Homogenate dilution Number of colonies Calculated number of organism / mL 
0 — 2 	 10b 
2-20 106 
20 — 200 	 107 
> 200 108 
1:10 000 
	
0 — 10 	 10 
1 : 2 	 11 —99 103  
> 100 	 104 
Table 7. Interpretation of sputum dilution cultures 
2.2.1.3 Mutant strains 
The B-band deficient, A-band strains of P. aeruginosa AK1401 and strain C28 of P. 
syringae pv. morsprunorum were obtained from LHCAI. The origins of these strains are 
listed in Table 5. Fimbriae and flagella mutant isolates (K pilr fla-, K3PO4 pir fla-, KPO4 
pir flak, K pir flat, K pilr flat, PAO1PO4 pir flat and PAOpir flat) and reference strains 
(PS propagation strain 7, PS18R, PS18S and PS7/1) were also obtained from LHCAI. The 
origins of these strains are listed in Table 8. 
The A-band mutants Rmd and Wbpm and core-mutant isolates (Rm1c/rind, MigA/rmd and 
WapR) of P. aeruginosa were a gift from Dr Joseph Lam at the Lam Laboratory, 
University of Guelph, Ontario, Canada (Table 8). 
Alginate mutants (PAO 381, PAO 568, PAO 578, PAO 579 and PAO 581) were a gift from 
Prof. John Govan at the University of Edinburgh, UK (Table 8). 
2.2.2 Species specificity strains 
Three species specificity panels were employed to evaluate whether various antigens of P. 
aeruginosa were unique to the species. Firstly, a panel of common CF pathogens (obtained 
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Table 8. Details of P. aeruginosa strains with mutations of 0-side chain and core LPS, 
fimbriae, flagella, alginate and polyagglutinable properties 
Strain 
Mutation 
(- = absent, + = present) 
Reference 
Rmd knockout / A-band - / B-band + 
wbpM knockout / A-band + / B-band - 
A-band - / B-band - / outer core -
A-band - / B-band + / outer core -
A-band - / B-band - / outer core + 
fimbriae retractile / flagellum - 
fimbriae - / flagellum - 
fimbriae - / flagellum + 
fimbriae non-retractile / flagellum + 
fimbriae retractile / flagellum + 
fimbriae - / flagellum + 
fimbriae non-retractile / flagellum + 
non-mucoid 
mucoid (muc2) 
mucoid (muc 22) 
mucoid (muc 23) 
mucoid (muc 25) 
parent 
polyagglutinable 
non-typable 
polyagglutinable 
(Rocchetta et al., 1998b) 
(Burrows et al., 2000) 
(Rahim et at, 2000) 
Lam Laboratory 
Lam Laboratory 
(Bradley and Pitt, 1974) 
(Bradley, 1973) 
(Bradley, 1973) 
(Bradley, 1974) 
(Bradley and Pitt, 1974) 
(Bradley, 1973) 
(Bradley and Pitt, 1974) 
(Pitt et al., 1986) 
(Pitt et at, 1986) 
(Pitt et al., 1986) 
(Pitt et aL, 1986) 
Rmd 
Wbpm 
Rmlc/rmd 
MigA/rmd 
WapR 
K pill. fla- 
K3PO4 pir fla- 
KPO4 Or flak 
K Or flak 
K pilr flak 
PAO1PO4 pir flak 
PAOpir flat 
PAO 381 
PAO 568 
PAO 578 
PAO 579 
PAO 581 
PS propagation strain 7 
PS18R 
PS18S 
PS7/1 
(Stanisich and Holloway, 1969) 
(Govan, 1975) 
(Govan and Fyfe, 1978) 
(Govan and Fyfe, 1978) 
(Govan, 1975) 
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from LHCAI) was used, consisting of B. cenocepacia genomovar II, B. cepacia genomovar 
IIIa, B. cenocepacia genomovar IIIb, S. maltophilia and A. xylosoxidans (LHCAI in-house 
controls). Additionally, H. influenzae strains 3287 and 3440 were provided by the 
Respiratory and Systemic Reference Laboratory (RSIL), HPA. 
A panel of pseudomonads was also included, to rule out the possibility of an antibody 
response being raised to an environmental Pseudomonas species or similar strain. This 
consisted of strains of P. fluorescens (NCTC 10038), P. putida (NCTC 10936), P. 
alcaligenes (NCTC 10367), P. diminuta (NCTC 8545), P. vesicularis (NCTC 10900), 
Comamonas acidovorans (NCTC 10683), Pandorea spp. and B. gladioli (LHCAI in-house 
controls). 
Finally, a panel of clinical strains of various Enterobacteriaceae (Escherichia coli K-12 
(EQ1), Vibrio cholerae (E38776), Salmonella Typhi (H065140355), S. Typhimurium 
(P100836) and S. Enteriditis (P132344)), were provided by Dr Henrik Chart (Laboratory of 
Enteric Pathogens (LEP), HPA), and used in specificity studies. 
2.2.2.1 Growth, storage and identification of strains 
The species identification of strains was confirmed by the HPA reference laboratories, 
LHCAI, RSIL and LEP. All strains were grown and stored according to Table 9. 
87 
Table 9. Growth requirements of strains used in this study 
Species Media 
Growth 
temperature 
Growth 
environment 
Storage 
P. aeruginosa King's A agar or nutrient agar' 37 °C Air Microbank-J  vials 
P. syringae pv 
morsprunorum 
Nutrient agar2 30 °C Air Microbank-3vials 
B. cepacia Nutrient agar2 37 °C Air MicrobanC 3 vials 
S. maftophilia Nutrient agar2 37 °C Air Microbank"3 vials 
A. xylosoxidans Nutrient agar2 37 cc Air Microbank-3vials 
H. influenzae Chocolate agar2 37 °C 5-10% CO2 Microbank-3vials 
P. fluorescens Nutrient agar2 37 °C Air Microbank-3 vials 
P. putida Nutrient agar2 37 °C Air MicrobanC3 vials 
P. alcaligenes Nutrient agar2 37 °C Air MicrobanC3 vials 
P. diminuta Nutrient agar2 37 °C Air Microbank-3 vials 
P. vesicularis Nutrient agar2 37 °C Air Microbank-3 vials 
C. acidovorans Nutrient agar2 37 °C Air MicrobanC 3 vials 
Pandorea spp. Nutrient agar2 37 oc Air Microbane3 vials 
B. gladioli Nutrient agar2 37 °C Air Microbane3 vials 
E. coli Columbia blood agar2 37 °C Air Dorset egg medium4 
V. cholerae Columbia blood agar2 37 °C Air Dorset egg medium4 
S. Typhi Columbia blood agar2 37 °C Air Dorset egg medium4 
S. Typhimurium Columbia blood agar2 37 °C Air Dorset egg medium4 
S. Enteriditis Columbia blood agar2 37 °C Air Dorset egg medium4 
I Difco/BD Diagnostics Systems 
2 Oxoid Ltd 
3 Prolab Diagnostics, Neston, UK 
4 Media Services, HPA 
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2.3 	Antibody samples 
Many antibody samples were used for initial investigation of the antigens of P. aeruginosa, 
developing and optimising various techniques, in-depth immunogenic analysis of P. 
aeruginosa antigens and clinical evaluation of developed assays. Preliminary studies 
employed stored serum samples referred to LHCAI from CF patients for P. aeruginosa 
serodiagnosis (section 2.5.2), stored serum samples from healthy blood donors, and hyper-
immune animal sera. Later, patients and volunteers were recruited and donated various 
body fluids. 
2.3.1 Stored serum samples from CF patients for preliminary analyses 
Pools of serum samples were constructed from a minimum of six patient samples, which 
had been referred to LHCAI for P. aeruginosa serodiagnosis testing and stored at 4 °C. The 
original laboratory results of the individual samples are detailed in Appendix V. The pools 
were made from samples with high positive (HP1 to HP4, HPP and Std), low positive (LP), 
medium (Med) and negative (N) serum samples. The pools were then tested by the in-house 
ELISA and by immunoblotting (section 2.5.3) for confirmation of Pseudomonas antibody 
titre. 
Additional individual serum samples used for antigen investigation and the development 
and optimisation of assays are listed in Appendix VI. 
Individual serum samples from two patients (patients 1 (y, DOB 25-Feb-87) and 2 (6, 
DOB 05-Apr-89)) referred over a long time period were used for the preliminary 
investigation of the longitudinal antibody response to P. aeruginosa. Details of these 
samples are listed in Appendix VII. 
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2.3.2 Stored serum samples from healthy volunteers 
Forty-four healthy human control sera (HNC1 to 6, 10 to 47 and 49), provided by Dr 
Henrik Chart were obtained from an anonymous healthy, non-CF population of blood 
donors. A human control sera pool (HCS) was constructed from human control sera 1 to 6 
samples. 
2.3.3 Sera from hyper-immune animals 
Rabbit sera raised to all 20 O-serotypes (normally used for serotyping of P. aentginosa 
strains) and AK1401, were obtained from LHCAI. One rabbit and one guinea pig were 
challenged with purified LPS from strain AK1401, according to the methods detailed in 
section 2.3.3.1. Pre-challenge serum and plasma samples (designated pre-challenge AWl 
and pre-challenge AW2) were obtained, as well as a hyper-immune post-challenge serum 
and plasma samples (designated AW1 and AW2), for the rabbit and guinea pig, 
respectively. 
Additionally, 15 further pre-challenge rabbit serum samples (NRS, HC76, HC87, HC89, 
HC90, HC92, HC95, HC96, HC101, HC102, 01, 02, 03, 04 and NoName) were obtained 
from Dr Henrik Chart. 
233.1 Preparation of antisera 
Animals, for the production of hyper-immune sera, were housed and maintained in the 
Biological Services Department (BSD), HPA. Briefly, on day 0, pre-challenge samples (5 
mL or 1 mL of blood for the rabbit or guinea pig, respectively) were taken and the sera 
reacted with a panel of P. aeruginosa strains by immunoblotting (details of methodology 
are listed in section 2.5.3). On day 3, 0.5 mL or 0.2 mL preparation of inoculum 1 (200 
µg/mL purified LPS from strain AK1401 (section 2.4.4)) was used to challenge the rabbit 
or guinea pig, respectively, and a 0.25 mL or 0.1 mL booster with inoculum 2 (200 µg/mL 
LPS in phosphate-buffered saline (PBS) (Oxoid Ltd)) was given on day 24. The rabbit was 
90 
challenged by intra-dermal injection and the guinea pig by sub-cutaneous injection, both at 
multiple sites across the back. At day 35, blood was taken for testing. 
2.3.4 Adsorbed serum samples 
Adsorbed antibodies to all 20 0-serotypes, AK1401 and C28 were made from the high 
positive sera and adsorbed antibodies to core LPS epitopes (using strain Rind) were made 
from hyper-immune rabbit serum AW1. 
Briefly, five plates of each Pseudomonas strain were harvested from overnight growth on 
nutrient agar, in 0.4 % (v/v) formol saline and centrifuged at 5000 g for 40 min in an IEC 
Micromax micro-centrifuge (Thermoquest Scientific Equipment, Basingstoke, UK). The 
cell deposits were washed three times in PBS before resuspending in 500 'IL sterile saline. 
In a microtube, 250 1.IL of cell suspension was mixed with 250 !IL high positive sera (serum 
pools for each strain are detailed in Table 10), incubated at 37 °C for 2 h and held at 4 °C 
overnight. The tubes were then centrifuged at 13000 g for 10 min, until the supernatant was 
clear. The latter was stored at 4 °C. 
Table 10. Serum pools and strains for adsorbed serum samples 
Serum pool Adsorbing strain Serum pool Adsorbing strain 
HP1 C28 HP2 011 
HP1 AK1401 HP1 012 
HP1 01 HP2 013 
HP2 02 HP2 014 
HP2 03 HP2 015 
HP2 04 HP2 016 
HP2 05 HP2 017 
HP1 06 HP1 018 
HP1 07 HP1 019 
HP2 08 HP1 020 
HP2 09 AW1 Rmd 
HP2 010 
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2.3.5 Monoclonal antibodies 
Monoclonal antibodies N1F1 0 (Lam et al., 1989), SC-101 (Rivera et al., 1992) and SC-7-4 
(Rivera et al., 1992) specific to the A-band, outer core and inner core LPS of strain 
AK1401, respectively, were purchased from Dr Joseph Lam. 
2.3.6 Recruited patients, volunteers and their samples 
During the study, 41 adult patients (15 y, mean age 25.7 y, SD 7.7 y, and 26 6, mean age 
29.4 y, SD 8.8 y) (RBH1 to 24, RBH38 to 41, CFSP1 to 10, CFSP12, CFSP14 and 
CFSP15) with CF attending outpatient clinics at the RBH donated samples of oral fluid, 
sputum, urine and serum. Details of these patients and the samples they donated are listed 
in Appendix VIII. Briefly, 28 patients donated oral fluid; of these, three also donated 
samples of urine, 16 donated serum and a further eight donated both urine and serum 
samples. Fourteen additional patients donated sputum for antibody analysis and 11 of these 
patients donated serum. The sputum culture results for these CF patients, performed by the 
RBH, are detailed in Appendix XI. 
Twelve paediatric patients (eight y, mean age 11.3 y, SD 5.3 y, and four 6, mean age 7.0 y 
SD 4.7 y) (RBH25 to 36) with primary ciliary dyskinesia (PCD) (detailed in Appendix IX) 
attending outpatient clinics at the RBH, were recruited as a clinical control group. All 
donated oral fluid samples and their sputum culture results are detailed in Appendix XII. 
A further control group of 37 healthy volunteers (21 y, mean age 27.8 y, SD 19.2 y, and 16 
5 mean age 24.1 y, SD 19.3 y) (HPA1 to 29 and NS1 to 8), detailed in Appendix X, 
donated oral fluid. 
The RBH ethics committee granted approval for the work and written consent was obtained 
from all subjects after adequate explanation of the project and time for reflection. Copies of 
these forms are detailed in Appendix XIII. 
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2.3.6.1 Oral fluid sample collection 
Oral fluid samples were taken using Oracol oral test kits (Malvern Medical Developments, 
Malvern, UK). The swabs were simply sterile sponges on sticks, which could be stored and 
transported in sterile sample containers (Figure 11). Patients took their own samples by 
rubbing the sponge across their gums for approximately 1 min. The samples were then 
placed in the sterile containers and transported to LHCAI at room temperature. One CF 
patient was recruited to provide multiple oral fluid samples over a five day period and to 
post the samples to LHCAI. Their instructions, which included how to take a sample, are 
shown in Appendix XIV. 
On receipt at LHCAI, swabs were maintained at room temperature and processed within 3 
days. 
Figure 11. Oral fluid collection device 
2.3.6.2 Sputum sample preliminary processing 
The donated sputum samples (from patients CFSP1 to 10, CFSP12, CFSP14 and CFSP15), 
were collected from the microbiology department at the RBH, where they were processed 
according to methods detailed in section 2.2.1.2.1 and thus pre-diluted 1:2 in Ringer's 
solution. 
On receipt at LHCAI, 1 mL of sputum homogenate was centrifuged at 13 000 g for 10 min 
and the supernatant (sol portion) was then stored at -20 °C for future antibody analysis. 
Additionally, serial dilutions were made from the sputum homogenate to isolate P. 
aeruginosa strains. Briefly, 200 ptL of the 1:2 diluted homogenate was added to 9.9 mL of 
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PBS (to give a 1/100 dilution). This was further diluted with PBS to give 1/104, 1/106 and 
1/109 dilutions. Two-hundred microlitres of the 1/2, 1/100 and 1/104 homogenates and 20 
pt of the 1/106 and 1/109 dilutions were spread on Kings' A agar for the isolation of single 
colonies and incubated for 48 h in air at 37 °C. 
2.3.6.3 Urine sample preliminary processing 
Urine samples were transported from the RBH at room temperature, and on receipt at 
LHCAI were each split into two aliquots. One aliquot was placed at 100 °C in a steamer for 
5 min whilst the other was filtered through a membrane 0.45 µM pore filter. All samples 
were stored at -20 °C until testing. 
2.3.7 Clinical evaluation study patients and samples 
For the clinical evaluation study, a total of 370 stored serum samples (from the LHCAI test 
archive and considered 'fit', i.e. normal appearance and not diminished) were selected from 
22 CF patients (13 y and nine (3; 17 AF508/AF508 and five AF508/other) attending Bristol 
Children's Hospital, Bristol, UK. Details including the date of birth, sex, CF genotype and 
date of first ever isolation of P. aeruginosa for these patients are listed in Appendix XV. 
The sputum culture results were examined by Dr Sally Painter at Bristol Children's 
Hospital and scored depending on the previous six months' results for each serum sample: 
if P. aeruginosa was not cultured, a negative score was given, if P. aeruginosa was 
identified once, an intermediate value was given and if isolated twice or more, a chronic 
status was given. The pulmonary function test data (percent of predicted FEV1 and FVC, 
done on a standard laboratory spirometer (Masterlab 4.0; Jaeger AG, Wfirzburg, Germany) 
according to the American Thoracic Society guidelines (Anon, 1995)) were also retrieved 
by Dr Sally Painter and are listed with the sputum data in Appendix XVI. 
2.3.7.1 Bristol microbiology procedures for culture of sputum from CF patients 
Unfortunately, it was not possible to obtain details of the microbiology procedures carried 
out at Bristol Children's Hospital. 
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2.4 	Identification and analysis of P. aeruginosa antigens 
To evaluate the antigens of P. aeruginosa, type strains, mutant strains, clinical isolates and 
species specificity strains, were investigated using the following techniques. Details of the 
SDS-PAGE procedure are given in section 2.4.6 and buffers, stains, gel volumes, etc, in 
Appendix I. 
2.4.1 Whole bacterial cells digested with Proteinase-K 
All isolates were grown overnight and growth was weighed in a microtube. SDS-PAGE 
solubilization buffer (62.5 mM Tris-HC1 pH 6.8 containing 10 % (v/v) glycerol, 5 % (v/v) 
P-mercaptoethanol, 3 % (w/v) SDS, 0.01 % (w/v) bromophenol blue) was added to give a 
final concentration of 1 mg bacterial mass per 30 I.J.L solubilization buffer. Tubes were 
vortexed, before heating for 10 min at 100 °C in a heating block. Any clumps of cells were 
disrupted by brief sonication using the fine sonic probe of an MSE sonicator (Sanyo 
Gallenkamp Plc, Leicester, UK). 
To each 30 µL of bacterial suspension, a further 30 }IL SDS-PAGE solubilization buffer 
mixed with 100 lig Proteinase-K was added. Tubes were sealed, mixed by vortexing and 
incubated at 60 °C in a heating block for 1 h. Finally, to destroy the Proteinase-K, the 
samples were incubated for a further 30 min at 100 °C before aliquotting for storage at -20 
°C. 
2.4.2 Outer membrane preparation of strains 
Bacterial strains were grown overnight on agar, a few colonies were used to inoculate 5 mL 
of tryptone soya broth (TSB) (Oxoid Ltd) and the cultures were incubated on a shaker at 37 
°C for approximately 6 h. Ten plates of nutrient (or chocolate) agar were seeded confluently 
with the broth culture strain. The plates were incubated overnight, growth harvested and 
stored in a glass universal at -20 °C. 
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The bacteria were disrupted by sonication as follows. In a Class II negative-flow safety 
cabinet, the bacteria were suspended in 5 mL chilled 25 mM Tris-HC1 pH 7.4 containing 1 
mM EDTA-Na2 and transferred to chilled sonication vessels. The bacterial suspensions 
were sonicated at 150W for 1 min using an Ultrasonic processor sonicator (Heat Sytems—
Ultrasonics Inc, Farmingdale, USA), until the suspension became clear and the probe was 
visible. The sonicate was added to 20 mL chilled 25 mM Tris-HC1, pH 7.4 in Oak Ridge 
polycarbonate centrifuge tubes (Fisher Scientific UK Ltd, Loughborough, UK). Residual 
whole bacteria were sedimented by centrifugation at 5000 g in a Sorvall RC-53 
ultracentrifuge (Kendro Laboratory Products, Bishop's Stortford, UK) for 30 min at 4 °C. 
The bacterial envelopes, in the supernatant, were separated from cytoplasmic proteins by 
centrifugation at 45000 g, at 4 °C for 1 h. The supernatants were discarded and pellets were 
resuspended in 20 mL of 25 mM Tris-HC1 pH 7.4. To separate the inner and outer 
membranes, the former were selectively solubilised by adding 1 mL Sarkosyl® and shaking 
the centrifuge tubes horizontally on a R100 Rotatest shaker (Luckham Ltd, Burgess Hill, 
UK) at 200 rpm for 30 min at room temperature. The insoluble outer membranes were then 
sedimented by centrifugation at 45000 g, at 4 °C for 1 h. The supernatants were discarded, 
the pellets resuspended in 200 4, 25 mM Tris-HCI pH 7.4 and stored at -20 °C. 
2.4.2.1 Lowry protein assay 
In order to standardise the amounts of outer membranes applied to SDS-PAGE gels, it was 
necessary to calculate the protein content of the samples. This was done by performing the 
Lowry protein assay (Lowry et at, 1951) using a 1 mg BSA /mL protein standard (diluted 
to 50, 100, 150 and 200 µg/mL) for calibration. For each test, 20 1AL of outer membrane 
sample preparation was added to 980 i.iL deionised water. To each tube, 5 mL of Lowry C 
(50 mL Lowry A (2 % (w/v) Na2CO3, 0.1 M NaOH) mixed with 1 mL of Lowly B (0.5 % 
(w/v) CuSO4.6H20 in 1 % (w/v) KNaC4H4O6)) was added, mixed thoroughly and left at 
room temperature for 10 min. Whilst vortexing, 0.5 mL of Lowry D (1 N Folin-Ciocalteau 
reagent) was added to each sample. After a minimum of 30 min, the absorbance of the 
samples was measured at 500 rim in an Eppendorf BioPhotometer spectrophotometer 
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(Anachem, Luton, UK). A standard curve was plotted and the protein concentration of test 
samples was determined by reference to the curve. 
2.4.2.2 Heat-modifiable proteins 
Two replicate outer membrane samples were prepared and diluted in the appropriate 
volume of solubilization buffer, to give 10 µg of protein per 5 µL. One sample was 
incubated at 100 °C for 5 min, whilst the duplicate sample was incubated at 37 °C for 5 
min. 
2.4.3 Fimbriae and flagella 
To visualise bacterial fimbriae and flagella, strains were inoculated into Craigie tubes 
(Media Services) which were incubated for 5 days at 37 °C. This was used to seed plates of 
nutrient agar confluently and plates were incubated overnight at 37 °C. The growth was 
harvested, resuspended in 3 mL PBS and split into 2 aliquots which were incubated at 100 
°C or 60 °C for 30 min, centrifuged at 12500 g for 10 min and stored at -20 °C for outer 
membrane preparation. 
2.4.4 Purification of LPS 
LPS was purified from outer membrane preparations. Samples were thawed and made up to 
5 mL volumes with distilled water. They were then added to 5 mL aliquots of 80 % (w/v) 
aqueous phenol (pre-heated to 68 °C in glass tubes plugged with non-absorbent cotton wool 
in a water bath). The aqueous-phenol suspension was mixed with a pipette to form an 
emulsion and then incubated at 68 °C for 15 min. The preparations were then centrifuged at 
3000 g in a Sorvall RC-53 ultracentrifuge for 45 min at room temperature. After 
centrifugation, the preparations formed three layers — a lower phenol layer, a white 
interface layer and an upper aqueous layer (containing the LPS). The aqueous layer was 
removed carefully with a pipette, and transferred to a glass universal. Five millilitres of 
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distilled water was added to the phenol layer and the extraction repeated. The LPS extracts 
were dialysed in semi-permeable tubing against 5 L distilled water for 24 h at 4 °C, with 
approximately five changes of distilled water, until all phenol odour had disappeared. The 
dialysate was recovered and frozen in a glass beaker with a foil lid for a few hours. Once 
frozen, the sample was lyophilized in a Modulyo freeze drier (Edwards, Crawley, UK) and 
the resultant LPS weighed. The purified LPS was reconstituted in distilled water to a 
concentration of 10 mg/mL; stock aliquots were stored at -20 °C and working aliquots held 
at 4 °C. 
2.4.5 CF morphotype experiments and expression of A-band LPS 
To assess whether A-band LPS was expressed in strains representing the typical CF 
morphotype, reference and alginate and polyagglutinable mutant strains were grown 
anaerobically. Additionally, P. aeruginosa colonies grown from the sputum samples were 
examined and colonies with different morphologies were genotyped by PFGE and 
investigated for A-band expression. Finally, the sequential isolates were examined for the 
persistence of A-band expression. 
2.4.5.1 Anaerobic growth and processing of strains 
Initial growth of strains was in air on nutrient agar but they were then subcultured in an 
anaerobic cabinet (10 % H2, 10 % CO2, 80 % N2) on nutrient agar or nutrient agar 
supplemented with 0.02 M potassium nitrate plates that had been reduced for 
approximately 4 h in the anaerobic cabinet. After incubation for 48 h at 37 °C in anaerobic 
conditions, the cells were harvested and digested with Proteinase-K, as detailed in section 
2.4.1. Samples were then immunoblotted alongside preparations grown aerobically and 
reacted with AW1 serum. 
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2.4.5.2 Pulsed-Field Gel Electrophoresis (PFGE) 
Strains were grown in TSB in universals and incubated on a shaker for 48 h at 37 °C. 
Bacteria were sedimented by centrifugation at 3000 g for 20 min, the supernatant discarded 
and the bacterial pellets resuspended in SE buffer (75 mM NaCI, 25 mM EDTA, pH 7.5) 
and transferred to a microtube. The pellets were washed thrice in SE buffer before being 
resuspended in SE buffer to a turbidity of 2.3 to 2.7 McFarland units in an API 
densitometer (bioMerieux, La Balme-les-Grottes, France). Bacterial suspensions were 
mixed with an equal volume of 2 % (w/v) low-gelling agarose (FMC BioProducts, 
Rockland, USA) in SE buffer at 50 to 56 °C, and dispensed into PFGE moulds. The moulds 
were maintained at 4 °C until the agarose had set and then transferred to bijou bottles 
containing 3 mL of lysis buffer A (6 mM Tris, 100 mM EDTA, 1 M NaC1, 0.5 % (w/v) Brij 
58, 0.2 % (w/v) sodium deoxycholate, 0.5 % (v/v) N-lauroyl sarcosine, 1 mM MgC12, 500 
µg/mL lysozyme). The bijou bottles were incubated overnight at 37 °C with gentle shaking. 
Lysis buffer A was replaced with 3 mL lysis buffer B (1 % (v/v) N-lauroyl sarcosine, 0.5 M 
EDTA, pH 9.5, 500 µg/mL Proteinase-K) and blocks were incubated overnight at 37 °C 
with gentle shaking. The next day, the agarose blocks were washed three times in 3 mL TE 
buffer (10 mM Tris, 10 mM EDTA, pH 7.5) and stored in 3 mL TE buffer at 4 °C until use. 
For the DNA restriction step, 2 mm sections of blocks were placed in 100 !IL of SuRE/Cut 
buffer H for restriction enzymes (Roche Applied Science, Lewes, UK) and incubated for at 
least 30 min at 4 °C. The buffer was refreshed and 2 tit Spel restriction enzyme (Roche 
Applied Science) added to each tube. 
Pulsed-field agarose gels (Bio-Rad certified agarose, Bio-Rad, Hemel Hempstead, UK) of 
225 x 140 x 10 mm at 1.2 % (w/v) (2.04 g agarose in 170 mL 0.5 x TBE (44.5 mM Tris, 
44.5 mM boric acid, 1 mM EDTA)) were used. The digested plugs were loaded into the 
wells, alongside molecular weight standards comprising a X concatemer ladder (Bio-Rad), 
which was previously incubated at 52 °C for 8 min. The wells were sealed with molten 
agarose and the gel placed in a contour-clamped homogeneous electric field (CHEF) DRII 
apparatus (Bio-Rad). Two litres of 0.5 x TBE buffer, previously chilled to 4 °C, were 
poured into the tank to cover the gel and PFGE was performed as follows: 1 sec initial 
switching time, 50 sec final switching time at 6 V/cm, for a duration of 30 h at 12 °C. Gels 
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were stained with 1 µg/mL ethidium bromide solution (Sigma-Aldrich) and fingerprints 
visualised and photographed under UV light on a UVP dual intensity transilluminator 
(Ultra Violet Products, Cambridge, UK). 
2.4.6 Preparation of SDS-PAGE gels 
A mini-gel electrophoresis system was employed for the SDS-PAGE (Atto Corporation, 
Japan). A 12.5 % separation gel (5 mL of lower gel buffer (1.5M Tris-HCI pH 8.8, 0.4 % 
(w/v) SDS), 8.3 mL acrylamide solution (30 % (w/v) acrylamide, 0.8 % (w/v) NN' 
methylene-bisacrylamide), 6.7 mL deionised water and 60 [AL ammonium persulfate (APS: 
10 % (w/v) aqueous solution), degassed before adding 20 µL of catalyst, N,N,N',N1 
tetramethylethylenediamine (TEMED)) combined with a 4.5 % stacking gel (2.5 mL upper 
gel buffer (0.5 M Tris-HC1 pH 6.8, 0.4 % (w/v) SDS), 1.5 mL acrylamide solution, 6 mL 
deionised water and 30 µI, APS ), degassed before adding 20 µL TEMED) was used. 
Five microlitres (or 10 1.LL for monoclonal antibody immunoblots) of sample (whole cell 
digest or outer membrane preparation in appropriate volume of solubilization buffer heated 
to 100 °C for 5 min) was added to each well and electrophoresis applied at a constant 
current of 50 mA in running buffer (0.025 M Tris, 0.19 M glycine, 0.1 % (w/v) SDS) for 30 
min (1 h if two gels were electrophoresed simultaneously). 
2.4.7 Staining SDS-PAGE gels 
2.4.7.1 Silver staining 
To visualise LPS profiles, gels were stained with a silver stain. Briefly, the gels were fixed 
in a solution (40 % (v/v) methanol, 5 % (v/v) acetic acid) for 2 h. The fixing solution was 
then discarded and 100 mL oxidizing solution (100 mL silver stain fixing solution 
containing 0.7g periodic acid) added for 5 min before thrice washing in deionised water for 
15 min. The gels were stained in silver stain (0.04 M AgNO3, 0.02 M NaOH, 0.34 M 
NH4OH) for 10 min before washing with deionised water (a further three times for 10 min). 
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Finally, 100 mL of developing solution (1% (w/v) citric acid, 0.5 ml formalin (38 % 
aqueous formaldehyde)) was added. Once profiles started to appear, the gels were 
transferred to a light-box and photographs taken. 
2.4.7.2 Coomassie brilliant blue staining 
To visualise protein, gels were stained with approximately 100 mL of Coomassie brilliant 
blue stain (0.1 % (w/v) Coomassie Blue R-250 (Sigma-Aldrich, Poole, UK), in 50 % (v/v) 
methanol, 10 % (v/v) acetic acid) for at least 2 h on an orbital shaker. The Coomassie blue 
stain was then replaced with destain (10 % (v/v) acetic acid) and agitated for a further 2 h. 
Gels were visualised on a light box and photographed. 
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2.5 	Antigenic analysis of P. aeruginosa strains 
The detection of specific antibodies, detailed in the following sections, involved using a 
`second' antibody that was specific for IgG, IgM and / or IgA and produced in a goat or a 
rabbit. This antibody was conjugated to alkaline-phosphatase, giving a visible colour 
change when reacted with substrate developing solution. These antibodies have been 
referred to as 'second' antibodies. 
2.5.1 Pre-test sample processing 
All human sera were incubated at 56 °C for 30 min prior to testing, to inactivate the 
fibrinogen, which can interfere with antibody analyses. 
Oral fluid was extracted from the Orocol oral test swabs by removing the sponge from the 
stick. This was achieved by cutting the tip off a 1 mL pipette tip, placing this over the stick 
(tapered end towards the sponge), placing the sponge in the barrel of a 5 mL syringe and 
firmly pulling the pipette tip and stick away from each other, leaving the sponge to remain 
in the syringe barrel. The oral fluid could then be squeezed from the sponge using the 
syringe. 
2.5.2 Enzyme-linked Immunosorbent Assays 
2.5.2.1 LHCAI in-house ELISA 
The ELISA routinely used by LHCAI for the serodiagnosis of P. aeruginosa employed 
sonicated whole cells of serotype stains 01, 06, 07 and 012 as well as strains AK1401 and 
C28. Briefly, strains were grown in TSB for at least 4 h at 37 °C and resultant growth used to 
inoculate four King's A agar plates which were then incubated overnight at 37 °C. Growth 
was harvested into bijou bottles with 3 mL 0.4 % (v/v) formol saline per plate before 
sonicating at 150 W, using an ultrasonic processor sonicator, over ice for 2 min. The samples 
were cooled on ice and sonication repeated, until extracts had a translucent appearance. Whole 
cells were sedimented by centrifugation at 4000 g for 5 min and the supernatants were diluted 
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in carbonate buffer (35 mM NaHCO3, 15 mM Na2CO3), at an optical density of 0.1 (A280), 
passed through a membrane 0.45 tiM pore filter and stored at 4 °C. 
Medium-binding, flat-bottomed Maxisorb ELISA plates (Nunc, Roskilde, Denmark) (96 
wells; columns 1 to 12 and rows A to H) were coated with 50 121, antigen per well. For 
subsequent tests, eight wells (one column of columns 1 to 12) were coated with each strain. 
The plates were incubated at 37°C for approximately 1 h and maintained at 4 °C for at least 48 
h, until required. 
To test sera for antibodies to P. aeruginosa, plates were washed four times with 0.05 % 
(v/v) Tween 20 in PBS. Serum samples and controls were diluted 1/250 in PBS. Fifty 
microlitres of PBS was dispensed into all ELISA wells and 50 1AL of sample added to six 
ELISA wells in row B, corresponding to each Pseudomonas strain. Samples were double-
diluted through to row G (thus giving titrations of 1 in 500, 1000, 2000, 4000, 8000 and 16 
000). Negative and positive serum controls were dispensed into wells in rows A and H, 
respectively. 
Plates were incubated for 1 h at 37 °C before washing four times with 0.05 % (v/v) Tween 
20 in PBS. Fifty microlitres of goat-anti-human IgG (p.-chain specific) conjugated with 
alkaline phosphatase (Sigma-Aldrich) diluted 1/10 000 in 0.05 % (v/v) Tween 20 in PBS, 
were added to each well and the plates incubated for 1 h at 37 °C. After washing four times 
with 0.05 % (v/v) Tween 20 in PBS, specific antibodies were detected by adding 50 tiL of 
substrate buffer (500 mM NaHCO3, 2mM MgC126H20 (containing 1 mg p-nitrophenol 
phosphate per mL). The resultant colour was quantified by measuring the absorbance at 405 
nm. Results were interpreted by an end-point titration, by recording the last well giving a 
value higher than the corresponding negative control serum result. 
The LHCAI in-house ELISA was performed by the routine staff in LHCAI. To aid 
interpretation of all six results, a single comment was added to sample result reports (Table 
11). These comments resulted from the feedback received from clinicans over a 10 year 
period and the interpretation of how the ELISA results compared to clinical presentation. 
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Antibody titre results Comment 
any titres 4000 or more 
any titres 2000 
any titres 1000 
any other circumstances 
Strong evidence of infection 
Suggestive of infection 
Slightly elevated titres 
Antibodies not elevated 
Table 11. Comments accompanying P. aeruginosa serology results from LHCAI in-house 
ELISA 
2.5.2.2 Genesis Diagnostics' P. aeruginosa IgG ELISA 
The Genesis Diagnostics' IgG-specific ELISA (Genesis Diagnostics Ltd, Littleport, UK), 
which comprises plates pre-coated with P. aeruginosa lipopolysaccharides (strains not 
detailed), was performed as per manufacturer's instructions. All samples were tested in 
duplicate on two separate occasions. 
Briefly, serum samples, six kit standards and a positive control serum were diluted 1/100 in 
sample diluent (150 mM Tris-buffered saline, pH 7.2 with "antimicrobial agent") and 100 
tiL added to appropriate wells before incubating for 30 min at room temperature. Wells 
were then washed three times with 100 AL wash buffer (100 mM Tris-buffered saline with 
detergent, pH 7.2) and 100 jiL of conjugate solution (rabbit anti-human IgG conjugated to 
horseradish peroxidase in protein stabilising solution with "antimicrobial agent") added 
before incubating the plates for 30 min at room temperature. Wells were washed again and 
antibody-binding detected by adding 100 µI, of TMB substrate (an aqueous solution of 
3,3',5,5'-tetramethylbenzidine (TMB) and hydrogen peroxide) per well for 10 min at room 
temperature before stopping the reaction with 100 µ1_, of stop solution (0.25 M sulphuric 
acid) per well. The optical density was read at 450 nm (with a 620 nm filter) and plotted 
against the kit standards. 
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2.5.2.3 Statens Serum Institute Pseudomonas-CF-IgG antigen ELISA 
The SSI (Copenhagen, Denmark) ELISA kit provided a "Pseudomonas-CF-IgG antigen" 
(obtained by the sonication of the "17 most common P. aentginosa serotypes (01 through 
017)") and a standard antiserum, but all other equipment and reagents were sought. The 
test was performed using manufacturer's instructions with the exception of employing a 
different substrate buffer, due to the unavailability of ortho-phenylenediamine solution. All 
samples were tested in duplicate on two separate occasions. 
The SSI antigen was diluted 1/2000 in coating buffer (CB) (2.5 mM NaH2PO4.H20, 0.2 M 
Na2HPO4.12H20, 0.145 M NaCI) and 100 1.i.L applied to medium-binding, flat-bottomed 
Maxisorb ELISA plate (Nunc) wells. Plates were incubated for 1 h at room temperature and 
then washed three times with a 3 min soak per wash in wash buffer (WB) (0.001 % (v/v) 
Tween 20 in CB). One hundred microlitres of dilution buffer (DB) (0.25 M NaC1, WB) was 
added to wells, the plate was incubated for 1 h at room temperature, washed twice and 100 
pt of samples (diluted 1/100 in DB) and standards (SSI standard antiserum double diluted 
1/500 through 1/64 000 in DB) was added to wells. After further incubation for 1 h at room 
temperature and washing thrice, 100 pt of rabbit anti-human IgG conjugated to horseradish 
peroxidise (Dako Cytomation, Ely, UK) diluted 1/20 000 in DB was added to wells and the 
plate incubated for 1 h at room temperature. One hundred microlitres of substrate buffer 
(TMB solution, Microimmune Ltd, Brentford, UK) was added to the wells and colour 
reaction was developed in the dark for 10 min at room temperature before stopping the 
reaction with 100111, 1 M H2SO4. The optical density was quantified at 450 nm with a 620 
nm filter, values plotted against the standard and results extrapolated from the standard 
curve and divided by 10, for the dilution factor. 
2.5.3 Immunoblotting 
To observe antibody-antigen binding, SDS-PAGE gel profiles were used for Western 
blotting. A Trans-blot® SD semi-dry transfer cell (Bio-Rad) was used with nitrocellulose 
paper (Bio-Rad) and absorbent pads, soaked in immunoblotting transfer buffer (25 mM 
Tris, 192 mM glycine, 20 % (v/v) methanol), sandwiching the SDS-PAGE gel. A constant 
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current of 12 V (24 V if two gels were electrophoresed simultaneously) was applied for 30 
min. 
Following electrophoresis, nitrocellulose paper blots were blocked with blocking solution 
(Table 12) for 5 min at room temperature. Primary antibody samples (Table 12) were then 
added directly to the initial blocking solution and reacted with the immunoblots for 1.5 h at 
room temperature before washing in 0.05 % (v/v) Tween 20 in PBS three times for 5 min. 
An alkaline phosphatase-conjugated 'second' antibody sample (Table 12) was then added 
with fresh blocking buffer for a further 1.5 h at room temperature. The blots were washed 
as above before being developed by adding developing solution (0.09 M MgC12, 0.1 M 
Tris, 0.1 M NaC1, 0.045 % (v/v) NBT, 0.035 % (v/v) BOP) at 37 °C. The developing 
reaction was stopped by washing the blots in distilled water. 
In the case of monoclonal antibody blots, the washing steps used PBS without added 
Tween 20. Additionally, after blocking, the blots were rinsed briefly in PBS and 50 mL of 
monoclonal antibody added. After reacting overnight at 4 °C, the monoclonal antibody 
sample was retrieved for further tests. The alkaline phosphatase-conjugated 'second' 
antibodies were added to 50 mL of fresh blocking solution and blots reacted and developed 
as above. 
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Table 12. Blocking solutions, primary antibodies and 'second' antibodies for 
immunoblotting experiments 
Blocking 
solution 
(in PBS) 
Primary antibody 'Second' antibody 
Sample 
Vol. 
per 
gel 
Vol. 
per 
lane 
VoL 
per 2 
lanes 
Sample 
Vol. 
per 
gel 
VoL 
per 
lane 
Vol. 
per 2 
lanes 
3 % (w/v) 
skimmed milk 
Human sera 
(including 
absorbed 
serum 
samples) 
50pL 20pL 30pL 
goat-anti-human IgA 
+ IgG + IgM" 
goat-anti-human IgG 
(p-chain specific)1  
goat-anti-human IgM 
(y-chain specific)1  
goat-anti-human IgA 
(a-chain specific)1  
20pL 5pL 10pL 
Oral fluid all* 5pL 
3 % (w/v) 
skimmed milk 
Sputum 200 pL 
goat-anti-human IgA 
+ IgG + lop 
5pL 
Urine 40pL or 100pL 5pL 
3 % (w/v) 
skimmed milk 
Animal sera or 
p  lasma 
(pre-challenge 
or hyper- 
immune) 
50pL 20pL 30pL 
goat-anti-rabbit IgG 
(whole molecule)1  
goat-anti-guinea pig 
IgG (whole 
molecule)1  
20pL 5pL 10pL 
5 % (w/v) 
skimmed milk 
3 % (w/v) 
skimmed milk 
3 % (w/v) 
foetal calf 
serum 
3 % (w/v) 
chicken egg 
albumin 
Monoclonal 
antibodies 50mL 
goat-anti-mouse IgG 
(Fab specific) ]  20pL 5pL 
(' = Sigma-Aldrich; 2 = KPL, Maryland, USA; * = except 100 AL if also testing on ELISA and only 200 }tL 
used if 'second' antibody comparison experiments) 
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True positive which 
tests positive 
True negative which 
tests positive 
Test positive 
True positive which 
tests negative 
True negative which 
tests negative 
Test negative 
True positives True negatives Total 
N
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  s
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e  
Positive 
Negative 
Total 
2.5.3.1 Comparison of paired samples tested by immunoblotting 
To compare the immunoblot data for different antibody samples from the same patient, the 
antibody binding strength was scored between 0 and 3. The area of binding (side-chain and 
/ or core LPS) was also noted. RxC tables were constructed (Figure 12), with the serum 
data acting as the gold standard. From these, the sensitivity and specificity were calculated. 
Figure 12. RxC table for calculating sensitivity and specificity of tests 
Gold standard 
Positive 	Negative 	Total 
Sensitivity = true positives which test positive 
all true positives 
Specificity = true negatives which test negative 
all true negatives 
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2.5.4 Dot blotting 
Dot blotting was employed for rapid investigations into the specificity of reagents, and as a 
means of concentrating the primary antibody samples. To ensure the specificity of the 
`second' antibodies, dot blots were performed with 1 µI, of primary antibody added directly 
to the nitrocellulose paper. Once the primary antibody had dried, the paper was blocked for 
5 min with the appropriate blocking solution, 5 [IL of 'second' antibody applied and 
incubated for 1.5 h, the paper washed and then developed as described in section 2.5.3. 
Non-specific binding between blocking solution and 'second' antibody was also 
investigated. Briefly, 10 [iL aliquots of different blocking solutions (1 % (w/v) bovine 
serum albumin (BSA), 1 % (w/v) skimmed milk and 1 % (w/v) chicken egg albumin) were 
added to nitrocellulose paper, and where the solutions bound was marked. Once dry, the 
nitrocellulose paper was blocked with 3 % (w/v) skimmed milk for 1 h and 20 p.L of 
`second' antibody added to the milk solution. The blots were reacted for a further 1.5 h, 
before washing and developing as described in section 2.5.3. 
Dot blotting was also employed for reactions with monoclonal antibodies and urine 
samples, using a Bio-Dot module (Bio-Rad) to concentrate the reaction area. For the 
monoclonal antibody experiments, 20 µL of whole cell digest was applied to the 
nitrocellulose paper under a vacuum. Once dry, the paper was blocked with 3 % (w/v) 
skimmed milk, the blot rinsed briefly in PBS before re-blocking and then rinsed again in 
PBS before applying the monoclonal antibody. The blots were then reacted and developed 
as described in section 2.5.3. 
2.5.4.1 Antigenic investigation of urine samples 
Urine samples were investigated for both human antibodies specific to A-band LPS and the 
P. aeruginosa A-band LPS itself. To test for the presence of P. aeruginosa LPS, the boiled 
and filtered urine samples were firstly defrosted and 200 [IL of each applied to the 
nitrocellulose paper using the Bio-Dot module. A control sample of 2 [IL of purified LPS 
(from strain AK1401) in 200 !IL of distilled water was also included. The nitrocellulose 
109 
paper was dried at 37 °C before immunoblotting as detailed in section 2.5.3. Firstly, 100 tiL 
of serum pool HP4 and 30 tit of polyvalent 'second' antibody were used. Thereafter, 
samples were tested in quadruplicate, with the blots being a quarter of the size, so 50 tiL of 
primary antibody and 20 µL of polyvalent anti-human or anti-rabbit 'second' antibody were 
used. 
Due to the antibodies present in the urine samples masking any antigen detection, dot blots 
were repeated after urines were pre-treated with Proteinase-K. Briefly, 420 tfir, of urine was 
added to 10 µ1., of 2 mg/mL Proteinase-K in solubilization buffer. The samples were 
incubated at 37 °C for 15 min, before increasing the temperature to 100 °C for 30 min. One 
hundred microlitres of each sample was then applied to the Bio-Dot module and the urines 
tested as above. 
For further investigation of the presence of P. aeruginosa LPS in urine, 5 mL of the urine 
samples which had been incubated at 100 °C and 5 mL of the filtered urine from two CF 
patients (RBH3 and RBH4) were dialysed against 4 L distilled water for 24 h at 4 °C, with 
three changes of distilled water. The dialysate was frozen and freeze-dried. The lyophilised 
urine was reconstituted in 65 121, of solubilization buffer. A very small loopful (using a 1 
[IL loop) of Proteinase-K was added to a 15 !IL aliquot of each sample and the samples 
incubated at 37 °C for 30 min before increasing to 100 °C for 30 min. Five microlitres of 
sample were added to wells for SDS-PAGE and gels were stained with silver. Fifty 
microlitres of the 65 tit aliquot was then heated to 100 °C for 5 min. The sample was 
double-diluted in solubilization buffer and 5 tit loaded onto SDS-PAGE gels, which were 
subsequently either stained with Coomassie blue or immunoblotted and reacted with AW1 
and HP4 serum samples. 
2.5.5 OMP band excision and blotting 
During the study, two particular protein bands (X and Y) were identified in outer 
membrane preparations. To study these antigens further, they were excised as detailed 
below. 
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A Shandon model 200 vertical slab unit gel electrophoresis system was employed for SDS-
PAGE (Shandon Scientific Ltd, Cheshire, UK). A large SDS-PAGE gel (190 mm by 200 
mm) was poured (using double the quantities detailed in section 2.4.6) with a single well 
spanning the width of the gel. Five hundred micrograms of outer membrane protein from 
strain PA01 was added to the well and electrophoresis applied at 50 mA for 2 h. The gel 
was stained with fresh Coomassie blue stain, but only until the target bands could be 
identified. Using a ruler and scalpel, the bands were excised and each transferred to the 
barrel of a syringe. The gels were then passed into separate bijou bottles, thus mincing 
them. Two millilitres of extraction buffer (0.5 % (w/v) SDS in PBS) were added to each 
bijou bottle, which were placed on an MMI Multimix roller mixer (Luckham Ltd) overnight 
at room temperature. The following day, the gel suspensions were each aliquotted into 2 
microtubes. The liquid was taken from each and centrifuged at high speed for 5 min. An 
excess of acetone was added to the samples to precipitate the proteins. The tubes were then 
centrifuged again and the supernatant discarded. The lids of the microtubes were left open 
to allow the evaporation of the remaining acetone. Ten microlitres of solubilization buffer 
were added to each tube, the samples vortexed, incubated for 5 min at 100 °C and used for 
SDS-PAGE as previously. Preparations of bands X and Y were either stained with 
Coomassie blue or reacted with 1-1P3 sera by immunoblotting. 
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2.6 	Molecular investigations of P. aeruginosa 
2.6.1 Confirmation of P. aeruginosa species identification 
For all P. aeruginosa strains, if there was doubt with the species identification, they were 
tested as follows. 
2.6.1.1 DNA extraction 
A cell lysis method was used for the extraction of DNA from strains. Briefly, a sweep of 
colonies were added to 200 µL of distilled water and incubated at 100 °C for 5 min. The 
cell suspension was then centrifuged at 13 000 g for 5 min in a micro-centrifuge. Two 
microlitres of supernatant were used as the DNA template in the subsequent PCR reaction. 
2.6.1.2 Polymerase chain reaction 
This was carried out in 200 µL thin walled PCR tubes, in a total reaction volume of 25 µL 
containing 2 !AL of extracted template DNA, described above. The PASS primers, as 
described by Spilker et al. (2004), were synthesised by Sigma-Genosys, Haverhill, UK. The 
reaction mixture consisted of: 0.5 µM of each primer (PASS-F: GGG GGA TCT TCG 
GAC CTC A and PASS-R: TCC TTA GAG TGC CCA CCC G), 0.5 µM of each dNTP, 
2.5 mM MgC12, 2.5 U Taq DNA polymerase and 1 x reaction buffer supplied by the 
manufacturer (Invitrogen BV, Renfrew, UK). PCR was carried out in an Eppendorf 
Mastercycler thermal cycler (Anachem, Luton, UK). The PCR comprised an initial 
denaturation step at 95 °C for 5 min followed by 30 cycles of 1 min at 95 °C, an annealing 
step of 1 min at 65 °C and 1 min at 72 °C. 
2.6.1.3 Separation of amplified products by gel electrophoresis 
Six microlitres of PCR product were diluted in 3µL of double-processed tissue culture 
water (Sigma-Aldrich) and mixed with 3 iaL of loading buffer blue (Bioline, London, UK). 
Ten microlitres of this mix was used for electrophoresis on a 1.2 % (w/v) agarose gel made 
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with certified molecular biology agarose (Bio-Rad) and 0.5 x TBE buffer (Invitrogen BV, 
Renfrew, UK) with molecular weight standards comprising a 123 bp ladder (Invitrogen 
BV). The gels were subjected to electrophoresis in 0.5 x TBE buffer at 120 kV for 2 h and 
stained in 1 pg/mL ethidium bromide solution. The PCR products were visualised and 
photographed under UV light on a transilluminator. A PCR product of 956 bp was 
indicative of a positive result. 
2.6.2 A-band biosynthesis gene detection 
2.6.2.1 Detection of gca 
Following the studies of Currie et al. (1995), the reference type strains of P. aentginosa 
were investigated for the presence of the gca gene which encodes the A-band GDP-D-
mannose dehydratase enzyme. 
2.6.2.1.1 DNA extraction 
DNA extraction was performed as section 2.6.1.1. 
2.6.2.1.2 Polymerase chain reaction 
PCR was carried out in 200 µL thin walled PCR tubes, in a total reaction volume of 25 1.1.1., 
containing 2 1.11_, of extracted template DNA, described above. The gca gene primers, HCR1 
and HCR2, as described by Currie et al. (1995), were synthesised by Sigma-Genosys. The 
reaction mixture consisted of: 0.5 1.1.M of each primer (HCR1: TGG CCA AGC TGC TGC 
TGG and HCR2: ACG GTG GTA GTG ACA ACG), 0.5 RM of each dNTP, 2.5 mM 
MgC12, 2.5 U Taq DNA polymerase and 1 x reaction buffer supplied by the manufacturer 
(Invitrogen BV). PCR was carried out in an Eppendorf Mastercycler thermal cycler. The 
PCR comprised 30 cycles of a denaturation step of 1 min at 95 °C, an annealing step of 1 
min at 55 °C and 1 min at 72 °C. A final extension step was for 5 min at 72 °C. 
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2.6.2.1.3 Separation of amplified products by gel electrophoresis 
The PCR products were processed and separated as in section 2.6.1.3. A PCR product of 
700 bp was indicative of a positive result. 
2.6.2.2 Design of new A-band primers 
To identify sequenced genes encoding A-band LPS biosynthesis, the search "A-band" was 
conducted at the Pseudomonas genome project website (www.pseudomonas.com/search.jsp). 
Two genes, wzm and wzt, were retrieved from both the PAO1 and PA14 strains, 
representing the "membrane subunit of A-band LPS efflux transporter" and "ABC subunit 
of A-band LPS efflux transporter", respectively. 
The target DNA sequences for both strains, as well as the whole genome sequences 
(retrieved from the Pseudomonas genome project website for strains PAO1 and PA14), 
were copied into Genebuilder®, where they were aligned. For each gene, an 18 bp sequence 
was selected that constituted a possible candidate (according to the properties outlined in 
Table 13), and from an area without mismatches. Potential primer sequences were copied 
into the Sigma-Aldrich online DNA oligosaccharide design tool (www.sigmaaldrich.com/cgi-
bin/hsrun/Suite7/Suite/HAHTpage/Suite.HsDesignTool.formAction) to check for suitability and 
compatibility, remembering to insert the complementary sequence for the reverse primers. 
Once primer pairs with compatible melting temperatures were selected, they were copied 
into the online BLAST (Basic Local Alignment Search Tool) (www.ncbi.nlm.nih.gov/BLAST/)  
to compare the sequences with those in the Genbank database and ensure an absence of 
cross-reactions. Since the melting temperatures for all four primers were similar, it was 
potentially possible to multiplex the reactions. To ensure both gene products could be easily 
distinguished, it was important to have different product sizes. To calculate the length of 
amplicons, the selected primer sequences were copied back into Genebuilder®. 
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Table 13. General guidelines for design of standard PCR primers 
Adapted from (Qiagen, 2006) 
Property Recommendation 
Length 
GC content 
Tm 
Sequence 
18 — 30 nucleotides 
40 — 60 % 
Simplified formula for estimating melting temperature (Tm): 
Tm =-2 °C x (A+T) + 4 °C x (c+c) 
Whenever possible, design primer pairs with similar Tm values. 
Optimal annealing temperatures may be above or below the estimated Tm. As a 
starting point, use an annealing temperature 5 °C below Tm. 
• Avoid complementarity of two or three bases at the 3' ends of primer pairs to 
reduce primer-dimer formation 
• Avoid runs of 3 or more Gs or Cs at the 3' end 
• Avoid a 3'-end T. Primers with a T at the 3' end have a greater tolerance of 
mismatch 
Avoid complementary sequences within a primer sequence and between the 
primer pair 
Commercially available computer software can be used for primer design 
Spectrophotometric conversion for primers: 
Absorbance of 1 at 260 nm = 20 — 30 pg 
Molecular conversions: 
Primer length 	pM / pg 	20pM 
18 mer 168 119 ng 
Concentration 
20 mer 152 132 ng 
25 mer 121 165 ng 
30 mer 101 198 ng 
Use 0.1 — 0.5 pM of each primer in PCR. For most applications, a 0.2 pM primer 
concentration will be sufficient 
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2.6.2.2.1 DNA extraction 
A crude cell lysis method was used for the extraction of DNA from P. aeruginosa strains. 
Briefly, a sweep of colonies was added to 100 !AL of distilled water and vortexed for 10 sec. 
The cell suspension was centrifuged at 13 000 g for 2 min in a micro-centrifuge. Three 
microlitres of supernatant were used as the DNA template in the subsequent PCR reaction. 
2.6.2.2.2 Polymerase chain reaction 
This was carried out in 200 µ1_, thin walled PCR tubes, in a total reaction volume of 25 uL 
containing 3 tiL of extracted template DNA, described above. The Wzm-F, Wzm-R, Wzt-F 
and Wzt-R primers (Table 14) were synthesised by Sigma-Genosys and the other reagents 
were from Qiagen's Taq PCR Core kits (Qiagen, Crawley, UK). Dilutions were made in 
double-processed tissue culture water. 
The multiplex reaction mixture consisted of: 10 pM of each primer, 200 I.A.M of dNTP mix, 
1.5 U of Taq DNA polymerase and 1 x PCR buffer (which included 1.5 mM MgC12). PCR 
was carried out in an Eppendorf Mastercycler thermal cycler. The PCR comprised an initial 
denaturation step at 94 °C for 3 min followed by 30 cycles of 30 sec at 94 °C, an annealing 
step of 1 min at 55 °C and an extension step of 1 min at 72 °C. A final extension step was 
for 5 min at 72 °C. 
Table 14. Primer details for amplification of wzm and wzt 
Target Primer Sequence 
Melting temperature 
(C) 
Amplicon size 
(bp) 
wzm 
wzt 
Wzm-F 
Wzm-R 
Wzt-F 
Wzt-R 
GGC CTA CAG CGT CTA TCT CT 
GAG AAA GCC GAG GAA CAA 
GCC TAT TTC CAG CAC MG 
60.02 
60.51 
58.33 
56.58 
203 
626 
TTG ATG ACA TGG MG ACC 
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2.6.2.2.3 Separation of amplified products by gel electrophoresis 
Eight microlitres of PCR product were mixed with 2 µL of loading buffer blue and 8 ttL 
resolved, along with Hyperladder II (Bioline) marker, by electrophoresis on a 1.5 % (w/v) 
agarose gel made with certified molecular biology agarose and 0.5 x TBE buffer. 
Electrophoresis was performed in 0.5 x TBE buffer at 120 kV for 2 h and stained in 1 
[ig/mL ethidium bromide solution. The PCR products were visualised and photographed 
under UV light on a transilluminator. 
2.7 Investigation into the antibody response of rabbits and guinea pigs to P. 
aeruginosa 
During the preparation of hyper-immune animal sera, antibodies to P. aeruginosa antigens 
were detected in pre-challenge sera. To investigate the possibility of an infection with P. 
aeruginosa in the animal-rearing building of BSD, swabs were taken from 16 
environmental sites (5 taps, 4 drains, 1 bottle and 6 rabbit pens) and 12 rabbit sites (4 rabbit 
noses, mouths, and anuses) and cultured on King's A agar in air for 48 h at 37 °C. The 
plates were then examined for the growth of characteristic colonies. 
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2.8 Development of ELISA 1 — a preliminary indirect assay for detection of 
antibodies to A-band LPS of P. aeruginosa in sera and oral fluid from CF patients 
2.8.1 Basic procedures 
Purified LPS (prepared as described in section 2.4.4) from strain AK1401 was used as the 
ELISA coating antigen. One hundred microlitres of 1 pg/mL LPS in carbonate coating 
buffer (15mM Na2CO3, 34.5 mM NaHCO2, p1-1 9.6) were applied to medium-binding, flat-
bottomed Maxisorb ELISA plate wells and plates incubated overnight at 4 °C. Wells were 
washed three times in 0.05 % (v/v) Tween 20 in PBS and 200 fiL of blocking solution (1 % 
(w/v) BSA in PBS) added, before incubating for 30 min at 37 °C. At this stage, an 
additional set of wells were coated with 1 % (w/v) BSA in PBS and incubated for 30 min at 
37 °C, to test for non-specific binding of the antibody samples to BSA. Serum samples 
were diluted 1/500 in PBS and oral fluid and urine samples used undiluted. After washing 
the wells three times in 0.05 % (v/v) Tween 20 in PBS, 100 µI, of diluted serum or 50 µ1., 
of oral fluid or urine were added to duplicate wells (one LPS-coated and one BSA-coated) 
and plates incubated for 1 h at room temperature. Plates were washed three times in 0.05 % 
(v/v) Tween 20 in PBS, 100 lit of alkaline phosphatase-conjugated goat-anti-human IgA + 
IgG + IgM (Sigma-Aldrich, KPL or Serotec, Oxford, UK) diluted 1/1000 in PBS added to 
wells and plates incubated for 1 h at room temperature. After washing the wells three times 
in 0.05 % (v/v) Tween 20 in PBS, to develop the ELISA, 200 µL of 1 mg/mL p-nitrophenol 
phosphate in substrate buffer (0.9 M diethanolamine, 2 mM MgC12, pH 9.6, brought to 
room temperature) were added to wells and plates maintained at room temperature. The 
optical density was measured at 405 nm after 30 min. 
2.8.2 Assay optimisation 
During development and optimisation of ELISA 1, different components and their 
concentrations were investigated, including the blocking solution, sample dilutions, 
`second' antibody and development time. 
o 	The LPS concentration was tested at 0.5 µg, 1 µg, 5 gig or 10 µg per well. 
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o 1 % (w/v) skimmed milk in PBS was investigated as an alternative blocking 
solution. 
o Serum samples were tested at 1/10 diluted through to 1/50000 
o The alkaline phosphatise-conjugated 'second' antibody concentration was tested at 
1/100 double diluted through to 1/102400 
o Additional 'second' antibodies tested were: goat-anti-human IgG (µ-chain specific), 
goat-anti-human 1gM (7-chain specific) and goat-anti-human IgA (a-chain specific) 
(Sigma-Aldrich) 
o Assay development times varied from 5 min through to 30 min. 
ELISA control samples were tested on different plates on different days to assess the 
variation between tests. Additionally, a single sample was used for an entire 96-well plate, 
to assess the variation within a single test. 
2.8.3 Statistical analyses 
The mean, standard deviation (SD) and coefficient of variation (CV) (Figure 13) between 
repeated samples were calculated to assess reproducibility. The accepted CV limit was 20 % 
(Findlay et al., 2000). For large sample sets, the data's distribution was investigated by 
dividing the data into appropriate categories and plotting their frequency. Samples were also 
tested by immunoblotting, to compare the visual blot with an optical density. To compare 
ELISA results from the CF and control populations, Student's t-tests were performed. Paired 
Student's t-tests were performed on paired samples from CF patients. 
2.8.4 Anti-BSA antibodies 
Due to the discovery of antibodies binding non-specifically to BSA, indicated by a raised 
titre in the BSA-coated wells but negative immunoblot results, sera were diluted in 
blocking solution for at least 30 min prior to adding to wells. 
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Figure 13. Formulae for standard deviation (SD) and coefficient of variation (CV) 
mean = adding a group of numbers and then dividing by the count of those numbers 
SD = 	1. (x _ :To: 	 where x is the sample 
11 	(n —1) 	 T is the mean 
n is the sample size 
CV (%) = (SD ri ) x 100 
median = 50th percentile - half the data points are greater than and half less than the 
median 
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2.9 	Development ELISA 2 — an indirect double antibody assay for the quantification 
of antibodies in sera 
To increase the reproducibility of ELISA 1 and to standardise the procedure, a standard 
anti-LPS control sample was prepared to be included on each plate to enable the 
construction of a standard curve. In order to measure accurately the anti-Pseudomonas LPS 
antibodies in HPP, an indirect double antibody assay for the quantification of antibodies in 
sera was developed. 
2.9.1 Basic procedures for IgG quantification 
One hundred microlitres of 2 ptg/mL polyclonal rabbit-anti-human IgG coating antibody 
(Dako Cytomation) in carbonate coating buffer (15mM Na2CO3, 34.5 mM NaHCO2, pH 
9.6) were applied to medium-binding, flat-bottomed Maxisorb ELISA plate wells and plates 
incubated overnight at 4 °C. Wells were washed once in 0.05 % (v/v) Tween 20 in PBS and 
200 tit of 3 % (w/v) skimmed milk in PBS blocking solution added, before incubating for 
30 min at 37 °C. Serum samples were serially diluted 1/10 000 through to 1/270 000 in 3 % 
(w/v) skimmed milk in PBS and human serum protein calibrator (Dako Cytomation) double 
diluted down from 0.8 lig/mL. After washing the wells four times in 0.05 % (v/v) Tween 20 
in PBS, 100 tit of samples were added to triplicate wells and plates incubated for 2 h at 37 
°C. Plates were washed four times in 0.05 % (v/v) Tween 20 in PBS and 100 pt of alkaline 
phosphatase-conjugated rabbit anti-human IgG 'second' antibody (Dako Cytomation) 
diluted 1/500 in 3 % (w/v) skimmed milk in PBS added to wells. After incubating for 1 h at 
37 °C, plates were washed four times in 0.05 % (v/v) Tween 20 in PBS. To develop the 
ELISA, 200 µ1_, of 1 mg/mL p-nitrophenol phosphate in substrate buffer (0.9 M 
diethanolamine, 2 mM MgC12, pH 9.6, brought to room temperature) were added to wells 
and plates maintained at room temperature. The optical density was read at 405 nm with a 
620 nm filter over a time course. The human serum protein calibrator values were plotted 
against antibody concentration and results extrapolated. 
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2.9.2 Assay optimisation 
Different components and their concentrations were investigated, during development and 
optimisation of ELISA 2, including the coating buffer, blocking solution, sample dilutions, 
`second' antibody and development time. 
o Alternate coating buffers (PBS (pH 7.2) and water (pH 5.9)) were investigated 
o Different blocking solutions (1 % (w/v) BSA in PBS, 1 % (w/v) chicken egg 
albumin in PBS, Microimmune blocking buffer (Microimmune Ltd)) were tested 
o Additional 'second' antibodies tested were: goat-anti-human IgG (µ-chain specific) 
(Sigma-Aldrich) with 1 % (v/v) added rabbit sera and goat-anti-human IgA + IgG + 
IgM rabbit-anti-human IgG (KPL) 
o Assay development times varied from 5 min through to 30 min. 
Samples were tested in quadruplicate and on four different days to asses the reproducibility, 
inter-run variation and intra-run variation. 
Statistical analyses were performed as in section 2.8.3. 
2.9.3 Basic procedures for IgM and IgA quantification 
The method detailed above in section 2.9.1 was repeated for the quantification of both IgM 
and IgA- classed antibodies. The procedure deviated by employing goat anti-human IgM 
(µ-chain specific) (Sigma-Aldrich) and goat anti-human IgA (a-chain specific) (Sigma-
Aldrich) coating antibodies and alkaline phosphatase-conjugated goat-anti-human IgM (y-
chain specific) (Sigma-Aldrich) and goat-anti-human IgA (a-chain specific) (Sigma-
Aldrich) 'second' antibodies. 
122 
2.9.4 LPS-adsorbed sera 
To create an anti-LPS control sample, three plates of strain AK1401 were grown overnight 
on nutrient agar at 37 °C. Approximately 2 mL formol saline was added to the plate and 
using a plastic spreader, the growth was harvested and incubated overnight at 4 °C. The 
cells were incubated at 100 °C for 1 h before being centrifuged at 12000 g for 10 min. The 
supernatant was removed and samples washed in PBS five times. After the final 
centrifugation, the supernatant was discarded and any remaining moisture removed with 
swab. Half a millilitre of HPP sera was added to the cell pellet and thoroughly mixed with a 
cocktail stick. The serum suspension was incubated for 2 h at 37 °C with gentle shaking and 
then overnight at 4 °C. The suspension was then centrifuged at 12000 g for 30 min and the 
supernatant stored at 4 °C until use. The adsorbed serum was tested alongside HPP sera by 
immunoblot and ELISA 2. 
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2.10 Development of ELISA 3 — an optimised indirect for detection of IgG and IgM-
classed antibodies to A-band LPS of P. aeruginosa in sera from CF patients 
Due to problems with the reproducibility of ELISA 2, a simpler format was developed 
combining methods from ELISA 1 and ELISA 2. ELISA 3 was then employed for the 
clinical evaluation study. 
2.10.1 Basic procedures 
One hundred microlitres of 1 µg/mL LPS from strain AK1401 in carbonate coating buffer 
(15mM Na2CO3, 34.5 mM NaHCO2, pH 9.6) were applied to medium-binding, flat-bottomed 
Maxisorb ELISA plate wells and plates incubated overnight at 4 °C. Serum samples, 
positive control (Std) and negative control (N) were diluted 1/200 in 1 % (w/v) BSA in 
PBS and maintained at room temperature 30 min prior to the following step. Wells were 
washed three times in 0.05 % (v/v) Tween 20 in PBS and 200 uL of blocking solution (1 % 
(w/v) BSA in PBS) added, before incubating for 30 min at 37 °C. After washing the wells 
three times in 0.05 % (v/v) Tween 20 in PBS, 100 III, of diluted serum were added to 
duplicate wells for both IgG and 1gM-classed antibody detection and a 1% (w/v) BSA in 
PBS blank included. Plates were incubated for 2 h at 37 °C, washed three times in 0.05 % 
(v/v) Tween 20 in PBS and 100 ftL of alkaline phosphatase-conjugated rabbit anti-human 
IgG 'second' antibody (Dako Cytomation) or goat-anti-human IgM (y-chain specific) 
(Sigma-Aldrich) diluted 1/1000 in 1 % (w/v) BSA in PBS added. Plates were then 
incubated for 1 h at 37 °C. After washing the wells three times in 0.05 % (v/v) Tween 20 in 
PBS, to develop the ELISA, 200 µI, of l mg/mL p-nitrophenol phosphate in substrate 
buffer (0.9 M diethanolamine, 2 mM MgC12, pH 9.6, brought to room temperature) were 
added to wells and plates maintained at room temperature. The optical density was 
quantified at 405 nm with a 620 nm filter when sample Std reached 2.5 A405 +1- 10 %. If the 
value for sample N was 0.5 A405 +/- 10 % or 1.5 A405 +1- 10 % for the IgG and IgM assays, 
respectively, the results were accepted. Additionally, the mean, SD and CV were calculated 
for duplicate samples. If the CV was less than 20 %, the mean value was accepted for the 
sample. The blank value also needed to fall below 1.0 A405. 
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2.10.2 Clinical evaluation study 
All 370 serum samples listed in section 2.3.7 were tested (328 in duplicate and 42 in 
quadruplicate) for IgM and IgG-classed antibodies to P. aeruginosa strain AK1401 purified 
LPS using the optimised ELISA 3 method. If duplicate values had a CV greater than the 
accepted 20 % (Findlay et al., 2000), they were re-tested. The first 20 control values 
(samples Std and N) were plotted on a graph, their distribution plotted and the cut-off 
values established (mean + (3 x SD)), for acceptance of the test results for that plate. Forty-
one healthy volunteer serum samples were tested in duplicate for IgM and IgG-classed 
antibodies to P. aeruginosa strain AK1401 purified LPS, the distribution for the sample 
absorbences was checked and the negative cut-off calculated (mean + 2 x SD). The 
specificity of the IgG assay using this cut-off was calculated, as described in Figure 12. 
All ELISA values were sorted from high to low for both IgM and IgG assays and alternate 
serum samples tested by immunoblotting with whole cell digests of strain AK1401 and 
reacted with the corresponding 'second' antibody. 
ELISA data were then collated with pulmonary function test and sputum microbiology data 
for each patient. For the comparison of IgM serology and sputum culture data, antibody 
baseline levels were determined for each patient by calculating their CV for early samples 
and a two or more fold increase from this was considered significant. 
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2.11 Comparison of ELISA 3 with in-house and commercially available tests 
2.11.1 Comparison of the LHCAI in-house ELISA antigen results 
Since the LHCAI in-house ELISA employed six antigens (01, 06, 07, 012, AK1401 and 
C28), the results from 370 serum samples listed in section 2.3.7 were examined in 
Microsoft Excel 2003 using pivot tables to identify whether the result from the AK1401 
antigen was representative. The level of agreement of the results from the different antigens 
with the AK1401 antigen was calculated and the percentage of results within one dilution 
were established. 
2.11.2 Comparison of ELISA 3 with the LHCAI in-house ELISA 
All 370 serum samples listed in section 2.3.7 were tested by ELISA 3 and the LHCAI in-
house ELISA. To assess the relationship between the two methods, the data were plotted on 
a scatter plot (with the "< 500" titre given the value of 250) and the R2 value (or coefficient 
of determination) calculated (Figure 14). 
Figure 14. Formula for R2 
R2 = 
  
(x— x)(y —;) 
  
2 
where: x and y are the samples 
rand Ty are the sample means 
       
       
        
2.11.3 Comparison of ELISA 3 with the Genesis Diagnostics and the SSI ELISAs 
Thirty-nine of these serum samples were also tested by ELISA 3, the Genesis Diagnostics 
ELISA and using the SSI antigen. These data were individually plotted against the 
corresponding results given by ELISA 3 and also against each other on scatter plots and the 
R2 values calculated (Figure 14). 
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CHAPTER 3 
RESULTS I: GENERAL INVESTIGATION OF THE 
ANTIGENS OF P. AERUGINOSA 
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In this chapter, the hypothesis investigated was 'a protein or LPS antigen of P. aeruginosa 
could be employed as a common and specific antigen for P. aeruginosa, so would be 
suitable to identify infections with this organism in patients with CF'. 
To identify and characterise a common antigen specific to P. aeruginosa, the outer 
membrane proteins and LPS of a panel of strains were investigated. These structures were 
chosen since they are on the outside of the bacterial cell so could therefore elicit an 
antibody response in a host. The aim was to find an antigen that was consistently present in 
all strains that cause disease and could therefore elicit an antibody response in a CF patient, 
was easy to isolate in sufficiently pure form and did not cross-react with other species to 
produce false-positive results. It was also important to identify a protein or LPS moiety that 
was highly antigenic so that a corresponding antibody response could be easily detected. 
3.1 	LPS and protein profiles by SDS-PAGE 
For the preliminary investigation of the protein and LPS antigens of P. aeruginosa, 
reference serotype strains, defined mutant strains and a species specificity panel of strains 
were profiled by separation on SDS-PAGE gels. Visual comparisons of silver or Coomassie 
blue stained profiles were made to identify a common, species-specific target suitable for 
further investigation. 
3.1.1 Type strains 
All 20 0-serotype strains, along with strains AK1401, PA01 and C28 were digested with 
Proteinase-K, their profiles separated by SDS-PAGE and visualised by silver staining 
(illustrated in Figure 15). The profiles show the low molecular weight core moiety, in the 
lower quarter of the gel, and the repeating characteristic ladder patterns of 0-side chains. 
The lipid A of LPS, which migrates with the dye-line in the gel, is not visible by silver 
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Figure 15. Silver-stained profiles of Proteinase-K digests (LPS) of reference type strains of 
P. aeruginosa 
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stain. Above the core region, the bands represent the polysaccharide chains of varying 
length — the shorter or less-branched chains migrate faster in the gel and high molecular-
weight longer chains resolve at the top of the gel. The large band approximately half way 
down the gel was shown to be a Proteinase-K-resistant protein of approximately 22 KDa 
(compared against protein standards on Coomassie blue stained gels). 
Silver staining of the gels revealed that the 0-serotype strains had different LPS structures. 
Strains C28 and AK1401 and 0-serotype strains 07, 09, 016 and 017 formed 
predominantly intermediate-length chain LPS, whereas strains PAO1, 01, 02, 03, 05, 06, 
08, 010 and 013 expressed both short-chain and intermediate-chain LPS; serotypes 04, 
011 and 019 expressed LPS of all lengths - short, intermediate and long-chain. Strain 015 
formed only long-chain LPS, and strains 012, 014, 018 and 020 expressed long and 
intermediate-chain LPS. 
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The outer membranes of all 20 0-serotype strains, AK1401, PA01 and C28 were stained 
with Coomassie blue protein stain (Figure 16). Several protein bands were revealed and 
strains shared very similar profiles with a number of common protein bands. The molecular 
weights of the main shared proteins were approximately 58.9, 55.6, 49.0, 39.8, 28.8, 26.3 
and 19.1 KDa in size (labelled A to G, respectively). There appeared to be a greater amount 
of the larger-sized proteins, particularly B and D, as these bands were more densely stained. 
Several of the larger proteins, including B, were modified by heat (Figure 17), thus 
suggesting that they may be porins, which characteristically denature on heating. 
The sizes of the main common proteins did not correlate exactly with sizes of published 
proteins, making absolute identification difficult. However, band G approximates closely to 
OprL and band D to OprF (21 KDa and 38 KDa, respectively), although band D (OprF) 
should be heat-modifiable if it is truly the porin identified by Hancock (1990). 
Figure 16. Bacterial outer membranes of reference type strains of P. aeruginosa stained 
with Coomassie blue 
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Figure 17. Heat modifiable proteins of P. aeruginosa: SDS-PAGE of outer membranes 
heated to 37 °C or 100 °C and stained with Coomassie blue 
3.1.2 Defined mutant strains 
The silver-stained SDS-PAGE profiles of the Proteinase-K digests of the defined mutant 
strains are shown in Figure 18. There was no significant difference in the LPS profiles of 
strains known to be deficient in fimbriae and flagella from their parent wild types (K pilr 
fla-, K3PO4 pir fla-, KPO4 pif flak, K pil" flak, K pilr flat, PAO1PO4 pir flak and PAOpir 
flat); all isolates expressed short, intermediate and long-chain LPS. Mutants with specific 
defects in alginate synthesis genes (PAO 381, PAO 568, PAO 578, PAO 579 and PAO 
581) also formed intermediate and long-chain LPS. 
The SDS-PAGE profiles of polyagglutinable strains commonly found in CF patients (PS7, 
PS7/1, PS18R and PS18S) showed the side-chains were more weakly stained with silver 
than other strains. Strains PS7 and PS7/1 both had visible intermediate-chain LPS, with the 
former also expressing short-chain LPS. However, strains from either PS18R and PS18S 
were devoid of side-chain LPS, explaining why it is not possible to serotype these strains, 
which relies on the ability of side-chain LPS to form immune complexes with 0-type 
specific antibodies in rabbit antisera. 
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Figure 18. Silver-stained profiles of Proteinase-K digests of wild type and defined mutant 
strains of P. aeruginosa 
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The A-band mutant strain Wbpm, which does not make B-band LPS, expressed 
intermediate-chain LPS, consistent with A-band LPS. None of the other LPS and core 
mutants (Rmd, Rmlc/rmd, MigA/rmd and WapR), formed an A-band profile, although Rmd 
and MigA/rmd showed side-chain LPS consistent with expression of B-band epitopes. No 
difference was observed between the core LPS region of strains Rmlc/rmd and MigA/rmd, 
neither appeared to form outer core LPS bands. 
The Coomassie blue-stained outer membrane protein profiles of the panel of mutant strains 
are shown in Figure 19. No significant differences between strains K pilr fla-, K3PO4 pil-
fla-, KPO4 pil- fla+, K pil" fla+, K pilr fla+ and PAOpir fla+ were found, despite the lack of 
flagella in strains K pilr fla and K3PO4 pil- fla. Strain PAO1PO4 pil- fla+ lacked several 
large proteins, seen in the profiles of the other fimbriae and flagella mutant strains. These 
missing bands were consistent with protein bands B and C (see Figure 16). Outer 
membranes of strains with specific defects in alginate synthesis genes were not prepared. 
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Figure 19. Outer membranes of wild type and defined mutant strains of P. aeruginosa 
stained with Coomassie blue 
O. 
±e
U
 	
to
d  
I  o
va
  
.0. .5. 	.0 
	
I fl.) /1)+ '17S '0 	'') I 
= I i 
Al+ 
1: 	11) -,- 
Cln 
3.1.3 Species specificity of antigens 
In order to ensure that potential candidate antigens were unique for P. aeruginosa, a panel 
of strains representing other Pseudomonas spp. and similar bacteria found in the CF lung 
were assembled. The outer membrane protein profiles of the strain panel are shown in 
Figure 20. Extensive variation in protein bands was found, with little similarity to proteins 
of P. aeruginosa, or indeed common between species. However, there were some common 
bands between species from the same genus; the Burkholderia spp. (B. multivorans, B. 
cenocepacia Ma, B. cenocepacia Mb and B. gladioli) profiles lacked any proteins smaller 
then 20 KDa; and, the H influenzae strains did not appear to possess any major proteins 
between 15 and 40 KDa. It seems likely therefore that the outer membrane profile of P. 
aeruginosa is unique when compared with other Gram-negatives occasionally isolated from 
the CF airway and cross reactivity with other species would not pose a significant problem. 
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Figure 20. Outer membranes of various bacterial species stained with Coomassie blue 
3.2 Antibody-antigen profiles 
As well as identifying a common, species-specific structure from P. aeruginosa for the 
investigation of new serodiagnostic techniques, the chosen target must elicit a strong 
antibody response in the host, if it is to be adopted as a reference antigen. Hyper-immune 
human and animal sera were therefore screened for their reactivity with candidate antigens. 
3.2.1 Human antibody reactions with type strains 
The results from testing the human serum pools using the LHCAI in-house ELISA are 
shown in Table 15. The negative serum pool (N) showed consistently no reactivity with the 
six reference strains. The medium (Med) and low positive (LP) pools gave similar and 
marginally higher titres, whereas the high positive pools (HP1 to HP4, HPP and Std) were 4 
to 6 fold higher in titre. 
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Table 15. Serum pools antibody titres in the LHCAI in-house ELISA. 
Pool 
01 06 
Antibody titre 
07 	012 AK1401 C28 
HP1 4000 2000 2000 4000 4000 4000 
HP2 4000 4000 4000 4000 4000 4000 
HP3 16000 8000 16000 16000 16000 16000 
HP4 4000 8000 4000 4000 4000 4000 
HPP 4000 8000 4000 8000 4000 4000 
Std 4000 8000 8000 4000 4000 8000 
LP 500 500 1000 500 1000 500 
Med 500 500 500 500 500 500 
N <500 <500 <500 <500 <500 <500 
The binding of the HP2 pooled sera with the Proteinase-K cell digests and outer membrane 
preparations of the reference panel are shown in Figure 21 and Figure 22, respectively. 
Similar profiles were seen with other high positive serum pools (data not shown). 
The Proteinase-K extracts of strains 07, 08, 012, 014, 015, 016 and 020 did not react 
with the high positive sera (Figure 21) and some extracts gave very weak immunoblot 
bands to intermediate-chain LPS (02, 04, 05 and 019). However, others (C28, PAO1, 
AK1401, 03, 09, 010, 011, 013, and 017) exhibited clear antibody binding to specific 
epitopes of intermediate-chain LPS. Serotypes 01, 06 and 018 demonstrated antibody 
binding to long-chain and intermediate-chain LPS. Furthermore, some extracts of strains 
(01, 03, 04, 06, 09, 011, 013, 014 and 017) showed strong immunoblot bands with 
core LPS epitopes. Immunoblotting also revealed LPS bands not visible in SDS-PAGE 
extracts by direct silver staining. Nevertheless, it was apparent that some parts of the LPS 
molecule did not elicit an antibody response in CF patients. 
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Figure 21. Immunoblot of antibodies in HP2 pooled sera with Proteinase-K extracts of 
reference type strains of P. aeruginosa 
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Figure 22. Immunoblot of antibodies in HP2 pooled sera with outer membranes of 
reference type strains of P. aeruginosa 
1— 1 8 KDa 
2 3; ?..>, 	2 9, 2 9, cs,) 	9 (,:c) o 0 0 0 c 	o o 0 0 2 00 	;2 .F- to 0 -4 00 VD 
Immunoblots of outer membrane proteins showed antibody binding to several protein 
epitopes as well as LPS. Despite not being one of the most visible of protein bands when 
stained directly with Coomassie blue, all strains contained an 18 KDa protein that reacted 
strongly with the CF serum pools (Figure 22). To investigate this protein further, this band 
(which appeared to be resolved as two separate proteins (X and Y) when stained with 
Coomassie blue) was excised and re-applied to SDS-PAGE gels. Very weakly stained 
bands were resolved and were considerably smaller than 18 KDa. It was therefore decided 
to discontinue pursuing this protein as a potential diagnostic target. 
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Figure 23. Binding of IgA, IgM and IgG-classed pooled human serum antibodies (N, Med 
and LP) with reference type strain of P. aeruginosa digested with Proteinase-K 
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Reduced binding was evident with the N, Med and LP pools (Figure 23). All panels were 
reacted with an anti-human polyvalent 'second' antibody, confirming antigens binding with 
IgA, IgG and IgM-classed antibodies. 
To confirm the antibody-antigen reactions visualised with the high positive pooled sera 
were representative of individual patient samples, six serum samples from CF patients 
(4031, 5968, 5543, 4027, 3884 and H04316345) were immunoblotted with the outer 
membrane proteins from the type strains. The resulting profiles are shown in Figure 24 and 
demonstrate clearly that the pooled sera did represent individual CF samples. 
The N serum pool was assembled with samples from CF patients that had given negative 
results in the LHCAI in-house ELISA. However, to ensure that serum from healthy, non-
CF subjects (also negative in the LHCAI in-house ELISA) would not react with the panel 
of strains, six serum samples from anonymous volunteers (HCS1 to HCS6) were tested by 
immunoblot with the outer membrane proteins from the type strains.. Figure 24 shows that 
apart from occasional weak binding to unspecified epitopes there were insignificant levels 
of antibody present in these samples. 
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Figure 24. Binding of antibodies from serum of six individuals with CF ((a) 4031, (b) 5968, 
(c) 5543, (d) 4027, (e) 3884 and (f) H04316345) and six healthy volunteer individuals ((g) 
HCS1, (h) HCS2, (i) HCS3, (j) HCS4, (k) HCS5 and (1) HCS6) to outer membranes of 
reference type strains of P. aeruginosa 
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3.2.2 Human antibody reactions with defined mutant strains 
Outer membranes from mutant strains were separated by SDS-PAGE and reacted strongly 
with high positive sera (Figure 25). Binding of antibodies to LPS and proteins was clearly 
visible with the fimbriae and flagella mutants as well as with the parent wild type strains. 
However, there was very little evidence of binding to the polyagglutinable strains, 
particularly strains 18R and 18S, reinforcing their description of being non-typable. 
Intermediate-chain LPS epitopes were, nevertheless, visible in strain PS7/1. 
The immunoblot profiles strongly resembled the Coomassie blue and silver stained profiles. 
For example, strain PAOIPO4 	flak, previously shown to lack several large proteins, 
also demonstrated reduced antibody-antigen binding in this region. Overall, the 
immunoblot reactions again confirmed that the high positive sera from CF patients 
contained many different antibodies that were specific to several different epitopes of the P. 
aeruginosa outer membrane. 
Figure 25. Binding of pooled human serum antibodies from CF patients with outer 
membranes of wild type and mutant strains of P. aeruginosa 
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3.2.3 Human antibody reactions with species specificity panel 
The immunoblots of sera from CF patients with other bacteria occasionally associated with 
CF pulmonary disease, other pseudomonads and members of the Enterobacteriaceae are 
shown in Figure 26. There was minimal binding with the Enterobacteriaceae and most of 
the CF associated pathogens and pseudomonads, indicating that previous infection of these 
patients with these organisms was unlikely. Moreover, this also confirmed that the protein 
profiles of these specificity panel of strains were distinct from those given by P. 
aeruginosa. 
However, H. influenzae, B. gladioli, P. alcaligenes, P. putida and P. fluorescens strains did 
reveal some antigen binding with the high positive sera. To eliminate the possibility of 
infection with these organisms, the Proteinase-K extracts were reacted with the healthy 
serum pool (HCS). Similarly low levels of binding were seen, but this was considered 
insignificant. It was therefore concluded that these strains may have elicited a sub-clinical 
antibody response but the weak strength of the reactions and distinct immunoblot patterns 
would not be interpreted as an antibody response to P. aeruginosa. 
3.2.4 Reactions of strains with monoclonal antibodies 
High levels of binding to the nitrocellulose paper background were observed when the 
monoclonal antibodies were reacted with Proteinase-K treated cells. Therefore, non-
specific binding of the 'second' antibodies to the blocking agents was investigated. Figure 
27 illustrates the binding of anti-mouse and anti-human 'second' antibodies to 3 % and 5 % 
skimmed milk, foetal calf serum and chicken egg albumin. Very high background staining 
can be seen with the skimmed milk solutions when reacted with the anti-mouse 'second' 
antibody. This background was reduced with foetal calf serum and chicken egg albumin. 
All reactions with the anti-human 'second' antibody were considered acceptable. 
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Figure 26. Binding of pooled human serum antibodies from CF patients with outer 
membranes of species specificity strains 
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Figure 27. Non-specific binding of anti-mouse and anti-human 'second' antibodies to 
different blocking agents 
skimmed milk 	3 % foetal 	3 % chicken 
5 % 	3 % 	calf serum 	egg albumin 
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Figure 28. Confirmation of binding of anti-mouse 'second' antibodies to monoclonal 
antibodies and high positive serum pool 
0 0 0 0 
HP3 	SC7-4 	SC101 	N1F10 
To confirm that the anti-mouse second antibody bound specifically to the monoclonal 
antibodies (SC7-4, SC101 and N1F10), a simple dot blot was performed. Figure 28 shows 
the binding of the 'second' antibody to all three monoclonal antibodies but not to the 
human, high positive HP3 pooled antibodies. 
Monoclonal antibody SC-7-4, specific to the inner core LPS of strain AK1401, was reacted 
with the Proteinase-K digests of the serotype strains and strain Wbpm for either 90 min or 
overnight, shown in Figure 29 a and b respectively. The extended incubation time did not 
increase the resolution of the immunoblot, but there was a small increase in the number of 
bands appearing on the nitrocellulose paper for some strains. For example, strain 011 
showed five bands when incubated with monoclonal SC-7-4 for 90 min, but eight bands 
when reacted overnight. However, the results did not justify the extended test time. 
All tested strains demonstrated binding with monoclonal SC-7-4, although the number and 
size of the bands varied. For example, SC-7-4 bound with a single, discrete band of strain 
015 but also with a diffuse band of strain 07 and multiple bands of strain 011. However, 
since all strains reacted with the antibody, this indicates that the inner cores of these strains 
are homogeneous and share a common epitope. 
Binding of monoclonal antibody SC-101, specific to the outer core LPS of strain AK1401, 
with the Proteinase-K digested type strains and strain Wbpm is shown in Figure 30. 
Thirteen of the 24 strains (02, 05, 07, 08, 010, 015, 016, 018 - 020, AK1401, PA01 
and Wbpm) reacted with the antibody. Some of the strains (08, 010, 015, 018 and 020) 
displayed discrete, single bands, whilst the other strains showed binding to additional 
142 
Figure 29. Binding of anti-inner core LPS monoclonal antibody SC7-4 with Proteinase-K 
digests of reference type strains of P. aeruginosa (a) for 90 min, (b) overnight 
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Figure 30. Binding of anti-outer core LPS monoclonal antibody SC101 with Proteinase-K 
digests of reference type strains of P. aeruginosa 
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Figure 31. Dot blot showing binding of monoclonal antibody SC101 with Proteinase-K 
digests of LPS mutant and reference type strains of P. aeruginosa 
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Rmd Rmd AK1401 WapR Wbpm 
epitopes. Fewer strains reacted with monoclonal antibody SC-101 in dot-blots (Figure 31), 
despite loading twice the volume of digested cells. Strains Rmd and WapR (deficient in A-
band LPS) were also included in this panel and bound to the monoclonal antibody. 
The lack of reactivity of monoclonal antibody SC-101 with all strains indicated that this 
region of the LPS core may be different across the serotype strains. Furthermore, the fact 
that the antibody was made against strain AK1401, which lacks expression of serotype-
specific B-band LPS, may be due to unknown technical factors but may also suggest that 
the outer core LPS is heterogeneous. 
The A-band LPS specific monoclonal antibody N1F10 bound epitopes of intermediate-
chain LPS from 11 of 23 strains (01, 03, 09, 010, 011, 013, 017, 019, C28, AK1401 
and PA01) (Figure 32). Apart from strain 011, 5 1,11_, of Proteinase-K digest was sufficient 
to demonstrate binding and the binding patterns were all similar. When comparing the 
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strains that reacted with monoclonal antibodies SC-101 and N1F10, there were only four 
common strains, suggesting that the SC101 monoclonal was not in fact specific to an A-
band LPS side chain. 
Despite previously revealing that chicken egg albumin or foetal calf serum elicited least 
non-specific binding, and were therefore most suitable for blocking solutions, the 
immunoblots with N1F10 showed maximal results when skimmed milk was used. 
Unfortunately, during the monoclonal antibody experiments, it became apparent that the 
antibodies were becoming exhausted and losing reactivity over time. It was therefore not 
possible to explore further reactions with other strains. If more stocks had been available, it 
would have been informative to react the monoclonal antibodies with the species specificity 
panel, to determine whether the LPS core and A-band epitopes were species specific by this 
method. 
Figure 32. An example of binding of monoclonal antibody N1F10 with Proteinase-K 
digests of reference serotype strains 09 and 010 of P. aeruginosa 
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3.2.5 Hyper-immune O-serotyping antibody samples 
To explore the epitope binding patterns of the hyper-immune rabbit serum samples, the sera 
used routinely for 0-serotyping of P. aeruginosa were reacted with the corresponding 
Proteinase-K digested type strains, with which the rabbits were challenged. The profiles, 
shown in Figure 33, were all distinct and all but three strains (AK1401, 04 and 017) 
showed antibodies binding to the core LPS. Otherwise, the binding patterns strongly 
resembled the silver stained banding patterns (see Figure 15). Strains 07, 09, 016, 017, 
C28 and AK1401 displayed homologous antibody binding to intermediate-chain LPS and 
antisera 01 - 03, 05, 06, 08, 010 and 013 bound to both short-chain and intermediate-
chain LPS, whilst sera 04, 011 and 019 reacted with LPS of all lengths - short, 
intermediate and long-chain in their homologous strains. Strain 015 revealed only long-
chain LPS binding to hyper-immune antibodies, and serotypes 012, 014 (although very 
weakly), 018 and 020 showed long and intermediate-chain LPS binding. The raising of 
hyper-immune rabbit sera to specific type strains therefore appears to be a very efficient 
way of producing antibodies to all side-chain epitopes from those strains. 
The reactions between Proteinase-K digested type strains and rabbit hyper-immune sera 
raised to strain AK1401 are illustrated in Figure 34. The observed binding patterns differed 
to those produced when 0-typing sera was reacted against the homologous type strain. 
However, the AK1401 serum cross reacted with several other type strains, except with 
serotype strains 07, 08, 012, 014 and 015. This pattern of reactivity resembles the HP 
antibody reactions (previously shown in Figure 21), though fewer antibodies bound to the 
core LPS epitopes. Since the AK1401 is the type strain for A-band LPS and does not 
express B-band LPS, it is likely that those strains that reacted with the AK1401 hyper-
immune antibodies possessed A-band LPS and this is supported by the fact that the high 
positive serum antibodies gave similar results. An explanation for this may be that the A-
band LPS is a more efficient antigen than the B-band LPS, thus stimulating a greater 
antibody response. 
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Figure 33. Binding of rabbit 0-typing serum antibodies with Proteinase-K digests of 
homologous reference serotype strains of P. aeruginosa 
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Figure 34. Binding of rabbit AK1401 0-typing serum antibodies with Proteinase-K digests 
of reference type strain of P. aeruginosa 
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3.2.6 Natural antibodies in rabbit sera 
During the production of the AW1 hyper-immune rabbit serum, raised to the purified LPS 
of strain AK1401, it was noticed that the pre-challenge serum sample contained antibodies 
that bound to the outer membrane profiles (Figure 35). The pre-challenge guinea pig 
plasma sample, from the production of AW2, did not, however, demonstrate any antibody 
binding (Figure 36). 
To eliminate the possibility of an infection of rabbit AW1 or contamination of the animals' 
environment, 28 swabs were taken and cultured. None of the swabs yielded P. aeruginosa, 
confirming there had been no contamination. 
The results of the reactions of a further 15 pre-challenge rabbit serum samples (IgG-
classed) are shown in Figure 37. In total, 12 of 16 pre-challenge samples (Awl, 01, 02, 03, 
04, HC01, HC92, NoName, NRS, HC87, HC89 and HC96) demonstrated high levels of 
IgG-classed antibodies specific to the LPS of P. aeruginosa. Many antibodies specific to 
outer membrane proteins were also observed, but it was felt that the LPS epitopes were a 
more reliable marker, since P. aeruginosa expressed several proteins common to other 
species. When strains were reacted to pre-challenge rabbit serum of the IgM-class, eight of 
the 12 samples tested (1-IC101, HC102, HC92, NoName, AW1, HC90, HC89 and NRS) 
demonstrated binding (Figure 38). Since none of the rabbits had yet been challenged with 
P. aeruginosa antigens when the serum was taken, and appeared healthy and free of 
infection or contamination, it was concluded that these antibodies were naturally occurring. 
This may possibly due have been to an ongoing subclinical infection or that P. aeruginosa 
forms part of the rabbits' normal flora. 
These findings illustrate the importance of screening rabbits for naturally occurring 
antibodies to P. aeruginosa antigens prior to subsequent antigen challenge. 
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Figure 35. Binding of IgG-classed AW1 pre-challenge rabbit serum antibodies IA ith outer 
membranes of reference type strains of P. aeruginosa 
Figure 36. Binding of IgG-classed AW2 pre-challenge guinea pig plasma antibodies with 
outer membranes of reference type strains of P. aeruginosa 
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Figure 37. Binding of IgG-classed pre-challenge rabbit serum antibodies with Proteinase-K 
digests of reference serotype strains 01 and 08 of P. aeruginosa 
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Figure 38. Binding of IgM-classed pre-challenge rabbit serum antibodies with Proteinase-K 
digests of reference serotype strain 01 of P. aeruginosa 
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3.3 	Results I Summary 
o Extracts of 0-serotype strains, strains AK1401, PAO1, C28 and defined mutant 
strains were separated by SDS-PAGE and stained with silver and Coomassie blue to 
show the LPS and protein profiles, respectively. 
o Different LPS side-chain and core LPS molecules were identified. 
o Identification and purification of particular proteins was problematic. 
o The immunoblot profiles of pooled serum from CF patients reacted with type strains 
correlated with the results from the LHCAI in-house ELISA. 
o Insignificant levels of antibody binding were observed with the type strains and 
healthy human serum antibodies. 
o Many reactions between antigens of P. aeruginosa and antibodies from CF patients 
were observed. All but seven serotype strains reacted with the high positive serum 
antibodies. 
o Insignificant levels of antibody binding were observed with the species specificity 
panel strains and high positive serum antibodies. 
o The inner core LPS moieties were common to all serotype strains, but the outer core 
and A-band side chain regions were not, according to binding with monoclonal 
antibodies SC-7-4, SC-101 and N1F10, respectively. 
o Rabbits appeared to possess natural antibodies to P. aeruginosa. 
o Hyper-immune rabbit sera raised to strain AK1401 showed similar binding patterns 
to the type strains of P. aeruginosa as the high positive serum antibodies from 
patients with CF. 
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The results from this chapter support the hypothesis investigated, since some of the LPS 
moieties of P. aeruginosa (in particular A-band LPS) appeared to be common and specific 
for P. aentginosa, so could potentially be employed to identify infections in patients with 
CF. However, further investigations would need to confirm this. 
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CHAPTER 4 
RESULTS II: THE OCCURRENCE OF A-BAND LPS OF P. 
AERUGINOSA 
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In this chapter, the hypothesis investigated was 'A-band LPS is a common and specific 
antigen for P. aeruginosa, so would be a suitable for employing in an assay to identify 
infections in patients with CF'. 
The A-band LPS moiety of P. aeruginosa was identified in Chapter 3 as a promising 
common, antigenic target. So the occurrence of A-band was further investigated in a 
number of different ways, to confirm that the antigen's presence in other strains, 
particularly those recently isolated from patients with CF. Its ubiquity would reinforce its 
suitability for employment in a diagnostic assay. 
4.1 	Antibody experiments to demonstrate A-band epitopes 
To investigate the occurrence of A-band LPS in P. aeruginosa, extracts of strains were 
reacted with high titre positive pooled serum from CF patients. These sera were also 
reacted with panels of 0-serotype and reference strains of P. aeruginosa, strains grown 
anaerobically, clinical isolates including sequential isolates from individual patients, and 
multiple isolates from the same sputum sample. Profiles of silver stained LPS extracts 
exhibiting intermediate length repeating units consistent with the profiles shown with the 
A-band specific monoclonal antibody N1F10 were considered to be rich in A-band LPS. 
4.1.1 Adsorbed serum samples 
The two species of LPS in P. aeruginosa are not readily distinguished by electrophoretic 
profile and silver staining alone as the predominant 0-serotype specific B-band LPS often 
masks the ladder profile given by A-band LPS. However, the latter can be visualised by its 
pan reactivity in immunoblots with antibodies in serum from patients infected with P. 
aeruginosa. The occurrence of A-band LPS was therefore sought in the species as a whole 
by its reaction with pooled serum samples from CF patients chronically infected with P. 
aeruginosa. The principle of antibody adsorption was used in that bacterial cell surface 
antigen epitopes bind to antibodies in the serum which are then removed by centrifugation 
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of the bacterial cells. Antibodies that do not bind to antigen epitopes remain in the 
supernatant and their reactivity with other antigens can be detected by immunoblotting. 
Thus a strain carrying the cross reactive A-band LPS will adsorb A-band antibodies from 
the serum and this is shown by the lack of reactivity of the adsorbed serum with the other 
A-band positive strains. 
A pool of high titre (positive) serum samples from CF patients was prepared and aliquots 
mixed with packed cells of each of the 20 0-serotype reference strains of P. aeruginosa and 
the A-band LPS reference strains AK1401 and C28. Following centrifugation, the 
supernatants were screened for reactivity in immunoblots with extracts of each strain and 
the profile compared with that given by the A-band specific monoclonal antibody N1F10. 
All reference type strains, except 08, 012, 014, 015 and 016, removed antibodies reactive 
with A-band strain AK1401, indicating that this epitope was present in 15 of the 20 0-
serotype strains. Figure 39 illustrates the LPS banding profiles of the adsorbed serum pool 
with selected representative reference strains. It can be seen that adsorption with strain 
AK1401 removed all reactivity with itself and strain C28, leaving behind antibodies 
reactive only with serotypes 06 and 01, which are apparently bound to B-band LPS spread 
across high, medium and low molecular weight components. A similar picture is shown in 
the C28 adsorption but close examination reveals faint medium to high molecular weight 
ladders with strain AK1401, suggesting the presence of residual A-band antibodies not 
removed completely by the adsorption process. Type-specific 06 and 01 antibodies were 
also shown by adsorption with the serotype strains. Reference strains 07 and 020 were the 
only two strains which did not react with the unadsorbed patients' serum. They clearly 
lacked A-band LPS as they did not adsorb A-band reactive antibody from serum. 
To separate core LPS antibody epitopes from the A-band antibody epitopes, the AW1 
serum sample was adsorbed with strain Rmd, as this strain lacked A-band LPS. This 
sample was reacted with Proteinase-K digests of strains 01, 02, 03, 06, 07, 08, 012, 
014, 015, AK1401, PAO1 and C28 (Figure 40). Comparison with the reaction of non-
adsorbed AW1 to the reference type strains (Figure 41.) revealed that there were no 
changes in the banding patterns with strains 02, 06, 07 and C28. The core LPS epitopes of 
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Figure 39. Immunoblots of Proteinase-K digests of reference type strains of P. aeruginosa 
(lower labels) with high positive sera adsorbed with reference type strains (upper labels) 
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Figure 39. Continued 
015 
	
016 
	
017 
	
018 
	
019 
	
020 
0 0 
000Lo 000?0 0>00000000 000V 000V 000(-= 74 U; tosg 74 u: 	t-> 	 t,, 	o• ,4o Ge 	00 0 •0 00 	00 	sO 00 	oo 
47: 	
00 Os th 	•—• C) 
8 
Figure 40. Binding of residual AW1 antibodies after adsorption with strain Rmd to SDS- 
PAGE profiles of P. aeruginosa LPS extracts 
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Figure 41. Immunoblots of AW1 antibodies with Proteinase-K extracts of reference type 
strains of P. aeruginosa 
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the profiles were removed by adsorption with strains 01, 03, 012 and 014, although the 
latter two strains had not demonstrated binding, whilst fewer side-chain bands were visible 
in strains AK1401 and PAO1, when reacted with the adsorbed serum. The side-chain 
antibodies were completely adsorbed from the serum by strains 08 and 015, leaving these 
profiles showing binding only with core LPS. The attempt to render serum AW1 (specific 
for A-band LPS) by adsorption was therefore unsuccessful. 
4.1.2 Reactions with AW1 hyper-immune rabbit sera 
The AWI rabbit antibody reactions with the Proteinase-K digested reference type strains 
(Figure 41) showed similar binding patterns to those obtained with the AK1401 typing 
serum (Figure 34). However, a few additional bands were evident with the AW1 sera, 
particularly, for example, with the core LPS epitopes of strains. All serotype strains 
exhibited some antibody binding, although strains 07, 012 and 014 only showed AW1 
antibodies bound to their core LPS. All other strains, except 08, 015 and 020 exhibited 
clear antibody binding to specific epitopes of intermediate-chain LPS. These three strains 
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showed some binding to side-chain LPS, but it was not consistent with the A-band hindinl._!. 
patterns previously displayed with monoclonal antibody N1F10. 
Serum AW1 exhibited strong binding to both protein and LPS antigens in outer membranes 
of reference type strains of P. aeruginosa (Figure 42). The profiles, when compared to the 
pre-challenge serum from AWl (Figure 35), illustrate the effectiveness of challenging 
rabbits with LPS. In contrast, Figure 42 also illustrates the poor binding of the AW2 
antibodies to Proteinase-K digests of reference type strains. It therefore appears that the 
immune systems of rabbits and guinea pigs react quite differently to challenge with LPS of 
P. aeruginosa. 
Figure 42. Binding of outer membranes of reference type strains of P. aeruginosa to AW1 
antibodies (upper) and Proteinase-K digests of reference type strains of P. aeruginosa to 
AW2 (lower) antibodies 
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4.1.3 The occurrence of A-band in CF strains grown anaerobically and with 
supplemented potassium nitrate 
Reference type strains 01, 012, 014 and AK1401, along with alginate mutant strains 
PA0578, PA0579, PA0581 and PA0568, were grown on nutrient agar (with and without 
potassium nitrate) and grown either in air or under anaerobic conditions. Those cultured on 
nutrient agar did not grow anaerobically, but did grow aerobically and when cultured on the 
supplemented agar in anaerobic conditions. Suspensions of colonies were digested with 
Proteinase-K, separated by SDS-PAGE and stained with silver (Figure 43) or reacted with 
AWl antibodies (Figure 44). 
The silver-stained reference strains show that when grown aerobically, there was little 
difference in the profiles between the bacteria grown on nutrient agar or nutrient agar 
supplemented with potassium nitrate. However, when grown anaerobically in the presence 
of nitrate, the strains expressed lower levels of LPS, indicated by profiles with reduced 
staining. The alginate mutant strains appeared to behave differently to the type strains, with 
those grown aerobically on nutrient agar displaying lower levels of side-chain LPS. 
When reacted with AW1 antibodies, there was greater binding with reference type strains 
grown in air, followed by strains grown on agar supplemented with potassium nitrate. The 
strains grown anaerobically showed least reactivity with AWI. Growth of strains 01, 012 
and 014 on agar supplemented with potassium nitrate caused the expression of an 
additional side-chain LPS moiety that bound with the AW1 antibodies (highlighted in 
Figure 44). The binding of antibodies to the alginate strains showed little difference 
between the different growth conditions. 
160 
Figure 43. Silver-stained profiles of reference type strains and alginate mutant strains of P. 
aeruginosa grown anaerobically and digested with Proteinase-K* 
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Figure 44. Binding of AW1 antibodies to reference type strains and alginate mutant strains 
of P. aeruginosa grown anaerobically and digested with Proteinase-K, highlighting a side- 
chain LPS band expressed when grown on agar supplemented with potassium nitrate* 
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* (KNO3 = strains grown on nutrient agar supplemented with potassium nitrate, NA = strains grown on 
nutrient agar, An02 = strains grown anaerobically, 02 — strains grown in air) 
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4.1.4 The persistence of A-band expression over time 
The immunoblots of the longitudinal series of isolates of P. aeruginosa bound to AW1 
antibodies showed that of the eight patients, six (P2, P14, P15, P16, P24 and P29) 
maintained the expression of A-band LPS. However, two patients (P6 and P17) showed 
loss of expression of the LPS moiety (highlighted in Figure 45). Within all patients, the 
same strain was maintained over the period, demonstrated by PFGE (Appendix IV). Indeed, 
the LPS profiles for each patient showed identical side-chains. The maximum time 
difference between the first isolate and last isolate tested for each patient (Appendix IV) 
was 44 m (demonstrated by patients P6, P17 and P29). 
It would have been interesting to correlate these strains with patient clinical details and 
antibody samples; however this was not possible since serum samples had not been taken 
from these individuals for antibody testing. Since previous data have shown that the A-
band LPS is the main antigen of the LPS, it would have been "significant to view any 
antibody binding from patients P6 and P17 at the time that strains P6D and P17C were 
isolated. 
Figure 45. Binding of AW1 antibodies to the sequential isolates from patients digested with 
Proteinase-K, highlighting the absence of A-band LPS epitopes of strains P6D and PI7C 
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4.1.5 The occurrence of A-band in colistin resistant strains 
The binding of AW1 antibodies to the ten colistin resistant strains tested showed that 
several of the 0-side chain epitopes were absent (Figure 46). Antibodies were shown to 
bind to the core region of the LPS for seven of the strains (8-2-3, 71-2-3, 113-3-3, 116-2-1, 
269-5-2, 279-4-1 and 321-5-2), but 0-antigen bands were not visible for five of the strains 
(221-1-3, 221-2-2, 222-6-1, 279-4-1 and 321-5-2). 
Figure 46. Immunoblot of AW1 antibodies with colistin resistant strains of Proteinase-K 
digests of P. aeruginosa 
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4.1.6 The occurrence of A-band in strains isolated from the same sputum sample 
Four of the sputum samples from patients (CFSP2, CFSP3, CFSP5 and CFSP7) attending 
the RBH were cultured on King's A agar on receipt in LHCAI and yielded colonies of P. 
aeruginosa with more than one colonial form. These were selected and grown on fresh 
King's A agar (Figure 47). Differences in morphology were either due to pigmentation (as 
in CFSP2, with cream and green colonies, and CFSP3 with blue/grey, blue and brown 
colonies) or size or texture of the colonies (as in CFSP5, with small and mucoid colonies, 
and CFSP7 with dry and mucoid colonies). When the strains were analysed by PFGE, 
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although they had different morphologies, all strains from the same patient (for CFSP2, 
CFSP5 and CFSP7) were indistinguishable in DNA profile. The strains from CFSP3 were 
similar, but had several bands different from each other (highlighted in Figure 48). 
Figure 47. Variations in colonial appearance of P. aeruginosa isolated from the same 
sputum samples 
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Figure 48. PFGE profiles of P. aeruginosa isolates from sputum, highlighting the differing 
banding patterns of isolates from patient CFSP3 
CFSP2 CFSP3 	CFSP5 CFSP7 
The first three generations of P. aeruginosa strains from the sputum samples were digested 
with Proteinase-K, separated by SDS-PAGE and either stained with silver or reacted with 
AW1 antibodies (Figure 49). The silver stained profile of the first generation of bacteria 
clearly shows that very little LPS was being expressed, with no side-chain LPS and very 
few core moieties. The corresponding immunoblot showed AW1 antibodies binding to the 
core LPS but also some side-chain LPS epitopes, which appear not to have bound to the 
silver stain. The second generation strains showed far more core LPS being expressed, with 
silver and AW1 antibodies binding to all strains. Side-chain LPS was also clearly seen in 
strains CFSP2 cream CFSP7 dry, by silver and antibodies. The silver stain of the third 
generation strains was disappointing, with only core LPS being stained. However, the 
immunoblots showed clear LPS profiles for both strains from patient CFSP7, although few 
epitopes were evident from any of the other strains. 
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Figure 49. Silver-stained profiles of and binding of AW1 antibodies to reference type 
strains of P. aeruginosa and the 1st (upper), 2"d (middle) and 3`d (lower) generations of 
strains isolated from sputum samples 
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4.1.7 The occurrence of A-band in clinical strains 
Eight of the clinical isolates (RBH1 PAM, RBH2 PAM, RBH2 PA, RBH5 PA, RBH8 
PAM, RBH13 PAM, C16) did not produce green pigmentation when grown on King's A 
agar. Since this is a characteristic feature for P. aeruginosa, these strains were tested by 
PCR for the presence of the PASS gene product. Strains RBH1 PAM, RBH2 PAM and Cl 
6 were found to lack the gene and were therefore not used in further work. 
The 49 clinical strains that were confirmed as P. aeruginosa, were digested with 
Proteinase-K, separated by SDS-PAGE and reacted with AW1 antibodies (Figure 50). The 
antibody profiles of the clinical strains showed 45 of the 49 strains demonstrated antibody 
epitopes consistent with A-band. Those that did not were strains RBH3 PAM, RBH14 PA, 
RBH14 PAM and CI 14. 
Figure 50. Binding of AW1 antibodies to clinical strains of P. aeruginosa digested with 
Proteinase-K 
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4.2 	Occurrence of A-hand biosynthesis genes 
All reference serotype strains (01 to 020) were investigated for the presence of the gca 
gene. The PCR product should have been a single band of 700 bp, but multiple bands of 
varying sizes were observed (Figure 51), thus rendering the results invalid. The cycling 
conditions used in this study were not exactly the same as those published by Currie et al. 
(1995). The annealing temperature had been increased from the published temperature of 
45 °C to 55 °C, due to the melting temperatures provided by Sigma-Genosys with the 
synthesised oligonucleotide primers (71.5 °C for HCR1 and 59.6 °C for HCR2). It is 
unclear as to why these primer sequences were chosen by Currie et al. (1995), when they 
are clearly incompatible for the prescribed conditions. The results from these experiments 
were therefore disregarded. 
Figure 51. Ethidium bromide stained gel showing results from investigation of the gca 
gene. 
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The reference type strains and 49 clinical isolates were investigated for the presence of the 
A-band biosynthesis genes wzt and wzm. All except one possessed both genes (Figure 52) 
and a PCR product of approximately 626 bp, consistent with the wzt gene was obtained. 
However, an exception (CI 29) lacked the product of 203 bp, consistent with wzm (Figure 
52) but still expressed A-band LPS when reacted with both AW1 antibodies and antibodies 
from high positive CF serum. This suggests there was a silent mismatch in the wzm 
sequence, thus preventing the primers binding but allowing expression of the gene. It is 
also important to bear in mind that although the strains may possess the genes, this does not 
necessarily mean that the genes are expressed. 
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Results II Summary 
A summary of the experiments concerning the occurrence of A-band LPS in the reference 
type strains and clinical strains of P. aeruginosa is given in Tables 16 and 17, respectively. 
Although there are conflicting results for some of the reference type strains, all strains 
except 07, 08, 012, 014 and 015 were deemed to express A-band LPS. Additionally, 45 
of the 49 clinical isolates were considered to be positive for A-band expression. 
Additional information gained regarding A-band LPS was: 
o A-band is expressed anaerobically 
o A-band LPS expression may persist for at least 44 m 
o Genetically identical strains from the same sputum sample may have different 
morphologies and LPS expression 
The results from this chapter support the hypothesis investigated, since A-band LPS was 
shown to be a common and specific antigen for P. aeruginosa, so would be suitable for 
employing in an assay to identify infections in patients with CF. 
Table 16. Summary of results from this and other studies to determine occurrence of A- 
band LPS in reference type strains 01 to 020 of P. aeruginosa 
Blot/gene AK1401 PAO1 01 02 03 04 05 06 07 08 09 
AK1401 sera + + + + + + + + - + 
AW1 + + + + + + + + - + 
Adsorbs AK1401 + + + + + + + + + + 
N1F10 + + + + - + 
HP sera + + + + + + + + + 
wzm + + + + + + + + + + + 
wzt + + + + + + + + + + + 
010 011 012 013 014 015 016 017 018 019 020 
AK1401 sera + + _ + + + + + + 
AW1 + + _ + + + + + + 
Adsorbs AK1401 + + + + + + + 
N1F10 + + + + + 
HP sera + + + + + + 
wzm + + + + + + + + + + + 
wzt + + + + + + + + + + + 
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Table 17. Summary of results to determine occurrence of A-band LPS in clinical strains of 
P. aeruginosa 
(PA = P. aeruginosa, PAM = mucoid P. aeruginosa, HP = high positive) 
Blot/gene RBH2 RBH3 RBH4 RBH5 RBH6 813116 RBI 17 RBH8 RBH8 RBH9 
PA PAM PAM PA PAM P.,\ PAM PAM PA PA 
	
AWl 	+ 	 + 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
HP sera 	+ + + + + + + + + 
wzm 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
wzt + + 	+ + + + + + + 
RBH10 RBHI I RBHI 2 RBH13 RBH13 RBH14 RBHI4 RBH15 RBH15 RB1-116 
PAM PAM PA PA PAM PA PAM PAM PA PAM 
AW1 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
HP sera 	+ + + + + + + + + + 
wzm 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
wzt + + + + + + + + + + 
RBHIO RBH11 RBH12 RBH13 RBHI3 RBH14 RBH14 RBH15 RBH15 RBH16 
PAM PAM PA PA PAM PA PAM PAM PA PAM 
AWl 
HP sera 
wzm 
wzt 
CI I 	CI 2 	CI 3 	CI 4 	CI 5 	CI 7 	CI 8 	CI 9 	CI 10 	CIII 
AWl 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
HP sera 	+ + + + + + + + + + 
wzm + 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
wzt 	+ + + + + + + + + 
CI 12 	CI 13 	CI 14 	CI 15 	CI 16 	( 1 17 	CI 18 	CI 19 	CI 20 	CI 21 
AWI 	+ 	+ + 	+ 	+ 	+ 	+ 	+ 	+ 
HP sera 	+ + 	 + + + + + + + 
wzm 	+ 	+ + 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
wzt + + 	+ + + + + + + + 
CI 22 	CI 23 	CI 24 	CI 25 	CI 26 	CI 27 	CI 28 	CI 29 	CI 30 
AWl 	+ + 	+ + + 	+ + + + 
HP sera 	+ 	+ + 	+ 	+ + 	+ 	+ 	+ 
wzm + + 	+ + + 	+ + + 
wzt 	+ 	+ + 	+ 	+ + 	+ 	+ 	+ 
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CHAPTER 5 
RESULTS III: THE A-BAND LPS ANTIBODY RESPONSE IN 
SERUM AND NON-INVASIVE SAMPLES 
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In this chapter, the hypothesis investigated was 'if oral fluid, sputum or urine could be 
shown to provide data comparable with serum antibodies, clinicians would be able to test 
patients more frequently and therefore gather more information on their patients regarding 
their infection status with P. aeruginosa'. 
Serum and non-invasive samples (sputum, oral fluid and urine) were tested by SDS-PAGE 
followed by immunoblotting, by dot-blotting (for urines) and by ELISA to evaluate the 
occurrence of antibodies to strain AK1401, and thereby A-band LPS, of P. aeruginosa in 
patients with CF. Samples from two control groups (patients with PCD and healthy 
volunteers) were also investigated. Where possible, paired samples (two sample types from 
the same patient) were collected and compared. 
5.1 	Antibody analysis by immunoblotting and dot-blotting 
SDS-PAGE and immunoblotting against strain AK1401 was performed on all serum 
samples collected from recruited CF patients, as well as stored longitudinal serum samples 
from patients 1 and 2 and nine further healthy volunteer samples, not previously tested in 
the A-band analysis studies. Additionally, sputum samples and oral fluids were tested from 
CF patients (including multiple samples from one patient), PCD patients and healthy 
volunteers. Urine samples from CF patients and one healthy volunteer were also evaluated 
by dot-blotting. The antibodies detected to A-band were classified according to 
immunoglobulin class (IgM, IgG and IgA-specific). 
5.1.1 The A-band antibody response in serum 
All 35 serum samples collected from CF patients attending the RBH (12 y, mean age 25.3 
y, SD 8.7 y, and 23 6, mean age 29.2 y, SD 9.4 y) were reacted with outer membranes of 
strain AK1401 separated by SDS-PAGE, employing a polyvalent 'second' antibody (Figure 
53). All of the sera with the RBH prefix (RBH1 to RBH 41) demonstrated strong binding 
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Figure 53. Binding of outer membranes of strain AK1401 to antibodies from serum from 
patients with CF, reacted with a polyvalent 'second' antibody 
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Figure 54. Binding of outer membranes of strain AK1401 to antibodies in serum samples 
from healthy volunteers 
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to the A-band side-chain, with all samples except RBH39 also showing binding to the core 
LPS. Nine of the 11 CFSP serum samples (CFSP1, CFSP2, CFSP3, CFSP6, CFSP7, 
CFSP8, CFSP10, CFSP12 and CFSP15) gave clear immunoblot results, demonstrating 
binding to the side-chain LPS. Only one of these samples (CFSP15) did not bind to the core 
moieties. Samples CFSP4 and CFSP9 demonstrated weak binding to the A-band side-chain, 
with the former also weakly binding to the core LPS. 
The strength of the antibody binding of the CF samples was apparent when compared to the 
reactions of strain AK1401 with serum from the healthy volunteers (Figure 54). Nine serum 
samples (HNC4, HCS11 to 17 and HCS) were reacted with strains AK1401; six of the 
samples (IINC11 and HCS13 toll) demonstrating some low levels of antibody binding, 
though only two samples (HCS13 and HCS16) bound to the core LPS. Six further healthy 
control sera (HCS1 to HCS6, which were pooled to create the HCS pool) had previously 
been tested against P. aeruginosa reference strains, including strain AK1401 (Figure 24), 
where no binding was demonstrated. The low levels of binding seen with the healthy 
volunteer control sera confirmed that a quantitative method was needed to prove whether 
an individual had an active infection with P. aeruginosa or if an antibody response had 
been mounted from a sub-clinical infection or simply environmental exposure. 
Two patients (patients 1 and 2) that had multiple serum samples stored in the LHCAI 
archive were tested for their longitudinal antibody response to strain AK1401. Antibodies 
from ten samples from patient 1 (from age 9 to 17 y old (details of sample dates are 
displayed in Appendix VII)) and 11 samples from patient 2 (from age 6 to 15 y old) were 
bound to strain AK1401 digested with Proteinase-K and reacted with polyvalent, IgM, IgG 
or IgA-specific 'second' antibody (Figure 55). The immunoblots with samples from patient 
1 clearly demonstrate an increase in the antibody binding to the side-chain LPS over time 
when reacted with the polyvalent, IgG or IgA-specific 'second' antibody. No binding was 
observed to the core LPS in any of the immunoblots. Far less binding was evident with the 
antibody samples from patient 2, which exhibited low levels of binding to side-chain LPS 
in immunoblots reacted with the IgM-specific 'second' antibody and even lower levels of 
binding to the core LPS with the later samples (8 to 11) with polyvalent or IgG- specific 
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Figure 55. Binding of Proteinase-K digested AK1401 to antibodies from serum from CF 
patients 1 (left) and 2 (right)+, reacted with polyvalent, IgM, IgG and IgA-specific 'second' 
antibodies 
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details of when the samples were taken and their results on the LHCAI in-house ELISA 
are listed in Appendix VII 
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`second' antibody. Comparison of the immunoblots from both patients with the results from 
the in-house ELISA (Appendix VII) (which used an IgG-specific 'second' antibody), 
revealed a strong correlation for all the samples from patient 1, with strong binding with 
samples 3 to 10. However, the levels of binding with samples 7 to 11 from patient 2 
appeared to be far less than indicated by the ELISA. 
5.1.2 The A-band antibody response in sputum 
All 13 sputum samples collected from CF patients attending the RBH (6 9, mean age 24.2 
y, SD 9.1 y, and 7 (3, mean age 25.4 y, SD 7.9 y) were reacted with outer membranes of 
strain AK1401 separated by SDS-PAGE, employing a polyvalent 'second' antibody (Figure 
56). All samples except CFSP4 demonstrated antibodies binding to AK1401. Six of the 
samples (CFSP1, CFSP3, CFSP6, CFSP8, CFSP10 and CFSP14) demonstrated excellent 
profiles, with strong binding to both side-chain and core LPS. Samples CFSP2, CFSP5 and 
CFSP12 reacted with both LPS moieties, but at a lower level, whilst CFSP7, CFSP9 and 
CFSP15 only bound to the side-chain LPS. Three of the samples (CFSP9, CFSP10 and 
CFSP12) were also reacted with an IgM-specific 'second' antibody, but this gave a 
negative result (Figure 57). 
5.1.3 The A-band antibody response in oral fluid 
Twenty-seven oral fluid samples from CF patients (8 9, mean age 24.9 y, SD 4.7 y, and 19 
(3, mean age 30.1 y, SD 8.8 y) were reacted with outer membranes of strain AK1401 
separated by SDS-PAGE, employing a polyvalent 'second' antibody (Figure 58). Ten of 
the oral fluid samples (RBH4, RBH6, RBH8 to 12, RBHI4, RBH16 and RBH17) showed 
very strong antibody binding to both side-chain and core LPS moieties of AK1401. 
Samples RBH2, RBH3, RBH13 and RBH15 also contained antibodies to both side-chain 
and core LPS, but gave a slightly weaker profile. Even weaker binding was demonstrated 
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Figure 56. Immunoblots of outer membranes of strain AK1401 with antibodies in sputum 
samples from patients with CF reacted with a polyvalent 'second' antibody 
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Figure 57. Immunoblots of outer membranes of strain AK1401 with antibodies in sputum 
samples from patients with CF reacted with an IgM-specific 'second' antibody 
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Figure 58. Representative immunoblots of outer membranes of strain AK1401 with 
antibodies in oral fluid samples from patients with CF reacted with a polyvalent 'second' 
antibody 
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by sample RBH 7, and sample RBH1 only bound very weakly to the side-chain LPS, with 
no core LPS epitopes being shown. 
Oral fluid samples from patients RBI-118 to 23 reacted with both outer membranes and 
Proteinase-K digests of strain AK1401 and two samples of each reacted with the separate 
IgA, IgM and IgG-specific 'second' antibodies (Figure 59). Binding was detected in all 
reactions except with RBH2O and Proteinase-K digests incubated with an IgM-classed 
`second' antibody. All immunoblots used 200 µ1., of the oral fluid sample and, although 
there is the issue of different oral fluid samples having different concentrations of 
antibodies, all classes of antibody showed greater binding to the outer membranes rather 
than the Proteinase-K digests and there were higher levels of the IgA and IgG-classed 
antibodies. 
Twelve oral fluid samples from the PCD patients (8 y, mean age 11.3 y, SD 5.3 y, and 4 a, 
mean age 7.0 y, SD 4.7 y) were immunoblotted with outer membranes and Proteinase-K 
digests of strain AK1401 separated by SDS-PAGE, employing a polyvalent 'second' 
antibody (Figure 60). No binding was observed to the Proteinase-K digests and only three 
samples (RBH29, RBH30 and RBH35) reacted with the outer membranes. Samples RBH29 
and RBH30 displayed low levels of binding to the side-chain LPS, whilst RBH35 also 
reacted weakly with the core LPS. Neither of the former patients (RBH29 or RBH30) had 
ever grown P. aeruginosa from their sputum, however, RBH35 had grown the organism 
(with a +++ grading) 3 years previously, but not from the two sputum samples tested 1 year 
previously (Appendix XII). Samples RBH27, RBH28 and RBH29 were also 
immunoblotted with outer membranes but with an IgM-specific 'second' antibody, but no 
binding was evident. 
Thirty-seven oral fluid samples from healthy volunteers (21 y, mean age 27.8 y, SD 19.3 y, 
and 16 6, mean age 24.1 y, SD 19.3 y) were incubated with outer membranes of strain 
AK1401 separated by SDS-PAGE, employing a polyvalent 'second' antibody (Figure 61). 
Ten of the samples (HPA2, HPA3, HPA10, HPA24 to 27, HPA29, NS1 and NS2) showed 
binding to the side-chain LPS of AK1401. This was very weak, although volunteers HPA I 0 
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Figure 59. Immunoblots of antibodies in oral fluid samples from CF patients with outer 
membranes and Proteinase K digests (left and right, respectively) of strain AK1401 and 
reacted with IgA, IgM and IgG-specific 'second' antibodies 
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Figure 60. Immunoblots of outer membranes (upper) and Proteinase-K digested (lower) 
AK1401 with antibodies from oral fluid samples from PCD patients, reacted with a 
polyvalent 'second' antibody 
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and NS2, showed slightly higher levels, and antibodies from HPA10 also bound to the core 
LPS. It was interesting to note that the mean age of the volunteers who expressed 
antibodies to P. aeruginosa was 32.7 y (SD = 22.8 y, n = 10). In fact, volunteer HPA10 and 
NS2 were 54 and 64 y old, respectively. Moreover, volunteer HPA10 had worked in a 
microbiology laboratory, specifically with P. aeniginosa, for many years. The mean age of 
those volunteers who had not demonstrated antibodies to P. aeruginosa was 23.8 y (SD = 
17.4, n = 27). 
CF patient RBH24 supplied multiple oral fluid samples, taken over a 4 day period (Table 
18). Sample 1 was taken at the CF clinic and transported to LHCAI the same day, while 
samples 2 to 7 were taken by the patient in their home and posted to LHCAI. Samples 
arrived between 1 and 6 days after being taken. The samples were all tested on the same 
day, therefore 10 to 13 days after being taken. When reacted with Proteinase-K digested 
AK1401, only weak antibody binding was found (Figure 62). Sample 7 (tested 10 days 
after being taken) demonstrated antibodies binding to the side-chain and core LPS, whilst 
all other samples only showed very weak reactivity with the core LPS. 
Table 18. Details of multiple oral fluid samples taken by patient RBH 24 
Sample 
Date sample 
taken 
Time sample 
taken 
Date sample arrived at 
laboratory 
Method of 
storage 
Date sample 
tested 
1 7-Mar-06 2:30pm 7-Mar-06 Frozen 20-Mar-06 
2 8-Mar-06 9:20am 14-Mar-06 Refrigerated 20-Mar-06 
3 8-Mar-06 11:55am 14-Mar-06 Refrigerated 20-Mar-06 
4 9-Mar-06 10:45am 10-Mar-06 Refrigerated 20-Mar-06 
5 9-Mar-06 3:10pm 10-Mar-06 Refrigerated 20-Mar-06 
6 10-Mar-06 9:00am 13-Mar-06 Refrigerated 20-Mar-06 
7 10-Mar-06 6:20pm 13-Mar-06 Refrigerated 20-Mar-06 
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Figure 62. lmmunoblot of Proteinase-K digested AK1401 with antibodies in oral fluid 
samples 1 to 7 from CF patient RBH24, reacted with a polyvalent 'second' antibody 
-,1 
5.1.4 The A-band antibody response in urine 
Eleven CF patients (RBH2 to 6, RBH9 to 12, RBH14 and RBH 16) and one healthy 
volunteer (NS5) donated urine samples. All samples were boiled and filtered, except 
RBH14 which was only boiled due to low sample volume. All the urines, along with 
purified LPS, were tested by dot-blot and reacted with AW1, HCS4 and H0431060345 (a 
high positive CF sample) serum samples for detection of antigens. (Figure 63 a to c). The 
pure LPS control sample bound strongly with both the AW1 and H0431060345 antibodies, 
but weakly with HCS4. Due to the high levels of binding with nearly all urine samples, the 
dot-blot was repeated but with urine samples pre-treated with Proteinase-K, to inactivate 
cross-reactive antibodies (Figure 63 e to g). The LPS control still bound strongly, but the 
results from the other samples were clearer to interpret. Both filtered and boiled samples 
from patients RBH2, RBH4, RBH6, RBH12 and RBH16 and just filtered samples from 
patients RBH 5 and 11 bound to AW1. However, so did the boiled urine sample from 
NS5B. Fewer samples bound to the high positive CF serum, with both filtered and boiled 
urine from patients RBH2, RBH12 and RBH16 and just filtered urine from patients RBH5, 
RBH6 and RBH11 reacting. However, exactly the same samples also reacted with the 
healthy negative control serum HCS4. It may have been that some of the colouring on the 
nitrocellulose paper was not in fact antibody binding, but discolouration by the urine 
samples. 
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Figure 63. Binding of pure LPS and antigens in urine from CF patients and a healthy 
volunteer to antibodies in: hyper-immune serum AW1 (a & e), healthy control serum HCS4 
(b & 0 and CF high positive serum H0431060345 (c & g). Additionally, samples were 
reacted directly with a 'second' antibody (d & h). Reactions with AW I were tested for IgG- 
specificity and all others with a polyvalent 'second' antibody. Samples e to h were pre- 
treated with Proteinase-K. Identification of sample blots is shown in the grid below, with F 
denoting filtered urine and B boiled urine samples. 
RBH 2F RBH 4F 	RBH6F RBH 1OF RBH 12F RBH 16F 
RBH 2B RBH 4B RBH 6B RBH 10B RBH 12B RBH 16B 
RBH 3F RBH 5F RBH 9F RBH 11F RBH 14B 	NS5F 
RBH 38 RBH 5B RBH 9B RBH 11B pure LPS 	NS5B 
a 	 e 	 g 
• 
4 
b 
	
d 
	
f 
	
h 
All samples were also reacted directly with a 'second' polyvalent antibody, to detect 
antibodies in urine (Figure 63 d and h). The LPS control did not bind on either blot and the 
reactions with the Proteinase-K pre-treated samples were very weak, but the colouration 
observed was probably not in fact antibody binding (Figure 63 h). However, the polyvalent 
`second' antibody (Figure 63 d) reacted with all filtered and boiled samples. Although 
antibodies were shown to be present in the urine samples, there was thus far no information 
as to their specificity. Urines from patients RBH2, RBH4, RBH6 and RBH12 were reacted 
with AK1401 and binding to side-chain LPS was demonstrated by sample RBH2, thus 
185 
Figure 64. Binding of antibodies from the urine of CF patients with Proteinase-K digested 
strain AK1401 
confirming the presence of antibodies specific to A-band LPS (Figure 64). 
Filtered and boiled urine samples from CF patient RBH4 were concentrated by freeze-
drying and resuspended at different dilutions in solubilization buffer before profiling by 
SDS-PAGE and staining with silver and Coomassie blue and reacting with HP4 antibodies 
(Figure 65). The silver-stained profiles showed profiles similar to core LPS, with the boiled 
urine sample also demonstrating two bands in the region of side-chain LPS. If these profiles 
were indeed LPS, it was not possible to identify the species to which they belonged. The 
Coomassie blue stained profiles showed several bands in the 'neat' samples, for example, 
of approximately 29, 51 and 65 KDa. The bands of 29 and 51 KDa also reacted with the 
HP4 antibodies. Since the antibody binding pattern was not consistent with the previous 
patterns seen with LPS molecules, it is unlikely that the bands represented A-band epitopes. 
Urine contains many different proteins and secretory products, so the proteins and other 
antigens seen in Figure 65 were most likely to be unrelated to P. aeruginosa. 
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Figure 65. Coomassie blue stain, silver stain and binding to HP4 antibodies of freeze-dried 
urine sample RBH4 that was boiled (left) or filtered (right) diluted 1/2, 1/4 and 1/8 before 
separation by SDS-PAGE 
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5.1.5 Paired data from CF patients 
Much of the data presented in section 5.1 relates to different samples taken from the same 
individual, for example, sputum and serum or oral fluid and serum. Eleven CF patients 
(CFSP1 to 4, CFSP6 to 10, CFSP12 and CFSP15) donated sputum and serum samples. In 
order to compare the data from these immunoblots, the profiles were scored (0 to 3), 
depending on the strength of the binding, and a note was made as to whether antibodies 
bound to the side-chain and / or core LPS (Table 19). Six of the patients (CFSP1, CFSP3, 
CFSP6 and CFSP8 to 10) gave identical profiles, with regard to binding strength score and 
reacting LPS moieties, with both sputum and serum samples. For these six samples, the 
mean number of days between the two samples being taken was 137 days (ranging from 28 
to 359 days, median = 100 days), compared to a mean number of 133 days (ranging from 
43 to 209 days, median = 134 days, n = 5), for samples that didn't match exactly. If binding 
strength scores 0 and 1 were deemed negative and 2 and 3 positive, the sensitivity and 
specificity of immunoblots with sputum, compared to the gold standard of serum, was 0.67 
and 1.00, respectively. However, if the presence of antibodies to both A-band side-chain 
and core LPS was indicative of a positive result, the sensitivity and specificity of sputum 
was 0.78 and 1.00, respectively. 
Table 19. Summary of immunoblot data of sputum and serum samples from CF patients, 
with scoring of antibody reactions (0 to 3) and clarification of whether A-band side-chain 
(side) or core (core) LPS epitopes were detected 
1 year less when serum taken 
Patient 
ID Sex Age Date taken 
Sputum 
score side core Date taken 
Serum 
score side core 
Days between 
serum and 
sputum 
samples 
CFSP1 6 34 14-Mar-06 3 y y 10-Jan-06 3 y y 63 
CFSP2 6 35* 14-Mar-06 1 y y 11-Oct-05 3 y y 154 
CFSP3 6 24* 14-Mar-06 3 y y 20-Mar-05 3 y y 359 
CFSP4 6 17* 14-Mar-06 0 n n 17-Aug-05 1 y y 209 
CFSP6 (3` 23 14-Mar-06 3 y y 11-Apr-06 3 y y -28 
CFSP7 y 16* 14-Mar-06 2 y n 30-Jan-06 3 y y 43 
CFSP8 g 15 14-Mar-06 3 y y 28-Oct-05 3 y y 137 
CFSP9 y 36 14-Mar-06 1 y n 12-Jul-05 1 y n 245 
CFSP10 y 32 14-Mar-06 3 y y 25-Jan-06 3 y y 48 
CFSP12 y 12 14-Mar-06 1 y y 08-Nov-05 3 y y 126 
CFSP15 y 25 14-Mar-06 1 y n 31-Oct-05 2 y n 134 
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Thirteen CF patients (RBH1 to 4, RBH7 to 11 and RBH14 to 17) donated oral fluid and 
serum samples. The results from scoring the profiles and whether antibodies bound to the 
side-chain and / or core LPS are detailed in Table 20. Eight of the patients (RBH4, RBH8 
to 14, RBH16 and RBH17) gave identical profiles, with both oral fluid and serum samples. 
For these eight samples, the mean number of days between the two samples being taken 
was 143 days (ranging from 0 to 287 days, median = 155 days), compared to a mean 
number of 67 days (ranging from 0 to 238 days, median = 39 days, n = 5), for samples that 
didn't match. If binding strength scores 0 and I were deemed negative and 2 and 3 positive, 
the sensitivity and specificity of immunoblots with oral fluid, compared to the gold 
standard of serum, was 0.85 and 1.00, respectively. However, if the presence of antibodies 
to both A-band side-chain and core LPS was indicative of a positive result, the sensitivity 
and specificity of oral fluid was 0.92 and 1.00, respectively. 
Table 20. Summary of immunoblot data of oral fluid and serum samples from CF patients, 
with scoring of antibody reactions (0 to 3) and clarification of whether A-band side-chain 
(side) or core (core) LPS epitopes were detected 
Patient ID Sex Age 
Date taken 
Oral fluid 
score side core Date taken 
Serum 
score side core 
Days between 
serum and 
sputum samples 
RBH1 6 37 18-Oct-05 1 y n 18-Oct-05 3 y y 0 
RBH2 (3' 34 18-Oct-05 2 y y 18-Oct-05 3 y y 0 
RBH3 g 37 18-Oct-05 2 y y 22-Feb-05 3 y y 238 
RBH4 y 31 21-Oct-05 3 y y 21-Oct-05 3 y y 0 
RBH7 d 47 25-Oct-05 1 y y 30-Aug-05 3 y y 56 
RBH8 11' 34 25-Oct-05 3 y y 14-Jun-05 3 y y 133 
RBH9 c3' 23 25-Oct-05 3 y y 31-May-05 3 y y 147 
RBH1 0 c3' 22 25-Oct-05 3 y y 16-Sep-05 3 y y 39 
RBH11 y 29 25-Oct-05 3 y y 16-May-05 3 y y 162 
RBH14 d 23 25-Oct-05 3 y y 11-Jan-05 3 y y 287 
RBH15 d 22 25-Oct-05 2 y y 16-Sep-05 3 y y 39 
RBH16 6 23 25-Oct-05 3 y y 26-Apr-05 3 y y 182 
RBH17 (-3 38 25-Oct-05 3 y y 15-Apr-05 3 y y 193 
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5.1.6 Summary of immunoblot results for serum and non-invasive samples 
o CF patients demonstrated strong binding to both side-chain and core LPS of strain 
AK1401 with serum, sputum and oral fluid antibodies. 
o Low levels of binding were seen with samples from healthy volunteers and PCD 
patients. 
o All antibody classes (IgM, IgG and IgA) were detected to AK1401 LPS in serum 
(with varying levels of binding demonstrated over time with samples from the same 
patient) and oral fluid samples. 
o Antibodies to the side-chain LPS of strain AK1401 were detected in a urine sample 
from a CF patient. 
o Comparison of paired sputum and serum samples demonstrated a sensitivity and 
specificity 0.67 and 1.00, respectively, when comparing binding strength scores and 
0.78 and 1.00, respectively, when comparing binding to the different LPS moieties. 
o Comparison of paired oral fluid and serum samples demonstrated a sensitivity and 
specificity 0.85 and 1.00, respectively, when comparing binding strength scores and 
0.92 and 1.00, respectively, when comparing binding to the different LPS moieties. 
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5.2 	Antibody analysis by ELISA 
Three ELISAs were developed during the study, starting with an indirect ELISA using 
purified LPS from AK1401 as the capture antigen (ELISA 1). This was developed to detect 
antibodies specific to AK1401 LPS in serum and non-invasive samples from patients with 
CF and healthy volunteers. The second assay (ELISA 2) was an indirect double antibody 
assay for the quantification of antibodies in sera, and was developed to produce a P. 
aeruginosa-specific antibody standard. The final ELISA developed here (ELISA 3) was for 
the detection of IgG and IgM-classed antibodies from serum. 
5.2.1 Serum, oral fluid and urine samples tested with ELISA 1 
ELISA I was optimised by comparing different concentrations of coating antigen, different 
blocking solutions, different dilutions of serum and 'second' antibodies and by testing the 
reproducibility across a microtitre plate (intra-plate variation), and between microtitre 
plates tested on different days (inter-plate variation). The assays were also read at different 
developing times. Serum, oral fluid and urine samples from CF patients and healthy 
volunteers were tested using the assay. 
To evaluate the amount of LPS to coat ELISA wells, high positive serum sample HPP and 
healthy volunteer serum sample NCS were diluted 1/500, 1/5000 or 1/50 000 in PBS and 
tested in ELISA 1 with wells coated with either 0.5 µg, 1 lig, 5 lig or 10 µg purified LPS 
(Figure 66). The CF and healthy serum samples showed a marked difference in their 
absorbances. There was little difference between the absorbance values given with wells 
coated with 5 µg or 10 µg of LPS at all serum dilutions, this showed that the wells were 
saturated with antigen. Wells coated with 1 µg of LPS showed increased levels of binding 
compared to wells coated with 0.5 lig, although the serum samples diluted 1/5000 and 1/50 
000 gave very low absorbance readings at 405 nm. Coating wells with 1 µg of purified LPS 
was chosen for the optimised test. 
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Figure 66. Detection of antibodies bound to purified LPS from strain AK1401 using ELISA 
1: Comparison of different LPS concentrations (0.5, 1, 5 or 10 j.ig per well) and different 
serum dilutions (1/500, 1/5000 or 1/50 000) of samples HPP and NCS. 
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Two different blocking solutions were compared (1 % skimmed milk and 1 % BSA, both 
diluted in PBS) with high positive CF (H04316345) and healthy volunteer serum (HCS4) 
tested in duplicate at dilutions ranging from 1/10 to 1/10 240 in PBS (Figure 67). The CF 
and healthy serum samples showed a marked difference in their absorbances, with the 
difference in their mean values ranging from 0.5 to 2.6 A405. There was no significant 
difference between the milk and BSA-blocked wells for the high positive serum sample for 
dilutions 1/10 through to 1/1280, since the coefficient of variation (CV) was less than 20 %. 
However, at the higher dilutions (1/2560 to 1/10 240), the duplicate samples tested with the 
BSA blocking solution, showed poor correlation. For HCS4, at dilutions 1/640 to 1/10 240, 
there was poor reproducubility in absorbance values, although the more concentrated 
samples showed good correlation. Since there was little difference between the blocking 
agents, BSA was chosen for the ELISA and a serum dilution of 1/500 was adopted for use 
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Figure 67. Detection of antibodies bound to purified LPS from strain AK1401 using ELISA 
1: Comparison of different serum dilutions (+ = positive CF serum (H04316345) and - = 
healthy volunteer serum (HCS4)), tested in duplicate, and 1 % skimmed milk (upper graph) 
versus 1 % BSA (lower graph) blocking solutions. 
1/500 
serum (elution 
since this was in the region showing the greatest discrimination in absorbance between the 
positive and negative serum samples. 
Serum samples H04316345 and HCS4 were reacted with polyvalent, IgA, IgM and 1gG-
classed 'second' antibodies diluted from 1/100 to 1/102 400 (Figure 68). For the CF serum 
sample (H04316345), there were very high levels of polyvalent and IgG-classed 
antibodies, with high absorbances (> 1.7 A405 and > 1.0 A405, respectively) demonstrated by 
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`second' antibody dilutions 1/100 to 1/1600, that titred out as the antibodies became less 
concentrated. In contrast, there were lower levels of IgA and IgM-classed H04316345 
antibodies, with the 1/200 and 1/400 'second' antibody dilutions showing the highest level 
of binding (2.680 and 0.458, respectively). This was unexpected since it was assumed that 
the most concentrated 'second' antibody would bind significantly greater, but the 
absorbance values for the 1/100 dilution were 0.660 and 0.150 for IgA and IgM, 
respectively. Since these samples were not tested in duplicate (due to very small sample 
volumes), it was not possible to determine whether there had been an error. The results for 
the healthy volunteer serum (HCS4) were all low (< 0.4 A405), however the general trend of 
reduced binding with increased dilution of 'second' antibody was still apparent. Due to the 
high cost of the 'second' antibodies, a 1/1000 dilution was deemed satisfactory for routine 
use. 
Four serum samples from CF patients (5534, 4027, 3884 and 4031) and four serum samples 
from healthy volunteers (HNC1 to 3 and HNC 5) were tested on ELISA 1 and the A.405 
values were read at 5 min intervals, from 5 to 30 min (Figure 69). The reactions all 
developed at a constant rate, indicated by the reasonably straight lines on the graph, with all 
samples ranked in the order of the most reactive through to the least. The CF samples all 
demonstrated high levels of specific antibodies (> 0.1 A405 at 30 min), clearly 
distinguishing them from volunteer samples which consistently gave low levels of 
absorbance (< 0.1 A405 at 30 min). 
To assess the intra-plate variation, samples HP4 was tested at a 1/500 dilution in all wells 
of a microtitre plate and reacted with a polyvalent 'second' antibody diluted 1/1000. The 
mean absorbance at 405 nm at 30 min was 1.893, with a minimum of 1.706 and a 
maximum of 2.089, giving an SD of 0.081. The CV was 4.3 %, therefore well within the 
accepted range (< 20 %), and so the intra-plate variation was deemed satisfactory. 
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Figure 68. Detection of antibodies bound to purified LPS from strain AK1401 using ELISA 
1: Comparison of different 'second' antibody concentrations for serum samples 
H04316345 and HCS4. (Arrows indicate 1/1000 dilution.) (arrows mark 1/1000 dilution) 
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Figure 69. Detection of antibodies bound to purified LPS from strain AK1401 using ELISA 
1: Comparison of different serum samples reacted for different lengths of time. 
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Figure 70. Detection of antibodies bound to purified LPS from strain AK1401 using ELISA 
1: Comparison of different serum samples tested in triplicate on three different days. 
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The inter-plate variation was assessed by testing seven samples, two low positive 
(H06026047801 and H06034053201), two medium positive (H05436008201 and 
H05428032701), two high positive (H05500046401 and H05464028501) and one high 
positive pool (HPP), in triplicate on three different days (Figure 70). The mean absorbances 
at 405 nm were 0.276, 0.638, 1.240, 1.907, 3.208, 2.807 and 3.098, respectively. The CVs 
were 9.026 %, 11.926 %, 9.946 %, 9.616 %, 4.199 %, 19.283 % and 6.973 %, respectively. 
This level of inter-plate variation was deemed acceptable. 
All 17 oral fluid samples from CF patients, eight healthy volunteer oral fluid samples (NS1 
to NS8), 17 CF serum samples (RBH1 to RBH4, RBH7 to RBH11, RBH14 to RBH17, 
5543, 4027, 3884 and 4031), four healthy volunteer serum samples (HCS1 to HCS3 and 
HCS5), serum samples from patients 1 and 2 and five pooled CF serum samples (HP4, 
HP3, LP, Med and N) were tested in ELISA 1 and reacted with a polyvalent 'second' 
antibody (Figure 71). Statistical analyses comparing the CF samples (oral fluid samples and 
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Figure 71. A-band LPS antibody levels in CF patient and healthy volunteer serum and oral 
fluid s amples as determined by ELISA 1, detected with a polyvalent' second' antibody 
serum samples RBH1 to RBH4, RBH7 to RBH11, RBH14 to RBH17, 5543, 4027, 3884 
and 4031) and healthy volunteer samples (oral fluid samples NS1 to NS6 and NS8, and 
serum samples HCS1 to HCS3 and HCS5), showed there was a significant difference 
between the two populations for both serum (P = 0.0001) and oral fluid (P = 0.0001) 
samples. The mean of the oral fluid and serum samples from healthy volunteers (with the 
exception of NS7, see below) was 0.367, with an SD of 0.179, giving a negative cut-off 
value of 0.9 A405. 
Fifteen of the oral fluid samples demonstrated absorbances of > 0.9, and thus interpreted as 
being positive. The two negative samples were RBH1 and RBH5 (0.785 A405 and 0.580 
A405, respectively), which also had weak reactions when tested by immunoblot (Figure 58). 
Seven of the oral fluid samples from healthy volunteers gave very low absorbance values 
(0.178 A405 to 0.623 A405), however, the results for NS7 was 1.908 A405. Non-specific 
binding was suspected for this outlier, which was confirmed by immunoblotting (see 
below). All CF serum samples were positive and all healthy volunteer serum samples 
negative, with the mean values of 2.393 A405 and 0.360 A405,  respectively. With the pooled 
CF serum samples, the high positive pools demonstrated high levels of antibody binding 
(1.672 A405 and 1.28 A405), the LP pool median levels (0.949 A405) and the Med and N 
pools were negative (0.647 A405 and 0.206 A405). The longitudinal serum samples from 
patients 1 and 2 showed fluctuating antibodies, with a general increase over time. This 
variation in titre was not evident from the immunoblots (Figure 55), which nearly all 
showed strongly positive binding of A-band LPS for patient 1 but only demonstrated 
binding to core and weakly to side-chain LPS for patient 2. 
CF patients RBH1 to RBH4, RBH7 to RBH11 and RBH14 to RBH17 donated both oral 
fluid and serum, which were all tested by ELISA 1 (Figure 72). The mean ELISA results 
for the oral fluid and serum were 1.722 A405 (SD = 0.569 A405, n = 13) and 2.648 A405 (SD 
= 0.498 A405, n = 13), respectively. Statistical analyses comparing the paired samples 
showed there was a significant difference between the two data sets (P = < 0.001). 
However, both samples from all patients except RBH1 (whose oral fluid sample had an 
absorbance of 0.785 A405), gave positive results in ELISA 1. 
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Figure 72. A-band LPS antibody levels in CF patients' paired serum and oral fluid samples, 
as determined by ELISA 1 and detected with a polyvalent 'second' antibody 
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Twelve of the CF serum samples were tested in ELISA 1, but with the antibodies 
distinguished into classes IgA, IgM or IgG (Figure 73). The mean values for the different 
isotypes were 2.060 A405 (SD = 1.138 A405, n = 12) 0.387 A405 (SD = 0.405 A405, n = 12) 
and 2.545 A405 (SD = 0.517 A405, n = 12), respectively. Although a negative cut-off value 
would need to be calculated to determine whether the sample values were indicative of 
infection, and allowing that the different 'second' antibodies may not be directly 
comparable, these results do show that the IgM-classed antibodies were detected in much 
lower quantities than the IgA and IgG-classed antibodies. 
Only urine samples from CF patients RBH4 and RBH12 demonstrated antibodies over the 
0.9 A405 threshold (1.391 A405 and 2.877 A405, respectively). Both of these samples were 
tested by immunoblot (Figure 64), but RBH12 was the only sample to show any binding to 
the LPS of strain AK1401, and this was very weak. 
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Figure 73. Detection of IgA, IgM and IgG antibodies from RBH serum samples bound to 
purified LPS from strain AK1401 using ELISA I. 
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Since ELISA 1 incorporated ELISA wells coated with BSA, it was possible to detect bound 
antibodies that were not specific to the LPS antigen. Three serum samples 
(H06034052901, H06026044001 and H06034053501) showed raised absorbances when 
tested against the BSA-coated wells (2.953 A405, 1.099 A405 and 1.716 A405 
respectively)(Figure 74). These samples were re-tested but diluted in a 1 % BSA solution, 
rather than a PBS diluent, and lower antibody levels were detected in the BSA-coated wells 
(0.052 A405,  0.037 A405 and 0.055 A405 respectively), presumably due to the BSA blocking 
any BSA-specific antibodies. This also had the effect of lowering the antibody titres to the 
LPS antigen, with the total values lowered by 0.997 A405,  0.984 A405 and 1.501 A405, 
respectively. The immunoblot results for these sera demonstrate binding for samples 
H06034052901 and H06026044001; however, binding was not seen with serum 
H06034053501 (Figure 75). This suggests that additional non-specific binding was 
occurring in the ELISA wells. 
Although low levels of binding were seen with the BSA-coated wells for healthy volunteer 
oral fluid samples NS7 (0.552 A405), the high absorbance (3.040 A405) seen with the LPS- 
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Figure 74. A-band LPS and BSA antibody levels in oral fluid from a healthy volunteer 
(NS7) and serum from CF (H06034052901, H06026044001 and H06034053501) diluted 
in PBS or BSA, as determined by ELISA I and detected with a polyvalent 'second' 
antibody 
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Figure 75. Binding of Proteinase-K digested strain AK1401 to antibodies in oral fluid 
(NS7) and serum (H06034052901, polyvalent 'second' antibody 
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coated wells was unexpected for a healthy, non-CF individual. On re-testing 250 [IL of the 
oral fluid sample mixed with 250 p.tL 1 % BSA (rather than 250 !IL PBS) and tested against 
the LPS antigen, the absorbancy was even higher (3.631 A405). However, when the sample 
was tested by immunoblot, no binding was seen (Figure 75). The ELISA result was 
therefore regarded as a false-positive result, with non-specific binding to an unidentified 
antigen. 
The final samples tested by ELISA 1 were the pre and post-challenge AW1 rabbit serum, 
which were used at dilutions from 1/10 through to 1/10 240 and reacted with an IgM or 
IgG-specific 'second' antibody (Figure 76). There was no significant difference between 
the IgG-classed antibodies from serum samples diluted 1/10 through to 1/640, with all 
reactions scoring > 3.0 A405. At these dilutions, the ELISA wells were saturated, so no 
difference between the sera could be detected. However, at dilutions from 1/1 280 to 1/10 
240, a clear difference was observed between the pre and post-challenge sample (1.541 
A405 through to 2.986 A405), demonstrating the antibody production by the rabbit in 
response to the LPS vaccine. There were far fewer IgM-classed antibodies detected from 
both the pre-challenge and post-challenge sera (the mean 1/10 values were 0.623 A405 and 
2.038 A4o5, respectively), although a significant difference between the absorbances at all 
dilutions was evident. 
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Figure 76. Detection of antibodies bound to purified LPS from strain AK1401 using ELISA 
I : Comparison of pre and post-challenge AW1 rabbit serum at different serum dilutions, 
tested in duplicate, and reacted with IgM or IgG 'second' antibody. 
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5.2.2 Serum samples tested with ELISA 2 
ELISA 2 was initially optimised by comparing different 'second' antibodies from different 
suppliers, different coating buffers and different blocking solutions and testing serum 
samples from CF patients and healthy volunteers. 
Initial testing of samples in ELISA 2 gave rise to many problems of non-specific binding, 
particularly concerning the 'second' antibodies (Table 21), although the CVs for repeated 
samples were all within range (below the accepted 20 % limit (Findlay et aL, 2000)). The 
results from various 'chequer-board' experiments showed that when no 'second' antibody 
was used in the ELISA there was no binding to wells (< 0.5 A405). Similarly, when wells 
were not coated with coating antibody, no binding occurred. However, raised absorbances 
were obtained when both coating antibodies and 'second' antibodies were included, 
whether the samples tested were serum HPP or just PBS, which should have given a blank 
reading. The PBS results were consistently lower than the corresponding HPP results; but 
were greater than expected (it might be thought they would have a 'negative' value, since 
PBS should not contain any antibodies), so presumably the 'second' antibodies were 
binding to the coating antibodies with varying degree. By incorporating a 'blocking' step in 
the ELISA protocol, using BSA solution, there was little effect, with only a 0.095, 0.030, 
0.232 and 0.175 difference between the PBS test samples and 0.057, 0.156, 0.041 and 
0.044 difference between the HPP samples for the goat anti-human IgG, goat anti-human 
polyvalent, goat anti-human IgG with added rabbit serum and rabbit anti-human IgG 
`second' antibodies, respectively. The same pattern of results was seen with the HPP sera 
for the blocked and unblocked wells, with most of the serum samples exhibiting greater 
binding with the goat anti-human polyvalent 'second' antibody, followed by the rabbit anti-
human IgG, goat anti-human IgG with added rabbit serum and finally the goat anti-human 
IgG 'second' antibodies. However, the lowest binding for the PBS sample was with the 
rabbit anti-human IgG 'second' antibody (0.531 A405 and 0.356 A405 for blocked and 
unblocked wells, respectively). When this 'second' antibody was employed, there was also 
a large difference between the PBS and HPP samples (1.064 A405 and 1.283 A405 for 
blocked and unblocked wells, respectively). It was therefore decided to continue the ELISA 
2 experiments using the rabbit anti-human IgG 'second' antibody, but to investigate the 
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Table 21. Summary of results from ELISA 2, comparing different 'second' antibodies 
(Ga-IgG = goat anti-human IgG, Ga-poly - goat anti-human polyvalent, Ga-IgG+R = goat anti-human IgG 
with added rabbit serum and Ra-IgG = rabbit anti-human IgG 'second' antibodies) 
Test sample PBS HPP 
coating antibody 
BSA 'blocker' 
'second' antibody 
x 
x 
x 
Y 
x 
x 
Y 
Y 
x 
x 
Y 
x 
Y 
x 
x 
Y 
Y 
x 
mean A405 -0.001 -0.004 0.102 -0.005 -0.004 -0.001 
coating antibody 
BSA 'blocker' 
'second' antibody 
x 
Y 
Ga-IgG 
x 
Y 
Ga-poly 
x 
Y 
Ga-IgG+R 
x 
Y 
Ga-IgG 
x 
Y 
Ga-poly 
x 
Y 
Ga-IgG+R 
mean A405 0.001 -0.002 -0.004 0.029 0.043 0.020 
coating antibody 
BSA 'blocker' 
'second' antibody 
Y 
x 
Ga-IgG 
Y 
x 
Ga-poly 
Y 
x 
Ga-IgG+R 
Y 
x 
Ra-IgG 
Y 
x 
Ga-IgG 
Y 
x 
Ga-poly 
Y 
x 
Ga-IgG+R 
Y 
x 
Ra-IgG 
mean A405 0.793 0.852 0.803 0.356 0.880 2.036 1.076 1.639 
coating antibody 
BSA 'blocker' 
'second' antibody 
Y 
Y 
Ga-IgG 
Y 
Y 
Ga-poly 
Y 
Y 
Ga-IgG+R 
Y 
Y 
Ra-IgG 
Y 
Y 
Ga-IgG 
Y 
Y 
Ga-poly 
Y 
Y 
Ga-IgG+R 
Y 
Y 
Ra-IgG 
mean A405 0.698 0.822 0.571 0.531 0.937 2.192 1.117 1.595 
blocking solutions further. 
PBS was tested in ELISA 2 with BSA, skimmed milk, chicken egg albumin and 
`Microimmune' blocking solutions (Figure 77). The developed wells were read at 5 min 
intervals, from 5 min to 30 min. The reactions all developed at a constant rate, indicated by 
the reasonably straight lines on the graph, with most samples keeping their positions in the 
order of the most reactive. After 30 min development, wells that were not blocked had a 
mean absorbance of 0.986 A405. This was lowered slightly to 0.796 A405 and 0.754 A405 for 
wells blocked with the Microimmune and BSA blocking solutions. Wells blocked with 
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Figure 77. Absorbances of wells tested with PBS and 'blocked' with BSA, skimmed milk, 
chicken egg albumin and Microimmune blocking solutions, read between 5 and 30 min 
development time. 
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skimmed milk demonstrated the lowest levels of non-specific binding (0.331 A405 after 30 
min), so this solution was used for further tests. 
The buffer in which the coating antibodies were diluted was also investigated. PBS and 
HPP samples were reacted with wells with the coating antibodies diluted in carbonate 
coating buffer, PBS and deionised water (Figure 78). The developed wells were read at 5 
min intervals, from 5 min to 30 min, with reactions all developing at a constant rate and all 
samples keeping their positions in the order of the most reactive. With both the PBS and 
HPP reactions, wells coated with PBS coating buffer demonstrated the lowest levels of 
binding (0.190 A405 and 1.564 A405 after 30 min, respectively). At 30 min development 
time, there was only a 0.146 A405 and 0.133 A405 difference between the wells coated with a 
deionised water and a carbonate coating buffer diluent, for the PBS and HPP reactions, 
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Figure 78. Absorbances of wells tested with PBS (upper graph) and HPP (lower graph) 
with coating antibodies diluted in carbonate coating buffer (CCB), PBS and deionised 
water, read between 5 and 30 min development time. 
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respectively. The final absorbance values for the PBS samples remained very low for all 
reactions (< 0.6 A405), however, it rose to 2.559 A405 and 2.691 A405 for the HPP samples 
diluted with deionised water and a carbonate coating buffer, respectively. The greatest 
difference between the HPP and PBS samples was observed with the carbonate coating 
buffer (2.275 A405), so this diluent was used for further tests. 
To ensure the serum sample produced from adsorbing HPP with strain AK1401 did not 
contain AK1401-specific epitopes, HPP and the adsorbed sample were reacted with outer 
membranes of strains AK1401, 01, 06, 07 and 012 (Figure 79). Although antibodies to 
the protein epitopes remained in the adsorbed sample, there was a marked reduction in 
binding to LPS moieties, consistent with the loss of AK1401 LPS and hence A-band LPS 
epitopes. 
Figure 79. Binding of outer membranes of reference type strains of P. aeruginosa with 
antibodies in HPP pooled serum (right) and HPP serum adsorbed with strain AK1401 (left) 
cp, 2 	0 0 00 a> cr, — 
NJ 	 NJ 
Five CF serum pool samples (HPP, HP3, LP, Med and N) and the adsorbed serum sample 
were tested using ELISA 2 in quadruplicate on four different occasions (Table 22). Despite 
previous assay optimisation, the inter-run variation was very poor, with the CV value 
exceeding 40 % for samples LP, N and adsorbed serum. The results for Day 4 appeared to 
be outliers with some of the samples, however, even if these data were excluded from the 
208 
Table 22. Summary of results (average single concentration of antibodies (m/mL)) from 
ELISA 2 for pooled CF serum samples and the HPP serum sample adsorbed with strain 
AK1401 reacted with an IgG (upper), IgM (middle) and IgA-specific (lower) 'second' 
antibody 
Average concentration of IgG-specific antibodies (pg/mL) 
Sample Day mean SD CV (%) 
1 	2 3 4 
HPP 59458 	68235 69770 86072 70884 11098 16 
HP3 55409 	48364 49653 60057 53371 5408 10 
LP 66102 68236 68065 67416 67455 969 1 
Med 105820 	110450 107080 222810 136540 57547 42 
N 162530 	42838 150980 115060 117852 53940 46 
adsorbed serum 62293 39154 55152 105800 66600 28493 43 
Average concentration of 1gM-specific antibodies (pg/mL) 
Sample Day mean SD CV (%) 
1 	2 	3 	4 	5 	6 
HPP 8266 	7109 	7106 	7147 	7106 	9393 7688 953 12 
LP 12105 	12378 	11731 	15293 	10488 	11243 12206 1654 14 
N 3928 	4805 	4642 	4855 	5692 	9551 5579 2026 36 
adsorbed serum 4148 	6894 	5215 	6525 	6813 	7903 6249 1344 22 
    
Average concentration of IgA-specific antibodies (pg/mL) 
 
 
Sample 
 
Day 
1 	56160 66016 24473 5 	6 
 
     
 
HPP 
LP 
N 
adsorbed serum 
14946 22966 17368 7968 13861 31340 
14613 39100 35988 28800 13541 34433 
11762 7 	8 	9 	8306 20725 
17074 53936 49875 30658 12540 27080 
 
        
  
Average concentration of IgA-specific antibodies (pg/mL) 
   
Sample 
 
Day 
7 	8 	9 	10 
 
mean SD CV (%) 
HPP 
LP 
N 
adsorbed serum 
53936 	49875 	30658 	15001 
56160 66016 24473 12779 
22966 	17368 	7968 	6290 
39100 35988 28800 20219 
 
26648 14774 55 
27106 19212 71 
12184 5944 49 
22699 9502 42 
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analyses, the LP and adsorbed samples' CV value still exceeded 20 %. Similarly, the 
reproducibility experiments with the IgM-specific antibodies (performed in quadruplicate 
on six occasions) and the IgA-specific antibodies (performed 10 times) demonstrated poor 
reproducibility. Two samples exceeded a CV of 20 % for IgM assays and the lowest CV for 
the IgA experiments was 42 %. Due to these inconsistent results, ELISA 2 was abandoned 
for further study. 
5.2.3 Summary of ELISA results for serum and non-invasive samples 
o 1 ug of purified LPS coating antigen, BSA blocking solution, 1/500 serum sample 
dilution and 1/1000 'second' antibody dilution were chosen as the optimal test 
parameters for ELISA 1. 
o Serum and oral fluid samples from CF patients demonstrated high levels of specific 
antibodies (> 0.9 A405) and serum and oral fluid samples from healthy volunteers 
demonstrated low levels of specific antibodies (< 0.9 A405). 
o Fluctuating antibody levels were seen for the longitudinal serum samples from CF 
patients 1 and 2. 
o High levels of IgA and IgG-classed antibodies specific to AK1401 LPS were 
demonstrated in CF sera. 
o BSA-specific antibodies were detected. 
o It was not possible to determine accurately the concentration of total antibodies in 
pooled serum samples. 
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5.3 	Results HI summary 
The results from this chapter support the hypothesis investigated, since oral fluid could be 
shown to provide data comparable with serum antibodies, therefore clinicians would be 
able to test patients more frequently and therefore gather more information on their patients 
regarding their infection status with P. aentginosa. 
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CHAPTER 6 
RESULTS IV: CLINICAL EVALUATION OF THE A-BAND 
LPS RESPONSE IN SERUM SAMPLES 
212 
In this chapter, the hypothesis investigated was 'serum antibodies to A-band LPS could be 
identified prior to P. aeruginosa being grown from sputum, thus allowing clinicians to 
identify infections in patients with CF at an earlier stage and therefore allow earlier therapy 
against P. aeruginosa'.  
The optimised ELISA 3 method was employed for the detection of serum antibodies to P. 
aeruginosa in patients with CF and to evaluate the method in a clinical context. Multiple 
serum samples from 22 patients were tested for both IgM and IgG-specific antibodies and 
these data were compared to results obtained from immunoblotting with the serum samples, 
to confirm the validity of the absorbance values. Serum samples from healthy volunteers 
were tested with ELISA 3 to calculate appropriate cut-off values for the assay in order to 
confirm whether there were sufficient antibodies present in a serum sample to indicate 
infection with P. aeruginosa. The ELISA data were then collated and analysed alongside 
the patients' sputum culture and pulmonary function test results (provided by Bristol 
Children's Hospital) to determine whether additional clinical data was gained from the 
testing of serum, in particular confirmation of an earlier diagnosis of infection with P. 
aeruginosa. 
6.1 	ELISA 3 serum antibody results 
Three-hundred and twenty-eight serum samples were tested in duplicate and 42 samples in 
quadruplicate using ELISA 3. The reproducibility of the sample results for serum tested in 
quadruplicate was excellent, with a mean CV of 5.97 % and a SD of 4.86 (n = 42), which 
was well below the accepted 20 % limit (Findlay et al., 2000). All samples had duplicate 
results with a CV value of < 20 % when reacted with both the IgM and IgG-specific 
`second' antibodies. The results from both assays for all samples are detailed in Appendix 
XVI. 
For all 370 serum samples, the IgG data ranged from 0.101 A405 to 2.432 A405, with a mean 
of 0.779 A405 (SD = 0.542) and the IgM data ranged from 0.225 A405 to 3.902 A405, with a 
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mean of 2.326 A405 (SD = 1.063). The distribution of these data is shown in Figure 80, for 
information. 
Two pooled serum samples (Std and N) were included on every ELISA plate. The reactions 
were considered complete when the Std serum sample had reached an absorbance of 2.5 
A405 +1— 10 % (i.e. 2.25 to 2.75). To act as an additional control, the values for the N 
samples were compared, to ensure they had remained constant. For each run, the 
absorbances for both Std and N were recorded (Figure 81) and the distribution of the results 
confirmed to be normal (Figure 82). The mean values for the first 20 plates for the Std 
sample for the IgG and IgM assays were 2.427 A405 (SD = 0.116 A405, n = 20) and 2.337 
Aaas (SD = 0.050 A405, n = 20), respectively. The cut-offs for further plates were calculated 
as 2.776 A405 to 2.078 A405 and 2.488 A405 to 2.186 A405 for the IgG and IgM assays, 
respectively. 
The mean values for the first 20 plates for the N control sample for the IgG and IgM assays 
were 1.350 A405 (SD = 0.102 A405, n = 20) and 0.409 A405 (SD = 0.037 A405, n = 20), 
respectively. The cut-offs for the N control sample for further plates were calculated as 
1.657 A405 to 1.043 A405 and 0.521 A405 to 0.298 A405 for the IgG and IgM assays, 
respectively. 
Figure 80. Distribution of IgM and IgG absorbances for sample from CF patient serum 
samples tested on ELISA 3. 
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Figure 81. Absorbances of control samples Std and N tested on different days for the IgM 
(upper graph) and IgG (lower graph) specific ELISA 3 assays 
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Figure 82. Distribution of the IgM and IgG absorbances for control samples Std and N. 
To confirm that the different absorbances obtained from ELISA 3 reflected different levels 
of antibody binding in the serum samples, the ELISA results were arranged in order from 
high to low and alternate samples were tested by immunoblotting and reacted with either 
the IgG or IgM-specific 'second' antibody (Figure 83 and Figure 84, respectively). Samples 
were tested until no antibody binding could consistently be detected, with 55 serum 
samples being tested for IgG-specific antibodies and 153 samples for IgM-specific 
antibodies. The immunoblots clearly correlated with the decreasing absorbance values from 
ELISA 3, with the limit of detection for the IgG and IgM assays being 1.3 A405 and 1.7 
A405, respectively. 
Figure 83. Reactions of antibodies with strains AK1401 of P. aeruginosa digested with 
Proteinase-K and reacted with an IgG-specific 'second' antibody, with their corresponding 
absorbance values from ELISA 3. 
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Figure 84. Reactions of antibodies with strains AK1401 of P. aeruginosa digested with 
Proteinase-K and reacted with an IgM-specific 'second' antibody, with their corresponding 
absorbance value from ELISA 3. 
Forty-one serum samples from healthy volunteers were tested in duplicate with ELISA 3 
(Figure 85). The mean IgG absorbance was 0.570 A405 (SD = 0.280). Although these data 
gave a skewed distribution (Figure 86), this was due to the minimum level of detection for 
the ELISA, since the mean of the blank wells was 0.092 A405 (SD 0.014 A405, n = 80). The 
data distribution was therefore considered reasonably normal. Theoretically, the cut-off 
(mean + (3 x SD)) between negative and positive on ELISA 3 for the IgG assay should be 
1.409, which was very similar to the immunoblot sensitivity level. However, this cut-off 
was so high that many of the samples from CF patients would have been interpreted as 
negative. Since in a clinical setting the cut-off should initially be set such that there are no, 
or minimal, false negatives and all immune responses can be detected (Findlay et al., 2000), 
the cut-off was lowered to 1.13 A405, which was the mean + (2 x SD). This threshold only 
classsified two of the healthy volunteer samples as positive. The specificity of the assay 
was therefore 95 %. 
The mean IgM absorbance of the 41 healthy volunteer serum samples was 1.850 A405 (SD 
= 0.712). The data had a wide span and was spread reasonably uniformly across the range 
(Figure 86). A cut-off of the mean + (2 x SD) was 3.274 A405, double the immunoblot 
sensitivity limit and close to the reading limit (4.0 A405) of the ELISA reader. This cut-off 
would interpret very few true positives as positive, however, the data did indicate that IgM 
antibodies specific to P. aeruginosa were widespread in the healthy population, some of 
which can reach very high levels. 
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Figure 85. ELISA 3 IgM and IgG results for healthy negative control volunteer samples 
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Figure 86. Distribution of the IgM and IgG absorbances for sample results for healthy and 
CF serum samples tested in ELISA 3. 
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6.2 	Correlation of serum antibody results with P. aeruginosa microbiology and lung 
function data 
All serum sample data, the sputum culture results and the pulmonary function test data 
(provided by Bristol Children's Hospital, as detailed in section 2.37, for the period that 
serum data was available) were collated to provide a clinical picture over time for each of 
the 22 CF patients (Figure 87). Details of the first ever isolation of P. aeruginosa (and 
mucoid P. aeruginosa, if present) were also included, as this event occurred in six patients 
(40, 43, 51, 189, 278 and 311) before serum had first been tested. 
6.2.1 Sputum culture results 
Sputum culture data was available for all 22 CF patients. The mean age when P. 
aeruginosa was first isolated from the patients was 5.2 y (SD 3.5 y, n = 22), although this 
ranged from 1 m to 12 y (patients 312 and 166, respectively). All patients except patient 
189 (who was termed chronically infected) were 'negative' for P. aeruginosa at the start of 
the time period analysed. All patients grew P. aeruginosa, but six of them (48, 51, 166, 
245, 247 and 314) never reached the 'chronic' status (where two or more isolates were 
grown in the 6 m prior to a serum sample being taken), despite significantly poor lung 
function (< 80 % of predicted FEV1 or FVC). Six patients (33, 40, 43, 48, 171 and 189) 
grew mucoid P. aeruginosa. 
6.2.2 Pulmonary function test data 
Data regarding the pulmonary function of the CF patients was only available for 19 of the 
patients, and even then it was not always available for the whole time period analysed. All 
of the 19 patients had at some point demonstrated significantly poor (< 80 % of predicted) 
FEV1 or FVC data. In total, 194 readings were available, with the percent predicted FEV1 
and FVC ranging from 29 % to 125 % and 37 % to 178 % respectively, with mean values 
of 74 % (SD = 21 %, n = 194) and 86 % (SD = 21 %, n = 194), respectively. For individual 
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clinical evaluation study 
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patients, a low FEVI score was not always coupled with a low FVC score. The difference 
between the highest and lowest percent predicted FEVI for each patient ranged from 19 % 
to 60 %, with the average being 35 %. For the FVC data, the difference between the highest 
and lowest ranged from 13 % to 90 %, with an average of 38%. Despite the large amount of 
pulmonary function test data, there was no suggestion of correlation with the serology data. 
6.2.3 Serology data 
The mean age of the CF patients when they provided their first 'fit' (i.e. not exhausted and 
of normal appearance) serum was 3.4 y (SD = 2.1 y), although this ranged from 1 m to 8 y 
(patients 312 and 278, respectively). Sixteen of the patients (33, 40, 43, 47, 48, 171, 189, 
233, 247, 257, 267, 276, 277, 278, 311 and 321; 73 %) had IgG titres that exceeded the 1.1 
A405 cut-off, despite four of these (48, 51, 166 and 247) never reaching a 'chronic' sputum 
culture status. None of the patients seroconverted (with IgG values > 1.1 A405) before non-
mucoid P. aeruginosa was first isolated from their sputum. The shortest time between 
growing non-mucoid P. aeruginosa and obtaining a positive IgG result was 9 m (patient 
171). ELISA 3 detected positive IgG levels in all six patients (33, 40, 43, 48, 171 and 189) 
who grew mucoid P. aeruginosa, prior to the mucoid strain being grown. The shortest time 
228 
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between growing mucoid P. aeruginosa and obtaining a positive IgG result was 7 m 
(patient 33) and the longest was almost 12 y (patient 189). 
Analysis of the IgM antibody levels was initially not performed, because of the high cut-off 
level and SD from the healthy volunteer serum samples. However, on closer inspection of 
the graphs in Figure 87, when individual patients' baseline IgM levels were calculated, a 
correlation was observed between the shapes of the graphs of sputum culture and the IgM 
serology results. Three examples have been re-plotted to display better this link in Figure 
88. Statistical analyses showed that 19 of the patients (33, 40, 43, 44, 47, 48, 51, 171, 189, 
245, 257, 267, 276, 277, 278, 311, 312, 314 and 321) demonstrated a significant rise from 
the baseline of IgM-classed antibodies that was associated with a change of sputum culture 
status. 
Figure 88. Correlation of ELISA 3 IgM antibody response over time with sputum culture 
results for patients 33 (top left), 171 (top right) and 257 (lower) 
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6.3 	Results 1V Summary 
o The ELISA 3 IgG and IgM results were confirmed by immunoblotting. The 
sensitivity of the IgG and IgM-specific immunoblot tests were 1.3 A405 and 1.7 
A405, respectively. 
o Testing of sera from healthy volunteers set the IgG cut-off as 1.13 A405. The IgM 
data needed to be compared to each individual's baseline level. 
o Of 22 CF patients studied, none were IgG-positive prior to non-mucoid P. 
aeruginosa being isolated from their sputum. 
o All 6 CF patients who grew mucoid P. aeruginosa, seroconverted (IgG) prior to the 
mucoid phenotype arising. 
o There was a significant correlation between the IgM antibody titres and the sputum 
culture results. 
The results from this chapter did not support the hypothesis investigated, since it was not 
possible to use serum antibodies to A-band LPS to identify infection prior to P. aeruginosa 
being grown from sputum. ELISA 3 therefore would not allow clinicians to identify 
infections in patients with CF at an earlier stage and therefore allow earlier therapy against 
P. aeruginosa. However, the IgG levels did indicate the development of chronic infection 
(associated with a mucoid phenotype) and the IgM levels did correlate with the sputum 
culture, so more frequent testing for antibodies may indeed support the hypothesis. 
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CHAPTER 7 
RESULTS V: COMPARISON OF ELISA 3 WITH LHCAI'S IN-
HOUSE ELISA AND COMMERCIALLY AVAILABLE KITS 
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In this chapter, the two hypotheses investigated were 'the detection of serum antibodies to 
A-band LPS, as tested by ELISA 3, could be comparable to detection of serum antibodies 
to whole cells of the six strains employed by the LHCAI in-house, thereby allowing the 
implementation of a new in-house assay that uses fewer laboratory reagents and resources' 
and 'the detection of serum antibodies to A-band LPS, as tested by ELISA 3, could be 
comparable to the detection of antibodies using commercially available assays'. 
To evaluate fully the ELISA 3 assay it was important to compare it with LHCAI's in-house 
ELISA and those commercial tests available in the UK (from Genesis Diagnostics and SSI). 
The first step was to establish whether the single AK1401 antigen result from the LHCAI 
in-house ELISA could be used for these analyses and replace results from all six antigens 
employed in the assay. ELISA 3 was therefore evaluated initially by comparing the results 
of 370 serum samples with the standard in-house assay. If ELISA 3 gave comparable 
results with the latter, this would justify its induction into the routine service. A smaller 
panel of samples (39) from the clinical evaluation study set was also tested with 
commercial assay kits and the degree of correlation between all assays was determined. 
7.1 	Comparison of antigens employed in the LHCAI in-house ELISA 
The 370 serum samples employed for the clinical evaluation study (Chapter 6) were 
selected from samples previously tested by the LHCAI in-house ELISA (Appendix XVII). 
Pivot tables (Table 23) were constructed of the values obtained for the six antigens 
(AK1401, 01, 06, 07, 012 and C28) to compare the results for each serum sample in order 
to establish a single result for AK1401 LPS. For antigen 01, 66.5 % (246) of serum 
samples correlated exactly, with the samples giving the same antibody titre to both the 01 
and AK1401 antigens. When results which differed by one dilution were included, 94.3 % 
(349) of sample results were concordant. For antigen 06, 61.4 % (227) of samples agreed 
exactly, and 93.2 % (345) were within one dilution. For antigens 07 and 012, 68.9 % (255) 
and 64.9 % (240) of samples gave exactly the same results, with 96.8 % (358) and 93.8 % 
(347) of samples giving results within one dilution, respectively. Antigen C28 also 
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Table 23. Pivot tables comparing results from antigens 01, 06, 07, 012 and C28 to 
AK1401 using the LHCAI in-house ELISA 
 
01 
<500 500 1000 2000 4000 8000 16000 
 
Total 
165 
80 
45 
33 
22 
16 
9 
370 
<500 
500 
1000 
E, 	2000 
yr 
2 	4000 
Q 
8000 
16000 
Total 
155 	8 	1 	1 
28 44 4 4 
4 	16 	20 	4 	1 
1 	3 	13 	13 	3 
3 	10 	9 
2 	12 	2 
1 5 	3 
 
188 	71 	41 	35 	25 	7 	3 
 
    
    
 
06 
<500 500 1000 2000 4000 8000 16000 
 
Total 
165 
80 
45 
33 
22 
16 
9 
370 
   
<500 
500 
1000 
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.2 	4000 
8000 
16000 
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136 	21 	8 
21 	38 	15 	5 	1 
1 	12 	21 	8 	3 
12 	16 	3 	2 
3 	3 	8 	7 	1 
9 	6 	1 
1 	6 	2 
 
158 	71 	59 	32 	25 	21 	4 
 
    
07 
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<500 
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80 
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45 
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22 
8000 1 	 5 	10 16 
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2 	7 
	
9 
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173 	72 	39 	41 	20 	18 	7 
	
370 
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Table 23. Continued. 
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9 
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1000 
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200 61 36 33 25 9 6 
 
     
C28 
<500 500 1000 2000 4000 8000 16000 Total 
<500 129 36 
	
165 
500 
	
18 	51 	8 	2 	1 
	
80 
1000 
	
1 	21 	20 	3 45 
2000 
	
2 	3 	12 	16 
	
33 
4000 2 	5 	4 	10 	1 
	
22 
8000 
	
1 	4 	5 	5 	1 
	
16 
16000 1 	2 	2 	3 	1 
	
9 
Total 150 113 47 31 18 9 2 370 
correlated strongly, with 62.7 % (232) of samples having the same result and 93.0 % (344) 
of sample results being within one dilution. These data demonstrate that the single AK1401 
strain consistently gave results that strongly agreed with the results for the other antigens. 
Additionally, since the LHCAI in-house ELISA had a final interpretive comment based on 
the results of all six antigens, it was therefore justified to use the single antigen result in 
further comparative analyses. 
7.2 	Comparison of ELISA 3 and the LHCAI in-house ELISA 
The ELISA 3 results for the 370 serum samples employed for the clinical evaluation study 
were compared to the results from previous testing with the LHCAI in-house ELISA 
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(Appendix XVH). There was moderate correlation between the two ELISAs, with an R2 
value of 0.6 (Figure 89). A closer inspection of the individual samples confirmed the 
correlation between the ELISA 3 and LHCAI in-house assays; over 95 % of samples which 
had an absorbance of < 0.5 A405 when tested in ELISA 3, also had a negative antibody titre 
(< 500 or 500) in the LHCAI in-house ELISA (Table 24). Where samples had an 
absorbance of 0.500 to 0.999 (still deemed negative by ELISA 3), a further 84 samples (73 
%) were also LHCAI in-house ELISA negative. Additionally, if those samples that were 
negative (< 500 or 500 titre) in the LHCAI in-house ELISA, 91.1 % were also negative (< 
1.0 A405) by ELISA 3. 
The correlation for the serum samples that had higher levels of antibodies to P. aeruginosa 
was not as good, with 45.8 % of samples with an absorbance of 1.0 to 1.5 A405, having a 
titre of 1000 or 2000. In fact, almost half of the samples which had this 'low-positive' titre 
of 1000 or 2000 were deemed negative by ELISA 3 and these outliers are clearly shown in 
Figure 89. The 'medium-positive' titres of 4000 to 8000 correlated well to ELISA 3, with 
70 % of samples having an absorbance of 1.0 to 2.0 A405 and the 'high positive' titre of 
16000 gave excellent correlation (80 %) with an absorbance of 1.5 A405 or above. Indeed, 
93.4 % of samples that gave a result of 2.0 A405 or above by ELISA 3 had a titre of 4000 or 
more. 
Figure 89. Correlation of ELISA 3 with the LHCAI in-house ELISA 
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Table 24. Comparison of the results of 370 serum samples tested in ELISA 3 and the 
LHCAI in-house ELISA 
LHCAI 
A K1401 titre Count A405 
ELISA 3 
Count 	% MM Max 
0.000 - 0.499 11 4.5 
0.500 - 0.999 214 86.6 
<500 or 500 247 1.000 - 1.499 16 6.5 0.101 1.812 
1.500 - 1.999 6 2.4 
2.000 + 0 0.0 
0.000 - 0.499 6 8.3 
0.500 - 0.999 27 37.5 
1000 or 2000 72 1.000 - 1.499 27 37.5 0.242 2.175 
1.500 - 1.999 10 13.9 
2.000 + 2 2.8 
0.000 - 0.499 0 0.0 
0.500 - 0.999 3 7.3 
4000 or 8000 41 1.000 - 1.499 14 34.1 0.869 2.231 
1.500 - 1.999 15 36.6 
2.000 + 9 22.0 
0.000 - 0.499 0 0.0 
0.500 - 0.999 0 0.0 
16000 10 1.000 - 1.499 2 20.0 1.317 2.432 
1.500 - 1.999 4 40.0 
2.000 + 4 40.0 
ELISA 3 LHCAI 
A405 Count AK1401 titre Count % Min Max 
<500 or 500 140 95.9 
0.000 - 0.499 145 
1000 or 2000 6 4.1 <500 2000 
4000 or 8000 0 0.0 
16000 0 0.0 
<500 or 500 84 73.0 
0.500 - 0.999 118 
1000 or 2000 28 24.3 <500 4000 
4000 or 8000 3 2.6 
16000 0 0.0 
<500 or 500 16 27.1 
1.000 - 1.499 60 
1000 or 2000 27 45.8 <500 16000 
4000 or 8000 14 23.7 
16000 2 3.4 
<500 or 500 6 17.1 
1.500 - 1.999 32 
1000 or 2000 10 28.6 <500 16000 
4000 or 8000 15 42.9 
16000 4 11.4 
<500 or 500 0 0.0 
2.000 + 15 
1000 or 2000 1 6.7 1000 16000 
4000 or 8000 10 66.7 
16000 4 26.7 
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7.3 	Detection of serum antibodies using the Genesis Diagnostics ELISA 
Thirty-nine serum samples previously tested by ELISA 3 and immunoblot in the clinical 
evaluation study (Chapter 6) were selected, representing a wide range of specific antibody 
levels (16 -, 8 +, 10 -HF and 5 1—i—F by immunoblot) (Table 25). They were assayed for 
antibodies to P. aeruginosa using the ELISA from Genesis Diagnostics. Samples were 
tested in duplicate on two separate days. Those duplicates tested on the same plate showed 
very good correlation, with 38 samples demonstrating CV values of < 10 % and one sample 
having a CV of 18.7 %. However, the variation between the mean values from the two 
days' assays was much greater (11 of the 39 samples had a CV greater than 20 %, with 
H0698521 showing a CV of 43.4 %) (Figure 90). 
Two of the serum samples (H05500464 and H070140138) had ELISA results greater than 
the maximum possible to extrapolate from the standard curve (the highest recorded value 
was 120.1 U/mL), so they were given the value of 150 U/mL. Their results on testing in 
ELISA 3 were 2.26 A405 and 2.432 A405, respectively and the values for the remaining 
samples ranged from 3.05 to 135.05 U/mL. The manufacturers of the Genesis Diagnostics 
ELISA recommend setting local cut-off values, but their data showed 95 % of healthy 
subjects had serum values less than 6 U/mL. Only eight of the serum samples (3497, 4064, 
4085, 5051, 5917, 5941, 3905 and H04242201) gave a value of < 6, and all of these 
(except 5917 and 5941) also had an absorbance of < 0.9 in ELISA 3. Ten of the 39 samples 
had an absorbance of < 0.9 in ELISA 3 and for these samples, eight (3497, 3905, 4064, 
4065, 4085, 5036, 5051 and H04242201) of them had values < 10 U/mL in the Genesis 
Diagnostics' assay, and two samples (3921 and H0698521) had values of 11.5 U/mL and 
33.75 U/mL, respectively. Overall, there was some correlation between ELISA 3 and the 
Genesis Diagnostics assay, with an R2 value of 0.5 (Figure 90). 
237 
Table 25. Summary of results from comparison of LHCAI (AK1401 result) in-house, 
ELISA 3, Genesis Diagnostics and SSI ELISAs and immunoblot data for 39 serum samples 
Sample Blot LHCAI (AK1401) 
ELISA 3 
mean Day 1 
mean 
Genesis 
Day 2 Mean mean CV (%) 
Day 1 
mean 
Day 2 
mean 
SS! 
Mean CV (%) 
4065 - <500 0.340 7.5 7.9 7.7 3.67 1149.5 1382.2 1265.85 13.00 
4085 - <500 0.310 4 2.9 3.45 22.55 1445.9 1607.3 1526.6 7.48 
4064 - <500 0.657 3.3 3 3.15 6.73 814.2 952.5 883.35 11.07 
H05440388 - <500 1.229 7.6 7.5 7.55 0.94 437.4 451.3 444.35 2.21 
5776 - <500 1.148 11.6 12 11.8 2.40 312.2 361.5 336.85 10.35 
3905 - 500 0.580 5.7 4.9 5.3 10.67 847.4 1125.1 986.25 19.91 
5036 - 500 0.676 6.9 5.5 6.2 15.97 414.9 664.5 539.7 32.70 
3497 - 500 0.809 3.2 2.9 3.05 6.96 1401.6 1665.8 1533.7 12.18 
5051 - 500 0.827 5.3 3.9 4.6 21.52 368.6 402.4 385.5 6.20 
H04242201 - 500 0.845 5.2 5.4 5.3 2.67 369.7 474.2 421.95 17.51 
5917 - 500 0.964 5.1 4.1 4.6 15.37 419.8 712.8 566.3 36.59 
H05082446 - 500 1.004 30.4 38.9 34.65 17.35 120.6 2000 1060.3 125.34 
5941 - 500 1.143 5.3 4.8 5.05 7.00 751.2 936.9 844.05 15.56 
110422629 - 500 1.272 20.7 24.6 22.65 12.18 328.6 344.2 336.4 3.28 
3921 - 1000 0.869 11.9 11.1 11.5 4.92 398.9 457.2 428.05 9.63 
5060 - 1000 1.660 53.8 72.1 62.95 20.56 68.5 2000 1034.25 132.05 
H0698521 + <500 0.593 23.4 44.1 33.75 43.37 1446.7 1656.3 1551.5 9.55 
5626 + 500 1.313 13.2 9.6 11.4 22.33 156.3 194.6 175.45 15.44 
3098 + 1000 1.300 19.4 23.2 21.3 12.62 285.1 271.3 278.2 3.51 
H06364493 + 1000 1.396 28 16.3 22.15 37.35 170.1 182.2 176.15 4.86 
5089 + 1000 1.703 43.9 36.6 40.25 12.82 2000 2000 2000 0.00 
3396 + 1000 1.723 62.7 66.3 64.5 3.95 1094.1 1251.6 1172.85 9.50 
5284 + 2000 1.604 120.1 150 135.05 15.66 2000 2000 2000 0.00 
5771 + 4000 1.582 42.7 40.5 41.6 3.74 2000 2000 2000 0.00 
2700 ++ 2000 1.510 28.7 38.9 33.8 21.34 103.3 2000 1051.65 127.53 
3751 ++ 2000 1.778 40.9 43.6 42.25 4.52 80.2 2000 1040.1 130.52 
5124 ++ 4000 1.441 41 38.3 39.65 4.82 2000 2000 2000 0.00 
2924 ++ 4000 1.445 30 22 26 21.76 125.9 2000 1062.95 124.67 
2489 ++ 4000 1.491 28.3 21.1 24.7 20.61 332.6 375.3 353.95 8.53 
H05266434 ++ 4000 1.685 24.5 17.6 21.05 23.18 263.9 189.9 226.9 23.06 
11064360293 ++ 4000 2.117 34.9 37.5 36.2 5.08 131.3 2000 1065.65 124.00 
4026 ++ 8000 2.085 37.6 48.5 43.05 17.90 2000 2000 2000 0.00 
H06024433 ++ 8000 2.125 30.3 31.2 30.75 2.07 129.5 2000 1064.75 124.22 
H05426294 ++ 16000 2.066 77 90.1 83.55 11.09 183.7 2000 1091.85 117.63 
3968 +++ 4000 1.649 18.7 24.2 21.45 18.13 2000 385.2 1192.6 95.74 
H05254304 +++ 8000 2.016 91.8 150 120.9 34.04 74.2 2000 1037.1 131.30 
1105500464 +++ 16000 2.260 150 150 150 0.00 141.2 2000 1070.6 122.77 
Std +++ 16000 2.338 61 79.1 70.05 18.27 82.5 2000 1041.25 130.22 
H070140138 +++ 16000 2.432 150 150 150 0.00 2000 2000 2000 0.00 
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Figure 90. Histogram of antibody levels in serum according to the Genesis Diagnostics 
ELISA compared with results from ELISA 3 (upper graph, error bars indicate difference 
between mean for each day) and a scatter graph showing the correlation of the two assays 
(lower graph) 
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7.4 	Detection of serum antibodies with the SSI ELISA 
The same 39 samples as in section 7.3 were tested in duplicate on two separate days using 
the St-Ag from the SSI (Table 25). Eighteen of the samples (2700, 2924, 3751, 3968, 4026, 
5060, 5089, 5124, 5284, 5771, H05082446, H05254304, H05426294, H05500464, 
H06024433, H064360293, H070140138 and Std) had ELISA results greater than the 
maximum possible to extrapolate from the standard curve (the highest recorded value was 
1665.8 U), so they were given the value of 2000 U. Six of the samples (4026, 5089, 5124, 
5284, 5771 and H070140138) had a value of 2000 U for all samples tested and the 
remaining ten had duplicate samples ranged from 68.5 U (for sample 5060) to 183.7 (for 
samples H05426294), thus their overall mean values ranged from 1034.3 to 1091.9 U, 
respectively (Figure 91). Of the remaining 21 samples the duplicates tested on the same 
plate showed very good correlation, with all samples demonstrating CV values of < 8 %. 
However, the variation between the mean values from the two separate days' assays was 
greater (three had a CV greater than 20 %). The results from these samples ranged from 
175.5 to 1551.5 U. 
The only guidance given by the manufacturers for interpretation of results was that sera 
from non-infected Danish CF patients gave a mean absorbance of 0.66 U (SD = 0.82). As 
none of the serum samples gave absorbances anywhere near this value, it was impossible to 
interpret the data according to the manufacturer's recommendations. Additionally, overall, 
there was poor correlation between ELISA 3 and the SSI assay, with an R2 value of 0.1 
(Figure 91). 
7.5 	Comparison of the Genesis Diagnostics ELISA with the SSI ELISA 
Comparison of the results from both the Genesis Diagnostics and SSI ELISAs, when 
plotted on a scatter graph, showed poor correlation with an R2 value of 0.2 (Figure 92). 
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Figure 91. Histogram of antibody levels in serum according to the SSI ELISA compared 
with results from ELISA 3 (upper graph, error bars indicate difference between mean for 
each day) and a scatter graph showing the correlation of the two assays (lower graph) 
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Figure 92. Scatter graph showing the correlation of the Genesis Diagnostics and SSI 
ELISAs 
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7.6 Comparison of all ELISAs and immunoblot results for the detection of P. 
aeruginosa-specific antibodies in serum 
A comparison of the results for the 39 samples tested using the Genesis Diagnostics and 
SSI ELISAs with their results from ELISA 3, the LHCAI in-house ELISA and by testing 
by immunoblot with P. aeruginosa strain AK1401 digested with Proteinase-K is 
summarised in Table 25 and Figure 93. The purpose was to compare the assay 
performances, rather than looking at their diagnostic value. The graphs clearly show the 
results from ELISA 3 closely corresponded to the immunoblot data. The LHCAI in-house 
ELISA also had good correlation, despite the occasional outlier. The results from the 
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Genesis Diagnostics assay showed the general tend of increasing antibody levels from left 
to right, however, there was no correlation with the SSI assay. 
7.7 	Results V Summary 
o The AK1401 results from the LHCAI in-house ELISA strongly correlated with the 
other five antigen results, therefore allowing use of the single antigen result in 
further analyses. 
o Results from ELISA 3 correlated well with the LHCAI in-house ELISA (R2 = 0.6). 
o The results from the Genesis Diagnostics assay correlated with ELISA 3 (R2 = 0.5). 
o The results from the SSI assay did not correlate with ELISA 3 (R2 = 0.1) or the 
Genesis Diagnostics assay (R2 = 0.2). 
o ELISA 3, LHCAI in-house ELISA and the Genesis Diagnostics assay all correlated 
with the results from immunoblotting with P. aeruginosa strain AK1401 digested 
with Proteinase-K. 
The results from this chapter did support both the hypothesis investigated, since the 
detection of serum antibodies to A-band LPS, as tested by ELISA 3, was comparable to the 
detection of serum antibodies by the LHCAI in-house and the commercially available 
assays. Therefore, the data supports the implementation of a new in-house assay that uses 
fewer laboratory reagents and resources than the LHCAI in-house ELISA. It also supports 
using the Genesis Diagnostics assay (although the exact antigen employed is unknown and 
the kit is quite expensive) but questions the validity of the results from the SSI assay. 
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CHAPTER 8 DISCUSSION 
245 
8.1 	The ideal test for detecting infection with P. aeruginosa in patients with CF 
In order to gauge the significance of the work presented in this thesis and to relate it to a 
clinical setting, it is important to consider the characteristics of an ideal test for detecting 
infection with P. aeruginosa in patients with CF, from the perspective of both clinicians 
and laboratory workers. 
The clinician requires a test that gives rapid results and ideally could be performed in the 
clinic by non-specialised staff, thus providing the necessary information to inform therapy 
and patient management. The test needs to be simple, although it might be based on 
relatively complex science, require minimal training of staff, employ non-invasive samples 
and use robust technology to give reproducible data. It should identify all patients with 
infections, and discriminate between newly acquired and long standing infections and 
reflect their response to therapy. 
The laboratory worker on the other hand, requires a test that is rapid and simple to perform 
(for example, requiring few dilutions and few experimental steps). It should have flexible 
incubation times in order to fit around other laboratory work and not require expensive 
equipment and reagents, and be easy to interpret. This would allow the reporting of results 
in a timely manner with confident quality assurance. Unfortunately, all diagnostic tests 
have some limitations but performance criteria such as sensitivity and positive and negative 
predictive values are suitable relative measures of their potential for clinical use. 
8.2 	Detection of P. aeruginosa in patients with CF 
There are problems of choosing an appropriate infection detection mechanism for P. 
aeruginosa since it is a ubiquitous, environmental organism. One would have to decide 
whether detection of nucleic acid or antigen, particularly from non-sterile sites, does in fact 
indicate an infection and require therapeutic intervention, or whether the presence of 
products of the organism may be the result of colonisation or even transient contamination 
of a body site. In practice, the only reliable means of identifying infection is to culture the 
organism from a normally sterile site or to detect an antibody response to bacterial antigens. 
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The diagnosis of respiratory infection in people with CF is even more problematic. The 
benchmark method is culture of respiratory secretions but this suffers from relatively poor 
sensitivity (detection threshold > 104 CFU/mL), slowly growing bacteria in the lungs, some 
of which appear to be respiring anaerobically or microaerobically, and the overgrowth of 
some species by others. An alternative to culture is specific nucleic acid detection but in the 
background of purulent sputum, rich in host and microbial DNA, this technology is beset 
with similar problems of sensitivity and its inability to distinguish between live and dead 
bacteria. 
For these reasons, this work has revisited the serodiagnostic approach with the additional 
aim of utilising non-invasive samples from patients. Serodiagnosis can offer same-day 
results, will confirm infection and is quantitative. Furthermore, the differentiation of early 
(IgM) and late (IgG) antibody responses can inform the time course of infection and 
potentially identify antibody spikes associated with infective exacerbations, and perhaps 
less so, reflect the effects of treatment of an infection. The introduction of the use of oral 
fluid samples is a novel approach for the diagnosis of Pseudomonas infection in people 
with CF and the focus on an antigen common to the great majority of strains of P. 
aeruginosa negates the use of multiple antigens that characterised much of the earlier 
studies in the field. 
8.3 	Antigens of P. aeruginosa 
The pioneering work of floiby (1974) showed that CF patients infected with P. aeruginosa 
formed antibodies to numerous (over 70) 'soluble' antigens contained in an extract of a 
single experimental strain. These antibodies were visualised by their formation of insoluble 
complexes, termed precipitins, with antigens in the extract. To separate and visualise their 
individual antigen-antibody reactions, 1-10iby used what was then the novel technology of 
crossed counter-immunoelectrophoresis. In this technique, the antigens in an extract were 
separated by one-dimensional electrophoresis in an agarose gel and then visualised by 
`running' the antigens into the patients' serum as antibodies migrated to the opposite pole. 
The number of precipitins formed by a patient was indicative of the severity of respiratory 
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infection and a tipping point into irreversible chronic infection was indicated by the 
appearance of approximately 10 or more precipitin bands. In practice, newly colonised 
patients formed few precipitins while chronically infected patients had over 50 precipitin 
bands. This procedure became the basis of the Danish strategy to manage CF patients 
which simply put was to prolong the time interval between first isolation and chronic 
infection. The longer chronic infection was delayed, the better patients did clinically and 
the long term benefits were clear. 
The crossed immunoelectrophoresis technique is relatively insensitive compared to modem 
technologies and is labour intensive. The subject was advanced by the application of 
ELISA technology by Littlewood and colleagues in the 1980s who advocated regular 
monitoring of patients' serum samples with crude extracts of several strains of P. 
aeruginosa (Brett et al., 1986a; Brett et al., 1986b; Brett et al., 1988a). They showed finer 
quantification of the antibody response and were able to correlate titres with clinical 
presentation even to the extent of observing fluctuations in titres correlated to antimicrobial 
therapy (Brett et al., 1986b). They adopted the Danish policy of screening for antibodies in 
patients growing Pseudomonas in their sputum and using aggressive antibiotic prophylaxis 
to delay chronic infection. 
It was clear from this and the Danish work that patients formed antibodies to several 
organelles (flagella and pili) and cell surface antigen epitopes (proteins, polysaccharides 
and lipids) as well as secreted enzymes (proteases, lipases, etc) and several papers in the 
literature describe the antibody response of CF patients to these antigens (Corech et al., 
2005; Likavcanova and Lagace, 1992; Proesmans et al., 2006; West et al., 2002). 
8.3.1 Surface proteins 
The introduction of SDS-PAGE as a means of separating and visualising bacterial 
macromolecules paved the way for the resolution of these structures and their reactivity 
with antibodies. Mutharia et al. (1982) defined the major outer membrane proteins and 
several studies documented serum antibody responses to individual proteins such as heat 
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shock protein (Ulanova et aL, 1997), iron regulated membrane proteins (Shand et al., 
1991), OprL, the peptidoglycan-associated lipoprotein, (Lim et al., 1997) and type III 
secretion apparatus (Moss et al., 2001), among others. Most studies had limitations either in 
the patient sample size tested or the absence of longitudinal samples from individual 
patients over a time course; and few gave correlations with bacterial culture. Nevertheless, 
it was clearly established that patients formed antibodies to all of the major outer membrane 
proteins as well as other cell associated proteins. The introduction of immunoblotting 
removed the need for purification of individual proteins for specific assay but the 
complexity of these proteins and susceptibility to modification as a result of heat, iron and 
phosphate limitation and potential antigenic cross reactivity with species other than P. 
aeruginosa, all contributed to restrict their adoption and utilization for clinical studies. 
In this study I revisited the documentation of surface protein antigens, specifically the outer 
membrane proteins, for the determination of antibody responses. As expected, antibodies in 
high positive pooled patient serum samples bound with a number of proteins, some of 
which could be identified by the scheme of Hancock et al. (1990) but molecular sizes of the 
main common proteins did not correlate exactly with published sizes. Nevertheless, at least 
six major proteins were tentatively identified according to Hancock; some of which were 
heat-modifiable. All strains had similar profiles including the series of mutant strains 
lacking in flagella and/or pili. Furthermore, the outer membrane protein profiles of P. 
aeruginosa appeared to be unique when compared with representative strains of other Gram 
negative species. 
High levels of antibodies of different classes (G, M and A) were demonstratable in pooled 
positive patient serum and were reactive with an 18 KDa protein which was conserved in 
different strains. Although it was poorly stained with Coomassie blue, it was highly visible 
in immunoblots with positive CF serum. However, excision of the protein from gels lead to 
its apparent degradation and curtailed further experimentation on this candidate 'universal' 
antigen for serodiagnosis. 
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Given the complexity of outer membrane proteins, it was considered that further progress 
could only be made by ultrapurification of individual protein bands. This would have been 
best achieved by using a technique such as high performance liquid chromatography 
(HPLC), but I did not have access to this apparatus. 
8.3.2 LPS profiles 
The heat-stable, somatic LPS antigens of P. aentginosa play a prominent role in the 
organisms' virulence and are utilized for the serotyping of strains of P. aeruginosa. Their 
structure has therefore been studied in great detail (Knirel et al., 1988; Knirel, 1990; Knirel 
et al., 2001; Knirel et al., 2006). The hydrophobic lipid A LPS moiety is the most 
conserved part of the molecule (Wilkinson, 1983; Wilkinson and Galbrath, 1975), but, 
unlike the core and side-chain LPS, it is not visible by staining with silver. The most 
variable part of the molecule is the B-band side-chain LPS, which protrudes from the cell 
surface and has intimate contact with the host and has been used by the many different 
typing schemes to determine and distinguish strains into different serologically reactive 
groups. Despite the presence of only 11 distinct LPS gene clusters (Raymond et al., 2002), 
the extensive IATS classifies strains into 20 serotypes. These well-defined antigens show a 
high degree of heterogeneity when separated by SDS-PAGE due to their variation in 
number and composition of 0-repeating units. 
The principle behind silver staining of LPS relies upon periodate-sensitive cis-glycols and 
adjacent hydroxyl groups (Tsai and Frasch, 1982). It is important to note its limitations -
that some strains do not possess cis-hydroxyls, whilst transdiequatorial-hydroxyls react 
much slower than cis-hydroxyls and transdiaxial glycols do not react at all in 
polysaccharides (Sklarz, 1967). Additionally, Palva and Makela (1980) showed that the 
staining intensity decreases with increasing molecular weight. Moreover, only a third of A-
band LPS side-chain units have adjacent hydroxyl groups, and thus would react with 
periodate (Smith et al., 1985). This potentially explains why the A-band LPS profiles in 
this study were far weaker than the B-band LPS and often the corresponding antibody 
binding profiles. An alternative method for the staining of LPS is phosphotungstic acid- 
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Coomassie blue 8250, which is specific for the side chains and does not stain the core LPS 
(Kropinski et aL, 1985). However, for the purposes of this study, whereby the LPS 
structures from different strains were compared and examined for the presence of particular 
banding patterns, the Tsai and Frasch silver stain method was considered suitable. 
The silver-stained LPS profiles of the reference type strains (Figure 15) clearly showed the 
molecules' separation and revealed the heterogeneity of the LPS, with the dense, fastest-
migrating bands near the bottom of the gel with the ladder-like banding patterns being 
revealed up the gel with increasing side-chain length. Comparing these profiles directly 
with published images is difficult, partly due to the fact that many papers describe strains 
from different typing schemes, particularly the seven irmnunotypes (Kocharova et al., 
1988; 1989; 1991), and also due to the quality of the images. A deliberate decision was 
made during this work to photograph and present the images in colour. The different 
colours probably indicated the depth of staining but possibly also reflected the different 
chemical reactions. This allowed greater discrimination of the profiles. However, the 
majority of the published images are monochrome and give little indication of the depth of 
staining and hence proportion of each LPS moiety. A particularly difficult set of profiles to 
compare have been published by Maclntyre et al. (1986), where whole sections of the LPS 
moieties appear to be missing from the lower parts of the gel. 
The LPS profiles of reference type strains AK1401 and PAO1 do indeed show similar 
banding patterns to images published by both Lam et al. (1989) and Makin and Beveridge 
(1996), with the two strains demonstrating intermediate and short and intermediate-chain 
LPS, respectively. However, Lam's core LPS and Makin and Beveridges's side-chain LPS 
regions appear more compact, probably due to the employment of 14 % and 12 % SDS-
PAGE separation gels, respectively, compared to the 12.5 % gel used in this study. 
Although many groups have studied the LPS of P. aeruginosa in great detail, due to the 
nature of the research, for example, elucidating the chemical structures (Sadovskaya et al., 
1998), very few have actually published SDS-PAGE profiles. The data presented in this 
thesis therefore provides a comprehensive summary for the reference strains of P. 
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aeruginosa. However, the limitations of what can be visualised need to acknowledged. The 
SDS-PAGE and silver staining method could potentially mask different LPS structural 
populations within a strain. A more thorough investigation of the LPS structures would be 
possible by the employment of chromatography, such as described by Rivera et aL (1988), 
where specific fractions were isolated and analysed chemically and by SDS-PAGE. Indeed, 
the determination of amino sugars in chromatographic fractions clearly show a peak 
corresponding with the A-band LPS moiety. Furthermore, their binding with a specific 
monoclonal antibody also revealed A-band patterns similar to that seen in this study. 
8.3.2.1 Monoclonal antibody binding 
Many studies have demonstrated the binding of antibodies (polyclonal and monoclonal) to 
the SDS-PAGE-separated LPS profiles of P. aeruginosa reference strains. For example, 
monoclonal antibody N1C9, whose reactivity is the same as N1F10 used here, 
demonstrated very similar binding patterns to intermediate-chain LPS, although sometimes 
to different reference strains (Lam et al., 1989). This will be discussed further in section 
8.3.3. 
Monoclonal antibodies to P. aeruginosa LPS often show different epitope specificity to that 
found with polyclonal antisera. This was shown by the work of Gaston et al. (1986) who 
reacted a panel of monoclonal antibodies against eight 0-serotype strains of P. aeruginosa. 
Forty-three of the antibodies reacted with whole cells of the vaccine strain while four 
reacted with more than one serotype strain. One antibody was shown by immunoblotting to 
react with core and lipid A components. Indeed, a panel of serotype-specific monoclonal 
antibodies proved useful for differentiating further between P. aeruginosa isolates of 
serotype 06 (Vale et al., 1988). De Kievet and Lam (1994) produced monoclonal 
antibodies that could distinguish between inner and outer core and lipid A regions of the P. 
aeruginosa LPS, but these were not available to use in this study. 
Many groups have used monoclonal antibodies to probe for specific epitopes of LPS. 
Yokota showed monoclonals prepared to core polysaccharide reacted with 60 % of P. 
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aeruginosa isolates, but there appears to be a higher binding efficiency when monoclonal 
antibodies to long-chain LPS were employed (Yokota et al., 1989). Sawada produced an 
E87 monoclonal antibody that bound to approximately 80 % of various P. aeruginosa 
serotype strains tested and chemical analyses confirm that Sawada's antigen is essentially 
A-band (Sawada et al., 1985). E87 has also been demonstrated to bind to intermediate-
chain LPS by Rivera and McGroaty (1989). However, E87 antibodies were not available to 
use in this study. 
8.3.2.2 Polyagglutinable strains 
A minority of CF P. aeruginosa strains are agglutinated by several rabbit antisera when 
serotyped by agglutination. These antisera are often unrelated and the strains are designated 
`polyagglutinable' or 'non-typable'. Indeed, a lack of antibody binding to a major antigen 
of P. aeruginosa, in vivo, conforms with the strong body of evidence that suggests this 
pathogen uses the loss of B-band LPS as a defence mechanism, facilitating the survival of 
these strains in the CF host (Govan and Deretic, 1996). 
The SDS-PAGE profiles of the polyagglutinable strains PS7, PS7/1, PS18R and PS18S 
(Figure 18) confirm the findings of Pitt et al. (1986), with both PS7 and PS7/1 propagation 
strains expressing intermediate-chain LPS and PS18R and PS18S lacking side-chain LPS 
bands. They concluded that the lack of bands may be due to the scarcity of periodate-
sensitive groups, however, they demonstrated the modification of the LPS from the 
propagation strains by loss of phage receptors, and agglutination with sera. Although they 
did not show antibody binding using an immunoblot method, their findings complement the 
results shown in Figure 26, where antibody binding was absent. An earlier study by the 
same group confirmed that the substance responsible for the polyagglutinability is heat-
stable and distinct from 0-antigen (Pitt and Erdman, 1978). It would be interesting to 
speculate that this epitope resided in A-band LPS. However, this cannot be the case since 
no A-band epitopes were observed in the immunoblotting profiles (Figure 26). The 
polyagglutinable antigen has, however, been linked to the core LPS (Marx et al., 1988). 
Indeed, all polyagglutinable strains employed in this study showed silver stain and antibody 
253 
binding to the core moieties, so it is possible that the polyagglutinating antigen was 
attached to this, even if it was not visible. 
83.3 Occurrence of A-band LPS 
The suggestion of a common LPS antigen that was expressed in isolates of P. aeruginosa 
from CF patients was first made by Brauner et aL (1993). They showed that sera from 35 
CF patients chronically colonised with P. aeruginosa possessed significantly higher levels 
of antibodies to all heterologous LPS antigens, which they interpreted to be indicative of a 
common antigen determinant. Although earlier work from Hoiby's laboratory had 
described a common antigen detected by immunoprecipitation, it had not been located as an 
LPS epitope. Further studies from Fomsgaard et al. (1993) confirmed that strains with 
defective LPS (polyagglutinable, B-band-less) also cross reacted, but they suggested this 
was due to core and lipid A moieties. These findings taken together with the original 
descriptions of Lam and colleagues (1989) support the ubiquity of A-band LPS in P. 
aeruginosa. 
The results from chapter 4 support the hypothesis that A-band is a suitable antigen to use in 
a diagnostic test. Several approaches were taken to determine the occurrence of A-band in 
the serotype reference strains of P. aeruginosa: they were reacted with hyper-immune 
rabbit sera (AW1) raised to the A-band type strain AK1401. Additionally, they were 
reacted with sera from CF patients where type-specific antibodies had been removed by 
adsorption and the type strains were also reacted with a monoclonal antibody specific to 
AK1401 (N1F10). Finally, a molecular approach was taken, with the detection of A-band 
specific genes (wzm and wzt). SDS-PAGE followed by silver-staining was not used as a 
method to determine the occurrence of A-band in strains, due to the problem of profiles 
being masked by B-band LPS. 
The results from the antigenic experimental approaches varied, but those strains that almost 
certainly lack A-band were 07, 08, 012, 014 and 015. The PCR results were more 
difficult to draw conclusions from, since although the specific DNA sequences were 
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detected in all strains, studies on mRNA expression were considered outside of the scope of 
the investigation. 
The results from the antigenic approaches employed in this study are summarised in Table 
26 along with data collected from two other studies investigating the occurrence of A-band 
by detection of specific genes and employing monoclonal antibodies. As mentioned 
previously, Currie et al. (1995) investigated the prevalence of the gca gene (GDP—D-
mannose involved in A-band synthesis). An attempt to repeat this work is detailed in 
section 4.2, but was unsuccessful. However, Currie's results revealed that A-band was 
conserved among all 20 0-serotypes with the exception of serotype 012. The study by Lam 
et al. (1989) reacted monoclonal antibody N1C9 (which behaved the same as monoclonal 
Table 26. Summary of results for occurrence of A-band in P. aeruginosa reference type 
strains from this and other studies 
NT = not tested 
Blot/gene 	AK1401 PAO1 01 02 03 04 05 06 07 08 09  
AK1401 sera + 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	 + 
AW1 	 + + + + + + + + + 
Adsorbs AK1401 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
N1F10 	 + 	+ 	+ + + 
HP sera + 	+ 	+ 	+ 	+ 	+ 	+ 	 + 
wzm 	 + + + + + + + + + + + 
wzt + + + + + + + + + + + 
gca (Currie et al., 1995) 	NT 	NT 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
N1C9 (Lam et aL, 1989) 	NT 	NT 	+ 	+ 	+ 	+ 	+ 	+ 	- 	+ 	+ 
010 	011 012 013 014 015 016 017 018 019 020 
AK1401 sera 	+ 	+ 	- 	+ 	- 	+ 	+ 	+ 	+ 	+ 
AW1 	 + + + + + + + + 
Adsorbs AK1401 	+ 	+ 	+ 	 - 	+ 	+ 	+ 	+ 
N1F10 	 + + + + + - 
HP sera + 	+ 	- 	+ 	 + 	+ 	+ 	- 
wzm 	 + + + + + + + + + + + 
wzt + + + + + + + + + + + 
gca (Currie et al., 1995) 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 
N1C9 (Lam et al., 1989) 	+ + 	- 	- - + 	NT NT NT 
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N1F10 in their study) with serotypes 01 to 017 using agglutination and immunoblotting 
techniques. Their agglutination reactions were unsuccessful (it was suggested that in 
agglutination tests the B-band may mask the A-band), but the immunoblot results showed 
11 of the 17 strains did possess A-band. Those lacking were 07, 012, 013, 014, 015 and 
016. This differs from the results found in the present study where serotypes 02, 04, 05, 
06, 08 (and 018 and 020) also lacked A-band according to immunoblots with an A-band 
specific monoclonal antibody. Additionally, strain 013 did react with the N1F10 antibody. 
The detection of A-band specific genes (wzm and wzt) clearly show that the nucleic acid 
sequences are present in all strains, thus indicating the molecular potential for all strains to 
produce A-band LPS. However, it is unknown whether these genes have been expressed 
and thus A-band is present. 
The antigenic methods used here all agree that strains of P. aeruginosa of serotypes 08, 
012, 014 and 015 do not possess A-band LPS, whilst in serotype 07 the presence of A-
band was suggested by the adsorbed serum experiments. It has been documented that P. 
aeruginosa serotype strains 07 and 08 share LPS epitopes (Pitt, 1988). This may explain 
why differing results were obtained with the AK1401 rabbit serum blot which clearly 
showed no reaction (Figure 34) but the adsorbed serum data did (Figure 39). Considering 
that the work with N1F10 and N1C9 underline that reference strain 07 does not possess A-
band, the results from the adsorbed sera may be explained if the 07 cells actually adsorbed 
out serotype 08 antibodies. Since this study shows that serotype 08 does not possess A-
band (which differs from the results of Lam et al. (1989), a positive result on adsorption 
would therefore be expected. 
The implications of serotype strains 07, 08, 012, 014 and 015 lacking A-band is unclear. 
The antigen is present in the vast majority of strains but cannot be deemed 100 % reliable. 
A past survey showed that these strains only account for 4.5 % of clinical specimens from 
British hospitals (Pitt, 1988), although few of the strains were from CF patients. The other 
serotypes where A-band is confirmed account for 75 %. However, it cannot be assumed 
that all strains belonging to a particular serotype behave the same as the reference type 
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strain as there is no evidence to link the presence of A-band with particular 0-serotypes 
outside of the reference strains. Many CF strains are serologically non-typable and even 
though other studies have shown that A-band is a major antigen, it was reassuring to show 
that 45 of the 49 clinical strains expressed A-band LPS. 
Perhaps the most exciting results are the immunoblots of all strains with the HP sera. Table 
26 includes a summary of those strains that were lacking a profile, showing a strong 
correlation with those strains to the presence of A-band, with serotypes 07, 012, 014, 015 
and 016 showing no antibody-antigen reactions. Since this correlation is so remarkable it 
suggests that the antibody response made by people with CF to P. aeruginosa is in fact to 
A-band LPS with few elevated antibodies to B-band. This finding supports the fact that 
many isolates of P. aeruginosa from CF have an altered LPS structure with loss of all or 
part of B-band, rendering the isolates serologically non-typable (Hancock et aL, 1983). 
A similar immunoblotting study has been reported by Kocharova et al. but employing the 
seven immunotype strains as designated by Fisher (Fisher et al., 1969; Kocharova et al., 
1991). They used rabbit sera raised to P. cerasi (now known as P. syringae pv. syringae), 
specific for a common antigen which they refer to as A-band. Indeed the profiles as shown 
do look like very similar to A-band epitopes. They found that immunotypes 5 and 7 lacked 
this profile. These types correspond to serotypes 010 and 05 (respectively) in the IATS 
whilst the remaining Fisher types used correspond to 01, 02, 06, 08 and 011. In 
comparison to the current study, this reinforces the presence of A-band in 01, 02, 06 and 
011, but the results from Kocharova et al. (1991) indicating 010 and 05 lack A-band and 
08 possessing A-band are not supported. However, it also emphasises the lack of 
correlation of A-band and B-band serotypes. 
8.3.4 A-band LPS in different environments 
It has been proposed that phenotypic variation in the relative expression of A- and B-band 
LPS is an important mechanism enabling this opportunistic pathogen to alter its surface 
characteristics to mediate adhesion and to survive under extreme conditions (Makin and 
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Beveridge, 1996). Type strain PAO1 shows reduced levels of B-band LPS expression when 
grown under stress conditions, but A-band is not significantly affected (McGroarty and 
Rivera, 1990). When conditions are not stressful, PA01 only agglutinates with serotype-
specific antibodies, suggesting the common antigen is masked by the long 0-side-chain. 
This masking of A-band by B-band LPS was also reported by Rivera and McGroarty 
(1989), since in non-typable strains B-band LPS appears to be lost but A-band is exposed. 
Worlitzsch et al. (2002) reported experiments which suggested that P. aeruginosa grows in 
the CF lung in anoxic conditions with greatly reduced oxygen concentrations. They 
speculated that the strictly aerobic organism could survive and multiply through an 
anaerobic mode of growth utilizing nitrate as a terminal electron acceptor. This was 
recently challenged by Alvarez-Ortega and Harwood (2007) who presented data in favour 
of an alternative hypothesis that P. aeruginosa grows microaerobically in the CF lung. 
Our experiments on the production of A-band in anaerobic culture on potassium nitrate 
agar showed that this LPS moiety was unaffected by growth conditions and there was equal 
expression in both anaerobic and aerobic culture. Similar levels of expression of A-band 
LPS was also found between mucoid and non-mucoid pairs of strains. Taken together, these 
results reinforce the view that A-band integrity is not influenced by culture conditions or 
the presence of alginate exopolysaccharide. This is in contrast to work previously reporting 
that LPS production is affected by specific growth conditions (McGroarty and Rivera, 
1990). 
It has been well documented that B-band and thus the serotypability of the strains is lost 
once the organisms have established a chronic infectious state. However, it was thought 
that this allowed the unmasking of A-band and therefore its detection. The work here seems 
to contradict this. Serum samples and bacterial isolates have been tested from two different 
patient sets (unfortunately it was not possible to obtain them from the same set). The serum 
analyses confirmed a high antibody response to A-band which persisted over time (Figure 
55), however, the P. aeruginosa isolates showed that the molecule itself was not always 
expressed after prolonged infection (Figure 45). It would have been interesting to have 
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studied the longitudinal response of CF patients to P. aeruginosa further. For completeness, 
PCR of the longitudinal strains could have been done, to confirm whether A-band specific 
genes had been lost. However, it would also have been interesting to look in greater detail 
at the other two key changes in the organism when a chronic infectious state has been 
reached — the loss of an 0-serotype reaction and sensitivity to normal human serum 
(Penketh et al., 1983). 
8.4 	Detection of Pseudomonas-specific antibodies 
As previously mentioned, P. aeruginosa is ubiquitous in nature so one might expect normal 
non-infected individuals to show some immunological evidence of prior exposure to the 
species. The presence of naturally occurring antibodies to P. aeruginosa was first 
demonstrated in healthy rabbits (Fox and Lowbury, 1953; Rehm et al., 1994) and 
subsequently in normal human adults (Pollack and Young, 1979). During this body of 
work, it was revealed that the rabbits employed for the raising of antisera already possessed 
antibodies specific to P. aeruginosa. This information has now been communicated in the 
Veterinary Record (Weisner et al., 2005). Since then, similar findings of naturally 
occurring antibodies in pre-immune rabbit sera have been reported (Lathrop et al., 2006). 
This work reinforced that any assay for antibodies formed as a result of infection must seek 
to differentiate either between antibodies to different antigens and/or be able to quantify 
different levels in non-colonised, colonised and infected individuals. 
This requirement became the focus of the second part of the investigation which explored 
the utility of detecting antibodies to A-band LPS (AK1401) in oral fluids, sputum and urine 
samples from human subjects with and without P. aeruginosa infection, and to determine 
whether these antibodies mirrored serum antibody levels. By showing comparable results 
from a non-invasive sample, patients could be tested more frequently and conveniently for 
infection, bringing the diagnosis closer to the ideal test. 
As expected, serum from CF patients bound strongly in immunoblots of 
electrophoretically-separated LPS extracts and provided a reference base against which 
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samples from healthy controls and patient controls (volunteers with PCD) could be 
compared. The low levels of binding exhibited by sera from healthy volunteers compared 
with CF and some PCD patients indicated that quantification of the antibodies to P. 
aeruginosa was necessary in order to distinguish clearly between infected and non-infected 
patients. Since the healthy volunteer sera was obtained from blood donors, although 
anonymous, this must mean they are older than 18 years, so it is unlikely that the sample 
sets were age-matched, adding another variable to the comparison. 
CF sputum samples also proved to be rich in Pseudomonas antibodies and only 1 of 13 CF 
sputum samples (all of which grew P. aeruginosa) failed to react in immunoblots with LPS. 
Oral fluids from CF patients also showed high antibody binding and although the protein 
content was not standardised to ensure similar antibody content in different samples, it was 
clear that their presence reflected the serum antibody response indicating the potential of 
this non-invasive sample to monitor antibody responses in individuals. 
The levels of antibodies in oral fluids from healthy volunteers ranged from weak to non-
existent but two individuals yielded 'positive' immunoblots and one of these was a 
laboratory technician whose main function was the characterisation of P. aeruginosa strains 
submitted to the reference laboratory. 
The few available urine samples from CF patients tested gave largely non-specific results in 
dot blots but some weak binding in immunoblots to side chain LPS, apparently due to 
antibody, was evident in one of the urine samples. 
A comparison of sputum antibodies with serum in paired samples from a selection of 
Pseudomonas positive CF patients showed that sensitivity and specificity of sputum 
(against serum) were 0.78 and 1.00 respectively. The respective values for oral fluids 
versus serum were 0.92 and 1.00. Thus no non-specific antibodies were detected in either 
sample and oral fluids offered better sensitivity than sputum. However, it must be noted 
that the paired samples were taken on different days, hindering an exact comparison. 
Nonetheless, oral fluids were technically easier to handle and available from all patients 
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while sputum needs to be liquefied and centrifuged, and may not be produced by all 
patients. 
It is promising that oral fluids offer a realistic alternative to serum. However, further 
validation work and assay manipulation would be required before any clinical diagnostic 
test could be implemented. Antibodies in oral fluid originate from the salivary ducts. When 
sampling, the sponge swab is passed along the gum line to collect antibodies that have 
collected there, thus increasing the concentration of sampled fluid. Moreover, it can be 
assumed that were serum samples taken at several intervals throughout a single day, their 
antibody concentration would be consistent. However, oral fluid samples are varied in 
protein (and thus antibody) concentration and influenced by teeth-brushing, eating and 
drinking (McKie et al., 2002). Furthermore, the volume obtained differs from person to 
person and sample to sample. It may be that by chewing something to encourage salivation, 
a larger sample could be collected and flush out salivary ducts, thus releasing more 
antibodies. An attempt was made to compare the antibody response of a single CF patient 
(RBH24) over several days, but logistical reasons hindered these results. Another problem 
encountered was the small volume size of oral fluid. It may have been beneficial to dilute 
the oral fluid swabs in transport buffer to increase sample volume. However, this may 
dilute out any detectable levels of antibody, so a very sensitive assay, for example, an 
antibody capture ELISA would need to be used (Samuel et al., 2003). 
8.4.1 Quantitative detection of Pseudomonas-specific antibodies 
While immunoblotting proved to be a sensitive method for the detection and specificity of 
antibody binding, for purposes of quantification and to increase sample throughput, it was 
necessary to develop a quantitative ELISA. Three strategies were evaluated: i) an indirect 
ELISA with AK1401 LPS for quantification of antibodies in serum and non-invasive 
samples, ii) an indirect double ELISA for serum to produce a P. aeruginosa-specific 
antibody standard and iii) an ELISA to differentiate between IgG and IgM-classed 
antibodies in serum. 
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Various technical parameters (LPS concentration per well, serum dilutions, blocking 
agents, etc), were evaluated to optimise each ELISA. In the first method, BSA was chosen 
as the blocking agent and a single serum dilution of 1 in 500 showed the greatest 
discrimination between positive and negative serum samples. Intra- and inter- plate 
variation was satisfactory and a cut-off absorbance value (A405) of 0.9 was adopted to 
distinguish positive from negative readings. Of 17 CF oral fluids, 15 were positive but 1 
oral fluid from a healthy volunteer which gave a high absorbance value was found to be due 
to non-specific binding which was confirmed by immunoblotting. Oral fluids generally 
gave absorbance values significantly lower than serum specimens from the same patient but 
oral fluid from a single patient did exceed the corresponding serum value. IgM-classed 
antibodies were detected in much lower titre than IgA and IgG antibodies in this panel of 
serum samples and this probably reflects the fact that the adult patients had all been 
infected with P. aeruginosa for some years. Only two urine samples from CF patients were 
classified as positive in ELISA 1 and by immunoblotting only one of these showed weak 
binding. As a result further study of urine samples was not undertaken. 
To quantify absolute antibody concentrations, a second ELISA (ELISA 2) was developed. 
The aim was to determine the total concentration of protein in two serum samples: i) a high 
positive pool of serum from CF patients, and ii) the same pooled serum but with the 
removal of AK1401 LPS-specific antibodies via adsorption. By incorporating a human 
serum protein calibrator and employing different classed 'second' antibodies, the idea was 
to subtract the adsorbed serum values from the pooled serum values to give absolute 
antibody concentrations. Despite successful initial optimisation studies for the assay, 
reproducibility when testing the serum samples was very poor. Indeed, the CV value for 
testing the IgG-classed adsorbed serum on several runs was 43 % and for the IgA-classed 
pooled serum 55 % (despite testing 10 times). Although the adsorbed samples were below 
the pooled antibody concentrations, the level of deviation was unacceptable. The poor 
reproducibility was probably due to the class-specific antibodies employed to coat the 
ELISA plates since most of the other reagents had been used successfully with ELISAs 1 
and 3. Indeed, many of the reagents were sensitive to changes in laboratory temperature, 
reflected by differing development times often seen with ELISAs. In order to confidently 
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assign a numerical value for use as a standard, reproducibility was paramount, so further 
work on ELISA 2 was not undertaken. 
The strategies for ELISA design and development used in this study have varied from those 
of other groups previously reported. Many assays have been of a different format, with 
crude (Pressler et aL, 1990) or purified antigens (Likavcanova and Lagace, 1992) bound to 
the ELISA plate, serum samples being tested at single dilution (Brauner et al., 1993) or 
being titrated (Schaad et al., 1990), and some studies employing standards (Likavcanova 
and Lagace, 1992). The benefits of a purified antigen are that it is less likely to bind non-
specifically to serum, which would give false-positive results. With purified antigens, the 
content of the preparation is known and one can determine specific antigens. This contrasts 
with a 'soup' of several and varied soluble cell components, which are likely to cross-react 
with antibodies raised to other organisms. It was therefore paramount for the LPS-ELISAs 
developed in this study to use the hot phenol-water purification method. 
The choice of using different single or multiple serum dilutions can reflect the detection 
range of the assay. For example, if a system can only detect high levels of antibody, over 
dilution of samples may give false negative results. Multiple dilutions can often assist 
choosing a suitable dilution, especially if a standard curve is being included whereby only a 
specific range of results can be calibrated. This however will use resources. To fmd a 
balance between ELISA sensitivity and specificity, multiple serum dilutions were tried, and 
after unsuccessfully attempting to produce a standard of known anti-AK1401 LPS 
antibodies, the inclusion of a standard was regarded to be unnecessary and not very helpful. 
In contrast to employing a standard as used by Brett and colleagues (1992) derived from 
pooled high positive sera, the high positive pooled serum (along with a pooled negative 
sample) was used as a positive control and monitored between assays over time to allow 
comparability between results from samples tested on different ELISA plates. To support 
this decision, it was important to know the reproducibility of the data, so SD and CV values 
were monitored. It is unknown if this level of standardisation for the determination of 
antibody content in the high positive pool was performed by Brett and colleagues, as no 
information is presented regarding their variation in results. Indeed, it is important to 
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mention that when the high positive pooled serum used in a study is near exhaustion, 
bridging studies are vital for continual comparison of data. Many of the early studies in the 
literature do not refer to the reproducibility of their ELISAs and often do not mention if 
assay controls were tested alongside unknown samples or if samples were tested more than 
once (Schaad et al., 1990). 
8.4.2 Clinical evaluation 
The most meaningful evaluation of the ELISA strategy was to assess its performance with 
multiple serum samples from a cohort of patients to establish whether the longitudinal 
measurement of antibodies yielded reproducible and consistent results, but, more 
importantly, to validate the relationship between serum responses of individuals and their 
clinical course. The incorporation of pooled positive and negative serum standards and the 
requirement that the distribution of their data points fell within statistically defined 
parameters provided a robust basis for reproducibility and routine performance. The clear 
correlation of decreasing ELISA values with immunoblots allowed identification of the 
limit of detection for both IgG and IgM and showed the better sensitivity of the ELISA 
method. Indeed, the high levels of IgM antibody to the LPS antigen exhibited by serum 
samples from healthy volunteers confirmed the widespread seroreactivity of non-CF 
patients to P. aeruginosa. However, there was a clear distinction in IgG responses between 
infected and healthy control subjects, as at the cut-off point only two healthy individuals 
would have been classified as seropositive giving this antibody ELISA a specificity of 95 
%. 
8.4.2.1 Relationship of antibody response with sputum culture 
An obvious application of serodiagnosis would be to screen culture negative patients for 
evidence of exposure to P. aeruginosa. The IgM response is a clear candidate but as 
mentioned above, a distinction between naturally occurring antibodies formed as a result of 
continuous transient exposure to the species, and persistent colonisation leading to an 
infected state, is necessary. Indeed, initially the IgM levels in serum specimens from the 22 
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Bristol CF patients was not determined owing to the high cut-off values of healthy 
volunteer samples. However, a correlation was evident, on closer inspection, between 
sputum culture positivity and IgM responses in 19 individuals which was statistically 
significant. 
Despite the high IgG specificity of ELISA 3, none of the 22 patients seroconverted prior to 
growing P. aeruginosa from their sputum. The data in Figure 87 clearly shows the trend 
that both antibody responses increased over time. The fact that these patients may not have 
appeared 'positive' prior to pathogen isolation is therefore more of a reflection on the 
implemented assay cut-offs. In reality, the cut-offs used with ELISA technology are 
arbitrary values decided by testing healthy control sera. This had to be done in this way 
here due to availability of serum samples. However, these samples were not age matched 
(and almost certainly did not match) and not from subjects with similar exposure to P. 
aeruginosa. Patients with CF are sometimes advised to avoid particular activities (for 
example, gardening) to reduce exposure to potential pathogens. It is therefore likely that 
non-CF persons living in a similar manner to patients with CF would have much lower 
antibody levels to Pseudomonas. Had serum from this control group been available in this 
study, it is very likely that that the ELISA cut-offs would have been much lower. 
Nevertheless, the measuring of serum antibody levels in CF patients with ELISA 3 is 
invaluable since the assay gives quantitative data. Indeed, ELISA 3 has now been 
implemented as the new in-house assay for LHCAI and is the method used by the HPA to 
screen CF patients for serum antibodies to P. aeruginosa. To help make sense of the ELISA 
values generated, comments (Table 27) are added to the laboratory reports sent to the 
clinicians. These interpretations are very important as they allow the clinicians to 
understand that the range in which an ELISA absorbance falls is perhaps more important 
than the absolute value. It also shows that there are antibodies present in healthy sera, so 
low level detection is not diagnostic for clinical infection. 
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Absorbance (A405) interpretation 
0.00 — 0.99 
1.00 —1.49 
1.50 —1.99 
> 2.00 
Not significantly different from normal human serum, infection unlikely 
Slightly elevated antibodies and possibly suggestive of infection 
Antibodies clearly elevated and indicative of infection 
Grossly elevated antibodies, strong evidence of chronic infection  
Table 27. Comments on laboratory reports where ELISA 3 has been used for the detection 
of antibodies to P. aeruginosa in serum from patients with CF 
It was unfortunate that quantitative sputum culture results were not available from Bristol 
Children's Hospital, as this may have correlated with serum antibody response. However, 
there were details of when isolates changed phenotype. The appearance of mucoid P. 
aeruginosa has become almost a cardinal sign of the establishment of chronic infection in 
the CF lung. The early work of Hoiby (1974), and demonstrated since by several others (Li 
et al., 2005; Pier, 1997), showed high seroreactivity to a range of Pseudomonas antigens in 
patients first showing evidence of conversion to the mucoid phenotype. It was therefore 
reassuring to note in the 6 patients who grew mucoid strains that they all had high IgG 
antibody titres prior to the appearance of the mucoid forms. This feature might be clinically 
useful in the management of a patient already growing non-mucoid Pseudomonas and may 
distinguish those individuals who go on to yield mucoid strains. One could consider that the 
appearance of high IgG levels in an individual who is not growing a mucoid form should be 
a stimulus to implement aggressive antibiotic therapy in the hope of arresting the 'slide' 
into mucoidy. Conversely, it may be that the increased IgG antibodies are merely reflective 
of conversion to a chronic state whether or not mucoid organisms are grown from the 
patient's sputum. Single antibody determinations are obviously of little diagnostic benefit 
but it is clear from the results with the Bristol series that more regular antibody testing may 
shed light on the kinetics of antibody formation in response to the maturation of 
Pseudomonas infection over time. Indeed, information on the duration of any of the 
antibody responses to P. aeruginosa would be of significant diagnostic value. 
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8.4.3 Evaluation of developed assays 
The final part of the study addressed the practical issue of establishing a test for routine 
determination of antibody in CF patients. The 6 antigen ELISA, then in routine use in 
LHCAI and offered as a service to the CF community, lacked the sensitivity of the A-band 
LPS ELISA developed here, but it was necessary to show that the new assay was 
comparable and to establish specific interpretive criteria for the test. The analysis showed 
that there was very good correlation between negative values, in other words when the 6-
antigen test was negative for a serum, the new test invariably agreed. Correlation was less 
strong for samples with higher antibody levels. Indeed, low positive titres in the old test 
were most often negative in the quantitative ELISA. This appeared intuitively correct as 
titres of 1000 and 2000 represented only single or two doubling dilutions over the baseline 
500 'normal value' and did not allow a meaningful interpretation for the clinician. 
Reassuringly, test values indicating grossly raised levels of antibody were highly correlated 
in both assays. This agreement also supports the question of whether the serum samples had 
degraded over time. Some samples had discoloured over the years or dried up, so were 
obviously unfit, but it is unknown whether those that appeared normal had survived long-
term storage. 
The developed ELISA showed some correlation with the Genesis Diagnostics ELISA (R2 = 
0.5), although it should be noted that the cut-offs recommended by the company were 
inappropriate. It seems strange that in the literature, there are no Pseudomonas studies 
using the Genesis Diagnostics assay. In fact, it was quite difficult to source the kit for the 
purposes of this study. By searching the literature, it is clear that the most popular assays 
use the three antigen system (exotoxin A, alkaline protease and elastase) (Kappler et al., 
2006; Li et al., 2005; Raj en et al., 2007; Tramper-Stranders et al., 2006; West et al., 2002) 
and the Danish SSI St-Ag (Giordano et al., 1998; Pressler et al., 1992). Unfortunately, it 
had not been possible to obtain a kit of the three antigen test for this study. 
Many European studies have used the St-Ag approach, suggesting antigen preference may 
be influenced by nationality. Indeed, many of the early UK studies used sonicated whole 
cells (Brett et al., 1992). However, searching the literature reveals that nowadays there is a 
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general trend of employing the three antigen system, with St-Ag not appearing in published 
studies since the 1990s. The fact that ELISA 3 did not correlate with the SSI ELISA (R2 = 
0.06) was unexpected and may be explained in several ways. Firstly, there may be cross-
reactivity between the St-Ag and the ELISA components (as these were not provided by the 
manufacturer). There may also have been cross-reactivity between the St-Ag and non-
Pseudomonas antibodies. Finally, the SSI ELISA detects Pseudomonas antibody responses 
that are not detected by the AK1401 LPS ELISA developed in this study or detects an 
antibody response has been mounted at a different time. Since the SSI assay antigen 
includes secreted proteins, there may be a delay in seroconversion, which is why there were 
discrepant results. However, since there was agreement between data produced using the 
LHCAI in-house ELISA, the Genesis Diagnostics ELISA and ELISA 3, it is unlikely that 
this last option is true. To truly see if the SSI assay is so discrepant, it would be useful to 
have the assay repeated by a laboratory more familiar with the product. 
8.5 	Future studies 
Even though the work presented here has resulted in the implementation of a new method 
in LHCAI for the detection of serum antibodies to P. aeruginosa, some areas briefly 
examined in this study deserve further attention. Genesis Diagnostics, from whom an IgG-
specific ELISA was purchased and tested for this body of work, also offer an IgA-specific 
ELISA. It has been reported that IgA is the first antibody response to be mounted in some 
patients (Brett et al., 1990) so could potentially allow detection of infection at an earlier 
stage. Since IgA is associated with mucosa( infections, lung infections with P. aeruginosa 
in CF patients may very well stimulate significant levels of IgA. Indeed, Figure 55 clearly 
shows high levels of IgA-specific antibodies in serum from patients with CF. Furthermore, 
oral fluids also showed high levels of IgA-specific antibodies (Figure 59). 
The proof of principle for using oral fluid as a diagnostic sample has been shown in 
Chapter 5. However, the technology was not developed to test the samples for antibodies in 
a quantitative manner. As previously mentioned, there is the problem of the dilution factor 
in oral fluid. It would therefore be appropriate to design an antibody capture ELISA, where 
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a set number of antibodies from oral fluid (or in fact serum, which could be tested in the 
same way and on the same plate) would be bound to the ELISA and quantitation would be 
measured by establishing the proportion of specific antibodies from this representative 
sample. Several studies have reported using this method for diagnostics employing oral 
fluid samples (Litt et al., 2006), whilst others prefer detecting bacterial antigens in oral 
fluid using immuno-PCR (Kakizaki et al., 1996; McKie et al., 2002), which could probably 
be adapted for the detection of specific antibodies. Should oral fluid sample testing be 
successful, a study where antibodies were tested for every month could produce very 
exciting data. The more frequent testing could correlate antibody response far more closely 
with clinical condition, allowing deeper understanding of the infection process and CF 
response. 
Another area of work that could evolve from this study is the separation of A-band from 
core LPS. This would allow a definitive evaluation of the antibody response to A-band LPS 
by enabling detection specific to this level using an ELISA format. Column 
chromatography has been reported as a successful method for isolating the different LPS 
fractions (Rivera et al., 1988). Additionally, the method could be used to definitively 
confirm the presence of A-band in purified LPS from a variety of different strains and 
therefore determine the occurrence of this LPS species. 
8.6 Conclusions 
In conclusion, this body of work has not resulted in the creation of an ideal diagnostic test. 
However, a relatively simple method, which is able quantitatively to discriminate antibody 
responses to P. aeruginosa in serum from patients with CF, has been successfully 
optimised and implemented in a diagnostic environment. The steps taken to reach the 
production of this diagnostic test involved investigations of several candidate antigens of P. 
aeruginosa. Not only did the target need to be highly specific and common to all strains, it 
needed to show a good interaction with the human immune system by provoking an 
antibody response of sufficient strength to be detected by laboratory methods. Different 
non-invasive samples were obtained from CF patients and volunteers, as well as traditional 
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serum, to determine their potential as diagnostic samples. Oral fluids showed promising 
results and should be investigated further, ideally via a prospective, randomised trial 
collecting paired oral fluid and serum samples as well as microbiological culture data from 
a large number of patients. The serum antibody response was further assessed by 
comparison to other clinical measures, whilst the assay itself was compared with other 
available kits. 
Finally, the hypothesis tested during this study (whether it is possible to detect serological 
evidence of P. aeruginosa infection in CF patients using novel assays employing serum and 
non-invasive samples, with the longer term aim of using the assay to detect early 
pulmonary infections with this organism in patients with CF) has been met. New 
technology employing oral fluid samples is now available, which was not available prior to 
this work. However, further studies with optimised assays are required to ascertain how 
early P. aeruginosa pulmonary infection can be detected. 
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CHAPTER 9 APPENDICES 
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Appendix I. 	Media, solutions and buffers used in this study and their 
suppliers 
Unless stated otherwise, the following were kindly provided by Media Services, HPA. 
Media 
Chocolate agar: 39 g/L Columbia blood agar (Oxoid Ltd), 50 mL/L chocolated horse 
blood 
Dorset egg medium: 20/L large eggs, 133 mL/L saline 
Columbia blood agar: 39 g/L Columbia blood agar (Oxoid Ltd), 1 g/L Agar no. 1 (Oxoid 
Ltd), 
King's A agar: 20 g/L bacto peptone (Difco/BD Diagnostics Systems 10 g/L glycerol, 10 
g/L K2SO4, 3 g/L MgCl2.6H20, 15 g/L bacto agar (Difco/BD Diagnostics Systems), 
adjusted to pH 7.2 
Nutrient agar: 25 g/L nutrient broth (Oxoid Ltd) 15 g/L bacto agar, adjusted to pH 7.3 
Nutrient agar with 0.02 M potassium nitrate: 0.02 M potassium nitrate in nutrient agar 
Dissolve 2 g potassium nitrate (KNO3) in 8 mL deionised water and add to 1 L of 
nutrient agar 
Tryptone soya broth (TSB): 30 g/L tryptone soya broth (Oxoid Ltd), adjusted to pH 7.3 
Craigie tubes: 25 g/L nutrient broth (Oxoid Ltd), 2.75 g/L Agar no. I (Oxoid Ltd), 
adjusted to pH 7.3 
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Solutions and Buffers 
I. For Miscellaneous 
Phosphate-buffered saline (PBS) (Oxoid Ltd) 
Ringer's Solution (Oxoid Ltd) 
Saline: 0.145 M NaC1 
Dissolve 8.5 sodium chloride (NaC1) in 1 L deionised water 
II. For whole cell preparations  
SDS-PAGE solubilization buffer: 62.5 mM Tris-HC1 pH 6.8 containing 10 % (v/v) 
glycerol, 5 % (v/v) p-mercaptoethanol, 3 % (w/v) SDS, 0.01 % (w/v) bromophenol blue 
Dissolve 3.785 g Tris (C41-111NO3) in approximately 200 mL deionised water, adjust 
pH to 6.8 with HC1 and make volume up to 500 mL. Within a fume cupboard, place 
approximately 250 mL of 62.5 mM Tris-HC1 pH 6.8 in a beaker on a magnetic 
stirrer; dissolve 50 mL glycerol, then add 25 mL P-mercaptoethanol and 0.05 g 
bromophenol blue and transfer to a volumetric flask. Add 15 g SDS and make up to 
500 mL with 62.5 mM Tris-HC1 pH 6.8. In a fume cupboard, distribute into 20 mL 
volumes, keep the aliquot in current use at 4 °C and store remaining aliquots at -20 °C. 
SDS-PAGE solubilization buffer / Proteinase-K: 100 ptg Proteinase-K/ 30 I.LL SDS-
PAGE solubilization buffer 
III. For outer membrane preparations  
25 mM Tris-HC1, pH 7.4 
Dissolve 3.03 g Tris (C41111NO3) in 800 mL deionised water and adjust pH to 7.4 
with HC1. Make up to 1 L with deionised water. Store at 4°C. 
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25 mM Tris-HC1, pH 7.4,1 mM EDTANa2 
Add 0.37 g EDTA disodium salt (C1oH14N2Na208.2H20) to 1 L of 25 mM Tris-HCI, 
pH 7.4. It is important to use the disodium salt of EDTA since EDTA alone is not very 
soluble. Store at 4°C. 
IV. For SDS-PAGE gels 
Formulae for preparing upper and lower gel solutions for small SDS-PAGE gels: 
Solutions Lower gel 
10.0% 12.5% 
Upper gel 
4.5% 
Lower gel buffer 10.0 mL 10.0 mL - 
Water 16.6 mL 13.4 mL 6.0 mL 
Acrylamide 13.4 mL 16.6 mL 1.5 mL 
APS 120µL 120µL 30µL 
TEMED 20µL 20µL 20µL 
Upper gel buffer 2.5 mL 
Glass gel plates were cleaned with acetone. 
Once the lower gel had been poured, it was overlaid with water-saturated butanol. 
Ammonium persulfate (APS): 10 % (w/v) aqueous solution 
Using a micro-centrifuge tube, weigh out approximately 0.05 g APS ((NH4)2S208). By 
moving the decimal point one step to the right (i.e. 0.5) gives you the required volume 
of water to be added in mL. Make fresh daily. 
Acrylamide solution: 30 % (w/v) acrylamide, 0.8 % (w/v) N,N'-methylenebisacrylamide 
(ratio of acrylamide:bisacrylamide is 37.5:1) 
Using a balance placed in a fume cupboard and with gloved hands, weigh out 150 g 
acrylamide (C3H5NO) and 4 g bisacrylamide (CH2(NHCOCH:CH2)2) and dissolve in 
400 mL deionised water (as these ingredients dissolve the solution goes cold). When 
the acrylamide has dissolved and the solution has reached room temperature, make up 
to 500 mL with deionised water. Filter the solution through a Whatman No. 1 filter 
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paper and store at 4 °C in a tinted bottle. CAUTION, this solution is neurotoxic and 
should only be handled whilst wearing latex gloves. 
Alternatively, can buy ready-made. 
Lower gel buffer: 1.5 M Tris-HC1 pH 8.8, 0.4 % (w/v) SDS 
Dissolve 90.87 g Tris (C4H11NO3) in approximately 400 mL deionised water and 
adjust pH to 8.8 with HCI. Dissolve 2 g SDS (NaC12H25SO4) and make up to 500 mL 
with deionised water. Store at 4 °C. 
Upper gel buffer: 0.5 M Tris-HC1 pH 6.8, 0.4 % (w/v) SDS 
Dissolve 30.29 g Tris (C4H11NO3) in approximately 400 mL deionised water and 
adjust pH to 6.8 with HC1. Dissolve 2 g SDS (NaC12H25SO4) and make up to 500 mL 
with deionised water. Store at 4 °C. 
Tank running buffer: 0.025 M Tris, 0.19 M glycine, 0.1 % (w/v) SDS 
Dissolve 6.06 g Tris (C41111NO3), 28.8 g glycine (HO2CCH2NH2) and 2 g SDS 
(NaC12H25SO4) in 1.8 L deionised water then make up to 2 L with deionised water. 
V. For silver staining 
Silver stain fixing solution: 40 % (v/v) methanol, 5 % (v/v) acetic acid 
Add 200 mL of methanol (CH3OH) and 25 mL acetic acid (CH3COOH) to 75 mL 
deionised water. 
Silver stain oxidising solution: 0.7 % (w/v) periodic acid in silver stain fixing solution 
Dissolve 0.7g of periodic acid (H5I06) in 100 mL silver stain fixing solution. 
Silver staining solution: 0.04 M AgNO3, 0.02 M NaOH, 0.34 M NH4OH 
Dissolve 1 g silver nitrate (AgNO3) in 5 mL deionised water. Place 28 mL 0.1 M 
sodium hydroxide (NaOH) (4g NaOH / L) in a 250 mL measuring cylinder 
containing a magnetic stirring bar. Whilst mixing, add 2 mL ammonia solution 
(specific gravity 0.88) and then using a pastette, drop-wise add the silver nitrate 
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solution (a brown precipitate will appear momentarily and then disappear). Make up 
to 150 mL with deionised water, mix and use within five min of preparation. 
Silver stain developer solution:_l % (w/v) citric acid, 0.5 ml formalin (38 % aqueous 
formaldehyde) 
Place 50 mg citric acid in a 1.5 L beaker, containing a magnetic stirring bar and 
dissolve in 1 L deionised water. Add formalin (CH2O) and mix. 
VI. For protein estimation, staining and excision  
Lowry A: 2 % (w/v) Na2CO3, 0.1 M NaOH 
Carefully weigh out 4 g sodium hydroxide (NaOH) into a plastic beaker and 
dissolve in 1 L deionised water. Dissolve into this 20 g sodium carbonate (Na2CO3). 
Store in a plastic container at room temperature. 
Lowry B: 0.5 % (w/v) CuSO4.6H20 in 1 % (w/v) KNaC4H4O6  
Dissolve 1 g sodium-potassium tartrate (KNaC4H4O6) in 100 mL deionised water. 
Add 0.5g copper sulphate (CuSO4.6H20). Blue crystals will form over time, but 
should not cause concern. 
Lowry C: 50 mL Lowry A mixed with 1 mL of Lowry B 
Lowry D: 1 N Folin-Ciocalteau reagent 
Folin-Ciocalteau reagent is purchased 2 N, so dilute 1:1 in deionised water 
Coomassie brilliant blue stain: 0.025 % (w/v) Coomassie brilliant blue, 50 % (v/v) 
methanol, 10 % (v/v) acetic acid 
Mix 500 mL methanol (CH3OH) with 100 mL acetic acid (CH3COOH) and make 
up to 1 L with deionised water. In this, dissolve 0.25 g Coomassie brilliant blue. 
Store in a tinted bottle. The stain can be used several times. 
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Protein destain: 10% (v/v) acetic acid 
Mix 100 mL acetic acid (CH3COOH) with 900 mL deionised water. 
Protein gel extraction buffer: 0.5 % (w/v) SDS in PBS 
Dissolve 1 g SDS (NaC12H25SO4) in 200 mL PBS. 
VII. For LPS purification  
Phenol (C6H5OH): 80 % (w/v) aqueous solution (Sigma-Aldrich) 
VIII. For electron microscopy  
Phosphate-buffered saline-formalin: 1 % (v/v) formalin in PBS 
Mix 1 mL formalin (40 % formaldehyde) (CH2O) with 100 mL PBS. 
Ammonium molybdate: l % (w/v) ammonium molybdate 
Dissolve 0.1 g ammonium molybdate ((NI-14)6M07024.4H20) in 10 mL deionised 
water and filter through a 0.4 gm Millipore filter. 
IX. For immunoblotting 
Transfer buffer: 25mM Tris, 192 mM glycine, 20% (v/v) methanol 
Dissolve Tris (C4HI1NO3) and glycine (HO2CCH2NH2) in  approximately 2 L 
deionised water and make up to 3.2 L with deionised water, add 800 mL methanol 
(CH3OH) and store at 4 °C. 
Blocking solutions: 3 % (w/v) skimmed milk or 5 % (w/v) skimmed milk or 3 % (w/v) 
chicken egg albumin in PBS or 3 % (w/v) foetal calf serum 
Dissolve 3 g skimmed milk (5 g if 5 %) / chicken egg albumin / foetal calf serum in 
100mL PBS. 
Dimethyl formamide (C3H7N0): 70 % (v/v) aqueous solution (Sigma-Aldrich) 
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Nitroblue tetrazolium (NBT): 75 mg/mL NBT 
Prepare 70 % (v/v) aqueous dimethyl formamide (in fume cupboard) and add 10.5 
mL of it and 4.5 mL water to 1 g NBT 
BCIP: 50 mg/mL 5-bromo-4-chloro-3-indolylphosphate.Na2 (BCIP) 
Add distilled water to the container it arrives in to give a concentration of 50 
mg/ML. Aliquot 1 mL volumes in screw cap eppendorf tubes and store at -20 °C. 
Do not use if develops a blue colour. 
Developing solution: 0.09 M MgC12, 0.1 M Tris, 0.1 M NaC1, 0.045 % (v/v) NBT, 0.035 
% (v/v) BCIP 
Mix 6 mL 0.15 M magnesium chloride (MgC12) solution (30 g/L), 2 mL 0.5 M Tris 
(C4H11NO3) solution (60 g/L), 2 mL 0.51 M sodium chloride (NaC1) solution (30 
g/L), 45 µL NBT and 35 µL BCIP. 
X. For ELISA  
Wash buffer: 0.05 % (v/v) Tween 20 in PBS 
Add 250 µL Tween 20 to 500 mL PBS. 
Carbonate coating buffer: 15mM Na2CO3, 34.5 mM NaHCO2, pH 9.6 
Dissolve 0.16 g sodium carbonate (Na2CO3) and 0.29 g sodium bicarbonate 
(NaHCO2) in 100 mL sterile distilled water. The pH should not need adjusting. 
Blocking solutions: 1 % (w/v) BSA in PBS or 1 % (w/v) skimmed milk in PBS or 3 % 
(w/v) skimmed milk or 1 % (w/v) chicken egg albumin in PBS or Microimmune blocking 
buffer 
Dissolve 1 g BSA / skimmed milk (3 g if 3 %) / chicken egg albumin in 100mL 
PBS. Use Microimmune blocking buffer neat. 
Sample and 'second' antibody diluent: Same as blocking buffer, unless stated otherwise. 
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Substrate buffer: 0.9 M diethanolamine, 2 mM MgC12, pH 9.6 
Add 48.5 mL diethanolamine (C4H111\102) to a 500 mL Schott bottle. Rinse the 
measuring cylinder with approx 100 mL distilled water and add to Schott bottle. 
Add 50 mg magnesium chloride (MgC12), add a magnetic stirrer and leave to 
dissolve. Adjust the pH to 9.6, return all contents to a large measuring cylinder and 
top up volume to 500 mL. Store in Schott bottle wrapped in foil at 4 °C. 
ELISA substrate: 1 mg/mL p-nitrophenol phosphate (pnpp) in substrate buffer 
Bring 20 mL substrate buffer to room temperature, ensuring the buffer is still 
wrapped in foil. Add 4 pnpp tablets and dissolve. 
XI. For PFGE  
SE buffer: 75 mM NaCI, 25 mM EDTANa2, pH 7.5 
Dissolve 4.38 g sodium chloride (NaCI) and 9.3 g EDTA disodium salt 
(C1al14N2Na208.2H20) in 900 mL distilled water. Adjust the pH to 7.5 and top up 
to 1 L. Store at 4 °C. 
Low gelling agarose: 2 % (w/v) Macrosieve agar 
Dissolve 0.2 g macrosieve agar in 10 mL SE buffer. Melt in the steamer and 
maintain at 56 °C. 
Lysis buffer A: 6mM Tris, 100 mM EDTANa2, 1 M NaCI, 0.5 % (w/v) Brij 58, 0.2 % 
(w/v) sodium deoxycholate, 0.5 % (v/v) N-Lauroyl sarcosine, 1 mM MgCl2, 500 µg/mL 
lysozyme 
To 200 mL of distilled water, add 100 mL EDTA disodium salt 
(C1oH14N2Na208.2H20) stock solution (0.5 M) and 100 mL NaCI stock solution (5 
M). Add 0.36 g Tris (C4H11NO3), 2.5 g Brij 58 (polyoxyethylene), 1 g sodium 
deoxycholate (C241139Na04) and 1 mL magnesium chloride (MgC12) stock solution 
(0.5 M) and place in 56 °C water bath until dissolved. Cool to room temperature, 
adjust to pH 7.5, add 8.25 mL Sarkosyl® (N-Lauroyl sarcosine) and make up to 500 
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mL with distilled water. Store at room temperature until use, when 1.5 mg of 
lysozyme is added to 3 mL. 
TE buffer: 10 mM Tris, 10 mM EDTANa2, pH 7.5 
Add 1.21 g Tris (C4H11 NO3) and 3.72 g EDTA disodium salt 
(C101-114N2Na208.2H20) to 80 mL distilled water. Adjust pH to 7.5 and make up to 
100 mL with distilled water. Autoclave to sterilise and store at 4 °C. 
Lysis buffer B: 1% (v/v) N-Lauroyl sarcosine, 0.5 M EDTANa2, pH 9.5, 500 µg/mL 
Proteinase-K 
Dissolve 93 g EDTA disodium salt (C1oH14N2Na208.2H20) and 16.7 mL Sarkosyl® 
(N- Lauroyl sarcosine) in 300 mL distilled water. Add approximately 50 mL 10 M 
NaOH to dissolve the EDTA, adjust the pH to 9.5 and make up to 500 mL with 
distilled water. Store at room temperature. When ready to use, add 3.6 pi, of 50 
mg/mL stock of Proteinase K per 3 mL buffer. 
0.5 M TBE buffer: 44.5 mM Tris, 44.5 mM boric acid, 1 mM EDTANa2 
Dissolve 162g Tris (C4H111\103), 11.16g EDTA disodium salt 
(C10H14N2Na2O8.2H20), and 83.5g boric acid (B(OH)3) in 2.5 L of distilled water, 
the pH should not need adjusting. Make volume up to 3 L. 
Alternatively, can buy ready-made. 
280 
Appendix II. 	List of chemicals, reagents and materials used in this study, and 
their suppliers. 
Chemicals, reagents or materials 	 Supplier 
guinea pig IgG (whole 
human IgA (a-chain specific) 
human IgA + IgG + IgM 
human IgA + IgG + IgM 
human IgA + IgG + IgM 
human IgA (a-chain specific) 
human IgG (p-chain specific) 
-human IgM (y-chain specific) 
-mouse IgG (Fab specific) 
-rabbit IgG (whole molecule) 
A concatamer ladder 
p-mercaptoethanol 
123 bp DNA ladder 
Acetic acid 
Acetone 
Acrylamide solution 
Agarose (low gelling temperature) 
Agarose (molecular biology certified) 
Alkaline phosphatase-conjugated goat-anti- 
molecule) 
Alkaline phosphatase-conjugated goat-anti- 
Alkaline phosphatase-conjugated goat-anti- 
Alkaline phosphatase-conjugated goat-anti- 
Alkaline phosphatase-conjugated goat-anti- 
Alkaline phosphatase-conjugated goat-anti- 
Alkaline phosphatase-conjugated goat-anti- 
Alkaline phosphatase-conjugated goat-anti 
Alkaline phosphatase-conjugated goat-anti 
Alkaline phosphatase-conjugated goat-anti 
Ammonia solution (specific gravity 0.88) 
Ammonium molybdate 
Ammonium persulfate (APS) 
BCIP 
Boric acid 
Bovine serum albumin (BSA) 
Brij 58 
Bromophenol blue 
Butanol 
Chicken egg albumin 
Citric acid 
Coomassie brilliant blue 
Copper sulphate  
Bio-Rad, Hemel Hempstead, UK 
BDH, VWR International, Poole, UK 
Invitrogen BV, Renfrew, UK 
BDH, VWR International, Poole, UK 
BDH, VWR International, Poole, UK 
Severn Biotec, Kidderminster, UK 
FMC BioProducts, Rockland, USA 
Bio-Rad, Hemel Hempstead, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
KPL, Maryland, USA 
Sigma-Aldrich, Poole, UK 
Serotec, Oxford, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
BDH, VWR International, Poole, UK 
BDH, VWR International, Poole, UK 
BDH, VWR International, Poole, UK 
Sigma-Aldrich, Poole, UK 
BDH, VWR International, Poole, UK 
Sigma-Aldrich, Poole, UK 
BDH, VWR International, Poole, UK 
BDH, VWR International, Poole, UK 
BDH, VWR International, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
BDH, VWR International, Poole, UK 
BDH, VWR International, Poole, UK 
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Appendix II. Continued 
Chemicals, reagents or materials 
	 Supplier 
Diethanolamine 
Dimethyl formamide 
Double-processed tissue culture water 
EDTA disodium salt 
Ethidium bromide 
Filter paper, extra thick 
Filter paper Whatman N1 
Foetal calf serum 
Folin-Ciocalteau reagent 
Formaldehyde 
Glass beads 
Glycerol 
Glycine 
Goat anti-human IgA (a-chain specific) 
Goat anti-human IgM (p-chain specific) 
Hydrochloric acid (HCI) 
Hyperladder II 
Loading buffer blue 
Lysozyme 
Macrosieve agar 
Magnesium chloride 
Membrane 0.45 pm pore filter 
Methanol 
Microtubes 
Microimmune blocking buffer 
NBT 
Nitrocellulose paper 
N-Lauroyl sarcosine (Sarkosyl®) 
N,N,N1,N1 tetramethylethylenediamine (TEMED) 
PCR dNTPs 
PCR MgCl2 
PCR primers  
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Bio-Rad, Hemel Hempstead, UK 
Whatman, Brentford, UK 
Sigma-Aldrich, Poole, UK 
BDH, VWR International, Poole, UK 
Sigma-Aldrich, Poole, UK 
Al Laboratory Supplies Ltd, Enfield, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
Sigma-Aldrich, Poole, UK 
BDH, VWR International, Poole, UK 
Bioline, London, UK 
Bioline, London, UK 
Sigma-Aldrich, Poole, UK 
Flowgen Bioscience Ltd, Nottingham, 
UK 
Sigma-Aldrich, Poole, UK 
Whatman Ltd, Maidstone, UK 
BDH, VWR International, Poole, UK 
Eppendorf, Anachem, Luton, UK 
Microimmune Ltd, Brentford, UK 
Sigma-Aldrich, Poole, UK 
Bio-Rad, Hemel Hempstead, UK 
BDH, VWR International, Poole, UK 
Sigma-Aldrich, Poole, UK 
Invitrogen BV, Renfrew, UK 
Invitrogen BV, Renfrew, UK 
Sigma-Genosys. Haverhill, UK 
282 
Appendix II. Continued 
Chemicals, reagents or materials 	 Supplier 
Periodic acid 	 Sigma-Aldrich, Poole, UK 
Phenol 	 Sigma-Aldrich, Poole, UK 
Phosphate-buffered saline (PBS) 	 Oxoid Ltd, Basingstoke, UK 
Polyclonal rabbit-anti-human IgG coating antibody 	Dako Cytomation, Ely, UK 
p-nitrophenol phosphate 	 Sigma-Aldrich, Poole, UK 
Potassium nitrate 	 Sigma-Aldrich, Poole, UK 
Proteinase-K 	 Sigma-Aldrich, Poole, UK 
Ringer's Solution Oxoid Ltd, Basingstoke, UK 
SDS-PAGE protein size marker 	 Sigma-Aldrich, Poole, UK 
Silver nitrate 	 BDH, VWR International, Poole, UK 
Skimmed milk (Marvel) 	 Sainsbury's Supermarkets Ltd, London, UK 
Sodium bicarbonate Sigma-Aldrich, Poole, UK 
Sodium carbonate 	 Sigma-Aldrich, Poole, UK 
Sodium chloride BDH, VWR International, Poole, UK 
Sodium deoxycholate 	 Sigma-Aldrich, Poole, UK 
Sodium dodecyl sulphate (SDS) 	 Sigma-Aldrich, Poole, UK 
Sodium hydroxide 	 Sigma-Aldrich, Poole, UK 
Sodium-potassium tartrate 	 Sigma-Aldrich, Poole, UK 
Spel Restrction Enzyme Roche Applied Science, Lewes, UK 
SuRE/Cut buffer H 	 Roche Applied Science, Lewes, UK 
Taq DNA polymerase Invitrogen BV, Renfrew, UK 
Taq PCR Core kit 	 Qiagen, Crawley, UK 
Tris borate (TBE) buffer 	 Invitrogen BV, Renfrew, UK 
Tris 	 BDH, VWR International, Poole, UK 
Tween 20 	 Sigma-Aldrich, Poole, UK 
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Appendix III. Clinical strains of P. aeruginosa used for antigen investigation 
Strain ID Lab ID Strain ID Isolate description 
CI 1 08670 RBH1 PAM mucoid P. aeruginosa 
CI 2 08685 RBH2 PA P. aeruginosa 
CI 3 08686 RBH2 PAM mucoid P. aeruginosa 
CI 4 10860 RBH3 PAM mucoid P. aeruginosa 
CI 5 10861 RBH4 PAM mucoid P. aeruginosa 
CI 6 H050400700 RBH5 PA P. aeruginosa 
CI 7 H050400704 RBH6 PAM mucoid P. aeruginosa 
CI 8 H050400705 RBH6 PA P. aeruginosa 
CI 9 H050400708 RBH7 PAM mucoid P. aeruginosa 
CI 10 H050400713 RBH8 PAM mucoid P. aeruginosa 
CI 11 H050400719 RBH8 PA P. aeruginosa 
CI 12 H050400725 RBH9 PA P. aeruginosa 
CI 13 H050400726 RBH10 PAM mucoid P. aeruginosa 
CI 14 H050420553 RBH11 PAM mucoid P. aeruginosa 
CI 15 H050920402 RBH12 PA P. aeruginosa 
CI 16 H050920406 RBH13 PAM mucoid P. aeruginosa 
CI 17 H050920413 RBH13 PA P. aeruginosa 
CI 18 H050920414 RBH14 PAM mucoid P. aeruginosa 
CI 19 H050920419 RBH14 PA P. aeruginosa 
CI 20 H050920420 RBH15 PAM mucoid P. aeruginosa 
CI 21 H050920421 RBH15 PA P. aeruginosa 
CI 22 H050920423 RBH16 PAM mucoid P. aeruginosa 
CI 23 H050920425 RBH16 PAM mucoid P. aeruginosa 
CI 24 H050920430/#1 
CI 25 H050920431 
CI 26 H050920432 
CI 27 H050920437 
CI 28 H050920442 
CI 29 F1050920449 
CI 30 H053040380 
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liA#1PP:•E Spel PFGE 
P24C 
P14B 
P14C 
P14A 
P29E 
P29F 
P290 
P29A 
PIK 
P160 
P150 
P15A 
P16A 
P16B 
P16C 
P178 
P17C 
P17A 
P2A 
P2B 
P2C 
PUB 
PBC 
P6D 
P6A 
If" fl" 	P24A 
111
:r  
11 	P24B 
P240 
11 
II!1 11111 1110 
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Appendix N. 	Details of sequential isolates and dendrogram of their PFGE 
profiles for the evaluation of the persistence of A-band over time 
Strain 	 Date 	Strain 	 Date 
Lab ID 	Patient 
	
Lab ID 	Patient 
ID isolated 
	
ID isolated 
P2A 
P2B 
P2C 
P6A 
P6B 
P6C 
P6D 
P14A 
P14B 
P14C 
P15A 
P15B 
P15C 
P15D 
H044280459 
H050240234 
H051980391 
P/9448 
H043260153 
H051760620 
H054900667 
P/9450 
H050380702 
H051760628 
P/9455 
P/10723 
H043980619 
H051760637  
Oct-04 
2 	Jan-05 
May-05 
Apr-02 
6 
	Aug-04 
Apr-05 
Dec-05 
Apr-02 
14 	Jan-05 
Dec-05 
Apr-02 
Jun-03 
15 
Sep-04 
Apr-05  
P16A 	P/9456 
P16B 	P/10914 
P160 H051760631 
P17A 	P/9600 
P17B H043460109 
P170 H054900657 
P24A 	P/9601 
P24B 	P/10920 
P24C H050380703 
P24D H051760649 
P29A 	P/9443 
P29E H044540424 
P29F H051760630 
P29G H054900659  
16 	Apr-02 
Jul-03 
Apr-05 
17 	Apr-02 
Aug-04 
Dec-05 
24 	Apr-02 
Jul-03 
Jan-05 
Apr-05 
29 	Apr-02 
Nov-04 
Apr-05 
Dec-05 
PFGE was performed and 
analysed by Dr Jane Turton, 
LHCAI 
Appendix V. 	Samples used to construct serum pools 
Pool Lab ID 
Antibody titre 
01 06 07 012 AK1401 C28 
3881 8000 16000 8000 16000 16000 16000 
3911 8000 16000 16000 16000 16000 8000 
4025 16000 16000 16000 16000 16000 16000 
4034 16000 8000 16000 16000 16000 8000 
HP1 5197 8000 8000 8000 8000 16000 8000 
5316 8000 16000 16000 16000 16000 16000 
5318 16000 16000 16000 16000 16000 8000 
5641 8000 16000 16000 16000 16000 8000 
5673 8000 16000 16000 16000 8000 8000 
3013 8000 16000 16000 16000 16000 8000 
3827 8000 16000 16000 16000 16000 16000 
3968 8000 16000 16000 16000 16000 4000 
HP2 5495 8000 16000 16000 8000 16000 8000 
5757 16000 16000 16000 16000 16000 8000 
H042221140 8000 8000 8000 8000 16000 4000 
H04274195 8000 16000 16000 16000 16000 4000 
2350 8000 16000 8000 8000 8000 2000 
3053 8000 16000 16000 8000 8000 8000 
3461 8000 8000 8000 8000 8000 8000 
HP3 5456 8000 8000 8000 8000 16000 8000 
5460 16000 8000 8000 16000 8000 8000 
5654 8000 8000 8000 16000 8000 1000 
5673 8000 16000 16000 16000 8000 8000 
5265 8000 16000 16000 8000 8000 4000 
5971 8000 16000 16000 16000 16000 8000 
H052120428 4000 8000 4000 8000 8000 8000 
HP4 
H052160011 8000 16000 16000 16000 16000 16000 
H052440089 2000 4000 8000 4000 4000 8000 
H052720500 8000 4000 8000 4000 8000 2000 
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Appendix V. Continued 
Pool 
	
Lab ID 
	 Antibody titre 
01 06 07 012 AK1401 C28 
H054060480 4000 4000 2000 1000 4000 1000 
H054260329 16000 16000 16000 16000 16000 16000 
H060180167 2000 1000 1000 1000 2000 500 
HPP 
H060240433 4000 8000 8000 4000 8000 8000 
H060440627 8000 8000 4000 4000 4000 4000 
H060440656 2000 4000 2000 2000 4000 2000 
2091 8000 8000 8000 8000 16000 8000 
2256 	8000 16000 8000 16000 16000 16000 
2331 8000 8000 8000 8000 16000 8000 
2350 	8000 16000 8000 8000 8000 2000 
2476 	8000 16000 8000 8000 8000 8000 
2707 	8000 16000 8000 8000 8000 2000 
2801 	16000 8000 16000 16000 16000 4000 
2828 	16000 16000 16000 16000 16000 16000 
2898 	16000 16000 16000 16000 16000 2000 
2912 	8000 16000 16000 16000 16000 
3053 	8000 16000 16000 8000 8000 8000 
3431 	8000 8000 8000 16000 8000 8000 
Std 3434 8000 8000 8000 8000 8000 16000 
3461 8000 8000 8000 8000 8000 8000 
3881 	8000 16000 8000 16000 16000 16000 
4034 	16000 8000 16000 16000 16000 8000 
4093 	16000 16000 8000 16000 16000 16000 
5197 8000 8000 8000 8000 16000 8000 
5316 	8000 16000 16000 16000 16000 16000 
5318 	16000 16000 16000 16000 16000 8000 
5337 	16000 16000 16000 16000 16000 8000 
5456 8000 8000 8000 8000 16000 8000 
5460 	16000 8000 8000 16000 8000 8000 
5522 	8000 16000 16000 8000 16000 4000 
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Appendix V. Continued 
Pool 
	
Lab ID 
	 Antibody titre 
01 06 07 012 AK1401 C28 
5550 	16000 16000 16000 8000 16000 8000 
5604 8000 8000 8000 8000 8000 8000 
5641 	8000 16000 16000 16000 16000 8000 
5654 	8000 8000 8000 16000 8000 1000 
5703 	8000 8000 8000 16000 8000 16000 
5969 	8000 16000 16000 8000 8000 2000 
5981 	16000 16000 16000 16000 16000 16000 
H062280452 8000 8000 4000 8000 8000 8000 
H062400223 8000 16000 16000 16000 16000 16000 
H062440246 8000 4000 4000 4000 4000 4000 
H062460527 4000 8000 8000 4000 4000 4000 
H062720614 4000 8000 8000 8000 8000 4000 
H062840586 8000 8000 4000 8000 8000 8000 
Std H063040453 8000 4000 4000 4000 16000 8000 
H063420513 4000 4000 4000 4000 4000 4000 
H063540348 2000 1000 2000 2000 2000 2000 
H063740304 4000 4000 4000 4000 4000 4000 
H063760327 4000 8000 4000 4000 8000 4000 
H063880204 8000 4000 8000 8000 4000 8000 
H063980181 4000 4000 4000 4000 4000 2000 
H063980256 2000 4000 4000 4000 8000 8000 
H064040567 8000 8000 8000 8000 8000 8000 
H064340568 4000 4000 4000 4000 4000 4000 
H064360293 2000 4000 2000 4000 4000 4000 
H064400366 4000 4000 4000 4000 4000 4000 
HP3 pool 	16000 8000 16000 16000 16000 16000 
HP4 pool 	4000 8000 4000 4000 	4000 	4000 
3162 2000 1000 2000 1000 2000 2000 
3518 2000 2000 2000 2000 2000 1000 
3619 2000 2000 2000 2000 2000 1000 
LP 
3751 2000 2000 2000 1000 2000 2000 
5704 2000 2000 2000 4000 2000 1000 
5860 2000 2000 2000 2000 2000 2000 
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Pool 
	
Lab ID 
	 Antibody titre 
01 06 07 012 AK1401 C28 
2935 1000 1000 1000 500 1000 1000 
3581 1000 1000 1000 500 500 500 
Med 
5024 1000 1000 1000 1000 500 1000 
5681 1000 500 1000 1000 500 1000 
5688 1000 500 1000 1000 500 500 
5694 1000 500 1000 500 500 500 
5302 <500 <500 <500 <500 <500 <500 
5304 <500 <500 <500 <500 <500 <500 
5305 <500 <500 <500 <500 <500 <500 
N 
	5312 <500 <500 <500 <500 <500 <500 
5351 <500 <500 <500 <500 <500 <500 
5353 <500 <500 <500 <500 <500 <500 
5378 <500 <500 <500 <500 <500 <500 
5379 <500 <500 <500 <500 <500 <500 
Appendix V. Continued 
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Appendix VI. 	Additional serum samples for antigen investigation and the 
development and optimisation of assays 
Lab ID 
01 06 
Antibody titre 
07 	012 AK1401 C28 
3884 4000 16000 16000 16000 16000 4000 
4027 8000 8000 8000 8000 8000 4000 
4031 8000 8000 16000 8000 16000 4000 
5543 8000 8000 8000 4000 16000 8000 
H04316345 4000 8000 4000 8000 16000 16000 
H05428032701 1000 2000 2000 2000 2000 2000 
H05436008201 <500 <500 500 <500 <500 500 
H05464028501 8000 16000 16000 8000 8000 4000 
H05500046401 8000 8000 16000 8000 16000 8000 
H06026044001 <500 <500 <500 <500 <500 <500 
H06026047801 <500 500 <500 500 500 500 
H06034053201 <500 <500 <500 <500 <500 <500 
H06034052901 <500 <500 <500 <500 <500 <500 
H06034053501 <500 500 <500 <500 <500 <500 
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Appendix VII. 	Serum samples 
antibody response 
for preliminary longitudinal 	evaluation of 
Patient Sample Lab ID Date Collected 
01 06 
Antibody titre 
07 	012 AK1401 C28 
1 2475 Mar-96 500 1000 <500 <500 500 <500 
2 2705 May-97 500 1000 <500 <500 500 500 
3 2856 Feb-98 4000 8000 1000 2000 4000 2000 
4 3071 Feb-99 1000 4000 2000 500 1000 1000 
1 
5 3251 Oct-99 1000 4000 2000 500 1000 1000 
6 3364 Apr-00 1000 2000 1000 1000 2000 1000 
7 3598 Mar-01 4000 8000 2000 1000 4000 2000 
8 3969 Feb-02 8000 2000 4000 2000 2000 2000 
9 5856 Aug-03 1000 4000 4000 2000 4000 2000 
10 H04316345 Jul-04 4000 8000 4000 8000 16000 16000 
1 2248 Aug-95 <500 <500 <500 <500 <500 <500 
2 2434 Mar-96 <500 <500 <500 <500 <500 <500 
3 3043 Dec-98 <500 <500 <500 <500 <500 500 
4 3095 Mar-99 <500 <500 <500 <500 <500 <500 
5 3261 Oct-99 <500 <500 <500 <500 <500 <500 
2 6 3395 Jun-00 <500 <500 <500 <500 <500 <500 
7 5066 Jul-02 2000 16000 1000 2000 4000 4000 
8 5620 May-03 8000 8000 16000 8000 16000 2000 
9 5968 Oct-03 8000 16000 16000 16000 16000 2000 
10 H04042327 Jan- 04 2000 8000 8000 4000 8000 8000 
11 H04268209 May-04 4000 8000 8000 8000 8000 4000 
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Appendix VIII. 	Recruited CF patients from the RBH and details of samples 
donated 
(* 1 year less when serum taken) 
Patient 
ID Sex DOB 
Age 
60 
Date oral fluid 	Date sputum 	Date urine 
taken 	taken taken 
Date serum 
taken 
RBH1 6 01-Jun-68 37 18-Oct-05 18-Oct-05 
RBH2 6 24-Oct-71 34 18-Oct-05 	 18-Oct-05 18-Oct-05 
RBH3 6 15-Sep-68 37 18-Oct-05 18-Oct-05 22-Feb-05 
RBH4 y 14-Oct-74 31 21-Oct-05 	 21-Oct-05 21-Oct-05 
RBH5 y 23-May-80 25 21-Oct-05 21-Oct-05 
RBH6 y 30-Jul-75 30 21-Oct-05 	 21-Oct-05 
RBH7 6 19-Aug-58 47 25-Oct-05 30-Aug-05 
RBH8 6' 25-Jun-71 34 25-Oct-05 14-Jun-05 
RBH9 6' 15-Jan-82 23 25-Oct-05 	 25-Oct-05 31-May-05 
RBH10 6` 24-Aug-83 22 25-Oct-05 25-Oct-05 16-Sep-05 
RBH11 y 28-Apr-76 29 25-Oct-05 	 25-Oct-05 16-May-05 
RBH12 e 28-Sep-78 27 25-Oct-05 25-Oct-05 
RBH13 6 07-Nov-75 30 25-Oct-05 
RBH14 6 05-Jul-82 23 25-Oct-05 	 25-Oct-05 11-Jan-05 
RBH15 6 10-Jun-83 22 25-Oct-05 16-Sep-05 
RBH16 6 11-Apr-82 23 25-Oct-05 	 25-Oct-05 26-Apr-05 
RBH17 6 20-Mar-67 38 25-Oct-05 15-Apr-05 
RBH18 6 14-Jun-56 50* 14-Feb-06 12-Sep-05 
RBH19 6 24-Aug-83 23* 14-Feb-06 16-Sep-05 
RBH2O y 20-Apr-85 21 14-Feb-06 24-Apr-06 
RBI-121 ? 14-Sep-83 23* 14-Feb-06 14-Sep-05 
RBH22 6 01-Apr-87 19* 14-Feb-06 21-Apr-05 
RBH23 6 15-Sep-68 38 14-Feb-06 15-Feb-06 
RBH24 y 19-Mar-64 41 Multiple oral fluid samples taken —see Table 18 25-Sep-05 
RBH38 6 17-Oct-77 29 21-Mar-06 22-Feb-06 
RBH39 y 27-Jan-88 18 21-Mar-06 25-Apr-06 
RBH40 6' 14-Sep-75 31* 21-Mar-06 17-Aug-05 
RBH41 y 09-May-84 22* 21-Mar-06 18-Jul-05 
CFSP1 6 10-Apr-72 34 14-Mar-06 10-Jan-06 
CFSP2 6 10-Mar-71 35* 14-Mar-06 11-Oct-05 
CFSP3 6' 01-Aug-82 24* 14-Mar-06 20-Mar-05 
CFSP4 6 24-Apr-89 17* 14-Mar-06 17-Aug-05 
CFSP5 6 09-Apr-76 30 14-Mar-06 
CFSP6 a 11-Nov-83 23 14-Mar-06 11-Apr-06 
CFSP7 y 03-Mar-90 16* 14-Mar-06 30-Jan-06 
CFSP8 6' 11-Jun-91 15 14-Mar-06 28-Oct-05 
CFSP9 y 08-Apr-70 36 14-Mar-06 12-Jul-05 
CFSP10 y 18-Nov-74 32 14-Mar-06 25-Jan-06 
CFSP12 ? 14-Nov-94 12 14-Mar-06 08-Nov-05 
CFSP14 ? 29-Nov-82 24 14-Mar-06 
CFSP15 y 13-Oct-81 25 14-Mar-06 31-Oct-05 
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Appendix IX. 	Recruited PCD patients from the RBH 
Patient ID Sex DOB Age (y) Date oral fluid taken 
RBH25 ? 22-Feb-99 7 14-Mar-06 
RBH26 9 12-Mar-94 12 14-Mar-06 
RBH27 y 16-Aug-92 14 14-Mar-06 
RBH28 ? 07-Jul-88 18 14-Mar-06 
RBH29 ? 18-Oct-90 15 14-Mar-06 
RBH30 y 17-Oct-02 3 14-Mar-06 
RBH31 5 09-Aug-96 10 14-Mar-06 
RBH32 5 24-Sep-93 12 14-Mar-06 
RBH33 6 14-Aug-03 3 14-Mar-06 
RBH34 5 21-Nov-02 3 14-Mar-06 
RBH35 y 02-Nov-90 15 14-Mar-06 
RBH36 ? 29-Jun-00 6 14-Mar-06 
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Appendix X. 	Recruited healthy volunteers 
Patient ID Sex Age (y) Date oral fluid taken 
HPA1 6 52 27-Sep-05 
HPA2 6 30 27-Sep-05 
HPA3 6 58 27-Sep-05 
HPA4 6 38 27-Sep-05 
HPA5 y 54 27-Sep-05 
HPA6 y 24 27-Sep-05 
HPA7 y 47 27-Sep-05 
HPAB 6 27 27-Sep-05 
HPA9 y 33 27-Sep-05 
HPA10 y 54 27-Sep-05 
HPA11 ? 17 28-Sep-05 
HPA12 6 15 28-Sep-05 
HPA13 6 2 28-Sep-05 
HPA14 y 47 28-Sep-05 
HPA15 6 57 28-Sep-05 
HPA16 y 11 28-Sep-05 
HPA17 y 8 28-Sep-05 
HPA18 y 11 28-Sep-05 
HPA19 9 6 28-Sep-05 
HPA20 6 11 28-Sep-05 
HPA21 6 1 04-Oct-05 
HPA22 9 1 04-Oct-05 
HPA23 (3' 6 04-Oct-05 
HPA24 a 15 04-Oct-05 
HPA25 ? 12 04-Oct-05 
HPA26 y 10 04-Oct-05 
HPA27 9 12 04-Oct-05 
HPA28 6 1 04-Oct-05 
HPA29 6 15 04-Oct-05 
NS1 y 57 23-Oct-05 
NS2 64 23-Oct-05 
NS3 y 30 23-Oct-05 
NS4 y 27 23-Oct-05 
NS5 y 29 23-Oct-05 
NS6 (3' 29 23-Oct-05 
NS7 (3' 29 25-Oct-05 
NS8 ? 29 25-Oct-05 
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Appendix XI. 	Sputum culture results from CF patients attending outpatient 
clinics at the RBH 
Patient Number Sample date Sample id Count 
18-Oct-05 Mucoid P. aeruginosa 104 
30-Sep-05 P. aeruginosa 106 
20-Sep-05 P. aeruginosa 107 
20-Sep-05 P. aeruginosa 106 
02-Mar-05 No significant bacterial growth 
RBH1 24-Jan-05 Candida sp. 103 
26-Oct-04 S. aureus 104 
22-Oct-04 S. aureus 106 
11-May-04 S. aureus 106 
11-May-04 P. aeruginosa 103 
11-May-04 Candida sp. 103 
18-Oct-05 A. xylosoxidans 104 
18-Oct-05 Mucoid P. aeruginosa 106 
18-Oct-05 P. aeruginosa 107 
18-Oct-05 Candida sp. 103 
06-Oct-04 P. aeruginosa 104 
06-Oct-04 S. aureus 
21-Jul-04 Mucoid P. aeruginosa 106 
21-Jul-04 P. aeruginosa 107 
23-Oct-04 S. aureus 104 
RBH2 21-Jul-04 S. aureus 106 
21-Jul-07 Candida sp. 104 
28-May-04 P. aeruginosa 108 
28-May-04 P. aeruginosa 107 
28-May-04 S. aureus 108 
28-May-04 Candida sp. 103 
16-Feb-00 Mucoid P. aeruginosa 106 
06-Feb-00 P. aeruginosa 106 
06-Feb-00 S. aureus 108 
06-Feb-00 Candida sp. 103 
19-Oct-05 Mucoid P. aeruginosa 10' 
01-Jun-05 Mucoid P. aeruginosa 107 
23-Feb-05 H. influenzae 107 
23-Feb-05 Mucoid P. aeruginosa 106 
29-Sep-04 Mucoid P. aeruginosa 107  
17-Aug-04 Mucoid P. aeruginosa 106 
RBH3 17-Aug-04 17-Aug-04 
P. aeruginosa 
Candida sp. 
105 
103 
17-Jul-04 Mucoid P. aeruginosa 104 
09-Jul-04 P. aeruginosa 106 
09-Jul-04 Mucoid P. aeruginosa 106 
09-Jul-04 Candida sp. 103 
14-Aug-99 P. aeruginosa 106 
14-Aug-99 Mucoid P. aeruginosa 108 
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Appendix XL Continued 
Patient Number Sample date Sample id 	 Count 
21-Oct-05 	Mucoid P. aeruginosa 10' 
01-Jun-05 	Mucoid P. aeruginosa 107 
06-Apr-04 	Mucoid P. aeruginosa 107 
RBH4 	20-Jan-04 	Mucoid P. aeruginosa 106 
20-Jan-04 	Candida sp. 	103 
03-Aug-99 	Mucoid P. aeruginosa 106 
03-Aug-99 	P. aeruginosa 	106  
21-Oct-05 	P. aeruginosa lob 
21-Oct-05 	Candida sp. 	104 
10-Oct-05 	Mucoid P. aeruginosa 106 
10-Oct-05 	Candida sp. 	103 
15-Jul-05 	Mucoid P. aeruginosa 106 
15-Jul-05 	P. aeruginosa 	106 
15-Jul-05 	Candida sp. 104 
28-Apr-05 	P. aeruginosa 	106 
28-Apr-05 	Candida sp. 104 
19-Apr-05 	P. aeruginosa 	107 
19-Apr-05 	Mucoid P. aeruginosa 106 
19-Apr-05 	Candida sp. 	103 
18-Jan-05 	P. aeruginosa 106 
18-Jan-05 	Mucoid P. aeruginosa 103 
18-Jan-05 	Candida sp. 	le 
27-Nov-04 	P. aeruginosa 107 
27-Nov-04 	Mucoid P. aeruginosa 105 
27-Nov-04 	Candida sp. 	le 
23-Oct-04 	Mucoid P. aeruginosa 104 
23-Oct-04 	Candida sp. 	103 
21-Oct-05 	Mucoid P. aeruginosa 106 
21-Oct-05 	P. aeruginosa 	105  
13-Oct-05 	Mucoid P. aeruginosa 106 
23-Sep-05 	Mucoid P. aeruginosa 106 
23-Sep-05 	P. aeruginosa 	104 
23-Sep-05 	Candida sp. le 
06-Jul-05 	Mucoid P. aeruginosa 106 
06-Jul-05 	P. aeruginosa 	104 
06-Jul-05 	Candida sp. 103 
23-Mar-05 	P. aeruginosa 	106 
23-Mar-05 	P. aeruginosa le 
22-Sep-04 	Mucoid P. aeruginosa 107 
22-Sep-04 	P. aeruginosa 	105 
17-Aug-04 	P. aeruginosa 106 
17-Aug-04 	Mucoid P. aeruginosa 105 
17-Aug-04 	A. fumigatus 	103 
17-Aug-04 	Candida sp. 103 
12-Aug-04 	Mucoid P. aeruginosa 106 
12-Aug-04 	P. aeruginosa 	104 
12-Aug-04 	Candida sp. 103 
01-Sep-99 	P. aeruginosa 	107 
01-Sep-99 	Mucoid P. aeruginosa 106 
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RBH5 
RBH6 
Appendix XI. Continued 
Patient Number Sample date Sample id 	 Count 
01-Sep-99 	S. aureus 104 RBH6 01-Sep-99 	A. fumigatus 	103 
30-Oct-05 	Mucoid P. aeruginosa 10' 
25-Oct-05 	Mucoid P. aeruginosa 108 
21-Oct-05 	Mucoid P. aeruginosa 106 
21-Oct-05 	P. aeruginosa 	106 
21-Oct-05 	Candida sp. 104 
12-Oct-05 	Mucoid P. aeruginosa 107 
12-Oct-05 	P. aeruginosa 	105  
05-Oct-05 	P. aeruginosa 107  
05-Oct-05 	Mucoid P. aeruginosa 106 
25-Sep-05 	P. aeruginosa 	107 
25-Sep-05 	Mucoid P. aeruginosa 107 
23-Sep-05 	Mucoid P. aeruginosa 106 
23-Sep-05 	P. aeruginosa 	106 
19-Sep-05 	P. aeruginosa 107  
19-Sep-05 	Mucoid P. aeruginosa 106 
07-Sep-05 	Mucoid P. aeruginosa 106 
07-Sep-05 	P. aeruginosa 	107  
30-Aug-05 	Mucoid P. aeruginosa 106 
30-Aug-05 	P. aeruginosa 	104 
26-Aug-05 	Mucoid P. aeruginosa 107 
19-Aug-05 	Mucoid P. aeruginosa 107 
17-Aug-05 	Mucoid P. aeruginosa 104 
15-Aug-05 	Mucoid P. aeruginosa 107 
08-Aug-05 	Mucoid P. aeruginosa 106 
03-Aug-05 	Mucoid P. aeruginosa 106 
29-Jul-05 	Mucoid P. aeruginosa le 
29-Jul-05 	P. aeruginosa 	106 
19-Jul-05 	Mucoid P. aeruginosa 106 
19-Jul-05 	P. aeruginosa 	107 
18-Jul-05 	P. aeruginosa 107  
18-Jul-05 	Mucoid P. aeruginosa 106 
18-Jul-05 	Candida sp. 	104 
15-Jul-05 	Mucoid P. aeruginosa 107 
15-Jul-05 	P. aeruginosa 	106 
15-Jul-05 	Candida sp. 103 
28-Jun-05 	P. aeruginosa 	106 
28-Jun-05 	Mucoid P. aeruginosa 106 
28-Jul-99 	P. aeruginosa 	106 
28-Jul-99 	Mucoid P. aeruginosa 106 
28-Jul-99 	A. fumigatus 	103 
25-Oct-05 	Mucoid P. aeruginosa 105 
25-Oct-05 	P. aeruginosa 	106 
17-Aug-05 	P. aeruginosa 107  
02-Aug-05 	P. aeruginosa 	104 
02-Aug-05 	Mucoid P. aeruginosa 104 
14-Jun-05 	P. aeruginosa 	107  
RBH7 
RBH8 
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Appendix XI. Continued 
Patient Number Sample date Sample id Count 
01-Mar-05 P. aeruginosa 10b 
08-Dec-04 P. aeruginosa 106 
05-Oct-04 P. aeruginosa 106 
05-Oct-04 H. influenzae 106 
RBH8 17-Apr-04 P. aeruginosa 107 
16-Aug-99 P. aeruginosa 106 
16-Aug-99 Mucoid P. aeruginosa 105 
16-Aug-99 MRSA 104 
16-Aug-99 S. aureus 104 
25-Oct-05 P. aeruginosa 10' 
25-Oct-05 Candida sp. 103 
06-Oct-05 P. aeruginosa 107 
06-Oct-05 P. aeruginosa 106 
29-Sep-05 P. aeruginosa 106 
29-Sep-05 S. aureus 103 
29-Sep-05 A. fumigatus 103 
31-Aug-05 P. aeruginosa 107 
31-Aug-05 Candida sp. 103 
26-Aug-05 
26-Aug-05 
P. aeruginosa 
P. aeruginosa 
07 
07 
RBH9 26-Aug-05 S. aureus 103 
02-Aug-05 P. aeruginosa 107 
02-Aug-05 S. aureus 104 
14-Jul-05 P. aeruginosa 106 
14-Jul-05 S. aureus 104 
01-Jun-05 P. aeruginosa 10' 
01-Jun-05 S. aureus 106 
10-May-05 P. aeruginosa 
10-May-05 S. aureus 103 
28-Jul-99 P. aeruginosa 107 
28-Jul-99 Mucoid P. aeruginosa 104 
28-Jul-99 S. aureus 104 
25-Oct-05 Mucoid P. aeruginosa 10' 
25-Oct-05 S. aureus 107 
15-Sep-05 Mucoid P. aeruginosa 106 
15-Sep-05 S. aureus 106 
15-Sep-05 Candida sp. 103 
30-Aug-05 Mucoid P. aeruginosa 10' 
19-Jul-05 Mucoid P. aeruginosa 106 
RBH10 19-Jul-05 21-Jun-05 
P. aeruginosa 
Mucoid P. aeruginosa 
104 
 
106 
09-Jun-05 
09-Jun-05 
Mucoid P. aeruginosa 
Candida sp. 
05 
04 
31-May-05 P. aeruginosa 107 
31-May-05 Mucoid P. aeruginosa 106 
31-May-05 Candida sp. 104 
20-May-05 Mucoid P. aeruginosa 105 
20-May-05 P. aeruginosa 105 
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Appendix XI. Continued 
Patient Number Sample date Sample id Count 
19-May-05 Mucoid P. aeruginosa 104 
19-May-05 Candida sp. 103 
17-May-05 Mucoid P. aeruginosa 105 
17-May-05 S. epidemidis 104 
17-May-05 Candida sp. 103 
RBH10 12-May-05 Mucoid P. aeruginosa 106 
09-May-05 Mucoid P. aeruginosa 106 
18-Aug-01 P. aeruginosa 107 
18-Aug-01 Mucoid P. aeruginosa 106 
18-Aug-01 S. aureus 104 
18-Aug-01 Candida sp. 104 
25-Oct-05 Mucoid P. aeruginosa 10' 
25-Oct-05 S. aureus 105 
06-Jul-05 Mucoid P. aeruginosa 106 
06-Jul-05 S. aureus 104 
13-May-05 Mucoid P. aeruginosa 106 
RBH11 13-May-05 19-Nov-05 
S. aureus 
Mucoid P. aeruginosa 
105 
106 
19-Nov-05 S. aureus 103 
20-Feb-04 Mucoid P. aeruginosa 106 
04-Aug-99 Mucoid P. aeruginosa 107 
04-Aug-99 S. aureus 105 
04-Aug-99 A. fumigatus 103 
25-Oct-05 P. aeruginosa 10' 
25-Oct-05 Mucoid P. aeruginosa 105 
28-Sep-05 Mucoid P. aeruginosa 107 
28-Sep-05 A. xylosoxidans 104 
07-Aug-05 P. aeruginosa 107 
28-Sep-05 Candida sp. 103 
07-Aug-05 Mucoid P. aeruginosa 104 
02-Aug-05 P. aeruginosa 106 
RBH12 02-Aug-05 15-Jul-05 
Mucoid P. aeruginosa 
Mucoid P. aeruginosa 
106 
106 
15-Jul-05 P. aeruginosa 106 
10-May-05 Mucoid P. aeruginosa 107  
10-May-05 P. aeruginosa 10' 
05-Apr-05 Mucoid P. aeruginosa 106 
30-Mar-05 Mucoid P. aeruginosa 106 
30-Mar-05 P. aeruginosa 105  
08-Sep-99 P. aeruginosa 106 
08-Sep-99 Mucoid P. aeruginosa 103 
25-Oct-05 P. aeruginosa 10° 
25-Oct-05 Mucoid P. aeruginosa 106 
RBH13 15-Feb-05 17-Aug-04 
Mucoid P. aeruginosa 
Mucoid P. aeruginosa 
107 
104 
17-Aug-04 Candida sp. 103 
06-Dec-00 Mucoid P. aeruginosa 106  
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Appendix XI. Continued 
Patient Number Sample date Sample id Count 
25-Oct-05 P. aeruginosa 10' 
25-Oct-05 Mucoid P. aeruginosa 107 
14-Oct-05 Mucoid P. aeruginosa 107 
14-Oct-05 P. aeruginosa 106 
23-Aug-05 P. aeruginosa 106 
RBH14 23-Aug-05 15-Jul-05 
Mucoid P. aeruginosa 
Mucoid P. aeruginosa 
106 
106 
15-Jul-05 P. aeruginosa 104 
27-May-05 Mucoid P. aeruginosa 107 
27-May-05 P. aeruginosa 107 
17-Dec-99 Mucoid P. aeruginosa 106 
17-Dec-99 P. aeruginosa 104 
25-Oct-05 S. aureus 10' 
25-Oct-05 Mucoid P. aeruginosa 107 
25-Oct-05 P. aeruginosa 107 
01-Nov-05 P. aeruginosa 107  
01-Nov-05 Mucoid P. aeruginosa 106 
01-Nov-05 S. aureus 105  
06-Sep-05 S. aureus 106 
06-Sep-05 P. aeruginosa 106 RBH15 07-Jun-05 P. aeruginosa 106 
07-Jun-05 S. aureus 105 
07-Jun-05 Candida sp. 103 
25-May-05 S. aureus 106 
25-May-05 Mucoid P. aeruginosa 106 
25-May-05 P. aeruginosa 104 
21-Apr-04 P. aeruginosa 1135 
21-Apr-04 S. aureus 105 
26-Oct-05 Mucoid P. aeruginosa 101  
14-Sep-05 Mucoid P. aeruginosa 106 
14-Sep-05 P. aeruginosa 106 
RBH16 14-Sep-05 07-Jun-05 
Candida sp. 
Mucoid P. aeruginosa 
103 
106 
31-Aug-04 P. aeruginosa 106 
22-Jun-01 P. aeruginosa 10' 
22-Jun-01 Mucoid P. aeruginosa 107  
13-Apr-02 P. aeruginosa 10' 
RBH17 13-Apr-02 S. aureus 104 
13-Apr-02 Mucoid P. aeruginosa 104 
03-Jan-06 P. aeruginosa 106 
03-Jan-06 S. aureus 105 
25-Oct-05 P. aeruginosa 107  
25-Oct-05 S. aureus 106 
RBH18 25-Oct-05 Mucoid P. aeruginosa 106 
09-Sep-05 P. aeruginosa 106 
09-Sep-05 S. aureus 104 
09-Sep-05 Mucoid P. aeruginosa 103 
19-Jul-05 P. aeruginosa 107  
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Patient Number Sample date Sample id Count 
RBH18 29-Apr-05 
29-Apr-05 103 P. aeruginosa 
Candida sp. 103 
11-Apr-06 Mucoid P. aeruginosa 10' 
11-Apr-06 P. aeruginosa 107 
14-Feb-06 Mucoid P. aeruginosa 107 
20-Jan-06 Mucoid P. aeruginosa 104 
20-Jan-06 Candida sp. 104 
06-Jan-06 P. aeruginosa 106 
06-Jan-06 Mucoid P. aeruginosa 106 
06-Jan-06 S. aureus 104 
RBH19 25-Oct-05 Mucoid P. aeruginosa 107 
25-Oct-05 S. aureus 107 
16-Sep-05 Mucoid P. aeruginosa 106 
16-Sep-05 S. aureus 106 
16-Sep-05 Candida sp. 103 
30-Aug-05 Mucoid P. aeruginosa 107 
20-Jul-05 Mucoid P. aeruginosa 106 
20-Jul-05 P. aeruginosa 104 
21-Jun-05 Mucoid P. aeruginosa 106 
RBH2O 14-Dec-05 14-Dec-05 
Mucoid P. aeruginosa 
P. aeruginosa 
106 
107  
14-Dec-06 Mucoid P. aeruginosa 10' 
15-Nov-05 P. aeruginosa 106 
15-Nov-05 Mucoid P. aeruginosa 107 
15-Nov-05 S. aureus 103 
03-Oct-05 Mucoid P. aeruginosa 106 
RBH21 03-Oct-05 S. aureus 104 
09-Sep-05 Mucoid P. aeruginosa 106 
09-Sep-05 P. aeruginosa 106 
09-Sep-05 S. aureus 104 
28-May-05 P. aeruginosa 106 
28-May-05 Mucoid P. aeruginosa 105 
28-Apr-06 P. aeruginosa 10' 
28-Apr-06 Mucoid P. aeruginosa 105 
24-Mar-06 Mucoid P. aeruginosa 104 
24-Mar-06 P. aeruginosa 107 
14-Feb-06 P. aeruginosa 107  
14-Feb-06 Mucoid P. aeruginosa 106 
05-Jan-06 P. aeruginosa 106 
RBH22 05-Jan-06 13-Dec-05 
Mucoid P. aeruginosa 
P. aeruginosa 
105 
107 
13-Dec-05 Mucoid P. aeruginosa 106 
14-Jan-05 P. aeruginosa 107  
14-Jan-05 Mucoid P. aeruginosa 106 
01-Nov-05 P. aeruginosa 107 
01-Nov-05 Mucoid P. aeruginosa 106 
27-Sep-05 P. aeruginosa 107  
27-Sep-05 Mucoid P. aeruginosa 106 
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15-Sep-05 P. aeruginosa 10' 
15-Sep-05 Mucoid P. aeruginosa 106 
06-Sep-05 P. aeruginosa 107 
RBH22 06-Sep-05 02-Aug-05 
Mucoid P. aeruginosa 
P. aeruginosa 
106 
107 
02-Aug-05 Mucoid P. aeruginosa 106 
19-Apr-05 P. aeruginosa 107 
19-Apr-05 Mucoid P. aeruginosa 107  
15-Feb-06 Mucoid P. aeruginosa 10' 
RBH23 15-Feb-06 Candida sp. 103 
19-Oct-05 Mucoid P. aeruginosa 107 
28-Mar-06 P. aeruginosa 10' 
28-Mar-06 Candida sp. .103 
07-Mar-06 Mucoid P. aeruginosa 103 
RBH24 07-Mar-06 P. aeruginosa 107 
13-May-05 Mucoid P. aeruginosa 107 
13-May-05 P. aeruginosa 10' 
13-May-05 Candida sp. 103 
RBH38 21-Mar-06 24-Feb-06 
S. aureus 
S. aureus 
10' )  
107 
12-Apr-06 S. aureus 104 
21-Mar-06 P. aeruginosa 107 
RBH39 21-Mar-06 21-Mar-06 
Mucoid P. aeruginosa 
S. aureus 
106 
104 
27-Aug-04 S. aureus 105 
27-Aug-04 P. aeruginosa 105 
27-Apr-06 P. aeruginosa 10' 
27-Apr-06 Mucoid P. aeruginosa 104 
27-Apr-06 Candida sp. 103 
11-Apr-06 Mucoid P. aeruginosa 105  
11-Apr-06 P. aeruginosa 106 
11-Apr-06 P. aeruginosa 105  
04-Apr-06 P. aeruginosa 106 
04-Apr-06 Mucoid P. aeruginosa 103 
21-Mar-06 Mucoid P. aeruginosa 103 RBH40 21-Mar-06 P. aeruginosa 104 
23-Feb-06 Mucoid P. aeruginosa 107 
07-Feb-06 Mucoid P. aeruginosa 106 
07-Feb-06 Candida sp. 103 
15-Nov-05 Mucoid P. aeruginosa 107 
15-Nov-05 P. aeruginosa 104 
06-Sep-05 P. aeruginosa 104 
06-Sep-05 Mucoid P. aeruginosa 103 
06-Sep-05 Candida sp. 103 
23-Mar-06 P. aeruginosa 10' 
RBH41 23-Mar-06 24-Jan-06 
S. aureus 
P. aeruginosa 
103 
105 
12-Dec-05 P. aeruginosa 103 
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12-Dec-05 S. aureus 102 
03-Dec-05 S. aureus 105 
03-Dec-05 A. fumigatus 103 
03-Dec-05 Candida sp. 103 
RBH41 08-Nov-05 S. aureus 106 
08-Nov-05 P. aeruginosa 105 
22-Oct-05 P. aeruginosa 104 
22-Oct-05 A. fumigatus 103 
23-Aug-05 S. aureus 106 
14-Mar-06 Mucoid P. aeruginosa 10' 
09-Jan-06 Mucoid P. aeruginosa 107 
27-Sep-05 Mucoid P. aeruginosa 107 
CFSP1 08-Aug-05 Mucoid P. aeruginosa 106 
08-Aug-05 P. aeruginosa 106 
09-May-05 Mucoid P. aeruginosa 107 
09-May-05 P. aeruginosa 106 
23-Mar-06 P. aeruginosa 106 
23-Mar-06 Mucoid P. aeruginosa 104 
14-Mar-06 P. aeruginosa 107 
14-Mar-06 
12-Jan-06 
Mucoid P. aeruginosa 
P. aeruginosa 
106 
07 
12-Jan-06 
06-Sep-05 
06-Sep-05 
Mucoid P. aeruginosa 
P. aeruginosa 
Mucoid P. aeruginosa 
106 
07 
07 
31-Aug-05 Mucoid P. aeruginosa 106 
CFSP2 31-Aug-05 P. aeruginosa 107 
24-Aug-05 Mucoid P. aeruginosa 106 
24-Aug-05 P. aeruginosa 106 
19-Aug-05 Mucoid P. aeruginosa 106 
19-Aug-05 P. aeruginosa 106 
03-Aug-05 
03-Aug-05 
Mucoid P. aeruginosa 
P. aeruginosa 
106 
03 
01-Aug-05 P. aeruginosa 107 
01-Aug-05 Mucoid P. aeruginosa 106 
01-Aug-05 Candida sp. 103 
21-Mar-06 Mucoid P. aeruginosa 106 
21-Mar-06 Candida sp. 103 
CFSP3 14-Mar-06 Mucoid P. aeruginosa 107 
14-Mar-06 Candida sp. 103 
24-May-05 Mucoid P. aeruginosa 106 
14-Mar-06 P. aeruginosa 10' 
14-Mar-06 Mucoid P. aeruginosa 104 
CFSP4 
09-Jan-06 
09-Jan-06 
31-Oct-05 
S. aureus 
A. fumigatus 
S. aureus 
106 
03 
107 
22-Aug-05 Candida sp. 103 
22-Aug-05 A. fumigatus 103 
16-Jul-05 S. aureus 106 
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16-Jul-05 A. fumigatus 10d  
CFSP4 04-Apr-05 04-Apr-05 
S. aureus 
A. fumigatus 
01-May-04 P. aeruginosa 103 
CFSP5 10-Apr-06 14-Mar-06 
P. aeruginosa 
Mucoid P. aeruginosa 
104 
106 
14-Mar-06 S. aureus 104 
14-Mar-06 Candida sp. 103 
14-Feb-06 S. aureus 106 
14-Feb-06 Candida sp. 103 
24-Jan-06 Mucoid P. aeruginosa 104 
24-Jan-06 S. aureus 104 
24-Jan-06 Candida sp. 103 
24-Jan-06 A. fumigatus 103 
CFSP5 10-Jan-06 10-Jan-06 
S. aureus 
P. aeruginosa 
105  
105 
07-Dec-05 P. aeruginosa 103 
07-Dec-05 S. aureus 103 
07-Nov-05 S. aureus 106 
07-Nov-05 Mucoid P. aeruginosa 106 
25-Oct-05 S. aureus 106 
25-Oct-05 Mucoid P. aeruginosa 106 
09-Aug-05 S. aureus 107  
09-Aug-05 Mucoid P. aeruginosa 103 
14-Mar-06 P. aeruginosa 10' 
14-Mar-06 S. aureus 106 
14-Mar-06 Mucoid P. aeruginosa 104 
06-Jan-06 P. aeruginosa 106 
06-Jan-06 Mucoid P. aeruginosa 106 
06-Jan-06 S. aureus 106 
CFSP6 13-Dec-05 P. aeruginosa 107  
13-Dec-05 S. aureus 103 
25-Oct-05 P. aeruginosa 107  
25-Oct-05 Mucoid P. aeruginosa 105 
23-Aug-05 P. aeruginosa 107  
23-Aug-05 Mucoid P. aeruginosa 106 
23-Aug-05 S. aureus 104 
25-Apr-06 P. aeruginosa 107  
25-Apr-06 Mucoid P. aeruginosa 105 
14-Mar-06 P. aeruginosa 106 
14-Mar-06 Mucoid P. aeruginosa 104 
CFSP7 21-Feb-06 21-Feb-06 
P. aeruginosa 
Mucoid P. aeruginosa 
106 
106 
28-Jan-06 P. aeruginosa 105  
28-Jan-06 Candida sp. 104 
28-Jan-06 A. fumigatus 103 
05-Jan-06 P. aeruginosa 106 
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05-Jan-06 Mucoid P. aeruginosa 10 
05-Jan-06 Candida sp. 104 
19-Aug-05 P. aeruginosa 107 
CFSP7 19-Aug-05 P. aeruginosa 106 
19-Aug-05 Mucoid P. aeruginosa 106 
16-Aug-05 S. aureus 106 
16-Aug-05 Candida sp. 103 
22-Apr-06 Mucoid P. aeruginosa 10' 
14-Mar-06 Mucoid P. aeruginosa 106 
17-Feb-06 Mucoid P. aeruginosa 106 
17-Feb-06 A. fumigatus 103 
CFSP8 23-Sep-05 Mucoid P. aeruginosa 106 
16-Sep-05 Mucoid P. aeruginosa 107  
16-Sep-05 Candida sp. 103 
31-Aug-05 Mucoid P. aeruginosa 107  
31-Aug-05 P. aeruginosa 106 
14-Mar-06 S. aureus 
CFSP9 13-Dec-05 13-Dec-05 
S. aureus 
H. influenzae 
106 
106 
03-Jul-01 P. aeruginosa 105 
02-May-06 Candida sp. 103 
CFSP10 14-Mar-06 28-Feb-06 
Candida sp. 
Candida sp. 
104 
104 
13-Dec-05 P. aeruginosa 103 
13-Apr-06 S. aureus lob 
13-Apr-06 A. fumigatus 103 
CFSP12 14-Mar-06 S. aureus 104 
14-Mar-06 A. fumigatus 103 
25-Apr-03 P. aeruginosa 103 
CFSP14 14-Mar-06 09-Mar-06 
Mucoid P. aeruginosa 
Mucoid P. aeruginosa 
104 
107  
14-Mar-06 Mucoid P. aeruginosa 104 
14-Mar-06 Serratia spp. 103 
15-Feb-06 P. aeruginosa 104 
13-Dec-05 A. xylosoxidans 105 
13-Dec-05 Scedosporium apiospermum 103 
08-Nov-05 P. aeruginosa 103 
08-Nov-05 Candida sp. 103 
CFSP15 08-Nov-05 04-Nov-05 
S. maltophilia 
P. aeruginosa 
103 
106 
04-Nov-05 Scedosporium apiospermum 
02-Nov-05 P. aeruginosa 107  
02-Nov-05 Scedosporium apiospermum 103 
28-Oct-05 P. aeruginosa 106 
16-Sep-05 P. aeruginosa 104 
16-Sep-05 A. fumigatus 103 
16-Sep-05 Scedosporium apiospermum 103 
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Patient Number 	Sample date 	Sample id 	Count 
RBH25 	 P. aeruginosa not isolated 
RBH26 P. aeruginosa not isolated 
RBH27 	 P. aeruginosa not isolated 
RBH28 11-Jun-01 	P. aeruginosa 
RBH29 	 P. aeruginosa not isolated 
RBH30 P. aeruginosa not isolated 
RBH31 	 P. aeruginosa not isolated 
RBH32 P. aeruginosa not isolated 
RBH33 	 P. aeruginosa not isolated 
RBH34 P. aeruginosa not isolated 
14-Mar-05 	No significant bacterial growth 
RBH35 	08-Mar-05 	No significant bacterial growth 
25-Jan-03 	P. aeruginosa 	+++ 
RBH36 	 P. aeruginosa not isolated 
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Appendix XIII. 	Copies of ethics approval and consent forms 
Application for Review of Proposed Research In the 
ETHICS COMMITTEE 
of the 
ROYAL I3ROMPTON & IIAREFIELD MIS TRUST and NATIONAL HEART & LUNG INSTITUTE 
la 	Project Title 
Can saliva. scrum and urine samples he used to identify infections in patients with cystic fibrosis? 
lb 	Short title 
Saliva, serum and urine in CF 
2a Investigators 
Jane Davies. Gene Therapy and Paediatric Respiratory Medicine 
Andrew Bush, Paediatric Respiratory Medicine 
'Tyrone Pitt. Centre for Infections, health Protection Agency, Colindale 
Abbie Weisner. Centre for Infections, health Protection Agency. Colindale 
2b 	Name and address for correspondence 
Jane Davies, 
Senior Lecturer in Gene 'therapy 
honorary Consultant in Paediatric Respiratory Medicine 
Royal Brampton Hospital 
2c 	Cont act telephone or bleep number 
c't 839S 
3a 	Principal Research Investigator accepting clinical responsibility 
Jane Davies 
4 	Aims and Objectives of the Study 
Subjects with cystic fibrosis (CI') sulfa from early infection with a narrow range of bacteria, in particular 
StapkvItk•occus aimits and Psendomonas aenigintwa. The latter is the organism most closely associated 
with progression of lung disease, related to the inflammation that ensues. Once infection with P. avniginomi 
becomes established, eradication is impossible, and infection persists for the life time of the patient. 
However, there is good evidence that early intervention with both systemic and topical tnebulised) 
antibiotics early after the first isolation, can eradicate the bacteria and prevent chronic infection. Current 
practice is to collect regular sputum samples, to culture for the presence of pathogens. However, many 
child= do not produce sputum, or swallow it, especially the younger ones and in these cases, we perform 
cough swabs, which are unfortunately less reliable. In children who are not doing well clinically, and in 
whom we are unable to obtain samples by these non-invasive methods, we will perform a bronehoscopy. 
'Ms procedure requires admission to hospital and a general anaesthetic. Research studies on infants as young 
as several months have shown however that infection and inflammation are present from an early age, even 
when the child is asymptomatic. We arc likely therefore to be missing some cases of infection, and surrogate. 
non-invasive methods would he extremely useful. 
Once bacteria arc encountered, the body forms antibodies in an attempt to fight off the infection. These can 
be detected in the blood, and certain centres perform such serology on an annual basis, although the impact 
of such infrequent monitoring on management is unclear. It could lead to failure of recognition of infection 
for up to a year, and we are therefore considering alternative approaches including testing several bod . fluids 
for antibodies. antigens and bacterial DNA. Many antibodies are secreted into other body fluids including the 
oral fluid and saliva. 'fasting of saliva for antibodies is used in other clinical situations, such as measles and 
HIV, but has never been done in the context of CF. We would like to assess the possibility of this approach 
in patients with CF, so that regular, non-invasive monitoring could be performed, which may detect infection 
and lead to =tier initiation of treatment. 
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The presence of bacterial products in the urine has also been widely employed as a sensitive diagnostic test 
and in some cases of Legionelta infection. bacterial antigens (proteins) in the urine can be detected in the 
absence of the organism in the sputum. We will therefore explore the detection of bacterial antigens and 
1)NA. 
The polymerase chain reaction (PCR) has been applied to detect the presence of pathogenic organisms in 
infections. P. ucruginosa has been detected by traditional PCR methods from a number of different clinical 
samples, including skin biopsies, synovial fluid and sputum. W'c have previously studied detection in BAL 
samples hut there are no studies to date using oral fluids or urine. As these techniques can be very rapid and 
sensitive. we will investigate using them in a CF setting. 
5a 	Number of centres of Study 
Single centre 
Ga 	Study Desilm 
Cross-sectional pilot study 
Larger longitudinal study. 
Gb Details of the interventions proposed 
i) 	Specially designed sponge swabs will he passed into the subject's mouth along the groove between 
gum and cheek to collect oral fluid, The sample will he analysed at the Health Protection Agency for 
the presence of antibodies to and nucleic acids from all CF pathogens, hut specifically P. acruginaret. 
b) Stored serum samples (or, if the patient is having a blood test during the study, fresh serum) will be 
analysed for the same antibody levels and bacterial nucleic acids. For healthy volunteers. we will 
request a 5m1 (one teaspoon) blood sample. For other subjects, the lest will be performed on blood or 
scrum left over from clinical testing. The volumes required are so small that no extra blood will need 
to be requested. 
c) Urine samples will be sent to the Health Protection Agency for the presence of antigens and nucleic acids 
from all CF pathogens, but specifically P. acruginusa 
The results will be compared with microbiological cultures obtained as part of routine clinical practice from 
either cough swab, sputum or bronehoalveolar lavage. Repeated samples may be obtained in the 
longitudinal arm of the study, although for blood sampling, repeated samples will only be requested if 
the patient is having a blood sample taken for clinical purposes anyway. 
7 Sources and Recruitment of Subjects: 
Patients (adults and children) will be recruited from out-patient clinics and in-patients (Paediatric Respiratory 
Medicine, Adult CF and Thoracic Medicine), Patients will either have CF., or other respiratory diseases 
(disease control group). We will also recruit heathy adult volunteers from within the Royal Brompton 
Hospital and National head and Lung Institute (negative control group). It is anticipated that such volunteers 
will be recruited from amongst the investigators' colleagues and that we will not have to advertise. 
7a. 	Inclusion criteria 
Subjects or parents or guardians will have given written informed consent 
7b 	Exclusion criteria 
Nil 
7g 	Number of subjects 
Initial pilot to include up to 20 adults of known infection status to confirm sensitivity of the assays used. Should 
these assays be useful, we would aim to recruit as many adult and paediatric CF patients as possible (up to 800). 
up to 100 disease controls and 50 healthy volunteers. 
8 	Financial and other Resources 
No financial implications for the hospital. 
8d 	Payment to subjects. 
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Nil 
9 	Pharmacology and Dispensing 
NA 
10 Radiation 
N/A 
11 Risks 
There are no risks involved in this minimally invasive procedure 
12 Indemnities 
Will be provided by Royal Itrompton and I fart:field NITS Trust 
13 	Ethical Implications 
Nil 
1:Th Potential benefits 
Infection may be recognised earlier than currently. Studies suggest that the earlier in the course of the 
infection treatment is initiated. the greater the likelihood of eradication 
14a InIiirmation/Consent form 
Attached 
14h 	Time for consideration 
Patients and parents will be approached in out patient clinic and on the wards. Anyone requesting time for 
further consideration will be re-approached at the next visit 
15 Confidentiality 
Information obtained will he kept confidential on art individual basis. 
16 	Informing the general practitioner 
At this preliminary stage, we do not propose to inform the GP as to their patient's involvement in this 
minimally invasive study. 
Should this he a requirement of the committee, we will happily comply 
17 	Untoward Events and Amendments to the Protocol 
We undertake to inform the Ethics Cmunittec and the consultant with clinical responsibility immediately 
should any untoward event be encountered. 
18 	Case Notes 
We confirm that we will flag case notes of patients participating. 
19 	Proposed starting date 
As soon as possible 
20 	Expected date of completion 
24 -30 months 
21 	Declaration of Principal Investigator 
The information contained in this submission is to the best of my knowledge and belief accurate, and I take full 
responsibility for It. 
I also accept clinical responsibility for the consequent study. 
I agree to provide interim and final reports on the study upon request, and confirm that I will immediately notify 
the Chairman (or in his absence, Deputy Chairman or Administrator) of any adverse or unexpected events that 
may occur during the study. 
Date: 
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Royal Brompton & HarefieId NHS Trust & National Heart and Lung Institute 
roRm Of'CONSE .VT  ADULT CI' PATIENT 
TITLE Of PROJECT: 
Can saliva. serum and urine sample,: he used to assess infection status in patients with cystic. fibrosis? 
We invite you to consider taking part in a research project. 
EXPLANATION 01' PROJECT: 
Monitoring of infection in children with cystic fibrosis is important to guide management, particularly so for Pseudomonas 
aerugino.sa, as early treatment is hichly beneficial in preventirro chronic infection. Many children, especially those in the younger 
age group cannot couch up sputum reliably. In these cares. as you know, we attempt to obtain cultures from the lower airway by 
cough swabs, which may not be as reliable. An alternative approach would he to look for the body's response to infection as well 
as products from the bacteria. This is pec.siblz because the body attempts to fight infection by the production of proteins in the 
blood adled antibodies. Such antibodies can be detected in the blood of CF children with chronic pseudomonas infection. but 
repeated blood tests arc obviously undesirable. W are looking at possible alternatives. 
Antibodies pass from the blood into other body fluids, such as saliva., and salivary testing has been found useful in certain 
infectious diseases such as measles. Nobody has looked at the possibility of testing saliva in patients with CF. in this study, we 
would like to see if we can measure antibodies to the common Ch• bacteria, such as RaphAlcocon aw-eits and Psendomonas 
aeruginosa in the saliva. If this was successful. we could monitor children at very regular intervals, and hopefully detect infection 
earlier than usual, 
The test is very simple and completely pain free. W will insert a sterile sponge swab into the mouth and nth it aently in the 
groove between the guns and cheek: This is where the mouth fluid is most rich in antibodies. We will then freeze the sample and 
analyse it for antibody levels. If you arc having a blood test, we will compute the mfivit with antibody levels in the bloat. If not. 
we will compare the saliva with serum obtained front a previous or future blood test. We would also like to look for bacterial 
products in urine as urine has been successfully used to detect infections in the lungs caused by ether bacteria. We wilt ask you to 
urinate into a sterile container and this will then he frozen and tested for bacterial products. 
We may ask you to provide samples on several occasions if early results look promising. Wc will then compare the results of 
these tests with cultures perforated as part of routine clinical care, such as cough swabs, sputum, where appropriate, 
bronchoscopic lavage. 
No human genetic analysis will he carried out on the samples, nor will they be tested for any unrelated infectious diseases such as 
hepatitis or HIV The samples will be coded with a number known only to the investigators and your identity will remain 
confidential, and will not be reported with results. In the early stages of this research project, the results are likely to be difficult to 
interpret, and we do not plan to feed back your results to you. However, if this test is shown to be useful, and we discover 
anythiry which could affect your management, we will inform you. You are under no obligation to take part in this project. If you 
do tierce, you may withdraw at any time without stating a reason. If you choose: not take part, your clinical management will in no 
way be affected. Thank you very much for your kindness in considering this project. Should you require any further information, 
please contact Dr Jane Davies at the Royal Brompton Hospital 020.7351-R30S. 
Signed by the person in charge of the Project 	 Date 
The Ethics Committee of the Royal 13tomptort & Hareficld NTIS Tiust/National Heart & Lung Institute Ras ttpprovrd the above 
statement. 
Signed by the ChainnruVRepresentative of the Committee 
Date 
DOCTOR'S DECLARATION 
I have explained the project to the Participant as outlined above in the presmcc/absenee* of a Witnc.ss" 
Date 	 Time 
delete as appropriate 	 "' every effort should he made to give the explanation in the presence of a witness 
Protocol Reference Number: 02-274 Amended version 1 (0K.06.05) 
Pagel 
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NOTES FOR PARENTS/GLTARDINS 
Please do not hesitate to ask the Doctor any questions you may have about this project before you decide whether you 
wish your child 'ward to participate. 
If you decide, now or at any other stage, that you no longer wish your child"ward to participate in the project. this will 
not in any way prejudice their future treatment. 
3. 	If you decide to take part in this project, you will he given a copy of this form for your infommtion. 
Form of Assert for use by ParentAluanlians' of Children under 18 undergoing investigations connected with Clinical Research 
(Please delete as appropriate) 
Name of Child 
 
Age 
Address 
   
    
of 
„being the .Parent'Ouardian* of the above named Child, consent 
to my childWard' undergoing the procedures described overleaf The nature, purpose and possible consequences have been fully 
explained tome. 
Signed (Parent'Guardian)  	Date 
*. %MN ESS (See 'Note 1) 
am satisfied that the procedures have been fully explained to the Parent"Guardian* (name of Child) 
	
 	. The Parent'Guardiart* has given consent in my presence. 
Name of Witness 
     
Position 
 
        
Address 
Signed 
       
    
Date 
 
       
NOTES 
**WITNESS: Wherever possible, a witness should be present whilst the doctor/sponsor explains the procedures to the 
patient. if this is impractical, complete the "Doctor's Declaration* accordingly. In the case of a patient, the 
witness should not br a doctor if the sponsor is a doctor. If the witness is a nurse, he or .the must be a ward 
sister or senior nurse in charge of the ward who is not undertaking a post-basic course. 
2. 	SAFE-KEEPING OF THIS FORM: In the case of a patient, a copy of this signed Firm must be kept in the patients 
case-notes, and the sponsor should retain a copy for subsequent examination if required by the. Ethics 
Committee, 
Page 2 
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Royal Brompton & Ilarefield NIIS Trust & National Heart and Lung Institute 
FORM OFCONSENT 	 Aiwur 	PXf1 ENT 
Mix OF PROJECT: 
Can saliva. serum and urine samples he used to assess infection status in patients with cystic fibrosis? 
We invite you to consider taking part in a research project. 
EXPLANATION OF PROJECT: 
We are interested in exploring new methods to detect infection in patient with respiratory problems, specifically cystic fibrosis 
(CF). you do not have this condition, or the infections commonly encountered in CF, and are bzirat included in this study as a 
'control' patient, one of a group with whom we can compare results. 
Many children, especially those in the younger age group cannot cough up sputum reliably. In these cases, we attempt to obtain 
cultures from the lower airway by cough swabs, which may not be as reliable. An altemrtive approach would be to look for the 
body's response to infection as well as products from the bacteria. This is possible because the body attempts to fight infection by 
the production of proteins in the hlood called antibodies. Such antibodies can he detected in the blood of CF children with chronic 
pseudomonas infection. but repeated blood tests are obviously undesirable. We are looking at possible alternatives. 
Antibodies pass front the blood into other body fluids, such as saliva, and salivary testing has been found useful in certain 
infectious diseases such as measles; Nobody has looked at the possibility of testing saliva in patients with CF. In this study, we 
would like to sec if we can measure antibodies to the common CF bacteria, such tr.; Staphylococcus aurora and Pseutionronas 
aeruginosa in the saliva. If this was successful, we could monitor children at very regular intervals, and hopefully detect infection 
earlier than usual. 
The test is very simple and completely pain free. We will insert a sterile sponge swab into the mouth and rub it gently in the 
groove between the gum and cheek. This is where the mouth fluid is most rich in antibodies. We will then freeze the sample and 
analyse it for antibody levels. If you are having a blood test. we will compare the saliva with antibody levels in the blood, If not, 
we will compare the saliva with serum obtained from a previous or future blood test (if no blood is available, the other types of 
samples will still he useful to us). We would also like to look for bacterial products in urine as urine has been successfully used to 
detect infections in the lungs caused by other bacteria. We will ask you to urinate into a sterile container and this will then he 
frozen and tested for bacterial products. 
We may ask you to provide samples on several occasions if early results look promising,. We will then compare the results of 
these tents with cultures performed as part Of routine clinical care, such as cough swabs, sputum, where appropriate, 
brortehoscopic lavage. 
No human genetic analysis will be carried out on the samples, nor will they be tested for any unrelated infectious diseases such as 
hepatitis or HIV. The samples wilt be coded with a number known only to the investigators and your identity will remain 
confidential, and will not be reported with resultss. In the early stages of this research project, the results are likely to be difficult to 
interpret, and we do not plan to feed hack your results to you. However, it' this test is shown to he useful, and we discover 
anything which could affect your management, we will inform you. You are under no obligation to take part in thin project. If you 
do agree, you may withdraw at any time without stating a reason. If you choose not take pan, your clinical management will in no 
way he affected. Thank you very much for your kindnexs in considering this project. Should you require any further information. 
please contact Dr Jane Davies at the Royal Brampton Hospital 020-7351=8398. 
Signed by the NI-son in. charge of the Project 	 Date 
The Ethics Committee of the Royal Brompton & Harefield NI-IS TrushNational lleart & Lung Institute lugs approved the above 
statement. 
Signed by the ChaimmniRepresentative of the Committee 
Date 
DOCTOR'S DECLARATION 
I have explained the project to the Participant as outlined above in the presence/'absence'" of a Witness"' 
Signed 
M 	delete as appropriate 
 
Date 	 Time 
  
 
"' 	every effort should Iv made to give the explanation in the presence of a witness 
Protocol Reference Number: 02-274 Amended version 1 (I 06.0.5) 
Page 1 
312 
Appendix XIII. Continued 
NOTES FOR PARENTS/GUARDIANS 
Please do not hesitate to ask the Doctor any questions you may have abut this project before you decide whether you 
wish your child:Ward to participate. 
If you decide, now or at arty other stage. that you no longer wish your child w: 	to participate in the project, this will 
not in any way prejudice their future treatment. 
3. 	If you decide to take part in this project, you will be given a copy of this form for your information. 
Form of Assent for use by Parcnt!Guardims" of Children under 18 undergoing investigations connected with Clinical Research 
(Please delete as appropriate) 
Name of Child 	 Age 
Address 
1, 	 of 
, being the ParentiGicirdian* of the above named Child, consent 
to my child:wore undergoing the procedures described overleaf The nature, purpose and possible consequences love been fully 
explained to me. 
Signed (Parent:Guardian) 	Date 	  
11  WITNESS (Sec Note I ) 
I am satisfied that the procedures have been fully explained to the ParentGuardian* (name of Child) 
	  The ParentiGuardian" has given consent in my presence. 
Name of Witness    Position 
Address 
Signed 
	
Date 
NOTES 
1. 	"WITNESS: Wherever possible, a witness should be present whilst the doctorilsponsor explains the procedures to the 
iciticnt, if this is impractical, complete the "Doctor's Declaration' accordingly, In the ease of a patient, the 
witness should not ben doctor if the sponsor is a doctor. If the witness is a nurse, he or she must he a ward 
sister or senior nurse in charge of the ward who is not undertaking a past-basic course, 
SAFE-KEEPING OF THIS FORM: In the case of a patient, a copy of this signed form must he kept in the patients 
case-notes, and the sponsor should retain a copy for subsequent examination if required by the Ethics 
Committee. 
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Appendix XIII. Continued 
Royal Brompton & Harefield NHS Trust & National Heart and Lung Institute 
FOR M 0 VC 0 ?VS E T 	 ADULT HEALTI 
VOLUNTEER 
irri,E 1W PROJECT 
Can saliva, scrum and urine samples be used to assess infection status in patients with cystic fibrosis? 
We invite you to consider taking part in a research project. 
EXPLANATION OF PROJECT: 
We are interested in exploring new methods to detect infection in patient with respiratory problem?, specifically cystic fibrosis 
(CE). You do not have this condition, or the infections commonly encountered in CF. and are being included in this study as a 
'control' patient, one of a group with whom we can compare results. 
Many children. especially those in the younger age group cannot cough up sputum reliably. In these cases. we attempt to obtain 
cultures from the lower airway ha' cough swabs, which may not be as reliable. An alternative approach would be to look for the 
body's resporive to infection as well as products from the bacteria This is possible because the body attempts to fioda infection by 
the production of proteins in the blood caned antibodies. Such antibodies can be detected in the blood of CF children with chronic 
nseudomonas infection, but repeated blood tests are obviously. undesirable. We are looking at possible alternatives. 
Antibodies pass from the blood into other body fluids, such vs saliva, and salivary testing has been found useful in certain 
infectious diseases such as measles. Nobody has looked at the possibility of testing saliva in patients with CF. In this study. we 
would like to see if we can measure antibodies to the common CF bacteria, such its Rogrylococern dwells 	Pseudomonas 
,winginosa in the saliva. If this was successful, we could monitor children at very regular intervals, and hopefully detect infection 
earlier than usual. 
The test is very simple and completely pain free. We will insert a sterile sponge swab into the mouth and rub it gently in the 
groove between the gum and check. This is where the mouth fluid is most rich in antibodies. We will then freeze the sample and 
analyse it for antibody levels. We would also like to perform a blood test, so that we can compare the saliva with antibody levels 
in the blood. This will require only Soil (one teaspoon) of blood. We would also like to look for bacterial products in urine as 
urine has been successfully used to detect infections in the lungs caused by other bacteria. We will ask you to urinate into a sterile 
container and this will then be frozen and tested for bacterial products. 
We may ask you to provide samples on several occasions if early results look promising. We will then compare the results of 
these tests with cultures performed as part of routine clinical care, such as cough swabs, sputum, where appropriate, 
bronchoscopie lavage. 
No human genetic analysis will be citified out on the samples, nor will they be tested for any unrelated infectious diseases such as 
hepatitis or HIV. The samples will be coded with a number known only to the investigators and your identity will remain 
confidential, and will not be reported with results, In the early stages of this research project the results are likely to be difficult to 
interpret. and we do not plan to feed hack your results to you. However, it' this test is shown to he useful, and we discover 
anything which could affect your management, we will inform you You are under no obligation to take part in this project. If you 
do agree, you may withdraw at any time without stating a reason. If you choose not take part, your clinical management will in no 
way be affected. Thank you very much for your kindness in considering this project. Should you require any further information. 
please contact Dr Jane Davies at the Royal Brompton Hospital 020-7351-839g. 
Signed by the person in charge of the Project 	 Date 
The Ethics Committee of the Royal Brampton & Hareficld NHS Truss/National Heart & Lung Institute has approved the above 
statement. 
Signed by the ChnimmeRepresentative of the Committee 
Date 
DOCTOR'S DECLARATION 
have explained the project to the Participant as outlined above in the presence/absence" of a Witness" 
Signed 
delete as appropriate 	 " every effort should he made to give the explanation in the presence of a witness 
Protocol Reference Number: 02-274 Amended version 1 (06.0(.05) 
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Appendix XM. Continued 
NOTES FOR PARENTS/GUARD1ANS 
Please do not hesitate to ask the Doctor any questions you may have about this project before you decide whether you 
wish your child:ward to participate. 
If you decide, now or at any other stage. that you no longer wish your child'ward to participate in the project. this will 
not in any way prejudice their future treatment. 
3. 	If you decide to take part in this project. you will he given a copy of this form for your information. 
Form of Assent for use. by Parent:Guardians* of Children under 18 undergoing investigations connected with Clinical Research 
(Please delete as appropriate) 
Name of Child 
	
Age 
Address 
, being the Parent'Cltrirdian* of the above named Child, consent 
to my childward* undergoing the procedures described overleaf The nature, purpose rind possible consequences have been fully 
explained to me. 
Signed (Parent"Guardian) 	Date 	  
VIITNESS (See Note 1) 
I am satisfied that the procedures have been fully explained to the Parentlinardian* (name of child) 
The Parent/Guardian* has given consent in toy presence. 
Name of Witness 
Address 
   
Position 	  
     
      
Signed__ 
VOTES 
**WITNESS: Wherever possible, a witness should he present whilst the doctor/sponsor explains the procedures to the 
patient. If this is impractical, complete the "Doctor's Declaration' accordingly, In the case of a patient, the 
witness should not be a doctor if the sponsor is a doctor. if the witness is a nurse, he or she must be a ward 
sister or senior nurse in charge of the ward who is not undertaking a pmt-basic course. 
;SAIllsKETIPING OF THIS FORM: In the case of a patient, a copy of this signed form must he kept in the patients 
case-notes, and the sponsor should retain n copy for sutocquent examination if required by the Ethics 
Committee. 
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Appendix XIII. Continued 
Royal Brompton & Ilarefield NIIS Trust & National Heart and Lung Institute 
FO I? M 0 PCONSENT 	 PAEDIATRIC CE 
PATIENT 
012 PROJECT: 
Can saliva, serum and urine samples be used to assess infection status in patients with cystic fibrosis'? 
We invite you to consider allowing your child r ward to take part in a research project. 
EXPLANATION OF PROJECT: 
Monitoring of infection in children with cystic fibrosis is important to guide management, particularly so for Psetauflioneis 
aertiginosa. as early treatment is highly beneficial in preventirr chronic infection. Many children. especially those in the younger 
ace group cannot cough up sputum reliably. In these cases, as you know, we attempt to obtain cultures front the lower airway by 
cough swabs, which may not be as reliable. An alternative approach would be to look for the body's response to infection as wet 
as products from the bacteria. This is possible because the body attempts to fight infection by the production of proteins in the 
blood called antibodies. Such antibodies can he detected in the blood of CF children with chronic pseudomonas infection, but 
repeated blond tents are obv iously undesirable. We are look ins at rxwahle alternative,: 
Antibodies pass from the blood into other body fluids, such as saliva. and salivary testing has been found useful in certain 
infectious diseases such as measles. Nobody has looked at the possibility of testing saliva in patients with CF. In this study, we 
would like to see if we can measure antibodies to the common CF bacteria, such its NiaptTlacuccus curries and Pseudonionos 
aeniginosa in the saliva. If this was successful, we could monitor children at very regular intervals, and hopefully detect infection 
earlier than usual. 
The test is very simple and completely pain free. We will insert a sterile sponge swab into the mouth and rub it gently in the 
groove hetween the gum and cheek. This is where the mouth fluid is most rich in antibodies We will then frimze the sample and 
analyse it for antibody levels. If your child is having a blood test, we will compare the saliva with antibody levels in the blood. If 
not, we will compare the saliva with serum obtained front a previous or future blood test. We would also like to look for bacterial 
products in urine as urine has been successfully used to detect infections in the lungs caused by other tocteria. We will ask your 
child to urinate into a sterile container and this will then be frozen and tested for bacterial products. 
We may ask your child to provide samples on several occasions it-early results look promising. We will then compare the results 
of these tests with cultures performed as part of routine clinical care, such as cough swabs, sputum, where appropriate. 
bronchoscopieliwage. 
No human genetic analysis will be carried out on the samples, nor will they be tested for any unrelated infectious diseases such as 
hepatitis or HIV. The samples will be coded with a number known only to the investigators and the identity of your child will 
remain confidential, and will not he reported wah results. In the early stages of this research project, the results are likely to he 
difficult to interpret, and we do not plan to feed hack your child's results to you. However, if this test is shown to he useful, and 
we discover anything which could affect yew child's management, we will inform you. You are under no obligation to take part 
in this project if you do agree, you may withdraw at any time without stating a reason. If you choose nor take part, your child's 
clinical management will in no way he affected Thank you very much for your kindness in considering this project Should you 
require arty further information, please contact Dr Jane Davies at the Royal Drompton I.lospital 020-735 I -83'..)8. 
Signed by the person in charge of the Project 	 Date 
The Ethics Committee of the Royal Brompton S Harefield NTIS Trust/National Heart & Lung Institute has approved the shove 
statement. 
Signed by the ChainnantRemesentative of the Committee 
Date 
DOCTOR'S DECLARATION 
I have explained the project to the Participant as outlined above in the prestmcelabisenee* of a Witness** 
Signed 
	
Date 	 Time 
delete as appropriate 	 " every effort should he made to give the explanation in the presence of a witness 
Protocol Reference Number: 02-274 .Ant ended version 1 (00:06.05) 
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Appendix XHI. Continued 
NOTES FOR PARENTS/GUARDIANS 
Please do not hesitate to ask the Doctor any questions you may have about this project before you decide whether you 
wish your child'ward to participate. 
2. 	If you decide, now or at arty other stage, that you no longer wish your chihrward to participate in the project, this will 
not in any way prejudice their future treatment. 
If you decide to take pan in this project, you will be given a copy of this form for your information. 
Form of Assent for use by Parent/Guardians° of Children under Ill undergoing investigations connected with Clinical Research 
(Please delete as appropriate) 
Name of Child 
Address 
of 
, being the Parent'Ottudian* of the above named Child, consent 
to my chi lirward'" undergoing the procedures described overleaf The nature, purpose and possible consequences have been fully 
explained tome. 
Signed (Parent'Guardian) 	  Date 	  
" WITNESS (See Note 1) 
I am satisfied that the procedures have been fully explained to the ParentGuardian* (name of Child) 
. The Parent/Guardian* has given consent in my presence. 
Name of Witness 
 
Position 
   
     
Address 
Signed..  Date 
   
     
44 4 ,1 	 :4414 4 L. 
NOTES 
1. "WTFNESS: Wherever possible, a witness should he present whilst the doctor/sponsor explains the procedures to the 
usitient. If this is impractical, complete the "Doctoes Deelanition' accordingly. In the case of a patient, the 
witness should not he a doctor if the sponsor is a doctor. If the witness is a nurse, he or she must be a ward 
sister or senior nurse in charge of the ward who is not undertaking a post-basic course. 
2. SAFE-KITTING OF THIS FORM: In the case of a patient, a copy of this signed form must be kept in the patients 
case-notes, and the sponsor should retain a copy for suhtequent examination if required by the Ethics 
Comm ittee. 
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Appendix XIII. Continued 
Royal Brompton & Harefield NIIS Trust & National Heart and Lung Institute 
voRAI 0 r coNsE NT  
PATIENT 
PAEDIATRIC 
TITLE OF PROJECT: 
Can saliva, scrum and urine samples be used to assess infection status in patients with cystic fibrosis? 
We invite you to consider allowing your child / ward to take part in a research project 
EXPLANATION OF PROJECT: 
We arc interested in exploring new methods to detect infection in children with respiratmy problems, specifically cystic fibrosis 
(CF). Your child does nos have this condition. or the infections commonly encountered in CF. and is being Mcluded in this study 
as a 'control' [-talent, one of a group with whom we can compare results. 
Many children, especially those in the younger age group cannot cough up sputum reliably. In these eases, we attempt to obtain 
cultures from the lower airway by cough swabs, which stay not be as reliable. An alternative approach would be to look for the 
body's response to infection as well as products from the bacteria This is possible because the body attempts to light infection by 
the production of proteins in the blood called antibodies. Such antibodies can be detected in the blood of CF children with chronic 
pseudomonas infection. hut repeated blood tests arc obviously undesirable. We arc looking at possible alternatives. 
Antibodies pass from the blood into other body fluids, such as saliva, and salivary testing has been found useful in certain 
infectious diseases such as measles. Nobody has looked at the possibility of testing saliva in patients with CF. In this study, we 
would like to see if we can measure antibodies to the common Cf.,  bacteria, such as Staphylococcus aureus rind Pseutlornonas. 
zeruginava in the saliva. If this was successful, we could monitor children at very regular intervals, and hopefully detect infection 
earlier than usual. 
The test is very• simple and completely pain free. We will insert a sterile sponge swab into the mouth and rub it gently in the 
groove between the gum and cheek. This is where the mouth fluid is most rich in antibodies. We will then freeze the sample and 
analyse it for antibody levels. If your child is having a blood test, we will compare the saliva with antibody levels in the blood. If 
not, we will compare the saliva with serum obtained from a previous or future blood test Id no blood is available, the other types 
of samples will still be useful to us). We would also like to look for bacterial products in urine as urine has been successfully used 
to detect infections in the lungs caused by other bacteria. We will ask your child to urinate into a sterile container and this will 
then be frozen and tested for bacterial products. 
We may ask your child to provide samples on several occasions if early results look prom isirro We will then compare the results 
of these tests with cultures performed as part of routine clinical care. such its cough swabs, sputum, where appropriate, 
bronchoseopic !wage. 
No human genetic analysis will be carried out on the samples, nor will they be tested for any unrelated infectious diseases such as 
hepatitis or HIV. The samples will be coded with a number known only to the investigators and the identity of your child will 
remain confidential, and will not be reported with results. In the early stages of this research project, the results are likely to he 
difficult to interpret, and we do not plan to feed hack your child's results to you. However, if this test is shown to be useful. and 
we discover anything which could affect your child's management, we will inform you. You are under no obligation to take part 
in this project. If you do agree, you may withdraw at any time without stating a reason. If you choose not take part, your child's 
clinical management will in no way be affected Thank you very much for your kindness in considering this project. Should you 
require any further information, please contact Dr Jane Davies at the Royal Brompton 11 gtital 020-7351-839g. 
Signed by the person in charge of the Project 
The Ethics Committee of the Royal Brisnptori & Harefield MIS Trust/National Heart & Lung, Institute has approved the above 
statement. 
Signed by the ChaimiantRepresentative of the Committee 
Date 
DOCTOWSDEcLARArtoN 
I have explained the project to the Participant as outlined above in the presmacerabsence* of a Witness** 
Signed   Date 	 Time 
* 	delete as appropriate 	 ** every effort should be made to give the explanation in the presence of a witness 
Protocol Reference Number: 02-274 Amended version I (06.06.05) 
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Appendix XIII. Continued 
NOTES FOR P.tRENTS7GUARDIANS 
Please do not hesitate to ask the Doctor any questions you may have about this project before you decide whether you 
wish your child ward to participate. 
If you decide, now or at nay other stage, that you no longer wish your child'ward to participate in the project, this will 
not in any way prejudice their future treatment. 
3. 	If you decide to take pan in this project, you will he given a copy of this form for your information. 
Form of Assent for use by Parent"Guardians° of Children under IS undergoing it-we:sties:that; connected with Clinical Research 
(Please delete as appropriate) 
Name of Child 
Address 
	 , being, the ParentiGirardian* of the above named Child, consent 
to my child:Ward* undergoing the procedures described overleaf The nature, purpose and possible consequences rewe been folly 
explained to me. 
Signed (Parent'Guardian) 
 
Date 
 
   
   
** "WITNFSS (Sec Note 1) 
  
I am satisfied that the procedures have been fully explained to the ParentfGuardian* (name of Child) 
. The Parent/Guardian°  has given consent in my presence. 
Name of Witness 
Address 
Signed 
	 Date 
'LULA- 	 . • • 
NOTES 
1. 	"WITNESS: Wherever possible, a witness should be present whilst the doctor/sponsor explains the procedures to the 
isitient. if this is impractical, complete the "Doctor's Declaration" accordingly. In the case of a patient, the 
witness should not he a doctor if the sponsor is a doctor. lf the witness is a nurse, he or she must be a ward 
sister or senior nurse in charge of the ward who is not undertaking a post-basic course. 
SAFE-KEEPING OF THIS FORM: In the case of a patient, a copy of this signed form must be kept in the patients 
casemotes, and the sponsor should retain n copy for subsequent examination if required by the Ethics 
Committee. 
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Appendix XIV. 	Instructions for CF patient taking multiple oral fluid samples 
CYSTIC FIBROSIS PATIENT ORAL FLUID SAMPLES 
Background 
We are carrying out a joint study between the Royal Brompton Hospital and the Health Protection Agency 
to develop new tests for detecting Pseudomonas infections in patients with cystic fibrosis. The new tests 
use oral fluid (saliva) and aim to be highly sensitive, potentially detecting any infection earlier than the 
current methods with sputum. 
For several months we have been collecting oral fluid samples from patients attending clinics, but we 
would now like to explore the possibility of patients taking their own samples at home and sending them in 
the post directly to the laboratory. 
You have been identified as someone who would be suitable for this study. If you are happy to take part, 
we require you to take ten samples over five days. You can take the samples yourself at home, using a 
simple, pain-free swab. The swabs can then be posted in the pre-paid packaging provided. 
Instructions for taking an oral swab 
1.Please try and take the first daily sample in the morning before eating or brushing your teeth. Before 
handling the swab, please ensure that your hands have been washed. Try to avoid touching the sponge 
end. 
2.The swab is designed to be used as a toothbrush. Following the instructions on the packet, rub the swab 
along the gum until the swab is thoroughly wet (about a minute). 
3. Place the wet swab back inside the clear tube and replace the lid securely. 
4.Please write the time and the date the swab has been taken on the label on the tube. 
5.The holder should then be placed in the green plastic tube and into the cardboard box provided. 
6.We would like you to take two swabs each day for five days. Please wait at least an hour before taking 
the second swab for the day, and again not directly after eating. Two swabs and their holders can be 
placed in each box. 
7.A pre-paid envelope has been enclosed so each box can be posted off straight away, once both swabs 
for that day have been taken. Please post the same day as you take the sample. 
We are always very grateful for patient participation in our studies. Research studies such as this cannot 
succeed without the generous input by patients. We hope you are happy to participate and should you 
have any questions about the study or how to take a swab, please do not hesitate to contact me on 0208 
327 7259. 
Any problems/questions, please do not hesitate to call Abbie Weisner : 0208 327 7259 
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Appendix XV. 	Recruited CF patients from Bristol Children's Hospital 
Patient ID DOB Sex Genotype 1st Isolate of P. aeruginosa Age 1st isolate (m) 
33 18-Mar-89 y AF508/AF508 29-Sep-00 138 
40 06-Jan-90 6 AF508/AF508 08-Feb-91 13 
43 28-Jul-90 c AF508/N1303K 24-Oct-91 15 
44 16-Sep-90 y AF508/AF508 15-Oct-92 25 
47 12-Apr-92 y AF508/AF508 15-May-00 97 
48 30-Jan-94 y AF508/AF508 12-Nov-98 58 
51 05-Apr-88 6 AF508/AF508 17-Oct-91 42 
166 27-Feb-89 y AF508/AF508 12-Sep-01 151 
171 11-Dec-93 y AF508/unknown 28-Oct-99 70 
189 23-Jun-86 6 AF508/AF508 25-Jan-90 43 
233 18-Jun-91 y AF508/e60x 13-Nov-98 89 
245 22-Jun-91 y AF508/AF508 01-Oct-01 124 
247 15-Apr-97 y AF508/AF508 17-Dec-98 20 
257 23-Oct-91 6 AF508/AF508 22-Sep-94 35 
267 24-Mar-88 c3` AF508/AF508 25-Apr-96 97 
276 05-Apr-89 6 AF508/G551D 23-Jan-97 93 
277 05-Jun-94 y AF508/AF508 31-Jan-02 91 
278 01-Dec-84 y AF508/unknown 29-Nov-90 71 
311 06-Aug-88 ? AF508/AF508 25-Jul-91 35 
312 04-Oct-96 y AF508/AF508 11-Nov-96 1 
314 30-Apr-91 6 AF508/6F508 12-Feb-96 58 
321 21-Dec-89 6 AF508/AF508 23-Jul-92 31 
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Appendix XVI. 	Antibody, lung function and sputum culture results from CF 
patients from Bristol Children's Hospital 
Patient ID LHCAI Ref Date Collected 1gM 	IgG FEV1 FVC Culture 
2496 01-May-96 1.52 	0.316 
2513 02-May-96 1.40 	0.293 106.00 109.00 N 
3078 16-Feb-99 0.82 	0.333 97.60 102.00 N 
3394 12-Jun-00 1.43 	0.390 91.00 92.00 N 
1st isolate 29-Sep-00 
3471 06-Oct-00 2.26 	0.185 95.70 108.00 I 
33 3577 23-Feb-01 2.55 	0.357 94.50 105.50 I 
4054 19-Apr-02 1.96 	0.360 101.00 109.00 I 
5446 31-Jan-03 0.56 	0.112 88.00 96.00 N 
5513 06-Mar-03 2.61 	0.444 103.00 178.00 C 
H04092504 20-Feb-04 3.34 	0.855 82.00 96.00 C 
H05082446 18-Feb-05 3.21 	1.004 76.00 88.00 C 
H06166532 13-Apr-06 3.43 	1.212 94.8 101.8 C 
1st mucoid isolate 31-Oct-06 
1st isolate 08-Feb-91 
1792 02-Apr-93 0.97 	0.512 N 
1815 18-May-93 0.85 	0.624 N 
1892 02-Sep-93 1.48 	0.526 N 
1914 28-Sep-93 0.88 	0.429 N 
2000 23-Mar-94 0.61 	0.479 I 
2191 26-Jan-95 1.79 	0.244 I 
2433 15-Feb-96 1.43 	1.257 I 
2700 28-Apr-97 1.49 	1.510 51 62 C 
08-Jan-98 42 54 C 
40 2924 10-Jun-98 1.78 	1.445 58 57 C 
3329 20-Feb-00 2.43 	1.214 32 37 C 
3968 01-Feb-02 3.27 	1.649 42 54 C 
4050 11-Apr-02 3.55 	1.833 47.7 57.5 C 
5089 22-Jul-02 2.98 	1.703 43 57 C 
1st mucoid isolate 09-Jan-03 
5452 04-Feb-03 2.47 	1.724 34 45 C 
H05422244 12-Oct-05 2.10 	2.049 41 59.2 C 
H06024433 05-Jan-06 3.33 	2.125 42 57 C 
H06096434 01-Mar-06 3.19 	1.972 41.7 57 C 
H064360293 20-Oct-06 2.99 	2.117 31.4 38.3 C 
1st isolate 24-Oct-91 
1858 12-Jul-93 1.31 0.571 
2081 09-Aug-94 1.13 0.410 54 57 
2284 28-Sep-95 1.50 0.513 70 74 
43 2534 2767 
15-Aug-96 
18-Sep-97 
2.46 
1.19 
0.876 
0.242 
2859 26-Feb-98 1.30 0.241 36 50 
2944 01-Jul-98 1.66 0.262 
3168 13-Jul-98 2.81 1.136 
3474 11-Oct-00 2.29 1.040 
N = P. aeruginosa not grown, I = P. aeruginosa identified once, C = P. aeruginosa isolated twice or more 
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Appendix XVI. Continued 
Patient ID LHCAI Ref Date Collected 1gM IgG FEV1 FVC Culture 
43 
4062 
5141 
5341 
5771 
H042709 
H05272500 
H06086412 
1st mucoid isolate 04-May-01 
29-Apr-02 	2.39 	1.244 
22-Aug-02 	3.69 	1.269 	42 
05-Dec-02 	2.52 	1.256 	39 
18-Jul-03 	2.45 	1.582 	48 
23-Jun-04 	3.29 	1.655 	48 
01-Jul-05 	3.49 	1.778 	35 
20-Feb-06 	3.77 	1.730 	49 
58 
54 
75 
65 
57 
75 
1714 24-Sep-92 2.00 0.157 
1st isolate 15-Oct-92 
1805 11-May-93 3.38 0.327 
1866 13-Jul-93 0.48 0.130 
1909 21-Sep-93 1.78 0.193 
2297 05-Oct-95 3.49 0.583 84 115 N 
2511 01-Jun-96 3.80 0.257 95 112 N 
2094 20-Sep-96 3.67 0.424 125 123 N 
2617 11-Oct-96 3.68 0.262 120 108 N 
2785 24-Oct-97 3.60 0.429 
3163 01-Jul-99 3.45 0.530 91 109 N 
44 3192 09-Aug-99 3.35 0.474 
3266 26-Oct-99 3.60 0.753 86 89 
3385 01-Jun-00 3.74 0.657 78 83 
3487 24-Oct-00 3.64 0.511 
3534 04-Jan-01 3.71 0.327 73.1 104 N 
3572 21-Feb-01 3.71 0.827 70.2 103 N 
3830 04-Oct-01 3.47 0.670 
4064 30-Apr-02 3.65 0.657 104 115 N 
5207 28-Sep-02 3.90 0.858 113 115 N 
5833 15-Aug-03 3.67 0.683 89 101.9 N 
H0436464 27-Aug-04 3.40 0.560 109 109 N 
H05340242 17-Aug-05 3.76 0.672 107 108 N 
2484 04-Apr-96 1.98 0.350 
2640 05-Dec-96 2.60 0.392 59 82 
2687 29-Mar-97 2.13 0.353 43 129 N 
2902 07-May-98 2.19 0.409 92 128 N 
3117 13-Apr-99 2.22 0.415 93 93 
1st isolate 15-May-00 
47 3375 3468 
15-May-00 
05-Oct-00 
3.75 
3.75 
0.731 
0.769 84 102 
3526 14-Dec-00 3.61 0.975 92 108 N 
3551 25-May-01 3.52 1.151 
3674 25-May-01 3.61 0.892 92 97 
3921 10-Jan-02 3.56 0.869 103 107 N 
4067 02-May-02 3.65 0.779 97 99 
5627 09-May-03 3.62 0.837 90 99 
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Appendix XVI. Continued 
Patient ID LHCAI Ref Date Collected 1gM IgG FEV FVC Culture 
5993 23-Oct-03 3.59 0.965 101 104 N 
H042221506 21-May-04 3.60 0.847 87 103 N 
47 H04430342 14-Oct-04 3.71 0.901 100 103 I 
H05184177 03-May-05 3.74 0.926 100 103 N 
H06224380 25-May-06 3.64 0.867 81.1 96.7 N 
2345 22-Nov-95 1.50 0.220 
2468 27-Mar-96 1.41 0.218 N 
2494 24-Apr-96 1.17 0.112 N 
2526 23-Jul-96 1.11 0.121 N 
2668 19-Feb-97 1.00 0.257 N 
1st isolate 12-Nov-98 
19-Aug-99 I 
48 3371 02-May-00 1.51 0.304 88 92 N 
3533 02-Jan-01 1.54 0.298 N 
4065 30-Apr-02 1.54 0.340 N 
5123 15-Aug-02 2.41 0.403 100 106 I 
5475 13-Feb-03 1.55 0.892 101 117 N 
H0422629 25-May-04 1.68 1.272 74 81 N 
H05056328 01-Feb-05 1.45 1.175 78 81 I 
1st mucoid isolate 3-Oct-06 
1st isolate 17-Oct-91 
1844 15-Jun-93 0.49 0.320 93 N 
2164 19-Dec-94 0.60 0.363 N 
2220 20-Apr-95 0.60 0.292 64 72 N 
2435 05-Mar-96 0.47 0.259 93 100 N 
2718 03-Jun-97 0.45 0.305 99 100 N 
2922 01-Jun-98 0.26 0.253 N 
51 3106 3497 
23-Mar-99 
14-Nov-00 
0.51 
1.17 
0.274 
0.809 
69 72 N 
N 
3662 18-May-01 0.50 0.452 N 
4071 03-May-02 0.73 0.486 66 69 N 
5007 27-May-02 0.51 0.406 78.1 80 N 
5439 27-Jan-03 0.57 0.430 I 
5639 16-May-03 0.65 0.397 51 60 I 
H03478220 19-Nov-03 0.63 0.410 45 57 N 
H041980177 04-May-04 0.63 0.356 51 73 N 
2038 02-Jun-94 2.04 0.285 N/A N/A N 
2196 02-Feb-95 2.39 0.348 N/A N/A N 
2481 12-Feb-95 2.63 0.478 N/A N/A 
2683 21-Mar-97 2.76 0.307 N/A N/A N 
166 2888 02-Apr-98 2.80 0.507 N/A N/A N 
3090 01-Mar-99 2.25 0.489 N/A N/A N 
3363 19-Apr-00 2.79 0.277 N/A N/A N 
3648 04-May-01 2.73 0.608 N/A N/A N 
1st isolate 12-Sep-01 
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Appendix XVI. Continued 
PID 	LHCAI Ref 
3905 
4012 
4043 
166 	5365 
5607 
H04194130 
H05112405 
2219 
2378 
2654 
2655 
2694 
3023 
3268 
3330 
3427 
3463 
171 	3521 
3748 
3896 
4023 
5070 
5284 
5852 
Date Collected 1gM IgG 
19-Dec-01 3.29 0.580 
15-Mar-02 3.03 0.538 
04-Apr-02 3.17 0.456 
19-Dec-02 3.27 0.676 
25-Apr-03 3.19 0.706 
30-Apr-04 3.29 0.624 
11-Mar-05 3.53 0.786  
20-Apr-95 0.96 0.342 
04-Jan-96 0.73 0.269 
28-Jan-97 1.02 0.166 
30-Jan-97 0.67 0.317 
13-Apr-97 1.04 0.213 
03-Nov-98 1.49 0.278 
1st isolate 26-Oct-99 
26-Oct-99 2.81 0.492 
24-Feb-00 2.92 0.576 
01-Aug-00 2.39 1.168 
03-Oct-00 2.89 0.738 
08-Dec-00 2.82 0.612 
31-Jul-01 
	
3.18 0.918 
07-Dec-01 3.42 0.680 
22-Mar-02 3.48 0.674 
10-Jul-02 2.81 1.328 
12-Nov-02 3.17 1.604 
21-Aug-03 3.16 1.574  
FEV FVC Culture 
N/A N/A I 
N/A N/A N 
N/A N/A N 
N/A N/A N 
N/A N/A N 
N/A N/A 
N/A N/A 
N 
N 
N 
N 
N 
N 
62 63 
61.7 71.2 	C 
C 
74 76 C 
58 82 C 
45 45 
N 
50.4 49.9 	N 
58 69 C 
1st mucoid isolate 16-Aug-05 
18-Oct-05 3.62 2.066 43.1 56.2 
08-Dec-05 3.85 2.260 44 52.8 
16-Mar-06 3.70 2.119 29.3 46.1 
03-Jan-07 3.69 2.432 31.4 46.4 
1st isolate 25-Jan-90 
14-Oct-92 0.85 0.956 100 100 
18-May-93 2.51 0.590 70 88 
03-Nov-93 3.02 1.288 
05-Apr-94 3.76 1.030 
09-Aug-94 3.32 1.162 
07-Oct-94 3.34 1.280 80 92 
28-Sep-95 3.49 1.286 66 93 
11-Feb-96 3.74 0.886 70 93 
11-Ju I-96 	 86 	120 
17-Feb-97 3.49 1.112 85 118 
14-May-97 3.76 1.081 74 105 
18-Sep-97 3.68 1.285 84 104 
15-May-98 3.59 1.189 71 94 
10-Jun-99 3.81 1.208 71 94 
H05426294 
H05500464 
H06122422 
H070140138 
1724 
1810 
1948 
2004 
2080 
2107 
189 	2285 
2523 
2662 
2717 
2766 
2909 
3137 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
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Appendix XVI. Continued 
Patient 
ID LHCAI Ref Date Collected IgM lgG FEV FVC Culture 
3165 03-Jul-99 3.73 1.179 78 99 C 
3345 23-Mar-00 3.63 1.421 90 106 C 
3751 03-Aug-01 3.63 1.778 102 128 C 
189 5109 03-Aug-02 3.21 0.584 
5796 01-Aug-03 3.02 1.966 
H05254304 20-Jun-05 3.37 2.016 76.8 97.9 C 
1st mucoid isolate 8-Aug-05 
1758 02-Feb-93 1.47 0.161 
1991 01-Mar-94 1.89 0.191 
2072 26-Jul-94 1.07 0.270 
2229 13-Jun-95 0.56 0.314 
2377 28-Dec-95 1.42 0.208 
2611 19-Sep-96 1.39 0.203 
2762 11-Sep-97 1.47 0.218 
2911 14-May-98 1.63 0.213 
2948 28-Jul-98 1.46 0.184 
1st isolate 13-Nov-98 
08-Jun-99 
233 3129 29-Apr-99 2.26 0.317 
3447 08-Apr-00 2.13 0.873 
08-Sep-00 78 78 C 
3517 05-Dec-00 2.57 0.345 
3676 30-May-01 1.70 0.906 81 86 N 
3736 20-Jul-01 2.37 0.714 82.9 92 
5050 26-Jun-02 2.53 0.634 80 82 N 
5701 18-Jun-03 3.48 0.935 78 89 N 
5917 19-Sep-03 2.84 0.964 84.4 89.6 N 
H04242201 04-Jun-04 3.14 0.845 66.2 74 N 
H05440388 27-Oct-05 3.43 1.229 75 83 N 
H06242218 06-Jun-06 3.74 1.248 85 93 N 
1869 15-Jul-93 0.23 0.104 
1935 15-Oct-93 2.22 0.184 
2076 02-Aug-94 1.95 0.491 
2253 24-Aug-95 2.50 0.487 
2530 01-Aug-96 1.95 0.561 
2741 10-Jul-97 3.20 0.429 
3155 22-Jun-99 2.86 0.417 77 78 N 
245 3194 10-Aug-99 0.29 0.141 
3454 23-Sep-00 3.71 0.438 89 100 N 
3698 19-Jun-01 2.93 0.753 79 89.5 N 
3794 07-Sep-01 3.46 0.824 79 90 N 
1st isolate 01-Oct-01 
4006 10-Mar-02 3.68 0.609 78 84 
5036 14-Jun-02 3.63 0.676 77 85 
5756 10-Jul-03 3.58 0.694 71 76 N 
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Appendix XVI. Continued 
Patient ID LHCAI Ref Date Collected IgM IgG FEV FVC Culture 
H04310453 22-Jul-04 3.58 0.813 63 65 N 
245 H05200179 12-May-05 3.76 0.721 47 54 N 
H05356630 29-Aug-05 3.76 0.667 50.2 65.2 N 
H070320081 10-Jan-07 3.62 0.851 63.6 92.4 N 
2972 20-Aug-98 0.89 0.416 
1st isolate 17-Dec-98 
3058 08-Jan-99 0.96 0.145 
3133 04-May-99 0.59 0.110 
3317 26-Jan-00 1.41 0.455 
3448 11-Sep-00 1.48 0.589 
247 3539 11-Jan-01 1.44 0.791 
3678 01-Jun-01 0.77 0.623 
4010 15-Mar-02 2.11 0.517 
5052 25-Jun-02 3.29 0.621 
5941 02-Oct-03 2.49 1.143 76 70.5 N 
H04280255 01-Jul-04 3.03 0.781 89 83 N 
H0521612 23-May-05 3.49 0.784 65 79 N 
1959 24-Nov-93 0.64 0.283 
1st isolate 22-Sep-94 
2109 21-Oct-94 0.53 0.448 
2160 08-Dec-94 0.60 0.284 
2379 11-Jan-96 2.81 1.133 
2660 13-Feb-97 1.52 0.405 66 68 C 
2730 11-Jun-97 1.48 0.697 69 75 C 
2782 16-Oct-97 1.14 1.145 69 138 C 
257 2842 06-Feb-98 1.46 1.004 91 102 C 
3464 02-Oct-00 1.79 0.729 74.5 87.6 I 
3538 11-Jan-01 0.97 0.938 80.2 89 
5076 05-Jul-02 2.74 1.048 
5776 22-Jul-03 1.79 1.142 
5965 10-Oct-03 1.23 1.204 
H04422220 07-Oct-04 1.49 1.581 75.5 88.7 N 
H05340243 18-Aug-05 1.52 1.900 63.3 76.8 I 
H064620141 14-Nov-06 1.43 2.139 71.8 84 C 
1964 07-Dec-93 1.77 0.561 
2044 07-Jun-94 1.73 0.557 
1st isolate 25-Apr-96 
2492 25-Apr-96 1.53 1.104 
2696 16-Apr-97 2.40 1.147 
267 16-Jun-98 71 81 
2755 22-Aug-98 3.00 2.175 56 84 C 
2932 02-Jul-98 2.46 1.351 88 106 C 
3098 09-Mar-99 3.14 1.300 66 73 
3051 01-Sep-99 2.42 1.305 
3396 12-Jun-00 2.55 1.723 
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Appendix XVI. Continued 
PID 	LHCAI Ref Date Collected IgM IgG FEV FVC Culture  
4031 	26-Mar-02 2.60 1.536 82 96 	N 
5060 	01-Jul-02 3.81 1.660 79 99 	I 
267 	5222 	08-Oct-02 0.79 1.993 	 I 
5619 	02-May-03 2.86 1.630 87 99 	N 
H04164766 14-Apr-04 3.51 1.714 79 106 N  
2036 	25-May-94 1.69 0.187 N/A N/A 	N 
2139 	23-Nov-94 2.26 0.328 N/A N/A 	N 
2248 	17-Aug-95 1.69 0.337 N/A N/A 	N 
2434 	05-Mar-96 2.12 0.347 N/A N/A 	N 
1st isolate 23-Jan-97 
3043 	01-Dec-98 2.29 0.407 N/A N/A 	N 
3095 	08-Mar-99 1.73 0.375 N/A N/A 	N 
3261 21-Oct-99 2.57 0.341 N/A N/A 	I 
276 	3395 	12-Jun-00 1.92 0.468 N/A N/A 	N 
5066 07-Jul-02 2.24 1.237 N/A N/A 	C 
5124 	15-Aug-02 2.79 1.441 N/A N/A 	C 
5430 	23-Jan-03 3.19 1.317 N/A N/A 	I 
5620 	02-May-03 3.41 1.423 N/A N/A C 
5968 	10-Oct-03 3.11 1.576 N/A N/A C 
H04042327 14-Jan-04 2.92 1.508 N/A N/A 	C 
H04268209 18-May-04 3.29 1.583 N/A NIA 	C 
H05178187 25-Apr-05 3.52 1.564 N/A N/A 	C  
2501 	08-May-96 1.99 0.132 	 N 
2722 	28-May-97 2.05 0.538 N 
2937 09-Jul-98 0.40 0.125 	 N 
3032 	17-Nov-98 2.05 0.614 N 
3307 	08-Jan-00 2.28 0.475 	 N 
3321 31-Jan-00 3.13 0.511 N 
3524 	12-Dec-00 3.22 0.857 	 N 
3558 	01-Feb-01 2.51 0.959 47 66.1 N 
3656 	08-May-01 2.54 0.857 62.9 58.6 	N 
277 	
1st isolate 31-Jan-02 
5023 	06-Jun-02 3.02 0.517 69 86 	C 
5051 	25-Jun-02 3.66 0.827 69 86 	C 
5218 	04-Oct-02 0.69 0.528 42.7 62.9 	I 
5626 	09-May-03 3.21 1.313 38 57 	N 
5707 	16-Jun-03 3.53 1.261 49.1 71 	N 
H04310454 22-Jul-04 3.23 1.370 51 71 	C 
H05266434 28-Jun-05 3.57 1.685 49.2 70.7 	C 
H06066252 06-Feb-06 3.41 1.812 31 45 	N 
H06242219 13-Jun-06 3.18 1.645 64 86 	N 
H06364493 06-Sep-06 3.12 1.396 46.6 69 	N  
1st isolate 29-Nov-90 
278 	1743 	24-Nov-92 2.06 0.756 	 C 
1835 	10-Jun-93 1.66 0.501 N 
328 
Appendix XVI. Continued 
Patient 1D LHCAI Ref Date Collected 1gM lgG FEV FVC Culture 
1961 07-Dec-93 1.78 0.706 
2167 29-Dec-94 2.25 0.909 
2489 19-Apr-96 1.87 1.491 
2669 21-Feb-97 2.24 1.925 
278 2765 2904 
18-Sep-97 
07-May-98 
2.24 
2.17 
2.231 
2.139 
64.7 
72 
71 
78 
3289 16-Nov-99 2.17 1.915 49 56 
3514 30-Nov-00 3.27 2.062 54.1 80 
4026 25-Mar-02 2.77 2.085 36 50.7 C 
5543 25-Mar-03 2.56 2.127 33 47 
1st isolate 25-Jul-91 
1772 24-Feb-93 0.87 0.247 
1817 15-May-93 1.53 0.305 
1823 27-May-93 1.61 0.171 
1893 02-Sep-93 2.07 0.204 
1969 09-Dec-93 2.48 0.188 
2110 12-Oct-94 2.21 0.299 
03-Jan-95 
09-Feb-95 
2266 04-Sep-95 1.76 0.413 
2332 08-Nov-95 2.41 0.539 
2691 03-Apr-97 2.54 0.759 
311 2889 3008 
04-Apr-98 
08-Oct-98 
2.92 
2.35 
0.642 
0.793 
09-Aug-99 53 51 
3249 08-Oct-99 2.83 0.663 57 60 C 
3450 15-Sep-00 3.50 0.575 63 66 C 
3459 25-Sep-00 2.92 1.386 63 66 C 
3537 07-Jan-01 2.43 1.262 
3780 25-Aug-01 0.58 0.185 81 92 N 
3857 26-Oct-01 2.45 1.245 84 95.6 N 
5071 09-Jul-02 3.43 0.607 83 94 N 
5201 21-Sep-02 1.51 1.320 83 96 N 
5352 14-Dec-02 3.02 1.089 68.6 81.5 C 
5888 05-Sep-03 3.68 1.444 68 75 C 
H04342118 13-Aug-04 3.63 1.853 82 90 C 
2634 01-Nov-96 0.25 0.580 
1st isolate 11-Nov-96 
2777 03-Oct-97 1.07 0.281 
2939 09-Jul-98 0.41 0.346 
312 3245 04-Oct-99 2.01 0.300 
3287 16-Nov-99 1.86 0.223 
3485 15-Sep-00 1.50 0.750 
3858 26-Oct-01 3.05 0.425 114 114 N 
08-Aug-02 97 90 
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Appendix XVI. Continued 
Patient 
ID LHCAI Ref Date Collected 1gM lgG FEV FVC Culture 
312 
5355 
5541 
5642 
5857 
H03492206 
H0440298 
H06030400 
H06038390 
13-Dec-02 
21-Mar-03 
18-May-03 
20-Aug-03 
28-Nov-03 
24-Sep-04 
18-Oct-05 
11-Jan-06 
18-Jan-06 
2.86 
2.33 
2.67 
2.82 
3.50 
3.71 
3.24 
3.50 
0.511 
0.547 
0.626 
0.722 
0.534 
0.659 
0.833 
0.855 
78 
99 
104 
96 
90 
86 
98.6 
95 
88 
118 
105 
100 
98 
95 
83 
96.1 
94 
90 
I 
I 
C 
314 
1731 
1786 
1787 
1992 
2033 
2131 
2304 
2471 
2483 
2704 
2921 
3121 
3381 
3410 
3606 
3690 
4085 
5257 
5387 
5628 
5804 
H05096443 
H06142428 
27-Oct-92 	0.34 	0.199 
10-Mar-93 	0.45 	0.138 
16-Mar-93 	0.80 	0.137 
08-Mar-94 	0.76 	0.211 
25-May-94 	0.54 	0.201 
10-Nov-94 	0.67 	0.245 
24-Oct-95 	0.85 	0.196 
1st isolate 12-Feb-96 
1.01 12-Feb-96 	0.300 
0.86 04-Apr-96 0.178 
0.99 01-May-97 	0.184 
0.54 04-Jun-98 0.293 
0.86 23-Apr-99 	0.300 
26-May-00 0.264 1.04 
1.24 07-Jul-00 	0.329 
16-Mar-01 0.310 1.14 
15-Jun-01 	0.512 0.53 
0.75 20-May-02 0.310 
25-Oct-02 	0.500 0.55 
0.72 07-Jan-03 0.294 
0.84 09-May-03 	0.307 
31-Jul-03 0.293 1.52 
1.82 01-Mar-05 	0.640 
1.79 04-Apr-06 0.527 
95 
95 
92 
94 
89 
76 
82.5 
71.5 
99 
103 
98 
101 
98 
86 
92.5 
93.8 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
321 
1718 
1796 
1952 
2064 
2093 
2346 
2635 
2677 
2874 
3305 
3519 
02-Jul-92 	1.58 	0.168 
1st isolate 23-Jul-92 
08-Mar-93 	1.86 	0.101 
09-Aug-93 	3.78 	0.402 
18-Jul-94 	3.00 	0.447 
15-Sep-94 	2.93 	0.357 
23-Nov-95 	2.82 	0.186 
21-Nov-96 	2.84 	0.247 
14-Mar-97 	2.55 	0.191 
12-May-98 	2.52 	0.952 
06-Jan-00 	3.26 	1.144 
08-Dec-00 	3.50 	0.768 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N 
I 
I 
N 
N 
N 
C 
C 
C 
C 
N 
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Appendix XVI. Continued 
Patient ID LHCAI Ref Date Collected IgM IgG FEV FVC Culture  
5297 	18-Nov-02 3.14 1.137 N/A N/A 	C 
	
321 	H04250168 10-Jun-04 3.61 1.511 N/A N/A 
	C 
H04456300 02-Nov-04 3.40 1.639 N/A N/A 	C 
H05022566 06-Jan-05 3.65 1.353 N/A N/A 	C 
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Appendix XVII. 	Serum samples results for six antigens tested LHCAI's in-house 
ELISA 
LHCAI Ref AK1401 01 06 07 012 C28 ELISA 3 
1714 <500 <500 <500 <500 <500 <500 0.956 
1718 500 <500 1000 500 <500 500 0.168 
1724 2000 500 1000 1000 500 1000 0.666 
1731 <500 <500 <500 <500 <500 <500 0.199 
1743 <500 <500 <500 <500 <500 <500 0.756 
1758 <500 <500 <500 <500 <500 <500 0.161 
1772 <500 <500 <500 <500 <500 <500 0.247 
1786 <500 <500 <500 <500 <500 <500 0.138 
1787 <500 <500 <500 <500 <500 <500 0.137 
1792 1000 1000 500 500 500 500 0.512 
1796 <500 <500 <500 <500 <500 <500 0.101 
1805 <500 <500 <500 <500 <500 <500 0.327 
1810 1000 1000 1000 1000 1000 1000 0.59 
1815 500 500 500 500 500 500 0.624 
1817 <500 <500 <500 <500 <500 <500 0.305 
1823 500 500 500 500 500 500 0.171 
1835 <500 <500 <500 <500 <500 <500 0.501 
1844 500 <500 <500 500 <500 500 0.32 
1858 <500 <500 <500 <500 <500 <500 0.571 
1866 <500 <500 <500 <500 <500 <500 0.13 
1869 <500 <500 <500 <500 <500 <500 0.104 
1892 1000 1000 500 1000 500 1000 0.526 
1893 <500 <500 <500 <500 <500 <500 0.204 
1909 <500 <500 <500 <500 <500 <500 0.193 
1914 1000 1000 500 1000 1000 1000 0.429 
1935 <500 <500 <500 <500 <500 <500 0.184 
1948 2000 2000 2000 2000 2000 2000 1.288 
1952 <500 <500 <500 <500 <500 <500 0.402 
1959 <500 <500 <500 500 500 500 0.283 
1961 500 500 <500 <500 <500 500 0.706 
1964 500 500 <500 500 500 500 0.561 
1969 <500 <500 <500 <500 <500 <500 0.188 
1991 <500 <500 500 <500 <500 <500 0.191 
1992 <500 <500 <500 <500 <500 500 0.211 
2000 1000 1000 500 1000 1000 1000 0.479 
2004 2000 2000 2000 2000 1000 500 1.03 
2033 <500 <500 <500 <500 <500 500 0.201 
2036 <500 <500 <500 <500 <500 <500 0.187 
2038 <500 <500 <500 <500 <500 <500 0.285 
2044 500 500 1000 1000 500 1000 0.557 
2064 <500 <500 <500 <500 <500 <500 0.447 
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Appendix XVII. Continued. 
LHCAI Ref AK1401 01 06 07 012 C28 ELISA 3 
2072 <500 <500 <500 500 <500 <500 0.27 
2076 <500 <500 <500 <500 <500 <500 0.491 
2080 2000 1000 2000 2000 1000 1000 1.162 
2081 500 500 500 1000 500 500 0.41 
2093 <500 <500 <500 <500 <500 <500 0.357 
2094 <500 <500 <500 <500 <500 <500 0.424 
2107 2000 2000 2000 2000 1000 1000 1.28 
2109 <500 <500 <500 <500 <500 <500 0.448 
2110 <500 <500 <500 <500 <500 <500 0.299 
2131 <500 <500 <500 <500 <500 <500 0.245 
2139 <500 <500 <500 <500 <500 <500 0.328 
2160 500 <500 <500 500 <500 <500 0.284 
2164 <500 <500 <500 <500 <500 <500 0.363 
2167 500 500 500 <500 <500 <500 0.909 
2191 2000 1000 2000 2000 2000 2000 0.244 
2196 <500 <500 <500 <500 <500 <500 0.348 
2219 <500 <500 <500 <500 <500 <500 0.342 
2220 <500 <500 <500 <500 <500 <500 0.292 
2229 <500 <500 <500 500 <500 <500 0.314 
2248 <500 <500 <500 <500 <500 <500 0.337 
2253 <500 <500 <500 <500 <500 <500 0.886 
2266 <500 <500 500 <500 <500 <500 0.413 
2284 500 <500 <500 1000 500 1000 0.513 
2285 4000 2000 8000 4000 2000 1000 1.286 
2297 <500 <500 <500 <500 <500 <500 0.583 
2304 <500 <500 <500 <500 <500 <500 0.196 
2332 500 500 1000 <500 <500 500 0.539 
2345 <500 <500 <500 <500 <500 <500 0.22 
2346 <500 <500 <500 <500 <500 <500 0.186 
2377 <500 <500 <500 500 <500 <500 0.208 
2378 <500 <500 <500 <500 <500 <500 0.269 
2379 2000 <500 1000 1000 500 <500 1.03 
2433 4000 4000 8000 4000 4000 2000 1.257 
2434 <500 <500 <500 <500 <500 <500 0.347 
2435 <500 <500 <500 <500 <500 <500 0.259 
2468 <500 <500 <500 <500 <500 <500 0.218 
2471 <500 <500 <500 <500 <500 <500 0.3 
2481 <500 <500 <500 <500 <500 <500 0.478 
2483 500 500 500 <500 <500 <500 0.178 
2484 <500 <500 <500 <500 <500 <500 0.35 
2489 4000 2000 2000 2000 2000 4000 1.491 
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2492 1000 500 1000 500 <500 500 1.094 
2494 <500 <500 <500 <500 <500 <500 0.112 
2496 <500 <500 1000 <500 <500 <500 0.316 
2501 <500 <500 <500 <500 <500 <500 0.132 
2511 <500 <500 1000 <500 <500 <500 0.257 
2513 <500 <500 500 <500 <500 <500 0.293 
2523 4000 2000 8000 2000 2000 1000 0.89 
2526 <500 <500 <500 <500 <500 500 0.121 
2530 <500 <500 500 <500 <500 <500 0.561 
2534 1000 500 2000 500 500 1000 0.876 
2611 <500 <500 <500 <500 <500 <500 0.203 
2617 <500 <500 1000 <500 <500 <500 0.262 
2634 500 500 500 <500 <500 500 0.58 
2635 <500 <500 <500 <500 <500 <500 0.247 
2640 <500 <500 <500 500 500 <500 0.392 
2654 <500 <500 <500 <500 <500 <500 0.166 
2655 <500 <500 <500 <500 <500 <500 0.317 
2660 1000 500 500 1000 500 500 0.405 
2662 2000 2000 8000 4000 1000 500 1.112 
2668 <500 <500 <500 <500 <500 <500 0.257 
2669 4000 4000 4000 4000 16000 2000 1.925 
2677 <500 <500 <500 <500 <500 <500 0.191 
2683 <500 <500 <500 <500 <500 <500 0.307 
2687 <500 <500 <500 <500 500 <500 0.353 
2691 500 2000 4000 2000 2000 500 0.759 
2694 <500 <500 <500 <500 <500 <500 0.213 
2696 500 <500 <500 <500 <500 500 1.147 
2700 2000 2000 8000 4000 2000 2000 1.51 
2704 <500 <500 <500 <500 <500 <500 0.184 
2717 4000 1000 4000 2000 2000 1000 1.081 
2718 500 <500 <500 500 <500 <500 0.305 
2722 <500 <500 <500 <500 <500 <500 0.538 
2730 1000 <500 1000 1000 1000 1000 0.697 
2741 500 500 500 500 500 <500 0.429 
2755 1000 2000 2000 <500 <500 500 2.175 
2762 <500 <500 <500 <500 <500 <500 0.218 
2765 4000 4000 8000 4000 4000 1000 2.231 
2766 2000 4000 2000 2000 500 500 1.285 
2767 1000 <500 <500 1000 <500 500 0.242 
2777 500 500 500 500 500 500 0.281 
2782 2000 1000 1000 1000 1000 1000 1.145 
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2785 500 <500 1000 <500 <500 500 0.429 
2842 2000 500 1000 1000 2000 1000 1.004 
2859 500 <500 <500 <500 1000 <500 0.241 
2874 500 <500 <500 <500 <500 <500 0.952 
2888 <500 <500 <500 500 1000 500 0.507 
2889 500 500 1000 1000 500 500 0.642 
2902 <500 <500 <500 <500 <500 <500 0.409 
2904 8000 4000 4000 8000 8000 2000 2.139 
2909 1000 2000 1000 1000 1000 500 1.189 
2911 500 500 500 500 <500 500 0.213 
2921 <500 <500 <500 <500 <500 <500 0.293 
2922 500 <500 <500 500 500 <500 0.253 
2924 4000 4000 4000 8000 4000 4000 1.445 
2932 2000 2000 2000 1000 1000 <500 1.351 
2937 <500 <500 <500 <500 <500 <500 0.125 
2939 <500 <500 <500 <500 <500 500 0.346 
2944 1000 500 500 2000 1000 500 0.262 
2948 <500 <500 <500 <500 <500 <500 0.184 
2972 <500 <500 <500 <500 <500 <500 0.416 
3008 1000 1000 1000 500 1000 1000 0.793 
3023 <500 <500 500 <500 <500 500 0.278 
3032 <500 <500 <500 <500 <500 500 0.614 
3043 <500 <500 <500 <500 <500 500 0.407 
3051 1000 1000 1000 1000 500 1000 1.305 
3058 <500 500 <500 <500 <500 500 0.145 
3078 <500 <500 500 <500 <500 <500 0.333 
3090 <500 <500 <500 <500 <500 <500 0.489 
3095 <500 <500 <500 <500 <500 <500 0.375 
3098 1000 500 500 1000 500 500 1.3 
3106 500 <500 <500 500 <500 <500 0.274 
3117 <500 <500 <500 500 <500 <500 0.415 
3121 <500 <500 500 500 <500 <500 0.3 
3129 <500 500 <500 <500 <500 <500 0.317 
3133 <500 <500 <500 <500 <500 500 0.11 
3137 4000 2000 4000 4000 1000 1000 1.208 
3155 <500 <500 500 <500 <500 500 0.417 
3163 <500 <500 <500 <500 <500 <500 0.53 
3165 4000 2000 4000 4000 2000 2000 1.179 
3168 2000 2000 1000 1000 2000 2000 1.116 
3192 <500 <500 500 <500 <500 <500 0.474 
3194 <500 <500 <500 <500 <500 500 0.141 
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3245 <500 <500 500 <500 <500 500 0.3 
3249 500 500 1000 500 <500 500 0.663 
3261 <500 <500 <500 <500 <500 <500 0.341 
3266 <500 <500 1000 <500 <500 <500 0.753 
3268 500 <500 500 500 500 500 0.492 
3287 <500 <500 500 <500 <500 500 0.223 
3289 2000 4000 4000 8000 2000 2000 1.915 
3305 2000 2000 2000 4000 4000 2000 1.044 
3307 <500 <500 500 <500 <500 500 0.475 
3317 <500 <500 <500 <500 <500 500 0.455 
3321 500 <500 500 <500 500 500 0.511 
3329 4000 4000 4000 4000 4000 4000 1.214 
3330 500 500 1000 500 <500 500 0.576 
3345 1000 1000 4000 2000 500 500 1.421 
3363 <500 500 <500 <500 500 500 0.277 
3371 <500 <500 <500 <500 <500 <500 0.304 
3375 500 <500 500 <500 500 <500 0.731 
3381 <500 <500 500 <500 <500 <500 0.264 
3385 500 500 1000 500 500 500 0.657 
3394 <500 <500 <500 <500 <500 500 0.39 
3395 <500 <500 <500 <500 <500 <500 0.468 
3396 1000 1000 1000 500 1000 500 1.723 
3410 <500 <500 <500 <500 <500 <500 0.329 
3427 2000 1000 1000 1000 1000 1000 1.168 
3447 <500 2000 1000 500 <500 500 0.873 
3448 <500 <500 <500 <500 <500 500 0.589 
3450 500 500 1000 500 500 500 0.575 
3454 <500 <500 <500 <500 <500 <500 0.438 
3459 500 500 1000 500 500 500 1.386 
3463 1000 500 2000 1000 500 1000 0.738 
3464 500 <500 500 500 1000 500 0.729 
3468 1000 <500 1000 1000 500 500 0.769 
3471 <500 <500 500 <500 <500 <500 0.185 
3474 2000 2000 1000 1000 2000 2000 1.04 
3485 <500 <500 500 500 <500 <500 0.75 
3487 500 500 1000 <500 <500 500 0.511 
3497 500 <500 <500 <500 <500 <500 0.809 
3514 4000 4000 4000 8000 4000 4000 2.062 
3517 <500 1000 1000 <500 <500 500 0.345 
3519 1000 500 1000 2000 500 500 0.768 
3521 1000 500 2000 2000 <500 1000 0.612 
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3524 500 500 500 500 500 500 0.857 
3526 4000 1000 1000 2000 1000 500 0.974 
3533 <500 <500 <500 <500 <500 500 0.298 
3534 <500 <500 1000 <500 <500 <500 0.327 
3537 500 <500 500 500 500 500 1.262 
3538 500 500 500 500 <500 500 0.938 
3539 500 <500 <500 <500 <500 500 0.791 
3551 4000 1000 1000 2000 1000 500 1.151 
3558 500 500 500 500 500 500 0.959 
3572 <500 <500 1000 <500 <500 <500 0.827 
3577 <500 <500 <500 <500 <500 <500 0.357 
3606 <500 <500 <500 <500 <500 <500 0.31 
3648 <500 <500 <500 <500 <500 500 0.608 
3656 <500 <500 500 <500 <500 <500 0.857 
3662 <500 <500 <500 <500 <500 <500 0.452 
3674 1000 500 1000 2000 1000 500 1.174 
3676 500 1000 2000 500 <500 500 0.906 
3678 <500 <500 <500 <500 <500 <500 0.623 
3690 <500 <500 <500 <500 <500 <500 0.512 
3698 500 <500 500 <500 <500 500 0.753 
3736 500 500 1000 500 <500 500 0.714 
3748 1000 500 1000 2000 1000 500 0.918 
3751 2000 2000 2000 2000 1000 2000 1.778 
3780 500 1000 2000 2000 2000 1000 0.185 
3794 <500 <500 <500 <500 <500 500 0.824 
3830 500 <500 500 500 <500 <500 0.67 
3857 1000 1000 2000 1000 1000 1000 1.245 
3858 <500 <500 <500 <500 500 <500 0.457 
3896 500 500 500 1000 500 500 0.68 
3905 500 <500 <500 <500 <500 500 0.483 
3921 1000 500 1000 1000 1000 1000 0.892 
3968 4000 2000 8000 2000 2000 8000 1.392 
4006 500 <500 <500 <500 <500 <500 0.573 
4010 <500 <500 <500 <500 <500 500 0.533 
4012 500 <500 <500 <500 <500 500 0.466 
4023 1000 500 1000 1000 500 500 0.507 
4026 8000 2000 4000 500 1000 8000 2.01 
4031 16000 8000 8000 16000 8000 4000 1.536 
4043 500 <500 <500 <500 <500 500 0.454 
4050 4000 2000 4000 4000 2000 4000 1.951 
4054 <500 <500 <500 <500 <500 <500 0.36 
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4062 2000 2000 4000 8000 8000 2000 1.244 
4064 <500 <500 <500 <500 <500 <500 0.618 
4065 <500 <500 <500 <500 <500 <500 0.322 
4067 1000 1000 1000 2000 2000 1000 0.779 
4071 <500 <500 <500 <500 <500 <500 0.486 
4085 <500 <500 <500 <500 <500 <500 0.31 
5007 <500 <500 <500 <500 <500 <500 0.406 
5023 500 500 500 500 500 500 0.517 
5036 500 500 2000 <500 <500 500 0.676 
5050 500 1000 <500 500 <500 1000 0.634 
5051 500 2000 500 500 500 500 0.827 
5052 <500 <500 <500 <500 <500 500 0.621 
5060 1000 1000 2000 500 1000 1000 1.66 
5066 4000 2000 16000 1000 2000 4000 1.237 
5070 2000 1000 2000 2000 2000 2000 1.328 
5071 1000 1000 2000 2000 2000 2000 0.607 
5076 <500 <500 <500 <500 <500 <500 0.436 
5089 1000 4000 4000 8000 2000 2000 1.703 
5109 1000 1000 1000 2000 1000 2000 0.584 
5123 <500 <500 <500 <500 <500 <500 0.403 
5124 4000 2000 8000 2000 2000 4000 1.441 
5141 2000 4000 1000 1000 8000 2000 1.269 
5201 2000 1000 1000 2000 4000 2000 1.32 
5207 <500 <500 <500 <500 <500 <500 0.858 
5218 500 500 <500 <500 <500 <500 0.528 
5222 8000 4000 16000 4000 4000 16000 1.933 
5257 <500 <500 <500 <500 <500 <500 0.5 
5284 2000 1000 1000 2000 2000 1000 1.604 
5297 1000 1000 1000 2000 1000 1000 1.137 
5341 2000 2000 2000 2000 2000 2000 1.256 
5352 2000 1000 2000 2000 4000 2000 1.089 
5355 500 500 500 500 500 <500 0.511 
5365 <500 <500 <500 500 <500 500 0.676 
5387 <500 <500 <500 <500 <500 <500 0.294 
5430 16000 16000 16000 16000 16000 4000 1.317 
5439 <500 <500 <500 <500 <500 <500 0.43 
5446 <500 500 500 500 <500 <500 0.112 
5452 8000 4000 8000 8000 4000 2000 1.724 
5475 <500 500 <500 <500 500 500 0.892 
5513 <500 <500 <500 <500 <500 <500 0.444 
5541 500 500 500 500 500 500 0.547 
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5543 16000 8000 8000 8000 4000 8000 2.127 
5607 <500 <500 <500 <500 <500 <500 0.706 
5619 8000 4000 4000 8000 4000 2000 1.63 
5620 16000 8000 8000 16000 8000 2000 1.423 
5626 500 2000 500 2000 500 1000 1.313 
5627 500 500 1000 1000 500 500 0.837 
5628 <500 <500 <500 <500 <500 500 0.307 
5639 <500 500 <500 500 500 <500 0.397 
5642 2000 1000 1000 2000 2000 1000 0.626 
5701 500 2000 1000 2000 2000 1000 0.935 
5707 1000 2000 1000 <500 500 500 1.261 
5756 500 500 2000 1000 2000 2000 0.694 
5771 4000 4000 8000 8000 4000 4000 1.582 
5776 <500 <500 500 <500 500 500 1.048 
5796 8000 4000 4000 4000 4000 4000 1.966 
5804 <500 <500 <500 <500 500 500 0.293 
5833 <500 <500 <500 <500 <500 <500 0.683 
5852 2000 500 2000 2000 2000 1000 1.574 
5857 1000 500 1000 1000 1000 500 0.722 
5888 2000 1000 4000 4000 2000 2000 1.444 
5917 500 500 500 <500 <500 2000 0.964 
5941 500 <500 500 <500 <500 4000 1.043 
5965 500 <500 <500 500 <500 <500 1.204 
5968 16000 8000 16000 16000 16000 2000 1.576 
5993 1000 <500 500 1000 500 500 0.965 
H03478220 <500 <500 <500 <500 <500 500 0.41 
H03492206 1000 500 2000 2000 2000 1000 0.534 
H04042327 8000 2000 8000 8000 4000 1000 1.508 
H04092504 <500 500 500 500 <500 <500 0.855 
H04164766 16000 2000 4000 8000 8000 1000 1.714 
H04194130 <500 <500 500 500 <500 <500 0.624 
H041980177 <500 <500 <500 <500 <500 <500 0.356 
H042221506 1000 2000 4000 4000 4000 1000 0.847 
H0422629 500 <500 500 500 <500 <500 1.272 
H04242201 500 500 500 <500 <500 1000 0.845 
H04250168 1000 1000 500 1000 500 1000 1.511 
H04268209 8000 4000 8000 8000 8000 4000 1.583 
H042709 8000 4000 4000 8000 4000 4000 1.655 
H04280255 <500 <500 <500 <500 <500 500 0.781 
H04310453 500 500 2000 500 500 1000 0.813 
H04310454 500 1000 500 500 500 500 1.37 
339 
Appendix XVII. Continued. 
LHCA1Ref AK1401 01 06 07 012 C28 ELISA 3 
H04342118 2000 1000 2000 2000 2000 2000 1.853 
H0436464 <500 <500 <500 500 <500 <500 0.56 
H0440298 1000 500 500 500 1000 500 0.659 
H04422220 500 500 500 500 500 500 1.581 
H04430342 1000 1000 1000 1000 1000 1000 0.901 
H04456300 500 500 500 500 <500 500 1.639 
1105022566 500 500 500 500 500 500 1.353 
H05056328 <500 <500 <500 <500 <500 <500 1.175 
H05082446 500 500 500 500 500 500 1.004 
H05096443 <500 <500 500 500 <500 <500 0.64 
H05112405 <500 500 <500 500 500 500 0.786 
H05178187 8000 4000 8000 8000 4000 8000 1.564 
H05184177 500 500 1000 1000 500 500 0.926 
H05200179 <500 <500 <500 500 <500 <500 0.721 
H0521612 <500 <500 <500 <500 <500 <500 0.784 
H05254304 8000 4000 4000 4000 4000 4000 2.016 
H05266434 4000 4000 1000 4000 4000 4000 1.685 
H05272500 8000 8000 4000 8000 4000 2000 1.778 
H05340242 <500 <500 <500 <500 <500 <500 0.672 
H05340243 2000 2000 2000 2000 2000 1000 1.9 
H05356630 <500 <500 <500 <500 <500 <500 0.667 
H05422244 8000 8000 8000 8000 16000 8000 2.049 
H05426294 16000 16000 8000 16000 16000 8000 2.066 
H05440388 <500 <500 <500 <500 <500 500 1.229 
H05500464 16000 8000 8000 16000 8000 8000 2.26 
H06024433 8000 4000 8000 8000 4000 8000 2.125 
H06030400 1000 500 1000 1000 <500 <500 0.833 
H06038390 1000 1000 1000 500 1000 1000 0.855 
H06066252 500 500 500 500 500 500 1.812 
H06086412 4000 4000 2000 2000 4000 2000 1.73 
H06096434 8000 4000 4000 4000 8000 4000 1.972 
H06122422 8000 4000 4000 4000 4000 8000 2.119 
H06142428 500 <500 500 500 <500 <500 0.527 
H06166532 1000 1000 500 500 <500 500 1.212 
H06224380 2000 1000 1000 2000 2000 1000 0.867 
H06242218 500 500 <500 <500 <500 500 1.248 
H06242219 500 500 500 500 500 500 1.645 
H06364493 1000 1000 500 1000 1000 500 1.396 
H064360293 4000 2000 2000 4000 4000 4000 2.117 
H064620141 2000 1000 2000 2000 1000 1000 2.139 
H070140138 16000 16000 8000 16000 16000 16000 2.432 
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H070320081 500 500 500 500 <500 500 0.851 
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Cystic fibrosis (CF) patients who are chronically infected with Pseudomonas aeruginosa make 
serum antibodies to bacterial surface LPS as well as other pseudomonas antigens. This study 
investigated the feasibility of using oral fluid samples for the detection of pseudomonas antibodies 
in CF patients and compared these results with corresponding serum antibodies. Most strains of 
P. aeruginosa produce two forms of LPS molecule, termed A-band (described as a common 
antigen) and B-band (0-serotype-specific antigen), apparently bound to a common core 
oligosaccharide moiety. A-band LPS was demonstrated in 45 out of 49 clinical isolates of 
P. aeruginosa by SDS-PAGE and immunoblotting with a specific antibody. Oral fluids were 
collected from 17 adult CF patients, all of whom were sputum culture positive for P. aeruginosa 
(13 also provided serum samples), 11 primary ciliary dyskinesia (PCD) patients and 37 healthy 
volunteers. Antibodies to A-band LPS were detected by immunoblotting in all of the CF patients' 
oral fluids but 10 of the volunteer samples gave weak reactions with immunoblotting. Six of 
the PCD patients gave a weak reaction with A-hand antibodies and only one demonstrated 
antibodies to core LPS. In a quantitative ELISA, 15 of the 17 CF patients' oral fluids were 
shown to contain antibodies to A-band LPS, whilst none of the volunteer samples contained 
antibodies to A-band LPS. All serum samples from the CF patients were positive by both 
methods. Thus this is a sensitive procedure for the detection of antibodies to A-band LPS 
of P. aeruginosa in oral fluid and serum from patients with CF. 
INTRODUCTION 
Pseudomonas acruginosa causes chronic lung infections in 
approximately 80% of patients with cystic fibrosis (CF) 
and this is associated with a dramatic decline in the 
patients' clinical status (Doring et al., 2000). It is widely 
agreed that treatment early after initial isolation has been 
shown both to eradicate the organism and to delay the 
onset of chronic infection (Frederiksen et liL, 1997). 
Patients who are chronically infected with P. neruginasa 
produce serum antibodies to the organism, but there is 
little consensus regarding the clinical value of their 
measurement, except in those patients where the initial 
appearance of antibodies predates culture positivity (West 
ct arl., 2(K)2). This is due in part to poor standardization of 
protocols and assays among different centres and some 
Abbreviations: CF, cystic fibrosis; HP, high positive; PCD, primary chin 
dyskine6a 
have relatively poor positive and negative predictive values. 
Oral fluid samples offer an attractive serological alternative 
approach to invasive sample collection and are increasingly 
being used to provide evidence of infections caused by a 
wide variety of agents (McKie et a)., 2002), hut not, as yet, 
for P. aeruginosa. The samples are simple to obtain, even in 
young children, who may not o:pectorate sputum. 
A number of techniques for the detection of serum anti-
bodies to P. aeruginosa have been reported utilizing a wide 
range of antigens including outer-membrane proteins, 
alginate, enzymes and LPS (Brett et al., 1986; Diving & 
Hoihy, 1983; Fomsgaard et at, 1988; Likavcanova 
Lagace, 1992; Rehm et al., 1994). LPS consists of three 
domains: a hydrophobic, membrane-anchoring lipid A 
moiety, a conserved oligosaccharide core region and a side 
chain of repeating oligosaccharide units. In I'. arrusitosa, 
two forms of LPS determined by the side chain are recogn-
ized: (I) a homogeneous 'A-band' consisting of trisaccharide 
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repeating units of D-rhamnose and (ii) a heterogeneous, 
high-molecular-mass, serotype-specific 'B-hand' (Arsenault 
et al., 1991; Kochamra er al., 1988; Lam et aL, 1989). During 
pulmonary disease progression, P. aeruginosa undergoes 
phenotypic changes, including changes in LI'S expression, 
with gradual repression of expression of B-hand LPS 
(Hancock et aL, 1983). Along with alginate, the major 
surface antigen of these serotype-deficient strains is A-
hand LPS, and this is reported to he common amongst 
strains of the species (Govan & Deretic, 1996; Hatano 
et al., 1993; Lam ct al, 1989). 
We report here the detection of antibodies to A-band LPS 
of P. aeruginosa in oral fluids and serum from patients with 
CF and comparison of the results with those from oral 
fluids from healthy volunteers and a clinical control group. 
Approval for patients' samples was given by the Ethics 
Committee of the Royal Brompton & Harefield NHS 
Trust/National Heart & Lung Institute, with. all subjects 
giving informed consent. 
METHODS 
Bacterial strains. Forty-nine isolates of P. aeruginosa, each from 
different CF patients from a number of CF clinics, were investigated 
for the presence of A-hand LPS. Strains of Burkholderia eeparia geno-
movars 11.111a and 11th, Stenotrophomonas maltophilia. Achromobacter 
xylosoxiclans, Salmonella Typhi, Salmonella Typhimurium, Salmonella 
Enteriditis, Eselterichia coli R-12, Vibrio cholerae and Haemophilia 
infittettme were selected from culture collections at the Centre for 
Infections, 11PA, Colindale, London, UK. P. acruginesa strain 
A1:1401. rich in A-hand I.PS, was a gift from Dr Andrew Kropinski 
Lipopolysaccharides. LPS for visualization by SDS PAGE and silver 
staining was prepared by digesting whole bacteria with proteinase K 
(Chart et aL, 2003). For immunobloning, outer•membrane prepara-
tions were used (Chart et al, 2002). LI'S for coating ELISA plates was 
purified from outer membranes using hot phenol (Chart et aL, 2002). 
Sera. Pools of sera from CF patients with high pseudorrionas 
.lysate antibody titres, determined by an in-house whole-cell ELISA, 
were designated high positive (11P) and comprised sera from a 
minimum of six patients. Six control serum samples were obtained 
from healthy non-CF subjects. Rabbit antibodies were raised to 1.1'S 
prepared from P. aeruginosa strain AK 101, under Home Office 
Licence number 70(5503. using 2 ml Saffan (56e:ring-Plough) 
injected intravenously as an anaesthetic. Briefly, a New Zealand 
White rabbit was challenged with 50 pg purified LPS in Freund's 
incomplete adjuvant at multiple sites across the back. Three weeks 
later. the animal was boosted intramuscularly with 50 pg purified LPS 
in PBS. Seroconversion was confirmed by a test bleed 10 days later 
and immunoblotting with a panel of P. aeruginosa outer-membrane 
preparations, 
SOS-PAGE and Immunoblotting.SDS-PACE was performed using 
an Atto mini-gel apparatus (Genetic Research Instruments). Prepara-
tions containing either 83 pg digested cell mass or 10 pg outer-
membrane protein were loaded into wells of SDS-polyacryksmidc gels 
(4.5 % stacking gel and 12.5% separation gel) and electrophoresis was 
performed (50 mA) for 30 min (Chart et al., 2003). Gels were stained 
with silver (Tsai & Frasch, 1982) to visualize LPS profiles and 
photographed, or, alternatively, profiles were transferred to nitro-
cellulose paper by immunoblotting. 
Following electrophoresis, nitrocellulose paper blots were 'blocked' 
with 3% skimmed milk in PBS for S min at room temperature. Sera 
(5 pl rabbit scrum. 30 pl human scrum) and oral fluid samples were 
added directly to the initial blocking solution and antibodies were 
allowed to react with the immunoblots for 15 h at room temperature 
before washing in 0.05% Tween 20/PBS three times for 15 min cash. 
Profiles were reacted with 5 pl per lane of goat anti-human or goat 
anti-rabbit polyvalent 1g conjugated to alkaline phosphataw for a 
further 1.5 hat room temperature. The blots were washed three times 
for IS min each with 0.05% Tween 20/PBS before developing with 
immunoblotting developing solution [6 ml 0.15 M NtgC1, 2 ml 0.5 NI 
Tris/11C1 (p11 9.5), 2 ml 0.5 NI NaCI. 45 pl nitro blue tetrazolium. 
35 µI 5-promo-4-ehloro- 3-indoly1 phosphate]. 
Patients. Seventeen CF patients (four females, group mean age 28.8 
years: and 13 malo, group mean age 30.4 years) were recruited and all 
were sputum culture positive for P. aentginosa for at least 6 months at 
the time of the study. All 17 volunteered oral fluid samples and 13 
volunteered sera. Three of the scrum samples were taken on the same 
day as oral fluid was donated. but the mean number of days between 
collection of the two samples was 114 days (e=97. n=13), with a 
maximum of 287 days. Eleven patients with primary ciliary dyskineda 
(PCD) (eight females, group mean age 113 years; and three males, 
group mean age 6.1 years) volunteered oral fluid samples. Nine of 
the patients had never yielded P. aeruginosa from sputum and the 
remainder had not grown this organism for at least 3 years. 
Volunteers. Samples of control oral fluid were obtained from 37 
members of laboratory- staff and their families (21 females. group 
mean age 27.8 years; and t6 males. group mean age 24.1 years). All 
were considered healthy. with no signs of respiratory infection. 
Oral fluid sampling. Oral fluid was obtained using Oracol test kits 
(Malvern Medical Developments). On arrival at the laboratory, the 
swabs were maintained at room temperature and processed within 
3 days. Sponges were detached from the collection swabs, placed in a 
5 mi syringe barrel and the fluid was pressed front the sponge. For 
each sample, 100 pl was set aside for ['LISA and the remainder was 
tested by immunoblot. 
ELISA. ELSA plates (Greiner Laboratories) were coated with 1 pg 
LPS per well in 100 pl coating buffer (1.5 mS1 74a2C.0„ 34.5 mM 
Nal1CO3,4 'C overnight) and washed in 0,05% Tweat 20 PBS before 
blocking with 200 pl 1 9i, BSA/PBS. Samples were added to LPS-
coated wells and to duplicate wells that had been blocked with BSA 
only. Oral flu ids (5014 per well) or sera diluted 1 500 in PBS (100 pl . 
per well) were added and antibody binding was detected with goat 
antihuman polyvalent 1g conjugated to alkaline phosphatase diluted 
: 1000 in PITS (100 pl per well). Antibodies conjugated to alkaline 
phosphatasc were detected by adding 200 pl  diethanolamine buffer 
(1 M diethanolamine, 2 wild mgo, p11 9.6) containing 1 mg p-
nitrophenol phosphate m1-1. The resultant colour was quantified by 
measuring A405. Sample values >0.9 A105 after 30 min were con- 
sidered positive (cut-off calculated as mean 	s; c of volunteer oral 
fluid samples and human negative control sera). 
Statistical analyses. Student's r-tests were performed to compare 
the ELISA results from the CF and control populations for oral fluid 
and serum samples. 
RESULTS AND DISCUSSION 
SDS-PAGE and silver staining of whole-cell digests of the 
0-serotype strains demonstrated long-chain LPS in most 
of the strains. To visualize A-hand LPS, profiles were 
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Fig. 1. Antibody-antigen reactions with outer-membrane pre-
parations of P. aeruginosa strain AK1401 using CF patient sera 
(a), CF patient oral fluid (b) and volunteer oral fluid (c). 
immunoblotted with the hyped mmune rabbit antiserum to 
strain AK14OI, which expresses A-band LPS. Fifteen of the 
20 0-serotype strains (01-06, 09-011, 013 and 016-
020) were found to express A-band LPS, as were 45 out of 
99 clinical strains. These results confirmed that the major-
ity of P. aeruginosa clinical strains produce A-band LPS 
and have the potential to elicit an A-hand :sped tic antibody 
response in animals (Lain et A, 1989). Interestingly, the 
type strains listed above also reacted with the control HP 
serum pool, suggesting that the main serum LPS antibody 
response in patients with CF was to the A-hand. None of 
the 0-serotype strains reacted with the healthy human 
control sera; similarly, the pooled HP CF sera failed to 
react with the other bacterial species tested. 
Each of the 13 CF patient serum samples was found to 
contain antibodies to A-band and core LPS by immuno-
blotting (Fig. la) and ELISA (Fig. 2) and all 17 CF oral 
fluid samples were shown to contain antibodies to A-band 
LPS by immunoblotting (Fig. lb). Fifteen of the 17 oral 
fluids also contained antibodies to A-band LPS by ELISA, 
giving the ELISA a sensitivity of 1.00 with serum samples 
and 0.88 with oral fluids. Oral fluid samples from the PCD 
patients were only tested by immunoblotting with A-band 
LPS and six of them gave weak antibody reactions with A-
band. Moreover, one of these subjects expressed antibody 
to the core LPS of AK 1401, despite not having been culture 
positive for the past 3 years. 
Ten of the 37 healthy volunteers had low levels of oral fluid 
antibodies binding to A-band LPS, as illustrated by faint 
bands in immunoblots (Fig. lc), and one of the volunteers 
(a Pseodomonns-laboratory worker) had oral fluid anti-
bodies to A-band LPS, as indicated by a strong immuno-
blot reaction, which included antibodies to cure LPS. Oral 
fluids from eight healthy volunteers were tested by ELISA 
(Fig. 2) and seven of these samples (including two that had 
demonstrated faint bands by immunoblot) were shown 
not to contain antibodies to A-band LPS. The outlier was 
revealed to he due to non-specific antibodies binding to 
BSA, as this sample was immunoblot negative for A-band 
LPS. Statistical analyses comparing the ELISA results from 
the CF patients and the healthy volunteers showed that 
there was a significant difference between the two popula-
tions for both the serum (P=0.0001) and oral fluid (P= 
0.11)01) samples. 
The observation that antibodies from oral fluid may bind 
non-specifically to RSA illustrates the importance of ensur-
ing that immunoassays include a BSA control to avoid 
false-positive results. The salivary carriage rate of P. aerugi-
nosa in hospital patients and normal controls has been 
reported as appioximately 5% (Botzenhart et al., 1985), 
hut it is not known if etch colonization leads to stimula-
don of circulating antibodies. Antibodies to several 0-
serotype LPS antigens have been detected in human sera 
Fig. 2. Summary of A-band LPS antibody 
levels in CF patient and healthy volunteer 
samples as determined by ELISA. U, CF oral 
fluid; CD, healthy volunteer oral fluid; A., CF 
sera; G, healthy volunteer sera; • , pooled MP 
CF sera. 
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P. aeroginoss serum and oral fluid andbcdies 
(Grzybowski et at, 1989), but the levels in the general 
population, specifically to A-band LPS, remain unknown. 
As P. aeraginosa is ubiquitous, it seems likely that healthy 
subjects are ccposed to environmental strains and mount 
an antibody response. 
Antibodies to the core LPS moiety of strain AK1401 were 
demonstrated in all 17 CF patients, one PCD patient (who 
had grown P. acruginosa from sputum 3 years previously) 
and one of the volunteers, who had had occupational expo-
sure to 1'. acruginosa in the laboratory fur several years. in 
our experience, the appearance of anti-core [PS antibodies 
most often suggests prolonged infection (unpublished 
results) and .xplains, in part, the immunohlot reactions 
presented here. 
It was observed during the course of this study that the oral 
fluids collected from patients with CF were of a 
significantly lower volume than samples collected from 
either control group. This may suggest that the oral fluids 
of CF patients are more concentrated or that they are as 
concentrated as controls but contain fewer antibodies. We 
are currently developing a quantitative assay to explore this 
observation. 
The immunoblotting data presented were obtained with a 
polyvalent anti-human antibody. Further blots (two per 1g 
class) were performed employing paired oral fluid and sem 
to investigate the class of the A-band [PS-specific  anti-
bodies collected from CI' patients. Strong banding patterns 
were observed with both anti-human IgA and IgG second-
ary antibodies and weaker bands were seen when blotted with 
an anti-human 104 antibody for both oral fluids and sera. 
The fact that the oral fluid results corresponded closely to 
the serum results was promising. Current studies involve 
screening a much larger cohort of healthy volunteers in 
order to calculate an ELISA cut-off value with more preci-
sion, thus hopefully reducing the number of false-negative 
ELISA results such as the two CF oral fluid outliers in Fig. 2. 
However, immunoblotting oral fluids against AK1401 LPS 
differentiated positive and negative samples, with all CF 
patients demonstrating a strong antibody response to A-
band and core LPS. Although the presence of antibodies 
was not necessarily indicative of a current infection, the 
detection of initial responses and subsequent rises in levels 
is of potential clinical value and oral fluids may provide a 
convenient means for the frequent monitoring of the 
antibody response to P. aernginosa in CF patients. Further 
prospective longitudinal studies are needed to address the 
clinical utility of this approach. 
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LETTFIlts 	  
oundations? Have we, at the very least, 
moved from basing our judgements on 
ungrounded assumptions to plausible 
inferences? 
The EVA Ethics Committee and the 
Universities Federation for Animal 
Welfare (LrF.sw) are organising an inter-
national symposium entitled 'Quality of 
life: the heart of the matter: at the Royal 
Society. London, September 13 to 1 
2006, to hear presentations from world 
authorities on aspects ranging from how 
the bra in generates feelings to approaches 
to quality of life assessment and ethical 
and legal implications. and to discuss all 
aspects of the subject. 
We hope that the symposium will be of 
interest to many veterinarians. The pro-
gramme is not finalised and we would be 
pleased to receive offers for papers on r-
ious aspects including have we selected 
for apprehension and fearfulness in some 
breeds?: pharmacological approaches to 
improving quality of life — what can be 
done and what should be done?: and. 
quality of life decision making in veteri-
nary practice. For further details of the 
event visit www.ulaw.org.uk, or contact 
telephone 01582 831818, e-mail: 
scioffthifinv. orguk 
James K. Kirkwood, trFAsv, The ohl 
School, Brewhause Hill, tOteiniampsteaci. 
Hertfordshire AL4 RAS 
Professor Lard Soulsby of 
Swan ham Prior. am Ethics COminitke, 
Rut, 7 Mansfield Street. London WIG rct? 
Cytological versus 
histopathological 
diagnosis in canine 
osteosarcoma 
SIR,—The role of cytology in the diagno-
sis of primary' hone tumours is less estab-
lished and perhaps not comprehensively 
studied compared with the diagnosis of 
soft tissue tumours. We evaluated the 
diagnostic accuracy of the cytological 
examination of canine osteosarcoma, 
comparing the cytological diagnoses 
offered with subsequent histopathological 
diagnoses on the same lesions. 
One hundred and eighty-four histo-
logically confirmed canine osteosarcoma 
cases Isere retrieved from the University of 
Queenslandveterinarypathologyan:hives. 
27 (15 per cent) of which were examined 
cytologically. In three cases (II per cent) 
the cytological diagnosis was not specific 
or the examination was inconclusive. In 
fire (19 percent) the cytological diagno-
sis did not agree with the histopatho-
logkal diagnosis and was considered 
m islead ing. The cytological diagnosiswas 
osteosarcoma, In full agreement with the 
histopathological diagnosis, in six of the 
27 cases (22 per cent); sarcoma (that is, it 
differentiated between sarcomatous and  
carcinomatous malig,nancies), in a further 
eight cases (30 per cent): and a malig- 
nancy in five (19 per 	Nineteen cases 
(70 per cent) had cytological and 
histopathological diagnoses in partial or 
full agreement. Cytology was misleading 
to a degree comparable with that of hist°. 
pathological diagnosis observed in the 
same series (1B per cent and 20 per cent 
respectively, P. Loukopoulos,unpublished 
data). Sensitivity of 65 per cent and accu-
racy of 95 per cent has been reported for 
the cytological diagnosis of human 
osteosarcoma (Dodd and others 2002). 
Comparisons of cytological with sub-
sequent histopathological diagnosis are 
very sparse in the veterinary literature, 
despite the common use of the technique 
in practice. A study of 140 cases reported 
a partial or full agreement between cytol-
ogy and histopathology of 90 per cent 
(Mills and Griffiths 1 9 84).wh ich is higher 
than the one reported here. In a more 
recent study of 269 samples from various 
species, the sensitivity of cytological 
examination ranged from 33-3 to 66.1 per 
cent and depended on the location of the 
lesion, being most accurate for cutaneous 
and subcutaneous lesions and least accu-
rate for liver lesions, and on the type of 
lesion. It was most effective in the diag-
nosis of neoplasia and least effect ive in the 
diagnosis of dysplasia or hyperplasia 
(Cohen and others 2003). 
Good correspondence was shown 
between cytological and historuthological 
diagnoses of external ear masses in the cat. 
with 100 per cent (27 of 27) agreement in 
the diagnosis of inflammatory polyps v 
neoplasia: histopathological examination 
was,however, recommended for differen-
tiation ofbenign proliferation and malig-
nant neoplasia (De Lorenzi and others 
2005). Although only 22 per cent of cases 
in our series p rovide.d a preliminary cyto-
logical diagnosis that was in full agree-
ment with the conclusive histopatho-
logical diagnosis of osteosarcoma, in 70 
per cent of cases cytological examination 
was accurate enough to differentiate 
between a malignant and a non-malig-
nant lesion, which is often sufficient for 
the clinician to proceed to the next step of 
dealing with the case, particularly when 
combined with clinical and imaging data. 
A larger number of cases needs to 
be examined to confirm these results. 
However, based on the above, the cyto-
logical evaluation of canine osteosarcoma 
patients is adequately accurate and useful 
to be justified, provided it is followed by 
histopathological confirmation. 
P. Loukopoidos, M. Rozmanec. 
R. H. Sutton, DiViSidti of lkterintry 
ffithebielogy and Anatomy. Scheel of 
Veterinary Science, University of 
Queensland, Brisbane, Queensland 4072. 
Australia 
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Naturally occurring 
antibodies in rabbit 
antisera to 
Pseudomonas 
aeruginosa 
SIR, — A study involving the preparation 
of hyperimmune rabbit :ulnae ra to 
Tseudernanas acres irrosa was undertaken 
at the Health Protection Agency (RoA). As 
a prelude to challenging New Zealand 
white rabbits with purified P earn ginosa 
bacterial components, prechallenge sera 
were prepared and tested for naturally 
occurring serum antibodies to the anti-
gens of interest, using 5.1)S-PACE and 
immunoblotting. An unexpected finding 
was that prechallenge sera had very high 
levels of antibodies of the immunoglab-
unit G (18G) class to both outer mem-
brane proteins and lipopolysaccharide 
antigens to 20 different wrotypes of 
P arrogitima. 
Rabbit sera from a collection of 
prechallenge sera. accrued by the NPA over 
the past 20 years, were tested for antibod-
ies to P aer tighten' and 12 of 16 rabbits 
had high levels of IgG class serum anti-
bodies to this organism. Bacteriological 
examination of rabbits holding facilities 
fulled to detect 1' aerminesa. and since the 
rabbits appeared healthy and had pre-
dominantly I9G class serum antibodies, 
this indicated that they may have had an 
ongoing subc lin ical infection or that these 
organisms fonts part of the rabbits' nor-
mal flora. 
From the published literature, it can be 
seen that there has been extensive use of 
rabbit antibodies as reagents for the 
serotyping of strains of P arrugineso and 
research involving this organism. The 
experience we report here illustrates the 
importance of screening rabbits for nat-
urally occurring serum antibodies to 
P aeruginosa antigens as a prelude to sub-
sequent antigen challenge. 
A. M. Weisner H. Chart T. L Pitt. 
Ceetrmfrr Infeetiant, MA, 61 Co1indrie 
A1C1lue, Lenders 1911,51IT 
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Evaluation of anti-A-band LPS 
antibodies to Pseudomonas aeruginosa 
in serum from patients with cystic fibrosis 
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Detection of antibodies to Pseudomonas aeruginosa 
in oral fluid and sputum samples from patients with cystic fibrosis 
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INTRODUCTION 
Psel.,:amanas aerugr.csa causes ol-rarec lurg I-fee-bons c aoproc-
malety 60% of patients with cystic f tress ICI j wan I.! au-AMA, 
associated with a c-amatic decline In patients' clinical staves Ea-ly 
tsetse:nor of the organism and aggressive specific rinttleore remanent 
e benerictal to the pa forrt and delays Ire once W ehr, lung 
election. Therefore. paten's are routinely screened by microliter/ulcer 
careen, of sputum Wa** la sine cough swabs and DAL earnests). 
with sore elnioiarts est monttoong Psoudornones-epecilic antibody 
levels 
Several slurries trace demonstrated that serodiagnosts can predate 
Gesture postlinty t West el ai.,2306, eaoplet of al. 2006. Tramper  
St'ande'e et at, 2006 but sit: not Cl cl -soars ',slew artitorles. This 
may tie Cue in the coneeversy sunotteding the value of entbort, 
levels. but pc-haps also because Pi tePsnliqucts employ senor soma en 
Oral foal samples offer a non.invesree method and ere *Addy used tor 
phi dettaton ttl a edo variety of agents. but as yet net P antscaonn 
We have previously deSC-4)PC employing A-band LPS as an anager 
for ea detect*, d P oc.vorosa-$060I,e Imbe,O4Iika (Woen.,  or 
2006) We have now investgaied the occurrence at antibtetiee to A. 
bard LPS in oral fields sputum este serum samples from cyslrc %broths 
patients. a cancel control group and healthy volunteers. 
MATERIALS AND METHODS 
SOS-PAGE and Immunobloteng. ten mciograms of octal membranes 
Creel et at 2002) prepared horn A-band reference easel AK1401 
were run on SOS-PAGE gala (4.5% slacking gel and 12.5% sepatation 
geli andtrans?erred tio nitrocellulose paper by inerunobtotting The blots 
were blackest' wen 3% Mammal sulk In PBS for S min, antrearty earn 
ples ;see tsetse,) added directly to the initial beekng solution and 
reacted to 1.5 hours. Eacn proftle was then reacted wile 5 pt. of 
potpie ont etiretaleightibtelle =resealed with Cies ind oespnettiso with 
frost blocking buffer far a further I hours before devetoping site 
invnersehlotting developing Setultan 16 ref MgCl, 2 int Tes, 2 tit Neel. 
45 pl. RBI, 35 el- BGIP). 
Vishinteeett Group A consisted of 	P &erste/oat sputum culiuro• 
positive CF patents (mean age 30.0 years, a = 7 0 years. n = 171cent:tali  
vokeiteered ore 	saimples lean 13 volcoleered sera Group B were 
10 P aeraginosa sputum culture-positive CF patients Imo*,  age 24.3 
years a 7.1 years, 	10) who or veluniarned sputum samples and 
8 sere Group B also wets 4 P aerogerosa sputum toilturienegative CF 
patents (mean age 28.0 years, ti = fiC ft years. 	41 with veunleered 
sputa and 3 sera. G101,11 C cunasted of 11 fairreet P epergnes. 
sputum torture-negatere (9 or whore had never ,nelded P. aerugthase 
primary okay dyslanesa (PC0) wheels (mean age 9 6 years o= 5 3 
years e T. 11) who volunteered one fluid samples. Group 0 consisted of 
unpaired control oral fluids and sera The (Val Nils were obtainer teen 
37 member; of 1-WA staff and their families (moan age 20.2 years, ar = 
19 1 years, r 31) and 12 sera were (Waned anonymeusly.  
Acilbady samples, Oral flu* was °Weise early Orme' oral test kits 
Menem Medical Developments, UK Figure 11.  Swabs were reritainee 
et morn termatralate and nnvottsral within 3 00)< Fn earn nano*. 
100 pL was set aside for another study and the remainder tested by 
prnmunntvta Sputum f..,^sinplef. were Magna with fin agile volume of 
Ringers solution lased). nomogensed with 6-7 glass beads and Intl 
spun et 13.000 rpm for 10 mnuies the supernatant was frozen urn 
use, when 200oL was used for irtenunetiolling Tweety MicrotheS of 
sere were used per blot 
Immuncialot interpretation: Innnurobluis were pralysod bind eat,  
side-shale antbody 52 offs graded negative. wean a positive. h core 
(primes were observed th s was also 'toted.  
RESULTS 
r,Imph,5 :tr,rntiVaiii01:5 nnen tikilakiq 
fr,un A1 ,1381, AK -I46 I wire 	uhramr.,i [cap 
p 
• We have demorseated a sensitive procedure for detecting antbodies 
In P. aPraginaaa N1 oral flora, sputum and serum samples hem 
patients with cyst* fibrosis, with oral lad samples exhibiting the 
closest correlation to serum. 
• Artteldels Moore LPS emotes were they detected MG? patents or 
in volunteers who had been infected with or worked with P aeruginate 
Antibodies to core L PS muietree era tardy detected she, prOknged 
infection (Foresgeard of al., 1988) so this reaction could define acne 
Intention in 100 pothrn 10.170 than environmental 0 pilalvre  
A summery of the immuneolot results is stivart n Table 1, wit,  maroons 
of the different antibody-binding inactions fee each group shows% in 
Fgt. 2 
All patients In Group A had detectable Prteudarnonasantthoeles in  real 
Void and serum samples with blots showing A-band LPS sitar-chant 
and core antbodee. The Group B subocils were seal/ley postive, with 
13 ol the 14 patients dernonstrattng sputum entltneess le Aband Sloe-
chain. The outer was Ilse same (and only) patient wino also lacked A-
bend serum antibodies, clasp* being P. adnvolOSS culture-bos,we. 
The 4 culture-negathre patients In Group B all demonstrated specific 
sale-Chain nelesodesis in their spurn 
Sic of the 11 PG0 patent oral fluid samples demonstrated weak 
antibodies 10 A-band 910 1 reacted weakly With °ere eptapea. This 
patent had previously grown P &engines& hoer cartons. Weakly pose 
live immurtehtele were obtained for 10 of the volunteers end only 1 
was CPU LPS reactive fa Peeper:went. laboretery worker). 
• The prelatic. of arbbodes to an organism does not 
necessaity ins/irate a current interline, but eccentric 
steeples ha antibodies M eortedreerit cAn provide yak,ethic 
information regendlrog the clinical stales of patients wile CF. 
• The ability lossO 0On-invasive sarnples will above easier 
undertaking at future set-clogs:re studies to establish the 
intone:lath beterreen entibedy rosponsu, retreat o0 the 
organism earn sputum and lung function 
Table Gorrirnnry of irnmrnoNot mode when op*: mornbenrins 50, 
afraid AIC 4411 Moe mfg.:tun with andbrair SaMpins nntsdnai burn CF, 
PC17 and tmeifhy 
ACKNOWLEDGEMENTS 
REFERENCES 
Ivor k 	Nve 
I row.. No...M. SA•41.14 broal,XLINGebnel 	II. 	41.2m,lo W .44 
Krt. 	4,4Ior 	 ban ara,anak J. t... 
' aan!an,anaa, *OW. nnmata ,va ea. ar 	wavow ga• 
4...••r no- an iltWeRVT MOM* 	annerM, 
ara,addaamay, ...valor amain. wadding magnolurednaa 111..5(.1-11.11110 
iosg 
iq 
CONCLUSIONS 
381 
 Sainting 
Ratan 4 Summary OtAband LPG ante-new hewn in ;amen alrliellantrx.- Sarr1111,n 11.1 drenorre ner 
Figure 1 Paewdertfonor• Mriegovsa 
lipopnbanothaddri abletture 
walla! lam WIN 
  
3.5 - 
30 	 
2.5 
2.0 
C 
1s 
3 	; 
• 
0.5 • 	
• 
0.0 
mew  /  • • 
Wanikald 	• 
• • 	
I s 	•um  2•  
  
Ca.11100. 
 
  
tilde Man 
  
• • 	, 
• 001.0 
cr cora 
UMW, • 
sett 
herein, 
teal fttelto 	 
illigilitmemamoommenuserie 
-111111111111S11111 
Cigar. 2 0n11 f old calkcenn dor. 
1:11.1.6.1 d Fie 21 0-14ee Miens (01-C6, 09-011. 011 016-021) cleumetruten. atm-
nedietepartin I PS consistent wren the A-band ontdtme lopetareall ny AS140C 
ArettnionAN 49 of the. 4g  51115a I strains sea toptedisad a pone earnielent wen A.band 
None or the Iron drains reacted at Ike Loma Pedrol sire and Mori) was species 
spacen. 
A assenwey al the knmanotear And ELSA negate roams 2 and 4) 600.4, 
• AK 13er robot -,,arm ea-reins annererneed P newiaWeasa a-bee LPS aresolum 
by arosuncbkr and Cif SA 
• AA tr CF oaten, derennstrired oat bud areibradiasendrng to tpa nrs inn/monk-Its 
and 05 of die 17 patents had .a 111.1d 01011Oes 41 delailea by ELISA, 
how crier 12 PCD point oral sari remake dm nasestod metopes In Ms A•bard 
Amon O Dia 37 Meng eolunture oral r*,,L,  seoploi Oemoretrated writ -card 4413. 
nodas no A•band LPS. but reek out temin landrag to Me sir:lecher,  LPS were 
Mimed m 10 mrierat by mourubnuttirg. 
Anti num anntborlys wore derromnated in 41 11 9100,4 are only .ha OO  Ina men 
leam ps emaurnoreni anther)  
t hoe woont mire:des Panne to BOA verso onsmad In I on) 11131E1 .entile 1900 
innininoLior rabid. Ica A-bard (PS). illostratno tre imotrtance or entrurrai 
MrrUrcinsarb a1,1,114 a EISAsertrut L, rowed Lulea secerva iambs 
The whim r-antogn mte n floweret pahento red TIMM 1x1.111/:0 Fns Iman roweled 
dl apprerdnmeare b10 Clierienhart et at, 1305) but the lestal al  0115034  0 Meson( pro. 
sumatar rot Irani astve intsotor riveters ,11,11.133.1 $11120 Ff lagAlaaaal ja a 5990taus 
Onctenwr ,, a moms ikely that belittle munk Ms trod '1300 insdemlanto bean momed 
trn ammonntental strains 1111rt, 11110900 a,  antibody roadonsa Aminones to crop IPS 
monies re only redo:red new malungod inteclitur freerrignard id M. 1780).00 his 
maven mini deloo nerve Infect.. ,n he mituml rather Wen ourconmerear naperoren. 
We hove demonstrated a sensitive ormuodure for 
neecting 11,111130d, M. 14 P sertgirces In Nenm and 
marl fluid 1311191011 10211 haterne Mtn CF. 
00411 Moles witoning a larger cohort of healthy 
velidltentS are rehefred 10 1014010 the ELI5A Cut-
off vetum to enema the number of takennagative 
EL130 remits 
Immisnohlalling wish oral fluid Ramon. confirms 
Mit al) CF p1liante Mend dernornetratco annitiodits 
MA-band tot).  
The let-leunte 0l a111,130disa Ivan unionism dime 
0001 01144511.111111y Indleate a r..kh1n1n1 MfactIOn, Mn 
exarnining Wag quids ander perm for antibodies 
to P waging.a can be deed to provide mimeo 
information regarding Dation% with CF. Long( 
lodes] maologicat studies north or al quid samples 
can new eti more ...say undemaren ro asnableh 
pie interaction behmen nor/hod/ respoom ere le 
grime, 01 the organism tram nninum 
10, coos owe( In atawaelnala al ,Iera10 me 
crakial seasq • 	1/.1 *am.. 
•04. 	•1.3, 1/•• 	am 	1113P 
to, 	end see 
no to slurenlost tomernoul tur prom;  e the 
Wet., lamp. 
own. ,,,rap,,,11114111,* 
CILSI 	WA.. 41a. 
1,0• •••••••••••••1 I
• 
. • 	 ',anon 
men
•14.• 
 PON WI 	
am
inlaMiael 4..6 a 9.1ion. 
*a... .11 10.1... COWS PS, •010 PM+ C 
mom* 
•••••••••••,ry •••••1Mmolln 	aarl Soaara•NMaarza 
Munn. a • wrwe immernew whin ern* 
r • 
.8.7.611Mer 
Figue0 
500110811 Of I 7.Mui.ullkg, From 
al Cr One a..1 sarrplm 
YII Volinlem onl Mud mopes 
SOM 
CFCYSTIC FIBROSIS TRUST 
Detection of antibodies to Pseudomonas aeruginosa in 
serum and oral fluid from patients with cystic fibrosis 
Abbie M Weisner', Henrik Chart?, Andrew Bush3, Jane C Davies3 and Tyrone L Pitt' 
Ilaboratory of Healthcare Associated Infections 2Laboratory of Enteric Pathogens 
Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ 
?Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London SW3 6NP, UK 
Pancomreom weichowasa causes chronic una 	e, MP cm/- 
Mann 805, ol pennants men pogo Smile (Cs Easy thrlecern al Me 
organ ien and asseatima meals ardente reamnard a venereal in be 
patient and delays Inn n,-set y chime lung preintion 
The detacer of term anibodias to P earaianowe his bean cepartan 
releing a mien range es Artemis inciudIng tedistmarnImana pains 
Monne mayors nnn loorrhenttionsta ILPS. 913.0..) 
P ilsrsIPPea ',Creams Pm 'Steam' of LPS It a homopornots OFtwod 
consoling 01 esecoharda tronalvas oft el Cr-themes. ant al a Polon-
oorecreg !nun 111L11/11:11 at mat* samiyersteculk 13•Lsed'. 
P mese/ma undergoes Menuiteric charge. Pacing aeons -Memo war 
a mardies an cd Booed LPS Otansoce at at 1901/ ;Mob soh aignme 
on maim seism antigen at Neap serobipa dafitaant WRY, a etwort 
LPS Witch B common anargotatrato of to SIMMS (Linnet si • 1965) 
51,11,1 nedration are prodileed m elmomenlly eh/Mot paten% but am 
0Ornateed al noitesi dagnoille value manor a aallenta wham a-111-
bodies modem mass posibully. Ore ISM ample are reanimate, and 
am weary omit ior tee aonelean of a was meaty ot pares OM as minas 
P moven* 
Von inmarigated ten norrnwn MA-band (PS In 20 Citypn 111.114 and 49 
crow eololiss itt P aortronasa ArtbeitioloA-be.rd LPS were assessed 
01 mom and oral feiC hoe CF ontlente mom ere toe lord kin nagelay 
velment, end oral quid tom a cense waned group.  
tiluselortal arenas retambens 01 b 020 al P anntsermsa, A-breut refeemm uneer 
AK142 1 and 40 Pinot Marna ham CF patent, were noetefigned fro Me 'memo fr4 
Aeand CP5 	spacles sterecirtely pane comprimid a ninon of CF (33.1111;.gera and 
winder Entoroldramaceers 
IPS: Fur SOS-PAGE end Ornmediedling. LPS nes a:kneeled Mae waiter wrtnerow. 
Probered.frwr, soar 9,411401 Onasr membranes Mare talent nerrod Lone a hot. 
trent. nOradrn fnr 8e ELISA (Chet P 2002) 
SDS•PAGE .red lannumblostIng/ Prima-thous went non on 3096-PAGE gets {4 9% 
Memo del and .2.4lni seismal/On rang end elftnt Parted eat silver Slain le mifuNae 
!Ma 195 wear on haorerrod to re rocAllulose payer by irranwioNc4hop The Not was 
Wormed with 2.1', serroled mat I. e410 le 5 men and sea (5 it 0 rubel stems 20 pl. 
numan ssouni) Cl toe nun ternples added Meetly ha Ma millar Wading solution and 
maned for 1.5 needs Problem wore masted eta, 5 Lk. par Ism pf Weraptiato 
dormant lo cennalatnet wim gikaliro pPoriptotase with fret blocking Went Ost a 
00100* 1.5 oars. norm csavatorg vat rthrurredottav catraiderg solston In mL 
119C19. 2 MI. ire. 2 rot. 10.01 45 sk NOT, 35 IA EICIPt 
Sera: Pores el CF paean Wm sound awe frOM • hinefe. nareCr croaker. and 
rata artiaodias tried lo LPS 0..e0earte1 from P ea(ax.. stein AK 1111I) 'NOM 
employed for ItnemostrY 
Patients and mensnemil Senerteen CF patent, rho ewe all spulunn culluni-pOulteit 
mr P newnein(0 urea AwalLogaleel {einedin Aga 10.0 mark rn = 78 years net .17) all 
17 anticanneron oral led 731.7411e0 am, 13 volunlenred seta Teem patterns fait sputum 
Odhure neginivri Mr P weiweinsoh web ontrent Merit dyskIrese (PC12)1 vntieNtewen 
oat tied 111311‘,011 Oman age S 8 soars, n - 92 you a n - 12). Samples of control teal 
fig)4 ems untanned Imo 37 rent:eta al 11Pri sloe and reit tamirea Oxon ego 28.2 
Wane, in 19 1 years n-371. 
Orel fluid amplest Ong Iluid war dstarned nano Greco, oral Met knp rettattern 
Matra' Ormtraprrents, 	repro 2). Swabs woe marremal sr mon ternburottura 
Bed brobessed wean 3 Pays Fir each sere*. 1130 0L1,18 sal mide ron the ELI5A 
4 ,11/111.11 n1171a1111111x11171011 by 4)00000099640, 
• ELIZA otels son umbel vdrn 1 Ao LOS Boa hell in 100 et coated buffer 175 
mid AliaiC0r. 34.5 rnVI Narg0.. 4"C. oviareshIL Minnie with 1% SSA and earrunos 
(50 hi me quid Or 100 AL sera a !wee 1 in 503 in P13.9) weed A docker* cat of 
samples ecro marled err worn roach rad been teOSIMP min n5,4 wry pragen, 
tindro was irsienrind rah flowerer, rg orpagatest enth /Marine phonetists', Fermi 
with clunnenciennt. niter (1 It ontharro-amine 0 MA Mips, off 96) cortoning I 
1715 puntrnphannl phew-ohne par 004 nod Mai is A,' Sangria velum v 	Auns alter 
30 mingles were consented potave trot-Orlaillsodeort its moan r 3 g o at vitturgent 
oral Pao isomers and human noosere WINO meat 
382 
